CUMULATIVE SUPPLEMENT 7
July 2023



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

43rd EDITION

Department of Health and Human Services
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2023

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

43rd EDITION

Cumulative Supplement 7
July 2023

CONTENTS

PAGE

Contents

1.0 INTRODUCTION v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT vi
1.2 CUMULATIVE SUPPLEMENT CONTENT vi
1.3 APPLICANT NAME CHANGES vii
1.4 LEVOTHYROXINE SODIUM viii
1.5 AVAILABILITY OF THE EDITION ix
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST x
1.7 CUMULATIVE SUPPLEMENT LEGEND xi

DRUG PRODUCT LISTS
Prescription Drug Product List 1-1
OTC Drug Product List 2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List 3-1
Orphan Products Designations and Approvals List 4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution 5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM
A. Patent and Exclusivity Lists A-1
B. Patent and Exclusivity Terms B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

43rd EDITION

CUMULATIVE SUPPLEMENT 7
JULY 2023

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ALEOR DERMACEUTICALS LTD (ALEOR DERMACEUTICALS)	ALEMBIC PHARMACEUTICALS LTD (ALEMBIC)
ALLERGAN (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN HOLDINGS UNLTD CO (ALLERGAN HOLDINGS)	ABBVIE INC (ABBVIE)
ALLERGAN INC (ALLERGAN)	ABBVIE INC (ABBVIE)
ALLERGAN SALES LLC (ALLERGAN)	ABBIE (ABBVIE)

ALLERGAN SALES LLC (ALLERGAN)	ABBVIE INC (ABBVIE)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
EMCURE PHARMACEUTICALS LTD (EMCURE PHARMS LTD)	AVET LIFESCIENCES LTD (AVET LIFESCIENCES)
EPIC PHARMA INC (EPIC PHARMA)	EPIC PHARMA LLC (EPIC PHARMA LLC)
EPIC PHARMA INC (EPIC PHARMA INC)	EPIC PHARMA LLC (EPIC PHARMA LLC)
HERITAGE PHARMA LABS INC (HERITAGE PHARMA)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
HERITAGE PHARMA LABS INC DBA AVET PHARMACEUTICALS LABS INC (HERITAGE PHARMA AVET)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MAYNE PHARMA INC (MAYNE PHARMA INC)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA INTERNATIONAL PTY LTD (MAYNE PHARMA)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA INTERNATIONAL PTY LTD (MAYNE PHARMA INTL)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
MAYNE PHARMA LLC (MAYNE PHARMA)	DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)
NEXUS PHARMACEUTICALS INC (NEXUS PHARMS)	NEXUS PHARMACEUTICALS LLC (NEXUS)

1.4 LEVOTHYROXINE SODIUM[1]

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2,

[1] In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.[2]

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	–
AB4	LEVOTHYROXINE SODIUM[3]	MYLAN	0.3MG	A076187	–	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange

[2] Please consult the Active Section of the Orange Book for information on other strengths.

[3] Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
https://www.fda.gov/about-fda/reports-manuals-forms/forms.

The current listing of the Orphan Product Designations and Approvals is available at https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of

product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2022	MAR 2023	JUN 2023	SEP 2023	DEC 2024
DRUG PRODUCTS	21983	22398	22632		
LISTED SINGLE SOURCE	2718 (12.4%)	2759 (12.3%)	2779 (12.3%)		
MULTISOURCE	19265 (87.6%)	19639 (87.7%)	19853 (87.7%)		
THERAPEUTICALLY EQUIVALENT	19165 (87.2%)	19554 (87.3%)	19781 (87.4%)		
NOT THERAPEUTICALLY EQUIVALENT	100 (0.5%)	85 (0.4%)	72 (0.3%)		
EXCEPTIONS[4]	46 (0.2%)	46 (0.2%)	46 (0.2%)		
NEW MOLECULAR ENTITIES APPROVED	8	19	11		
NUMBER OF APPLICANTS	1211	1222	1217		

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

[4] Amino acid containing products of varying composition (see Introduction, page xx of the List).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN[5]	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

[5] The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB	FLORIDA	500MG	A215086	001	Mar 23, 2023	Mar NEWA
AB	TEVA PHARMS USA	500MG	A210726	001	Jan 26, 2023	Jan NEWA

ACARBOSE

TABLET;ORAL

ACARBOSE

@	DASH PHARMS	25MG	A091053	001	Jan 06, 2011	Feb CAHN
@		50MG	A091053	002	Jan 06, 2011	Feb CAHN
@		100MG	A091053	003	Jan 06, 2011	Feb CAHN

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP	HQ SPCLT PHARMA	1GM/100ML (10MG/ML)	A215403	001	May 03, 2023	Apr NEWA
AP	WOCKHARDT BIO AG	1GM/100ML (10MG/ML)	A205746	001	Apr 18, 2023	Apr NEWA
@	ZYDUS PHARMS	1GM/100ML (10MG/ML)	A216467	001	Oct 25, 2022	Mar DISC

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL

APADAZ

+ @	KVK TECH INC	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Mar DISC
+ @		325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Mar DISC
+ @		325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Mar DISC
+ @	ZEVRA THERAP	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Jun CAHN
+ @		325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Jun CAHN
+ @		325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Jun CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

AA	SENORES PHARMS	300MG;50MG	A214088	001	Apr 07, 2022	Jan CAHN
AA		325MG;25MG	A214088	002	Apr 07, 2022	Jan CAHN
AA		325MG;50MG	A214088	003	Apr 07, 2022	Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@	NOSTRUM LABS INC	300MG;15MG	A088629	002	Mar 06, 1985	Apr DISC
@		300MG;30MG	A088629	003	Mar 06, 1985	Apr DISC
+ @		300MG;60MG	A088629	001	Mar 06, 1985	Apr DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@	SUN PHARM INDS INC	325MG;5MG	A090118	001	Dec 23, 2008	Jun DISC
@		325MG;7.5MG	A090118	002	Dec 23, 2008	Jun DISC
@		325MG;10MG	A090118	003	Dec 23, 2008	Jun DISC

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

COMBOGESIC

+!	AFT PHARMS LTD	325MG;97.5MG	N209471	001	Mar 01, 2023	Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

@	DR REDDYS LABS SA	325MG;2.5MG	A090177	001	Oct 20, 2008	Apr CAHN
@		325MG;5MG	A090177	002	Oct 20, 2008	Apr CAHN
@		325MG;7.5MG	A090177	003	Oct 20, 2008	Apr CAHN
@		325MG;10MG	A090177	004	Oct 20, 2008	Apr CAHN
@		500MG;7.5MG	A090177	005	Oct 20, 2008	Apr CAHN
@		650MG;10MG	A090177	006	Oct 20, 2008	Apr CAHN
@	MAYNE PHARMA INC	325MG;2.5MG	A090177	001	Oct 20, 2008	Apr DISC
@		325MG;5MG	A090177	002	Oct 20, 2008	Apr DISC
@		325MG;7.5MG	A090177	003	Oct 20, 2008	Apr DISC
@		325MG;10MG	A090177	004	Oct 20, 2008	Apr DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

	TABLET;ORAL						
	TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN						
AB	! AMNEAL PHARMS	325MG;37.5MG	A090485	001	Dec 09, 2009	Mar	CHRS
	ULTRACET						
	+ @ JANSSEN PHARMS	325MG;37.5MG	N021123	001	Aug 15, 2001	Mar	DISC

ACETAZOLAMIDE

	CAPSULE, EXTENDED RELEASE;ORAL						
	ACETAZOLAMIDE						
AB	INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011	Feb	CMFD
	TABLET;ORAL						
	ACETAZOLAMIDE						
AB	AARKISH PHARMS NJ	125MG	A217197	001	May 09, 2023	Apr	NEWA
AB		250MG	A217197	002	May 09, 2023	Apr	NEWA
	@ BRECKENRIDGE	125MG	A207503	001	Apr 30, 2020	Jan	DISC
	@	250MG	A207503	002	Apr 30, 2020	Jan	DISC
AB	ZYDUS	125MG	A211069	001	Apr 04, 2023	Mar	NEWA
AB		250MG	A211069	002	Apr 04, 2023	Mar	NEWA

ACETIC ACID, GLACIAL

	SOLUTION/DROPS;OTIC						
	ACETIC ACID						
	@ CHARTWELL RX	2%	A040166	001	Jul 26, 1996	Jan	CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONE

	SOLUTION/DROPS;OTIC						
	HYDROCORTISONE AND ACETIC ACID						
	@ COSETTE	2%;1%	A040609	001	Feb 06, 2006	Jun	DISC
AT	+! TARO	2%;1%	A088759	001	Mar 04, 1985	Jun	CHRS
AT	+	2%;1%	A088759	001	Mar 04, 1985	Jun	CRLD

ACETYLCYSTEINE

	INJECTABLE;INTRAVENOUS						
	ACETYLCYSTEINE						
AP	STERISCIENCE	6GM/30ML (200MG/ML)	A217182	001	Apr 19, 2023	Apr	NEWA

ACYCLOVIR

	CAPSULE;ORAL						
	ACYCLOVIR						
	@ AUROBINDO PHARMA USA	200MG	A074727	001	Apr 22, 1997	May	CAHN
	CREAM;TOPICAL						
	ACYCLOVIR						
AB	ZYDUS LIFESCIENCES	5%	A206770	001	Feb 28, 2023	Feb	NEWA
	SUSPENSION;ORAL						
	ACYCLOVIR						
AB	MSN	200MG/5ML	A217393	001	Mar 09, 2023	Mar	NEWA
AB	! NOVITIUM PHARMA	200MG/5ML	A212252	001	Jul 10, 2020	May	CHRS
	ZOVIRAX						
	+ @ MYLAN	200MG/5ML	N019909	001	Dec 22, 1989	May	DISC
	TABLET;ORAL						
	ACYCLOVIR						
	@ AUROBINDO PHARMA USA	400MG	A075211	001	Sep 28, 1998	Apr	CAHN
	@	800MG	A075211	002	Sep 28, 1998	Apr	CAHN

ADAPALENE

	GEL;TOPICAL						
	ADAPALENE						
AB	ENCUBE ETHICALS	0.3%	A200298	001	Jun 14, 2012	Apr	CMFD

ALBENDAZOLE

	TABLET;ORAL						
	ALBENDAZOLE						
	@ CHARTWELL RX	200MG	A211636	001	Jun 10, 2020	May	CAHN

ALBUTEROL SULFATE

SOLUTION;INHALATION

ACCUNEB

		+ @	MYLAN SPECIALITY LP	EQ 0.021% BASE	N020949	002	Apr 30, 2001	Jun DISC

ALBUTEROL SULFATE

>D>	AN		AKORN	EQ 0.5% BASE	A074543	001	Jan 15, 1998	Jul CAHN
	AN	!	RITEDOSE CORP	EQ 0.021% BASE	A214531	001	Dec 28, 2021	Jun CHRS
>A>	AN		SENTISS	EQ 0.5% BASE	A074543	001	Jan 15, 1998	Jul CAHN

TABLET;ORAL

ALBUTEROL SULFATE

	AB		DASH PHARMS NATCO	EQ 2MG BASE	A072894	002	Jan 17, 1991	Feb CAHN
	AB	!		EQ 4MG BASE	A072894	001	Jan 17, 1991	Feb CAHN

ALBUTEROL SULFATE; BUDESONIDE

AEROSOL, METERED;INHALATION

AIRSUPRA

		+!	ASTRAZENECA	EQ 90MCG BASE/INH;80MCG/INH	N214070	001	Jan 10, 2023	Feb CAHN
		+!	BOND	EQ 90MCG BASE/INH;80MCG/INH	N214070	001	Jan 10, 2023	Jan NEWA

ALENDRONATE SODIUM

SOLUTION;ORAL

ALENDRONATE SODIUM

	AA	!	HIKMA	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013	May CTEC
	AA		NOVITIUM PHARMA	EQ 70MG BASE/75ML	A214512	001	May 11, 2023	May NEWA

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

>D>	AB	!	ACCORD HLTHCARE	300MG	A203154	002	May 06, 2013	Jul CHRS
>A>	AB			300MG	A203154	002	May 06, 2013	Jul CHRS
>A>	AB		HETERO LABS LTD V	100MG	A217748	001	Aug 03, 2023	Jul NEWA
>A>	AB			300MG	A217748	002	Aug 03, 2023	Jul NEWA
>D>	AB		UNICHEM	300MG	A211820	002	Mar 12, 2019	Jul CHRS
>A>	AB	!		300MG	A211820	002	Mar 12, 2019	Jul CHRS

ALVIMOPAN

CAPSULE;ORAL

ALVIMOPAN

	AB		PAR PHARM	12MG	A216843	001	Jan 24, 2023	Jan NEWA
	AB	!	WATSON LABS TEVA	12MG	A208295	001	Dec 19, 2019	Jun CHRS

ENTEREG

		+ @	CUBIST PHARMS	12MG	N021775	001	May 20, 2008	Jun DISC

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

	AB		STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017	Feb CTEC

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

>D>	AA	!	AKORN	50MG/5ML	A074170	001	Oct 28, 1994	Jul CAHN
>A>	AA	!	AUROBINDO PHARMA USA	50MG/5ML	A074170	001	Oct 28, 1994	Jul CAHN

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

	AB		STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	Feb CTEC

AMIFOSTINE

INJECTABLE;INJECTION

>D>			AMIFOSTINE					
>D>	AP		SUN PHARM	500MG/VIAL	A077126	001	Mar 14, 2008	Jul DISC
>A>		@		500MG/VIAL	A077126	001	Mar 14, 2008	Jul DISC

ETHYOL

>D>	AP	+!	CLINIGEN	500MG/VIAL	N020221	001	Dec 08, 1995	Jul CTEC
>A>		+!		500MG/VIAL	N020221	001	Dec 08, 1995	Jul CTEC

AMIKACIN SULFATE

INJECTABLE;INJECTION

AMIKACIN SULFATE

		!	HIKMA	EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Feb CTEC

AMINO ACIDS

INJECTABLE;INJECTION

	FREAMINE HBC 6.9%					
	@ B BRAUN	6.9% (6.9GM/100ML)	N016822	006	May 17, 1983	Jan DISC
	FREAMINE III 10%					
	@ B BRAUN	10% (10GM/100ML)	N016822	005		Jan DISC
	FREAMINE III 8.5%					
	@ B BRAUN	8.5% (8.5GM/100ML)	N016822	004		Jan DISC
	HEPATAMINE 8%					
	@ B BRAUN	8% (8GM/100ML)	N018676	001	Aug 03, 1982	Jan DISC

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

	PROCALAMINE					
	@ B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N018582	001	May 08, 1982	Jan DISC

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTION

	FREAMINE III 8.5% W/ ELECTROLYTES					
	@ B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/100ML;440MG/100ML;690MG/100ML	N016822	007	Jul 01, 1988	Jan DISC

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

	FREAMINE III 3% W/ ELECTROLYTES					
	@ B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N016822	003		Jan DISC

AMINOCAPROIC ACID

SOLUTION;ORAL

	AMINOCAPROIC ACID					
AA	TARO	0.25GM/ML	A214458	001	Mar 24, 2023	May CAHN
AA	TARO PHARMS	0.25GM/ML	A214458	001	Mar 24, 2023	Mar NEWA
	@ VISTAPHARM	0.25GM/ML	A212814	001	Feb 26, 2020	Mar DISC

AMINOPHYLLINE

TABLET;ORAL

	AMINOPHYLLINE					
>A>	@ CHARTWELL MOLECULAR	100MG	A084588	001		Jul CAHN
>A>	@	200MG	A084588	002		Jul CAHN
>D>	@ LANNETT	100MG	A084588	001		Jul CAHN
>D>	@	200MG	A084588	002		Jul CAHN

AMIODARONE HYDROCHLORIDE

TABLET;ORAL

	AMIODARONE HYDROCHLORIDE					
AB	CHARTWELL RX	100MG	A077069	003	Oct 04, 2016	Jun CAHN
AB		200MG	A077069	001	Apr 08, 2005	Jun CAHN
AB		400MG	A077069	002	Apr 08, 2005	Jun CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

	AMITRIPTYLINE HYDROCHLORIDE					
AB	RUBICON	10MG	A215376	001	May 01, 2023	Apr NEWA
AB		25MG	A215376	002	May 01, 2023	Apr NEWA
AB		50MG	A215376	003	May 01, 2023	Apr NEWA
AB		75MG	A215376	004	May 01, 2023	Apr NEWA
AB		100MG	A215376	005	May 01, 2023	Apr NEWA
AB		150MG	A215376	006	May 01, 2023	Apr NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

	LIMBITROL					
+	@ CHARTWELL RX	EQ 12.5MG BASE;5MG	N016949	001		Mar CAHN
	LIMBITROL DS					
+	@ CHARTWELL RX	EQ 25MG BASE;10MG	N016949	002		Mar CAHN

AMLODIPINE BENZOATE

SUSPENSION;ORAL

AMLODIPINE BENZOATE

	@	AMNEAL	EQ 1MG BASE/ML	A215035	001	Jun 13, 2023	Jun DISC
AB			EQ 1MG BASE/ML	A215035	001	Jun 13, 2023	Jun NFTG

KATERZIA

	+!	AZURITY	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019	Jun CTEC
AB	+!		EQ 1MG BASE/ML	N211340	001	Jul 08, 2019	Jun CFTG

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB		COREPHARMA	EQ 2.5MG BASE	A076719	001	May 23, 2007	Feb CAHN
AB			EQ 5MG BASE	A076719	002	May 23, 2007	Feb CAHN
AB			EQ 10MG BASE	A076719	003	May 23, 2007	Feb CAHN

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

	@	SOFIE	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	May DISC

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN

	@	CHARTWELL RX	125MG/5ML	A062059	001		Jan CAHN
	@		250MG/5ML	A062059	002		Jan CAHN

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

AB	+	NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jun CFTG
AB	+		EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jun CFTG
AB	+		EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jun CFTG
AB	+		EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jun CFTG
AB	+		EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jun CFTG
AB	+!		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jun CFTG

AMPHETAMINE

AB		ACTAVIS LABS FL INC	EQ 3.1MG BASE	A209253	001	Jun 22, 2023	Jun NFTG
AB			EQ 6.3MG BASE	A209253	002	Jun 22, 2023	Jun NFTG
AB			EQ 9.4MG BASE	A209253	003	Jun 22, 2023	Jun NFTG
AB			EQ 12.5MG BASE	A209253	004	Jun 22, 2023	Jun NFTG
AB			EQ 15.7MG BASE	A209253	005	Jun 22, 2023	Jun NFTG
AB			EQ 18.8MG BASE	A209253	006	Jun 22, 2023	Jun NFTG

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		ANI PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Feb CMFD
AB		ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A214959	001	Sep 29, 2021	Feb CTNA
AB			2.5MG;2.5MG;2.5MG;2.5MG	A214959	002	Sep 29, 2021	Feb CTNA
AB			3.75MG;3.75MG;3.75MG;3.75MG	A214959	003	Sep 29, 2021	Feb CTNA
AB			5MG;5MG;5MG;5MG	A214959	004	Sep 29, 2021	Feb CTNA
AB			6.25MG;6.25MG;6.25MG;6.25MG	A214959	005	Sep 29, 2021	Feb CTNA
AB			7.5MG;7.5MG;7.5MG;7.5MG	A214959	006	Sep 29, 2021	Feb CTNA
AB		GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Feb CTNA
AB			1.25MG;1.25MG;1.25MG;1.25MG	A217027	001	Jan 23, 2023	Jan NEWA
AB			2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Feb CTNA
AB			2.5MG;2.5MG;2.5MG;2.5MG	A217027	002	Jan 23, 2023	Jan NEWA
AB			3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Feb CTNA
AB			3.75MG;3.75MG;3.75MG;3.75MG	A217027	003	Jan 23, 2023	Jan NEWA
AB			5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Feb CTNA
AB			5MG;5MG;5MG;5MG	A217027	004	Jan 23, 2023	Jan NEWA
AB			6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Feb CTNA
AB			6.25MG;6.25MG;6.25MG;6.25MG	A217027	005	Jan 23, 2023	Jan NEWA
AB			7.5MG;7.5MG;7.5MG;7.5MG	A217027	006	Jan 23, 2023	Jan NEWA
AB		LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Feb CMFD
	@		1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	Feb CTNA
AB			2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Feb CMFD
	@		2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	Feb CTNA
AB			3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Feb CMFD
	@		3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	Feb CTNA

```
        CAPSULE, EXTENDED RELEASE;ORAL
          DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE
    AB                            5MG;5MG;5MG;5MG                    A214403  004  Nov 26, 2021   Feb CMFD
          @                       5MG;5MG;5MG;5MG                    A214403  004  Nov 26, 2021   Feb CTNA
    AB                            6.25MG;6.25MG;6.25MG;6.25MG        A214403  005  Nov 26, 2021   Feb CMFD
          @                       6.25MG;6.25MG;6.25MG;6.25MG        A214403  005  Nov 26, 2021   Feb CTNA
    AB                            7.5MG;7.5MG;7.5MG;7.5MG            A214403  006  Nov 26, 2021   Feb CMFD
          @                       7.5MG;7.5MG;7.5MG;7.5MG            A214403  006  Nov 26, 2021   Feb CTNA
        TABLET;ORAL
          DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE
    AB      LANNETT CO INC        1.25MG;1.25MG;1.25MG;1.25MG        A215565  001  Jul 08, 2022   Feb CMFD
    AB                            1.875MG;1.875MG;1.875MG;1.875MG    A215565  002  Jul 08, 2022   Feb CMFD
    AB                            2.5MG;2.5MG;2.5MG;2.5MG            A215565  003  Jul 08, 2022   Feb CMFD
    AB                            3.125MG;3.125MG;3.125MG;3.125MG    A215565  004  Jul 08, 2022   Feb CMFD
    AB                            3.75MG;3.75MG;3.75MG;3.75MG        A215565  005  Jul 08, 2022   Feb CMFD
    AB                            5MG;5MG;5MG;5MG                    A215565  006  Jul 08, 2022   Feb CMFD
    AB                            7.5MG;7.5MG;7.5MG;7.5MG            A215565  007  Jul 08, 2022   Feb CMFD

      AMPICILLIN SODIUM
        INJECTABLE;INJECTION
          AMPICILLIN SODIUM
          @ STERISCIENCE          EQ 250MG BASE/VIAL                 A201025  001  Apr 09, 2014   Jan CAHN
          @                       EQ 500MG BASE/VIAL                 A201025  002  Apr 09, 2014   Jan CAHN
    AP                            EQ 1GM BASE/VIAL                   A201025  003  Apr 09, 2014   Jan CAHN
    AP                            EQ 2GM BASE/VIAL                   A201025  004  Apr 09, 2014   Jan CAHN
    AP                            EQ 10GM BASE/VIAL                  A202198  001  Apr 07, 2014   Jan CAHN

      AMPICILLIN SODIUM; SULBACTAM SODIUM
        INJECTABLE;INJECTION
          AMPICILLIN AND SULBACTAM
    AP      STERISCIENCE          EQ 1GM BASE/VIAL;EQ 500MG          A201024  001  Apr 07, 2014   Jan CAHN
                                  BASE/VIAL
    AP                            EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL  A201024  002  Apr 07, 2014   Jan CAHN
    AP                            EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL A202197  001  Apr 07, 2014   Jan CAHN

      AMPICILLIN/AMPICILLIN TRIHYDRATE
        CAPSULE;ORAL
          PRINCIPEN '250'
>D>       @ APOTHECON             EQ 250MG BASE                      N050056  001                Jul CRLD
>A>     + @                       EQ 250MG BASE                      N050056  001                Jul CRLD
          PRINCIPEN '500'
>D>       @ APOTHECON             EQ 500MG BASE                      N050056  002                Jul CRLD
>A>     + @                       EQ 500MG BASE                      N050056  002                Jul CRLD

      APALUTAMIDE
        TABLET;ORAL
          ERLEADA
        +   JANSSEN BIOTECH       60MG                               N210951  001  Feb 14, 2018   Feb CHRS
        +!                        240MG                              N210951  002  Feb 17, 2023   Feb NEWA

      APIXABAN
        TABLET;ORAL
          APIXABAN
          @ AUROBINDO PHARMA LTD  2.5MG                              A210026  001  May 26, 2023   Jun DISC
    AB                            2.5MG                              A210026  001  May 26, 2023   May NEWA
          @                       5MG                                A210026  002  May 26, 2023   Jun DISC
    AB                            5MG                                A210026  002  May 26, 2023   May NEWA
>D> AB      ZYDUS PHARMS          2.5MG                              A210185  001  Feb 27, 2023   Jul DISC
>A>       @                       2.5MG                              A210185  001  Feb 27, 2023   Jul DISC
    AB                            2.5MG                              A210185  001  Feb 27, 2023   Feb NEWA
>D> AB                            5MG                                A210185  002  Feb 27, 2023   Jul DISC
>A>       @                       5MG                                A210185  002  Feb 27, 2023   Jul DISC
    AB                            5MG                                A210185  002  Feb 27, 2023   Feb NEWA

      APOMORPHINE HYDROCHLORIDE
        FILM;SUBLINGUAL
          KYNMOBI
>A>     + @ SUMITOMO PHARMA AM    10MG                               N210875  001  May 21, 2020   Jul CAHN
>A>     + @                       15MG                               N210875  002  May 21, 2020   Jul CAHN
>A>     + @                       20MG                               N210875  003  May 21, 2020   Jul CAHN
>A>     + @                       25MG                               N210875  004  May 21, 2020   Jul CAHN
>A>     + @                       30MG                               N210875  005  May 21, 2020   Jul CAHN
>D>     +   SUNOVION PHARMS INC   10MG                               N210875  001  May 21, 2020   Jul CAHN
```

FILM;SUBLINGUAL
KYNMOBI

>D>		+		15MG	N210875	002	May 21, 2020	Jul CAHN
>D>		+		20MG	N210875	003	May 21, 2020	Jul CAHN
>D>		+		25MG	N210875	004	May 21, 2020	Jul CAHN
>D>		+!		30MG	N210875	005	May 21, 2020	Jul CAHN

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
IOPIDINE

	AT	+!	HARROW EYE	EQ 0.5% BASE	N020258	001	Jul 30, 1993	May CAHN
		+!		EQ 1% BASE	N019779	001	Dec 31, 1987	May CAHN

APREMILAST

TABLET;ORAL
APREMILAST

>A>	AB		ANNORA	10MG	A211878	001	Jul 26, 2023	Jul NEWA
>A>	AB			20MG	A211878	002	Jul 26, 2023	Jul NEWA
>A>	AB			30MG	A211878	003	Jul 26, 2023	Jul NEWA
>A>	AB		DR REDDYS	10MG	A211756	001	Jul 14, 2023	Jul NEWA
>A>	AB			20MG	A211756	002	Jul 14, 2023	Jul NEWA
>A>	AB			30MG	A211756	003	Jul 14, 2023	Jul NEWA
	AB		SHILPA	10MG	A211774	001	Apr 07, 2023	Mar NEWA
	AB			20MG	A211774	002	Apr 07, 2023	Mar NEWA
	AB			30MG	A211774	003	Apr 07, 2023	Mar NEWA
		@	TEVA PHARMS USA INC	10MG	A211897	001	Aug 18, 2022	Feb DISC
		@		20MG	A211897	002	Aug 18, 2022	Feb DISC
		@		30MG	A211897	003	Aug 18, 2022	Feb DISC

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION
ARFORMOTEROL TARTRATE

	AN		RITEDOSE CORP	EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Feb CMFD

ARGATROBAN

INJECTABLE;INJECTION
ARGATROBAN

>A>	AP		GLAND PHARMA LTD	50MG/50ML (1MG/ML)	A217848	001	Jul 31, 2023	Jul NEWA
	AP	+!	SANDOZ	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	May CAHN

ARIPIPRAZOLE

SOLUTION;ORAL
ARIPIPRAZOLE

	AA		CHARTWELL RX	1MG/ML	A215595	001	Oct 25, 2022	May CAHN

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILIFY ASIMTUFII

		+	OTSUKA	720MG/2.4ML (300MG/ML)	N217006	001	Apr 27, 2023	Apr NEWA
		+!		960MG/3.2ML (300MG/ML)	N217006	002	Apr 27, 2023	Apr NEWA

ARMODAFINIL

TABLET;ORAL
ARMODAFINIL

		@	COREPHARMA	50MG	A201514	001	Mar 25, 2019	Feb CAHN
		@		150MG	A201514	002	Mar 25, 2019	Feb CAHN
		@		250MG	A201514	003	Mar 25, 2019	Feb CAHN

ARSENIC TRIOXIDE

INJECTABLE;INJECTION
ARSENIC TRIOXIDE

	AP		ORBICULAR	1MG/ML	A217413	001	Apr 20, 2023	Apr NEWA
	AP			2MG/ML	A217413	002	Apr 20, 2023	Apr NEWA
	AP		PENN LIFE	1MG/ML	A209873	001	May 06, 2019	May CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

		@	DR REDDYS LABS SA	325MG;50MG;40MG;30MG	A203335	001	Oct 30, 2015	Apr CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

@	CHARTWELL RX	325MG;200MG	A089594	001	Mar 31, 1989	Mar CAHN

ASPIRIN; METHOCARBAMOL

TABLET;ORAL

ROBAXISAL

+ @	ROBINS AH	325MG;400MG	N012281	001		Mar CRLD

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

@	DR REDDYS LABS SA	325MG;4.8355MG	A091670	001	Mar 16, 2011	Apr CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

@	AUROBINDO PHARMA USA	50MG;25MG	A074203	001	Oct 31, 1993	Apr CAHN
@		100MG;25MG	A074203	002	Oct 31, 1993	Apr CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	10MG	A079017	007	Apr 05, 2023	Mar NEWA

ATORVASTATIN CALCIUM

SUSPENSION;ORAL

ATORVALIQ

+!	CMP DEV LLC	20MG/5ML	N213260	001	Feb 01, 2023	Feb NEWA

TABLET;ORAL

ATORVASTATIN CALCIUM

@	BIOCON PHARMA	EQ 10MG BASE	A216436	001	Nov 23, 2022	May DISC
@		EQ 20MG BASE	A216436	002	Nov 23, 2022	May DISC
@		EQ 40MG BASE	A216436	003	Nov 23, 2022	May DISC
@		EQ 80MG BASE	A216436	004	Nov 23, 2022	May DISC
@	LEPU PHARM	EQ 10MG BASE	A216848	001	Nov 03, 2022	Apr DISC
@		EQ 20MG BASE	A216848	002	Nov 03, 2022	Apr DISC
@		EQ 40MG BASE	A216848	003	Nov 03, 2022	Apr DISC
@		EQ 80MG BASE	A216848	004	Nov 03, 2022	Apr DISC

ATROPINE

SOLUTION;INTRAMUSCULAR

ATROPEN

+ @	MMT	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	May DISC
+ @		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	May DISC
+ @		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	May DISC
+ @		EQ 2MG SULFATE/0.7ML	N017106	001		May DISC

ATROPINE SULFATE

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

>D> AT	+! AKORN	1%	N206289	001	Jul 18, 2014	Jul CHRS
>A> AT	+	1%	N206289	001	Jul 18, 2014	Jul CHRS
>D> AT	AMNEAL	1%	A214752	001	Jul 14, 2022	Jul CHRS
>A> AT	!	1%	A214752	001	Jul 14, 2022	Jul CHRS

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@	UPSHER SMITH LABS	0.025MG;2.5MG	A210571	001	Aug 31, 2018	Jun DISC

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP	JIANGSU HANSOH PHARM	100MG/VIAL	A215905	001	Jun 28, 2023	Jun NEWA

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

FINACEA

	+!	LEO PHARMA AS	15%	N207071	001	Jul 29, 2015	Feb CTEC

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AB		BIONPHARMA	0.137MG/SPRAY	A090176	001	Jul 28, 2015	Jun CAHN

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

>A>	AB	HAINAN POLY	EQ 100MG BASE/5ML	A217036	001	Jul 27, 2023	Jul NEWA
>A>	AB		EQ 200MG BASE/5ML	A217036	002	Jul 27, 2023	Jul NEWA

TABLET;ORAL

AZITHROMYCIN

		@ ACI	EQ 250MG BASE	A215772	001	Jul 15, 2022	Jan DISC
		@	EQ 500MG BASE	A215773	001	Jul 12, 2022	Jan DISC
		@ AUROBINDO PHARMA USA	EQ 600MG BASE	A065360	001	Jan 08, 2007	May CAHN

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

		@ AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213	001	Jul 25, 2012	Jan DISC
	!	BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068	001	Oct 30, 1995	Jan CTEC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

		@ AKORN	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065088	001	Feb 06, 2004	Jan DISC

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP		RUBICON	0.5MG/ML	A217324	001	Feb 22, 2023	Feb NEWA
AP			1MG/ML	A217324	002	Feb 22, 2023	Feb NEWA
AP			2MG/ML	A217324	003	Feb 22, 2023	Feb NEWA

SUSPENSION;ORAL

BACLOFEN

AB		SLAYBACK PHARMA LLC	25MG/5ML	A217252	001	Jun 08, 2023	Jun NFTG

FLEQSUVY

AB	+!	AZURITY	25MG/5ML	N215602	001	Feb 04, 2022	Jun CFTG

TABLET;ORAL

BACLOFEN

AB		UNICHEM	5MG	A212067	003	Mar 09, 2023	Mar NEWA

BALOXAVIR MARBOXIL

TABLET;ORAL

XOFLUZA

	+ @	GENENTECH INC	20MG	N210854	001	Oct 24, 2018	Jun DISC
	+		40MG	N210854	002	Oct 24, 2018	Jun CHRS
	+!		80MG	N210854	003	Mar 18, 2021	Jun CHRS

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

		@ DASH PHARMS NATCO	750MG	A077807	001	Dec 28, 2007	Feb CAHN
AB		ZYDUS	750MG	A217592	001	Jun 08, 2023	Jun NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB		COREPHARMA	5MG	A077128	001	Mar 08, 2006	Mar CAHN
AB			10MG	A077128	002	Mar 08, 2006	Mar CAHN
AB			20MG	A077128	003	Mar 08, 2006	Mar CAHN
AB			40MG	A077128	004	Mar 08, 2006	Mar CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX	5MG;6.25MG	A078794	001	Aug 21, 2014	May CMFD
AB		10MG;12.5MG	A078794	002	Aug 21, 2014	May CMFD
AB		20MG;12.5MG	A078794	003	Aug 21, 2014	May CMFD
AB		20MG;25MG	A078794	004	Aug 21, 2014	May CMFD

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	APOTEX	25MG/VIAL	A204230	001	Jun 05, 2023	May NEWA
AP		100MG/VIAL	A204230	002	Jun 05, 2023	May NEWA
AP	BRECKENRIDGE	25MG/VIAL	A205447	001	Feb 14, 2023	Feb NEWA
AP		100MG/VIAL	A205447	002	Feb 14, 2023	Feb NEWA
AP	EUGIA PHARMA	25MG/VIAL	A214739	001	Jun 05, 2023	May NEWA
AP		100MG/VIAL	A214739	002	Jun 05, 2023	May NEWA
AP	KINDOS	25MG/VIAL	A211001	001	Jun 05, 2023	May NEWA
AP		100MG/VIAL	A211001	002	Jun 05, 2023	May NEWA
	@ MYLAN LABS LTD	25MG/VIAL	A204104	001	Apr 28, 2023	May DISC
AP		25MG/VIAL	A204104	001	Apr 28, 2023	Apr NEWA
	@	100MG/VIAL	A204104	002	Apr 28, 2023	May DISC
AP		100MG/VIAL	A204104	002	Apr 28, 2023	Apr NEWA
AP	NANG KUANG PHARM CO	25MG/VIAL	A206554	001	Jun 07, 2023	May NEWA
AP		100MG/VIAL	A206554	002	Jun 07, 2023	May NEWA

SOLUTION;INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

+ @	HOSPIRA	25MG/ML (25MG/ML)	N211530	001	Dec 15, 2022	Jan DISC
+ @		100MG/4ML (25MG/ML)	N211530	002	Dec 15, 2022	Jan DISC
+ @		200MG/8ML (25MG/ML)	N211530	003	Dec 15, 2022	Jan DISC

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA	CHARTWELL RX	100MG	A040682	001	Jul 30, 2007	Feb CAHN
AA		200MG	A040682	002	Jul 30, 2007	Feb CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

BENZACLIN

+ @	BAUSCH	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Feb DISC

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB !	GLENMARK PHARMS	5%;EQ 1% BASE	A209252	001	Mar 14, 2019	Feb CHRS

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

AT	ALEMBIC	1.5%	A214588	001	Apr 05, 2023	Mar NEWA

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB	HIKMA	3MG/ML;EQ 3MG BASE/ML	A077838	001	Jan 17, 2023	Jan NEWA

BETAMETHASONE DIPROPIONATE

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

@	PAI HOLDINGS PHARM	EQ 0.05% BASE	A206389	001	Feb 13, 2018	May DISC

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

@	PAI HOLDINGS PHARM	EQ 0.05% BASE	A206118	001	Nov 09, 2017	May DISC

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	GLENMARK PHARMS LTD	0.064%;0.005%	A214688	001	Mar 21, 2023	Mar NFTG

ENSTILAR

AB +!	LEO PHARMA AS	0.064%;0.005%	N207589	001	Oct 16, 2015	Mar CFTG

```
        OINTMENT;TOPICAL
          CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
          @ TOLMAR                0.064%;0.005%                     A201615  001  Jan 14, 2013   Feb DISC
        SUSPENSION;TOPICAL
          CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
    AB      COSETTE               0.064%;0.005%                     A210765  001  May 11, 2020   Feb CAHN

      BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE
        CREAM;TOPICAL
          CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE
    AB  !   TARO                   EQ 0.05% BASE;1%                  A075673  001  May 29, 2001   May CHRS
          LOTRISONE
      + @ ORGANON                 EQ 0.05% BASE;1%                  N018827  001  Jul 10, 1984   May DISC

      BETAMETHASONE VALERATE
        AEROSOL, FOAM;TOPICAL
          BETAMETHASONE VALERATE
    AB      XIROMED               0.12%                             A210639  001  Apr 18, 2023   Apr NEWA

      BETAXOLOL HYDROCHLORIDE
        SOLUTION/DROPS;OPHTHALMIC
          BETAXOLOL HYDROCHLORIDE
          @ AKORN                 EQ 0.5% BASE                      A075386  001  Jun 30, 2000   Feb DISC

      BETHANECHOL CHLORIDE
        TABLET;ORAL
          BETHANECHOL CHLORIDE
    AA      CHARTWELL RX          5MG                               A040728  002  Oct 26, 2007   May CAHN
    AA                            10MG                              A040728  003  Oct 26, 2007   May CAHN
    AA                            25MG                              A040728  004  Oct 26, 2007   May CAHN
    AA                            50MG                              A040728  001  Oct 26, 2007   May CAHN

      BEXAGLIFLOZIN
        TABLET;ORAL
          BRENZAVVY
      +!  THERACOSBIO             20MG                              N214373  001  Jan 20, 2023   Jan NEWA

      BICALUTAMIDE
        TABLET;ORAL
          BICALUTAMIDE
    AB      PINNACLE LIFE SCI     50MG                              A079089  001  Jul 06, 2009   Jan CAHN

      BIMATOPROST
        IMPLANT;OPHTHALMIC
          DURYSTA
      +!  ABBVIE                  10MCG                             N211911  001  Mar 04, 2020   Jan CAHN
        SOLUTION/DROPS;OPHTHALMIC
          LUMIGAN
>A>   +!  ABBVIE                  0.01%                             N022184  001  Aug 31, 2010   Jul CAHN
>A>   + @                         0.03%                             N021275  001  Mar 16, 2001   Jul CAHN
>D>   +!  ALLERGAN                0.01%                             N022184  001  Aug 31, 2010   Jul CAHN
>D>   + @                         0.03%                             N021275  001  Mar 16, 2001   Jul CAHN

      BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE
        CAPSULE;ORAL
          BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE
    AB      PAR PHARM             140MG;125MG;125MG                 A205770  001  Mar 06, 2023   Feb NFTG
    AB      RICONPHARMA LLC       140MG;125MG;125MG                 A217511  001  Jul 03, 2023   Jun NEWA
          PYLERA
    AB  +!  ABBVIE                140MG;125MG;125MG                 N050786  001  Sep 28, 2006   Mar CAHN
    AB  +!  ALLERGAN              140MG;125MG;125MG                 N050786  001  Sep 28, 2006   Feb CFTG

      BISOPROLOL FUMARATE
        TABLET;ORAL
          BISOPROLOL FUMARATE
    AB      ALEMBIC               5MG                               A204891  001  Jan 11, 2017   Feb CAHN
    AB                            10MG                              A204891  002  Jan 11, 2017   Feb CAHN
          @ DASH PHARMS NATCO     5MG                               A075831  001  Dec 14, 2005   Feb CAHN
          @                       10MG                              A075831  002  Dec 14, 2005   Feb CAHN
>A> AB      PRINSTON INC          5MG                               A217368  001  Jul 14, 2023   Jul NEWA
>A> AB                            10MG                              A217368  002  Jul 14, 2023   Jul NEWA
```

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

	@ ACCORD HLTHCARE	3.5MG/VIAL	A204405	001	Jul 26, 2022	Feb DISC

POWDER;INTRAVENOUS

BORTEZOMIB

	@ DR REDDYS	3.5MG/VIAL	N206927	001	Oct 04, 2019	May DISC
	@ FRESENIUS KABI USA	3.5MG/VIAL	N205004	001	Nov 06, 2017	May DISC

SOLUTION;INTRAVENOUS

BORTEZOMIB

+	@ ACCORD HLTHCARE	2.5MG/ML (2.5MG/ML)	N215441	001	Jul 26, 2022	Feb DISC
+	@	3.5MG/1.4ML (2.5MG/ML)	N215441	002	Jul 26, 2022	Feb DISC

BOSENTAN

TABLET;ORAL

BOSENTAN

	@ PAR PHARM INC	62.5MG	A205699	001	Apr 26, 2019	Apr DISC
	@	125MG	A205699	002	Apr 26, 2019	Apr DISC

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION

BRETYLIUM TOSYLATE

	@ BRECKENRIDGE	50MG/ML	A204386	001	Dec 21, 2018	Feb DISC

BREXPIPRAZOLE

TABLET;ORAL

BREXPIPRAZOLE

	@ AMNEAL	0.25MG	A213562	001	Jan 31, 2023	Mar DISC
AB		0.25MG	A213562	001	Jan 31, 2023	Jan NEWA
	@	0.5MG	A213562	002	Jan 31, 2023	Mar DISC
AB		0.5MG	A213562	002	Jan 31, 2023	Jan NEWA
	@	1MG	A213562	003	Jan 31, 2023	Mar DISC
AB		1MG	A213562	003	Jan 31, 2023	Jan NEWA
	@	2MG	A213562	004	Jan 31, 2023	Mar DISC
AB		2MG	A213562	004	Jan 31, 2023	Jan NEWA
	@	3MG	A213562	005	Jan 31, 2023	Mar DISC
AB		3MG	A213562	005	Jan 31, 2023	Jan NEWA
	@	4MG	A213562	006	Jan 31, 2023	Mar DISC
AB		4MG	A213562	006	Jan 31, 2023	Jan NEWA
	@ LUPIN LTD	0.25MG	A213512	001	Mar 17, 2023	May DISC
AB		0.25MG	A213512	001	Mar 17, 2023	Mar NEWA
	@	0.5MG	A213512	002	Mar 17, 2023	May DISC
AB		0.5MG	A213512	002	Mar 17, 2023	Mar NEWA
	@	1MG	A213512	003	Mar 17, 2023	May DISC
AB		1MG	A213512	003	Mar 17, 2023	Mar NEWA
	@	2MG	A213512	004	Mar 17, 2023	May DISC
AB		2MG	A213512	004	Mar 17, 2023	Mar NEWA
	@	3MG	A213512	005	Mar 17, 2023	May DISC
AB		3MG	A213512	005	Mar 17, 2023	Mar NEWA
	@	4MG	A213512	006	Mar 17, 2023	May DISC
AB		4MG	A213512	006	Mar 17, 2023	Mar NEWA
	@ TEVA PHARMS USA INC	0.25MG	A213692	001	Aug 11, 2022	Feb DISC
	@	0.5MG	A213692	002	Aug 11, 2022	Feb DISC
	@	1MG	A213692	003	Aug 11, 2022	Feb DISC
	@	2MG	A213692	004	Aug 11, 2022	Feb DISC
	@	3MG	A213692	005	Aug 11, 2022	Feb DISC
	@	4MG	A213692	006	Aug 11, 2022	Feb DISC
	@ ZYDUS PHARMS	0.25MG	A213660	001	Jan 10, 2023	Jun DISC
	@	0.5MG	A213660	002	Jan 10, 2023	Jun DISC
	@	1MG	A213660	003	Jan 10, 2023	Jun DISC
	@	2MG	A213660	004	Jan 10, 2023	Jun DISC
	@	3MG	A213660	005	Jan 10, 2023	Jun DISC
	@	4MG	A213660	006	Jan 10, 2023	Jun DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

>A> AB	ALEMBIC	0.1%	A216909	001	Aug 01, 2023	Jul NEWA
AT		0.15%	A215225	001	Mar 29, 2023	Mar NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

>D>	AB	AKORN	0.2%;EQ 0.5% BASE	A091086	001	Oct 31, 2022	Jul CAHN
>A>	AB	SENTISS	0.2%;EQ 0.5% BASE	A091086	001	Oct 31, 2022	Jul CAHN

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

BRINZOLAMIDE

>A>	AB	PADAGIS US	1%	A211914	001	Jul 28, 2023	Jul NEWA

BRIVARACETAM

TABLET;ORAL

BRIVARACETAM

		@ AUROBINDO PHARMA LTD	50MG	A214848	001	Jan 06, 2023	Mar DISC
		@	100MG	A214848	002	Jan 06, 2023	Mar DISC
		@ LUPIN LTD	10MG	A214918	001	Dec 20, 2022	Mar DISC
		@	25MG	A214918	002	Dec 20, 2022	Mar DISC
		@	50MG	A214918	003	Dec 20, 2022	Mar DISC
		@	75MG	A214918	004	Dec 20, 2022	Mar DISC
		@	100MG	A214918	005	Dec 20, 2022	Mar DISC

BRIVIACT

	+	UCB INC	10MG	N205836	001	May 12, 2016	Mar CTEC
	+		25MG	N205836	002	May 12, 2016	Mar CTEC
	+		50MG	N205836	003	May 12, 2016	Mar CTEC
	+		75MG	N205836	004	May 12, 2016	Mar CTEC
	+!		100MG	N205836	005	May 12, 2016	Mar CTEC

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

>D>	AT2	AKORN	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jul CAHN
	AT2		EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jun CHRS
	AT2	! ALEMBIC	EQ 0.09% ACID	A210560	001	Jun 21, 2019	Jun CHRS
>A>	AT2	SENTISS	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jul CAHN

BROMOCRIPTINE MESYLATE

TABLET;ORAL

BROMOCRIPTINE MESYLATE

		@ AUROBINDO PHARMA USA	EQ 2.5MG BASE	A076962	001	Sep 24, 2004	Apr CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

AA	+	WOCKHARDT BIO AG	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Jun CHRS
AA	+!		2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Jun CRLD

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

		@ BIONPHARMA	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	Jun CAHN
		@ BRECKENRIDGE	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	Jan DISC
AA	!	PADAGIS US	2MG/5ML;10MG/5ML;30MG/5ML	A205292	001	Jul 15, 2014	Jun CHRS

BUDESONIDE

AEROSOL, FOAM;RECTAL

BUDESONIDE

AB		PADAGIS ISRAEL	2MG/ACTUATION	A215328	001	Apr 12, 2023	Mar NFTG

UCERIS

AB	+!	SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Mar CFTG

BUDESONIDE; FORMOTEROL FUMARATE

AEROSOL, METERED;INHALATION

SYMBICORT AEROSPHERE

	+!	ASTRAZENECA	0.16MG/INH;0.0048MG/INH	N216579	001	Apr 28, 2023	Apr NEWA

BUMETANIDE

TABLET;ORAL

BUMETANIDE

>A>	AB	TARO	0.5MG	A213458	001	Jul 24, 2023	Jul NEWA
>A>	AB		1MG	A213458	002	Jul 24, 2023	Jul NEWA
>A>	AB		2MG	A213458	003	Jul 24, 2023	Jul NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

AP	KINDOS	0.25%	A216039	001	Jun 23, 2023	Jun NEWA
AP		0.5%	A216039	002	Jun 23, 2023	Jun NEWA
AP	STERISCIENCE	0.25%	A091503	001	Oct 18, 2011	Jun CMFD
AP		0.5%	A091503	002	Oct 18, 2011	Jun CMFD

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

AP	STERISCIENCE	0.25%	A091487	002	Oct 18, 2011	Jun CMFD
AP		0.5%	A091487	001	Oct 18, 2011	Jun CMFD
AP		0.75%	A091487	003	Oct 18, 2011	Jun CMFD

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUPRENORPHINE

AB	ALVOGEN	7.5MCG/HR	A207490	005	Mar 21, 2023	Mar NEWA

SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

BRIXADI

+	BRAEBURN	8MG/0.16ML (50MG/ML)	N210136	001	May 23, 2023	May NEWA
+		16MG/0.32ML (50MG/ML)	N210136	002	May 23, 2023	May NEWA
+		24MG/0.48ML (50MG/ML)	N210136	003	May 23, 2023	May NEWA
+		32MG/0.64ML (50MG/ML)	N210136	004	May 23, 2023	May NEWA
+		64MG/0.18ML (356MG/ML)	N210136	005	May 23, 2023	May NEWA
+		96MG/0.27ML (356MG/ML)	N210136	006	May 23, 2023	May NEWA
+!		128MG/0.36ML (356MG/ML)	N210136	007	May 23, 2023	May NEWA

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPRENEX

>D>						
>D> AP	+! INDIVIOR	EQ 0.3MG BASE/ML	N018401	001		Jul DISC
>A>	+ @	EQ 0.3MG BASE/ML	N018401	001		Jul DISC

BUPRENORPHINE HYDROCHLORIDE

>D> AP	PAR STERILE PRODUCTS	EQ 0.3MG BASE/ML	A206586	001	Jul 28, 2015	Jul CHRS
>A> AP	!	EQ 0.3MG BASE/ML	A206586	001	Jul 28, 2015	Jul CHRS

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

@	DR REDDYS LABS SA	EQ 2MG BASE;EQ 0.5MG BASE	A206953	001	Jul 17, 2020	Apr CAHN
@		EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	Apr CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	ANNORA PHARMA	100MG	A216800	001	May 31, 2023	May NEWA
AB1		150MG	A216800	002	May 31, 2023	May NEWA
AB1		200MG	A216800	003	May 31, 2023	May NEWA

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	ZYDUS PHARMS	7.5MG	A078888	005	Mar 21, 2023	Mar NEWA

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

@	AM REGENT	6MG/ML	A202259	001	Dec 22, 2015	Jan DISC
@	ARTHUR GRP	6MG/ML	A205106	001	Sep 21, 2018	Mar DISC

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

>D>						
>D>	+! MYLAN	1%	N020524	001	Oct 18, 1996	Jul DISC
>A>	+ @	1%	N020524	001	Oct 18, 1996	Jul DISC

CABAZITAXEL

SOLUTION;INTRAVENOUS

CABAZITAXEL

+!	ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Feb CMFD
AP	DR REDDYS	60MG/1.5ML (40MG/ML)	A207718	001	Feb 10, 2023	Feb NEWA
>D> AP	MYLAN LABS LTD	60MG/1.5ML (40MG/ML)	A207381	001	Jul 05, 2023	Jul DISC

```
          SOLUTION;INTRAVENOUS
            CABAZITAXEL
>A>         @                       60MG/1.5ML (40MG/ML)          A207381  001  Jul 05, 2023   Jul DISC
    AP                              60MG/1.5ML (40MG/ML)          A207381  001  Jul 05, 2023   Jun NEWA
          +!  SANDOZ                45MG/4.5ML (10MG/ML)          N208715  001  Jan 05, 2023   Jan NEWA
          +!                        60MG/6ML (10MG/ML)            N208715  002  Jan 05, 2023   Jan NEWA

        CABOZANTINIB S-MALATE
          CAPSULE;ORAL
            COMETRIQ
          +   EXELIXIS              EQ 20MG BASE                  N203756  001  Nov 29, 2012   Jun CHRS
          +!                        EQ 80MG BASE                  N203756  002  Nov 29, 2012   Jun CHRS

        CALCIPOTRIENE
          CREAM;TOPICAL
            CALCIPOTRIENE
            @ TOLMAR                0.005%                        A200935  001  May 30, 2012   Feb DISC
          SOLUTION;TOPICAL
            CALCIPOTRIENE
>A>         @ CHARTWELL RX          0.005%                        A077029  001  Nov 20, 2009   Jul CAHN
>A> AT                              0.005%                        A207163  001  Dec 26, 2017   Jul CAHN
    AT    !   COSETTE               0.005%                        A078468  001  Mar 24, 2011   Feb CHRS
>D> AT        NOVEL LABS INC        0.005%                        A207163  001  Dec 26, 2017   Jul CAHN
>D>         @ TOLMAR                0.005%                        A077029  001  Nov 20, 2009   Jul CAHN
            @                       0.005%                        A077029  001  Nov 20, 2009   Feb DISC

        CALCITRIOL
          CAPSULE;ORAL
            CALCITRIOL
    AB    !   STRIDES PHARMA        0.5MCG                        A091356  002  Dec 12, 2014   May CHRS
            ROCALTROL
    AB    +   VALIDUS PHARMS        0.5MCG                        N018044  002                 May CHRS
          SOLUTION;ORAL
            CALCITRIOL
>D> AA        ELYSIUM               1MCG/ML                       A209798  001  Nov 21, 2018   Jul CAHN
>A> AA        PATRIN                1MCG/ML                       A203973  001  Jul 28, 2023   Jul NEWA
>A> AA        RISING                1MCG/ML                       A209798  001  Nov 21, 2018   Jul CAHN

        CALCIUM ACETATE
          CAPSULE;ORAL
            CALCIUM ACETATE
    AB        SQUARE PHARMS         667MG                         A217205  001  Mar 13, 2023   Mar NEWA
          SOLUTION;ORAL
            PHOSLYRA
          + @ FRESENIUS MEDCL       667MG/5ML                     N022581  001  Apr 18, 2011   Jun DISC

        CANDESARTAN CILEXETIL
          TABLET;ORAL
            CANDESARTAN CILEXETIL
    AB        ZYDUS LIFESCIENCES    4MG                           A091390  001  Aug 23, 2017   May CAHN
    AB                              8MG                           A091390  002  Aug 23, 2017   May CAHN
    AB                              16MG                          A091390  003  Aug 23, 2017   May CAHN
    AB                              32MG                          A091390  004  Aug 23, 2017   May CAHN

        CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE
          TABLET;ORAL
            CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
    AB        ZYDUS LIFESCIENCES    16MG;12.5MG                   A203466  001  Nov 27, 2017   May CAHN
    AB                              32MG;12.5MG                   A203466  002  Nov 27, 2017   May CAHN
    AB                              32MG;25MG                     A203466  003  Nov 27, 2017   May CAHN

>A>     CANTHARIDIN
>A>       SOLUTION;TOPICAL
>A>         YCANTH
>A>       +!  VERRICA PHARMS        0.7%                          N212905  001  Jul 21, 2023   Jul NEWA
```

CAPECITABINE

TABLET;ORAL

XELODA

AB	+	CHEPLAPHARM	150MG	N020896	001	Apr 30, 1998	Apr CAHN
AB	+!		500MG	N020896	002	Apr 30, 1998	Apr CAHN

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

	@	AUROBINDO PHARMA USA	12.5MG	A074434	001	Feb 13, 1996	May CAHN
	@		25MG	A074434	002	Feb 13, 1996	May CAHN
	@		50MG	A074434	003	Feb 13, 1996	May CAHN
	@		100MG	A074434	004	Feb 13, 1996	May CAHN
AB		CHANGZHOU PHARM	12.5MG	A214442	001	Jan 27, 2023	Jan NEWA
AB			25MG	A214442	002	Jan 27, 2023	Jan NEWA
AB			50MG	A214442	003	Jan 27, 2023	Jan NEWA
AB			100MG	A214442	004	Jan 27, 2023	Jan NEWA
AB		COREPHARMA	12.5MG	A074737	001	Oct 28, 1998	Mar CAHN
AB			25MG	A074737	002	Oct 28, 1998	Mar CAHN
AB			50MG	A074737	003	Oct 28, 1998	Mar CAHN
AB			100MG	A074737	004	Oct 28, 1998	Mar CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

		RISING	25MG;15MG	A074896	001	Dec 29, 1997	May CMFD
	!		25MG;25MG	A074896	002	Dec 29, 1997	May CMFD
	!		50MG;15MG	A074896	004	Dec 29, 1997	May CMFD
			50MG;25MG	A074896	003	Dec 29, 1997	May CMFD

CARBAMAZEPINE

SUSPENSION;ORAL

CARBAMAZEPINE

AB		CHARTWELL RX	100MG/5ML	A075714	001	Jun 05, 2002	Jan CAHN

TABLET;ORAL

CARBAMAZEPINE

	@	RK PHARMA	200MG	A214328	001	Aug 16, 2021	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		AJANTA PHARMA LTD	100MG	A216193	001	Mar 24, 2023	Mar NEWA
AB			200MG	A216193	002	Mar 24, 2023	Mar NEWA
AB			400MG	A216193	003	Mar 24, 2023	Mar NEWA
AB		RICONPHARMA LLC	100MG	A216404	001	Dec 02, 2022	Jun CMFD
AB			200MG	A216404	002	Dec 02, 2022	Jun CMFD
AB			400MG	A216404	003	Dec 02, 2022	Jun CMFD
AB		SCIECURE PHARMA INC	100MG	A216235	001	Mar 02, 2023	Feb NEWA
AB			200MG	A216235	002	Mar 02, 2023	Feb NEWA
AB			400MG	A216235	003	Mar 02, 2023	Feb NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

AB	!	SCIEGEN PHARMS INC	50MG;200MG	A214091	002	Oct 05, 2021	May CHRS
AB		SUN PHARM INDS	50MG;200MG	A077828	002	Aug 23, 2007	May CHRS

TABLET, ORALLY DISINTEGRATING;ORAL

CARBIDOPA AND LEVODOPA

		SUN PHARM	10MG;100MG	A078690	001	Jul 31, 2009	Apr CTEC
			25MG;100MG	A078690	002	Jul 31, 2009	Apr CTEC

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

AP		NOVAST LABS	450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	May CMFD
AP			600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	May CMFD

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

CARBOPROST TROMETHAMINE

AP		ALEMBIC	EQ 0.25MG BASE/ML	A217198	001	Jun 15, 2023	Jun NEWA
AP		CAPLIN	EQ 0.25MG BASE/ML	A216882	001	Feb 13, 2023	Feb NEWA
AP		EUGIA PHARMA	EQ 0.25MG BASE/ML	A216939	001	May 25, 2023	May NEWA

INJECTABLE;INJECTION
CARBOPROST TROMETHAMINE

>A>	AP		GLAND PHARMA LTD	EQ 0.25MG BASE/ML	A217657	001	Aug 07, 2023	Jul NEWA
	AP		SOLA PHARMS	EQ 0.25MG BASE/ML	A216824	001	May 19, 2023	Jun CAHN
>A>	AP		STERISCIENCE	EQ 0.25MG BASE/ML	A216897	001	Jul 25, 2023	Jul NEWA
	AP		WELDING	EQ 0.25MG BASE/ML	A216824	001	May 19, 2023	May NEWA

CARFILZOMIB

POWDER;INTRAVENOUS
KYPROLIS

		+	ONYX PHARMS AMGEN	10MG/VIAL	N202714	003	Jun 07, 2018	Jun CAHN
		+		30MG/VIAL	N202714	002	Jun 03, 2016	Jun CAHN
	AP	+!		60MG/VIAL	N202714	001	Jul 20, 2012	Jun CAHN

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL
CARIPRAZINE HYDROCHLORIDE

		@	ZYDUS	EQ 1.5MG BASE	A213984	001	Sep 09, 2022	May CAHN
		@		EQ 3MG BASE	A213984	002	Sep 09, 2022	May CAHN
		@		EQ 4.5MG BASE	A213984	003	Sep 09, 2022	May CAHN
		@		EQ 6MG BASE	A213984	004	Sep 09, 2022	May CAHN

VRAYLAR

		+!	ABBVIE	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Jan CAHN
		+		EQ 3MG BASE	N204370	002	Sep 17, 2015	Jan CAHN
		+		EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Jan CAHN
		+		EQ 6MG BASE	N204370	004	Sep 17, 2015	Jan CAHN

CARMUSTINE

INJECTABLE;INJECTION
CARMUSTINE

>D>	AP		ACCORD HLTHCARE	100MG/VIAL	A214117	001	Dec 27, 2022	Jul DISC
>A>		@		100MG/VIAL	A214117	001	Dec 27, 2022	Jul DISC
	AP			100MG/VIAL	A214117	001	Dec 27, 2022	Mar CTNA
	AP		MSN	100MG/VIAL	A214814	001	May 11, 2023	May NEWA
		@	MYLAN LABS LTD	100MG/VIAL	A215368	001	Mar 03, 2023	Mar DISC
	AP			100MG/VIAL	A215368	001	Mar 03, 2023	Feb NEWA
	AP		PENN LIFE	100MG/VIAL	A209278	001	Apr 02, 2019	May CAHN

CEFAZOLIN SODIUM

POWDER;INTRAVENOUS
CEFAZOLIN SODIUM

		+!	HQ SPCLT PHARMA	EQ 2GM BASE/VIAL	N211413	001	May 08, 2023	May NEWA

CEFOTAXIME SODIUM

INJECTABLE;INJECTION
CEFOTAXIME

		@	HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002	Mar DISC
		@		EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002	Mar DISC
		@		EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002	Mar DISC
		@		EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002	Mar DISC

CEFOTETAN DISODIUM

INJECTABLE;INJECTION
CEFOTAN

		+ @	PAI HOLDINGS PHARM	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	May DISC
		+ @		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	May DISC

CEFOTETAN

		!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007	May CTEC
		!		EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007	May CTEC

CEFTAROLINE FOSAMIL

POWDER;INTRAVENOUS
TEFLARO

		+!	ABBVIE	400MG/VIAL	N200327	001	Oct 29, 2010	May CAHN
		+!		600MG/VIAL	N200327	002	Oct 29, 2010	May CAHN

CEFTAZIDIME

INJECTABLE;INJECTION
CEFTAZIDIME

	AP	!	ACS DOBFAR	1GM/VIAL	A062640	002	Nov 20, 1985	May CHRS
	AP	!		2GM/VIAL	A062640	003	Nov 20, 1985	May CHRS
	AP	!		6GM/VIAL	A062640	004	Feb 03, 1992	May CHRS

```
          INJECTABLE;INJECTION
            FORTAZ
          + @ PAI HOLDINGS PHARM     500MG/VIAL                        N050578  001  Jul 19, 1985   May DISC
          + @                        1GM/VIAL                          N050578  002  Jul 19, 1985   May DISC
          + @                        2GM/VIAL                          N050578  003  Jul 19, 1985   May DISC
          + @                        6GM/VIAL                          N050578  004  Jul 19, 1985   May DISC
            TAZICEF
            @ HOSPIRA                500MG/VIAL                        A062662  001  Mar 06, 1986   May DISC
                                     500MG/VIAL                        A062662  001  Mar 06, 1986   May CTEC

        CEFUROXIME SODIUM
          INJECTABLE;INJECTION
            CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER
          + @ B BRAUN                EQ 750MG BASE/VIAL                N050780  001  Feb 21, 2001   Jun DISC
          +!                         EQ 750MG BASE/VIAL                N050780  001  Feb 21, 2001   May CTEC
          + @                        EQ 1.5GM BASE/VIAL                N050780  002  Feb 21, 2001   Jun DISC
            CEFUROXIME SODIUM
            @ ACS DOBFAR SPA         EQ 7.5GM BASE/VIAL                A064124  001  May 30, 1997   Jun DISC
    AP    !   HIKMA                  EQ 1.5GM BASE/VIAL                A065048  002  Jan 09, 2004   Jun CHRS
            @                        EQ 7.5GM BASE/VIAL                A065046  001  Jan 09, 2004   Jun DISC
            ZINACEF
          + @ PAI HOLDINGS PHARM     EQ 1.5GM BASE/VIAL                N050558  003  Oct 19, 1983   Jun DISC
          + @                        EQ 7.5GM BASE/VIAL                N050558  004  Oct 23, 1986   Jun DISC
          INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
            CEFUROXIME SODIUM
    AB    !   HIKMA                  EQ 750MG BASE/VIAL                A065048  001  Jan 09, 2004   Jun CHRS
            ZINACEF
          + @ PAI HOLDINGS PHARM     EQ 750MG BASE/VIAL                N050558  002  Oct 19, 1983   Jun DISC

        CELECOXIB
          CAPSULE;ORAL
            CELECOXIB
            @ MYLAN                  50MG                              A078857  001  May 30, 2014   Jun DISC
            @                        100MG                             A078857  002  Feb 11, 2015   Mar DISC
            @                        200MG                             A078857  003  Feb 11, 2015   Jun DISC
            @                        400MG                             A078857  004  Feb 11, 2015   Jun DISC
    AB        YABAO PHARM            100MG                             A212564  001  Apr 10, 2023   Mar NEWA
    AB                               200MG                             A212564  002  Apr 10, 2023   Mar NEWA
    AB                               400MG                             A212564  003  Apr 10, 2023   Mar NEWA
          SOLUTION;ORAL
            ELYXYB
          + @ SCILEX HLDG            25MG/ML                           N212157  001  May 05, 2020   Feb CAHN

        CETIRIZINE HYDROCHLORIDE
          SYRUP;ORAL
            CETIRIZINE HYDROCHLORIDE
    AA        BIONPHARMA             5MG/5ML                           A078488  001  Oct 06, 2008   Jun CAHN

        CETRORELIX ACETATE
          POWDER;SUBCUTANEOUS
            CETRORELIX ACETATE
>D> AP        AKORN                  EQ 0.25MG BASE/VIAL               A215737  001  Aug 12, 2022   Jul CAHN
>A> AP        TEVA PHARMS INC        EQ 0.25MG BASE/VIAL               A215737  001  Aug 12, 2022   Jul CAHN

        CEVIMELINE HYDROCHLORIDE
          CAPSULE;ORAL
            CEVIMELINE HYDROCHLORIDE
    AB        AUROBINDO PHARMA       30MG                              A215056  001  Apr 18, 2023   Apr NEWA
    AB        RUBICON                30MG                              A216682  001  Apr 06, 2023   Mar NEWA

        CHLORHEXIDINE GLUCONATE
          SOLUTION;DENTAL
            CHLORHEXIDINE GLUCONATE
    AT        CHARTWELL RX           0.12%                             A075006  001  Mar 03, 2004   Jan CAHN

        CHLORPROMAZINE HYDROCHLORIDE
          TABLET;ORAL
            CHLORPROMAZINE HYDROCHLORIDE
>A> AB        ALEMBIC                10MG                              A217350  001  Jul 18, 2023   Jul NEWA
>A> AB                               25MG                              A217350  002  Jul 18, 2023   Jul NEWA
>A> AB                               50MG                              A217350  003  Jul 18, 2023   Jul NEWA
>A> AB                               100MG                             A217350  004  Jul 18, 2023   Jul NEWA
```

TABLET;ORAL
CHLORPROMAZINE HYDROCHLORIDE

>A>	AB		200MG	A217350	005	Jul 18, 2023	Jul NEWA
	AB	AMNEAL PHARMS CO	10MG	A209755	001	Sep 10, 2018	Apr CTEC
	AB		25MG	A209755	002	Sep 10, 2018	Apr CTEC
	AB		50MG	A209755	003	Sep 10, 2018	Apr CTEC
	AB		100MG	A209755	004	Sep 10, 2018	Apr CTEC
	AB		200MG	A209755	005	Sep 10, 2018	Apr CTEC
>D>		@ APPCO	10MG	A213590	001	Aug 31, 2020	Jul CMFD
>A>	AB		10MG	A213590	001	Aug 31, 2020	Jul CMFD
>D>		@	25MG	A213590	002	Aug 31, 2020	Jul CMFD
>A>	AB		25MG	A213590	002	Aug 31, 2020	Jul CMFD
>D>		@	50MG	A213590	003	Aug 31, 2020	Jul CMFD
>A>	AB		50MG	A213590	003	Aug 31, 2020	Jul CMFD
>D>		@	100MG	A213590	004	Aug 31, 2020	Jul CMFD
>A>	AB		100MG	A213590	004	Aug 31, 2020	Jul CMFD
>D>		@	200MG	A213590	005	Aug 31, 2020	Jul CMFD
>A>	AB		200MG	A213590	005	Aug 31, 2020	Jul CMFD
>A>	AB	LUPIN	10MG	A213327	001	Jul 13, 2023	Jul NEWA
>A>	AB		25MG	A213327	002	Jul 13, 2023	Jul NEWA
>A>	AB		50MG	A213327	003	Jul 13, 2023	Jul NEWA
>A>	AB		100MG	A213327	004	Jul 13, 2023	Jul NEWA
>A>	AB		200MG	A213327	005	Jul 13, 2023	Jul NEWA

CHLORZOXAZONE

TABLET;ORAL
CHLORZOXAZONE

	AA	ACME LABS	500MG	A214365	001	Apr 27, 2023	Apr NEWA
	AB	APPCO	375MG	A212047	001	Jan 27, 2023	Jan NEWA
	AB		750MG	A212047	002	Jan 27, 2023	Jan NEWA
	AA	BELCHER	250MG	A215540	001	Jan 24, 2023	Jan NEWA
	AA	COREPHARMA	250MG	A214702	001	Apr 10, 2023	Mar NEWA
>A>	AA	GRAVITI PHARMS	250MG	A216925	001	Aug 09, 2023	Jul NEWA

CHOLINE C-11

INJECTABLE;INTRAVENOUS
CHOLINE C-11

>D>	AP	WA UNIV SCH MED	4-33.1mCi/ML	A208413	001	Jan 10, 2017	Jul DISC
>A>		@	4-33.1mCi/ML	A208413	001	Jan 10, 2017	Jul DISC

CICLOPIROX

SHAMPOO;TOPICAL
CICLOPIROX

		@ PAI HOLDINGS PHARM	1%	A209975	001	Apr 05, 2018	May DISC

SOLUTION;TOPICAL
CICLOPIROX

	AT	! PADAGIS US	8%	A077623	001	Sep 18, 2007	Jan CHRS

PENLAC

	+	@ VALEANT BERMUDA	8%	N021022	001	Dec 17, 1999	Jan DISC

CILOSTAZOL

TABLET;ORAL
CILOSTAZOL

		@ AUROBINDO PHARMA USA	50MG	A077019	001	Nov 23, 2004	Apr CAHN
		@	100MG	A077019	002	Nov 23, 2004	Apr CAHN
	AB	EPIC PHARMA LLC	50MG	A077022	002	Mar 11, 2005	Jun CMFD
	AB		100MG	A077022	001	Nov 23, 2004	Jun CMFD

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL
CIMETIDINE HYDROCHLORIDE

>D>	AA	XTTRIUM LABS INC	EQ 300MG BASE/5ML	A074757	001	Oct 17, 1997	Jul DISC
>A>		@	EQ 300MG BASE/5ML	A074757	001	Oct 17, 1997	Jul DISC
	AA		EQ 300MG BASE/5ML	A074757	001	Oct 17, 1997	Mar CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL
CINACALCET HYDROCHLORIDE

	AB	CHARTWELL RX	EQ 30MG BASE	A213325	001	May 18, 2020	Jun CAHN
	AB		EQ 60MG BASE	A213325	002	May 18, 2020	Jun CAHN
	AB		EQ 90MG BASE	A213325	003	May 18, 2020	Jun CAHN

CIPROFLOXACIN

FOR SUSPENSION;ORAL

CIPRO

AB	+	BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997	May CTEC
AB	+!		500MG/5ML	N020780	002	Sep 26, 1997	May CTEC

CIPROFLOXACIN

AB		CHARTWELL	250MG/5ML	A200563	001	Mar 05, 2014	May CMFD
AB			500MG/5ML	A200563	002	Mar 05, 2014	May CMFD

INJECTABLE, SUSPENSION;OTIC

OTIPRIO

	+ @	ALK ABELLO	6% (60MG/ML)	N207986	001	Dec 10, 2015	Jan DISC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

	@	AKORN	EQ 0.3% BASE	A076555	001	Dec 11, 2008	Feb DISC

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB		AMNEAL	EQ 100MG BASE	A075939	001	Mar 03, 2005	Jun CMFD
AB			EQ 250MG BASE	A075939	002	Jun 09, 2004	Jun CMFD
AB			EQ 500MG BASE	A075939	003	Jun 09, 2004	Jun CMFD
AB			EQ 750MG BASE	A075939	004	Jun 09, 2004	Jun CMFD

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

	@	RISING	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007	Jun CAHN
	@		425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007	Jun CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP		CAPLIN	EQ 2MG BASE/ML	A217725	001	Jun 09, 2023	Jun NEWA
AP			EQ 10MG BASE/ML	A217725	002	Jun 09, 2023	Jun NEWA
AP		HIKMA	EQ 2MG BASE/ML	A203079	001	Apr 19, 2023	Apr NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CELEXA

AB	+	ABBVIE	EQ 10MG BASE	N020822	001	Apr 27, 2000	Feb CAHN
AB	+		EQ 20MG BASE	N020822	002	Jul 17, 1998	Feb CAHN
AB	+!		EQ 40MG BASE	N020822	003	Jul 17, 1998	Feb CAHN
	@		EQ 60MG BASE	N020822	004	Jul 17, 1998	Feb CAHN

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

		SANDOZ	125MG/5ML	A065283	002	Sep 04, 2007	May CTEC
	!		250MG/5ML	A065283	003	Sep 04, 2007	May CTEC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB		GLENMARK PHARMS LTD	EQ 75MG BASE	A216957	001	Mar 10, 2023	Mar NEWA
AB			EQ 150MG BASE	A216957	002	Mar 10, 2023	Mar NEWA
AB			EQ 300MG BASE	A216957	003	Mar 10, 2023	Mar NEWA

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA		CHARTWELL RX	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Feb CAHN

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

CLINDAMYCIN PHOSPHATE

AT	!	PADAGIS ISRAEL	1%	A090785	001	Mar 31, 2010	Jun CHRS

EVOCLIN

	+ @	MYLAN	1%	N050801	001	Oct 22, 2004	Jun DISC

INJECTABLE;INJECTION
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

AP	HIKMA	EQ 6MG BASE/ML	A214401	001	Apr 05, 2023	Mar NEWA
AP		EQ 12MG BASE/ML	A214401	002	Apr 05, 2023	Mar NEWA
AP		EQ 18MG BASE/ML	A214401	003	Apr 05, 2023	Mar NEWA

SOLUTION;TOPICAL
CLINDAMYCIN PHOSPHATE

AT	CHARTWELL RX	EQ 1% BASE	A209846	001	Feb 08, 2018	May CAHN
	@ XTTRIUM LABS INC	EQ 1% BASE	A063304	001	Jul 15, 1997	Jan CAHN

CLOBAZAM

SUSPENSION;ORAL
CLOBAZAM

	@ ACCORD HLTHCARE	2.5MG/ML	A216008	001	Sep 06, 2022	Mar DISC
	@ UPSHER SMITH LABS	2.5MG/ML	A210569	001	Oct 22, 2018	Mar DISC

CLOBETASOL PROPIONATE

CREAM;TOPICAL
CLOBETASOL PROPIONATE

	@ CHARTWELL RX	0.05%	A211207	001	Mar 26, 2021	May CAHN
AB1 !	ENCUBE	0.05%	A212982	001	Aug 28, 2020	Jun CHRS
	@ TORRENT	0.05%	A211836	001	Dec 30, 2019	Feb DISC
	CLOBETASOL PROPIONATE (EMOLLIENT)					
	@ ANI PHARMS	0.05%	A075733	001	Aug 22, 2001	Apr DISC
	CORMAX					
AB1	AKORN	0.05%	A074220	001	May 16, 1997	Jun CHRS

CLOFARABINE

SOLUTION;INTRAVENOUS
CLOFARABINE

	@ EUGIA PHARMA	20MG/20ML (1MG/ML)	A212457	001	Oct 03, 2022	Mar DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL
CLOMIPRAMINE HYDROCHLORIDE

AB	AUROBINDO PHARMA	25MG	A216440	001	Mar 20, 2023	Mar NEWA
AB		50MG	A216440	002	Mar 20, 2023	Mar NEWA
AB		75MG	A216440	003	Mar 20, 2023	Mar NEWA
AB	RK PHARMA	25MG	A213221	001	Jun 22, 2020	Jun CAHN
AB		50MG	A213221	002	Jun 22, 2020	Jun CAHN
AB		75MG	A213221	003	Jun 22, 2020	Jun CAHN

CLONAZEPAM

TABLET;ORAL
CLONAZEPAM

AB	AUROBINDO PHARMA USA	0.5MG	A075150	001	Oct 05, 1998	Jan CMFD
AB		1MG	A075150	002	Oct 05, 1998	Jan CMFD
AB		2MG	A075150	003	Oct 05, 1998	Jan CMFD

CLOPIDOGREL BISULFATE

TABLET;ORAL
CLOPIDOGREL BISULFATE

	@ CHARTWELL RX	EQ 75MG BASE	A202266	001	Aug 14, 2012	Jun CAHN
	@	EQ 300MG BASE	A202266	002	Nov 20, 2012	Jun CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL
CLORAZEPATE DIPOTASSIUM

	@ DASH PHARMS	3.75MG	A071509	001	Oct 19, 1987	Feb CAHN
	@	7.5MG	A071510	001	Oct 19, 1987	Feb CAHN
	@	15MG	A071511	001	Oct 19, 1987	Feb CAHN

CLOZAPINE

TABLET;ORAL
CLOZAPINE

	@ DR REDDYS LABS SA	25MG	A203807	001	Sep 17, 2015	Apr CAHN
	@	50MG	A203807	003	Aug 22, 2017	Apr CAHN
	@	100MG	A203807	002	Sep 17, 2015	Apr CAHN
	@	200MG	A203807	004	Aug 22, 2017	Apr CAHN
	@ MAYNE PHARMA	25MG	A203807	001	Sep 17, 2015	Apr DISC
	@	50MG	A203807	003	Aug 22, 2017	Apr DISC
	@	100MG	A203807	002	Sep 17, 2015	Apr DISC

```
          TABLET;ORAL
            CLOZAPINE
            @                       200MG                           A203807  004  Aug 22, 2017   Apr DISC
          TABLET, ORALLY DISINTEGRATING;ORAL
            CLOZAPINE
>A> AB        MYLAN                 150MG                           A201824  004  Aug 07, 2023   Jul NEWA
>A> AB                              200MG                           A201824  005  Aug 07, 2023   Jul NEWA
>D>           TEVA PHARMS USA       150MG                           A203039  001  Nov 25, 2015   Jul CTEC
>A> AB                              150MG                           A203039  001  Nov 25, 2015   Jul CTEC
>D>                                 200MG                           A203039  002  Nov 25, 2015   Jul CTEC
>A> AB                              200MG                           A203039  002  Nov 25, 2015   Jul CTEC

        CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
          SYRUP;ORAL
            TRIACIN-C
          !   ANIMA                 10MG/5ML;30MG/5ML;1.25MG/5ML    A088704  001  Mar 22, 1985   Mar CAHN

        COLCHICINE
          CAPSULE;ORAL
            COLCHICINE
    AB        PAR PHARM INC         0.6MG                           A208678  001  Nov 29, 2018   Jun CMFD
            MITIGARE
    AB    +!  HIKMA INTL PHARMS     0.6MG                           N204820  001  Sep 26, 2014   Jun CTEC
          TABLET;ORAL
            LODOCO
          +!  AGEPHA PHARMA FZ      0.5MG                           N215727  001  Jun 16, 2023   Jun NEWA

        COLESEVELAM HYDROCHLORIDE
          FOR SUSPENSION;ORAL
            COLESEVELAM HYDROCHLORIDE
    AB        IMPAX                 3.75GM/PACKET                   A212886  001  Jan 18, 2023   Jan NEWA
          TABLET;ORAL
            COLESEVELAM HYDROCHLORIDE
            @ CHARTWELL RX          625MG                           A201354  001  Dec 17, 2020   May CAHN

        COLESTIPOL HYDROCHLORIDE
          TABLET;ORAL
            COLESTIPOL HYDROCHLORIDE
    AB        ANI PHARMS            1GM                             A216517  001  Mar 10, 2023   Apr CAHN
    AB        PRAXGEN               1GM                             A216517  001  Mar 10, 2023   Mar NEWA

        CORTISONE ACETATE
>D>       TABLET;ORAL
>D>         CORTISONE ACETATE
>D>       !   HIKMA INTL PHARMS     25MG                            A080776  002                 Jul DISC
>A>         @                       25MG                            A080776  002                 Jul DISC

        CROMOLYN SODIUM
          SOLUTION;INHALATION
            CROMOLYN SODIUM
            @ EUGIA PHARMA          10MG/ML                         A074209  001  Apr 26, 1994   May CAHN
    AN        VIRTUS                10MG/ML                         A075437  001  Apr 21, 2000   Apr CAHN
          SOLUTION/DROPS;OPHTHALMIC
            CROMOLYN SODIUM
            @ AKORN                 4%                              A074706  001  Apr 29, 1998   Feb DISC
          !   SANDOZ                4%                              A075282  001  Jun 16, 1999   Feb CTEC
    AT    !   SANDOZ INC            4%                              A075282  001  Jun 16, 1999   Feb CHRS

        CYANOCOBALAMIN
          SPRAY, METERED;NASAL
            CYANOCOBALAMIN
    AB        LUPIN                 0.5MG/SPRAY                     A210629  001  Jun 30, 2023   Jun NEWA
            NASCOBAL
    AB    +!  ENDO PHARMS INC       0.5MG/SPRAY                     N021642  001  Jan 31, 2005   Jun CTEC

        CYCLOBENZAPRINE HYDROCHLORIDE
          CAPSULE, EXTENDED RELEASE;ORAL
            CYCLOBENZAPRINE HYDROCHLORIDE
            @ APOTEX                15MG                            A206703  001  Jul 24, 2018   Mar DISC
            @                       30MG                            A206703  002  Jul 24, 2018   Mar DISC
```

TABLET;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

AB		CHARTWELL RX	5MG	A078218	002	Jun 19, 2015	Feb CAHN
AB			7.5MG	A078218	003	Nov 03, 2020	Feb CAHN
AB			10MG	A078218	001	Apr 18, 2008	Feb CAHN

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CYCLOGYL

	+!	ALCON LABS INC	0.5%	A084109	001		Feb CTEC

CYCLOPENTOLATE HYDROCHLORIDE

	@	AKORN	0.5%	A205937	001	Dec 09, 2015	Feb DISC

CYCLOPHOSPHAMIDE

INJECTABLE;INJECTION
CYCLOPHOSPHAMIDE

>A>	AP	SAGENT PHARMS INC	500MG/VIAL	A214529	001	Jul 17, 2023	Jul NEWA
>A>	AP		1GM/VIAL	A214529	002	Jul 17, 2023	Jul NEWA
>A>	AP		2GM/VIAL	A214529	003	Jul 17, 2023	Jul NEWA
	AP	XGEN PHARMS	500MG/VIAL	A211757	001	Oct 18, 2022	May CAHN
	AP		1GM/VIAL	A211757	002	Oct 18, 2022	May CAHN
	AP		2GM/VIAL	A211757	003	Oct 18, 2022	May CAHN

SOLUTION;INTRAVENOUS
CYCLOPHOSPHAMIDE

	+!	DR REDDYS	500MG/ML (500MG/ML)	N210852	001	Jun 07, 2023	Jun NEWA
	+!		1GM/2ML (500MG/ML)	N210852	002	Jun 07, 2023	Jun NEWA
	+!		2GM/4ML (500MG/ML)	N210852	003	Jun 07, 2023	Jun NEWA
	+!	NEVAKAR INJECTABLES	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Jun NEWA
	+!		1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Jun NEWA

CYCLOSPORINE

EMULSION;OPHTHALMIC
CYCLOSPORINE

AB		APOTEX	0.05%	A207606	001	Jan 12, 2023	Jan NEWA

SOLUTION;OPHTHALMIC
VEVYE

	+!	NOVALIQ GMBH	0.1%	N217469	001	May 30, 2023	May NEWA

SOLUTION;ORAL
CYCLOSPORINE

>D>	AB2	XTTRIUM LABS INC	100MG/ML	A065133	001	Sep 17, 2004	Jul DISC
>A>		@	100MG/ML	A065133	001	Sep 17, 2004	Jul DISC
	AB2		100MG/ML	A065133	001	Sep 17, 2004	Jan CAHN

SANDIMMUNE

>D>	AB2	+! NOVARTIS	100MG/ML	N050574	001	Nov 14, 1983	Jul CTEC
>A>		+!	100MG/ML	N050574	001	Nov 14, 1983	Jul CTEC

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA		CHARTWELL RX	4MG	A088212	001	May 26, 1983	Mar CMFD
	@	RISING	4MG	A207783	001	Dec 29, 2016	May DISC

CYSTEINE HYDROCHLORIDE

INJECTABLE;INJECTION
CYSTEINE HYDROCHLORIDE

	@	HIKMA	7.25%	A213073	001	Jan 26, 2023	Apr CAHN
	@	NIVAGEN PHARMS INC	7.25%	A213073	001	Jan 26, 2023	Apr DISC
			7.25%	A213073	001	Jan 26, 2023	Jan NFTG

DABRAFENIB MESYLATE

TABLET, FOR SUSPENSION;ORAL
TAFINLAR

	+!	NOVARTIS	EQ 10MG BASE	N217514	001	Mar 16, 2023	Mar NEWA

DALBAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS
DALVANCE

	+!	ABBVIE	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Jun CAHN

DAPRODUSTAT

TABLET;ORAL

JESDUVROQ

	+	GLAXOSMITHKLINE	1MG	N216951	001	Feb 01, 2023	Feb NEWA
	+		2MG	N216951	002	Feb 01, 2023	Feb NEWA
	+		4MG	N216951	003	Feb 01, 2023	Feb NEWA
	+		6MG	N216951	004	Feb 01, 2023	Feb NEWA
	+!		8MG	N216951	005	Feb 01, 2023	Feb NEWA

DAPSONE

GEL;TOPICAL

ACZONE

AB	+!	ABBVIE	5%	N021794	001	Jul 07, 2005	Jun CAHN

DAPSONE

AB		ACRUX DDS	5%	A213907	001	Jun 06, 2023	May NEWA
AB		AMNEAL	7.5%	A212701	001	May 31, 2023	May NEWA

TABLET;ORAL

DAPSONE

AB	+	EVEREST LIFE SCI	100MG	A086842	001		Jun CHRS
AB	!	NOVITIUM PHARMA	100MG	A206505	002	Dec 01, 2016	Jun CHRS
>A> AB		RISING	25MG	A207165	002	Jul 20, 2023	Jul NEWA

DAPTOMYCIN

POWDER;INTRAVENOUS

DAPTOMYCIN

	@	HAINAN POLY PHARM	500MG/VIAL	A215890	001	Aug 18, 2022	Feb DISC
>A> AP		MYLAN	500MG/VIAL	A213966	001	Aug 07, 2023	Jul NEWA
AP	!	QILU PHARM HAINAN	500MG/VIAL	A215316	001	Aug 24, 2021	May CHRS
	+!	XELLIA PHARMS APS	350MG/VIAL	N217415	001	Jan 30, 2023	Jan NEWA
	+!		500MG/VIAL	N217415	002	Jan 30, 2023	Jan NEWA

SOLUTION;INTRAVENOUS

DAPTOMYCIN IN 0.9% SODIUM CHLORIDE

	+!	BAXTER HLTHCARE CORP	350MG/50ML (7MG/ML)	N213645	002	Feb 27, 2023	Mar NEWA
	+!		500MG/50ML (10MG/ML)	N213645	003	Feb 27, 2023	Mar NEWA
	+!		700MG/100ML (7MG/ML)	N213645	004	Feb 27, 2023	Mar NEWA
	+!		1GM/100ML (10MG/ML)	N213645	005	Feb 27, 2023	Mar NEWA

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

ENABLEX

	+ @	ABBVIE	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Apr CAHN
	+ @		EQ 15MG BASE	N021513	002	Dec 22, 2004	Apr CAHN

DEFERASIROX

GRANULE;ORAL

DEFERASIROX

AB		ANNORA PHARMA	90MG	A216229	003	Mar 16, 2023	Mar NEWA

TABLET;ORAL

DEFERASIROX

AB		CHARTWELL RX	90MG	A212669	001	May 27, 2021	Mar CAHN
AB			180MG	A212669	002	May 27, 2021	Mar CAHN
AB			360MG	A212669	003	May 27, 2021	Mar CAHN
	@	CIPLA	90MG	A211852	001	Feb 11, 2020	Mar DISC
	@		180MG	A211852	003	Jun 15, 2020	Mar DISC
	@		360MG	A211852	002	Feb 11, 2020	Mar DISC

TABLET, FOR SUSPENSION;ORAL

DEFERASIROX

	@	TEVA PHARMS USA	125MG	A207124	001	Sep 23, 2022	Mar DISC
	@		250MG	A207124	002	Sep 23, 2022	Mar DISC
	@		500MG	A207124	003	Sep 23, 2022	Mar DISC

DEFERIPRONE

TABLET;ORAL

DEFERIPRONE

AB	!	HIKMA	1GM	A213239	002	Feb 08, 2022	May CHRS

FERRIPROX

AB	+	CHIESI	1GM	N021825	002	Jul 25, 2019	May CHRS

DESLORATADINE

TABLET;ORAL

DESLORATADINE

	@	DASH PHARMS	5MG	A078351	001	Feb 10, 2012	Feb CAHN

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION

DESMOPRESSIN ACETATE

AP		GLAND	0.004MG/ML	A216904	001	Mar 20, 2023	Mar NEWA

DESONIDE

LOTION;TOPICAL

DESONIDE

	@	PAI HOLDINGS PHARM	0.05%	A207855	001	Sep 28, 2017	May DISC

DEUTETRABENAZINE

TABLET, EXTENDED RELEASE;ORAL

AUSTEDO XR

	+	TEVA	6MG	N216354	001	Feb 17, 2023	Feb NEWA
	+		12MG	N216354	002	Feb 17, 2023	Feb NEWA
	+!		24MG	N216354	003	Feb 17, 2023	Feb NEWA

DEXAMETHASONE

ELIXIR;ORAL

DEXAMETHASONE

	+ @	XTTRIUM LABS INC	0.5MG/5ML	A088254	001	Jul 27, 1983	Jan CAHN

SUSPENSION/DROPS;OPHTHALMIC

MAXIDEX

	+!	HARROW EYE	0.1%	N013422	001		May CAHN

TABLET;ORAL

DEXAMETHASONE

AB		ALVOGEN	4MG	A088481	004	Apr 28, 1983	Apr CTEC
AB			6MG	A088481	001	Nov 28, 1983	Apr CTEC
AB		BIONPHARMA	2MG	A217538	001	Apr 26, 2023	Apr NEWA
AB			4MG	A217001	001	Apr 19, 2023	Apr NEWA
AB			6MG	A217001	002	Apr 19, 2023	Apr NEWA
AB		NOVITIUM PHARMA	2MG	A217696	001	May 09, 2023	Apr NEWA
AB		PRASCO	4MG	A080399	002	Apr 20, 2022	Apr CMFD
	@		4MG	A080399	002	Apr 20, 2022	Feb DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

>A>	AP	GENE YORK PHARMS	EQ 4MG PHOSPHATE/ML	A214891	001	Jul 28, 2023	Jul NEWA
	AP	GENEYORK PHARMS	EQ 10MG PHOSPHATE/ML	A214890	001	Jul 07, 2023	Jun NEWA
>A>	AP	HIKMA	EQ 4MG PHOSPHATE/ML	A211451	001	Aug 01, 2023	Jul NEWA

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OPHTHALMIC

MAXITROL

AT	+!	HARROW EYE	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		May CAHN

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

TOBRAMYCIN AND DEXAMETHASONE

	@	AMNEAL	0.1%;0.3%	A212991	001	Jul 15, 2021	Jun DISC

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		AMNEAL	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A216604	001	May 15, 2023	May NEWA
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A216604	002	May 15, 2023	May NEWA
AP		MILLA PHARMS	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A217308	001	Jun 07, 2023	May NEWA
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A217308	002	Jun 07, 2023	May NEWA

DEXTROAMPHETAMINE SULFATE

SOLUTION;ORAL

DEXTROAMPHETAMINE SULFATE

AA	!	PRASCO	5MG/5ML	A040776	001	Jan 29, 2008	Mar CAHN

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	Jan CTEC
AA			7.5MG	A090533	003	Oct 25, 2011	Jan CTEC
AA			15MG	A090533	005	Oct 25, 2011	Jan CTEC
AA			20MG	A090533	006	Oct 25, 2011	Jan CTEC
AA			30MG	A090533	007	Oct 25, 2011	Jan CTEC
AA		WINDER LABS LLC	2.5MG	A212160	001	Jun 07, 2021	Jan CMFD
AA			5MG	A212160	002	Jun 07, 2021	Jan CMFD
AA			7.5MG	A212160	003	Jun 07, 2021	Jan CMFD
AA			10MG	A212160	004	Jun 07, 2021	Jan CMFD
AA			15MG	A212160	005	Jun 07, 2021	Jan CMFD
AA			20MG	A212160	006	Jun 07, 2021	Jan CMFD
AA			30MG	A212160	007	Jun 07, 2021	Jan CMFD

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348	001	Jul 30, 2021	Mar CMFD

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP		FRESENIUS KABI USA	5GM/100ML;74.5MG/100ML;450MG/100ML	A213523	001	Mar 09, 2021	Mar CMFD

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348	002	Jul 30, 2021	Mar CMFD
AP	+!	ICU MEDICAL INC	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Mar CHRS
AP	+		5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Mar CTEC

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP		FRESENIUS KABI USA	5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Mar CMFD

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

AP		FRESENIUS KABI USA	5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Mar CMFD

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP		FRESENIUS KABI USA	5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Mar CMFD

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%

AP		FRESENIUS KABI USA	5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Mar CMFD

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

AP		FRESENIUS KABI USA	5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Mar CMFD

DIAZEPAM

GEL;RECTAL

DIASTAT ACUDIAL

AB	+!	BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	May CFTG
AB	+!		20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	May CFTG

DIAZEPAM

AB		NOVEL LABS INC	10MG/2ML (5MG/ML)	A091076	001	May 30, 2023	May NFTG
AB			20MG/4ML (5MG/ML)	A091076	002	May 30, 2023	May NFTG

DICLOFENAC POTASSIUM

TABLET;ORAL

DICLOFENAC POTASSIUM

	@	CHARTWELL RX	50MG	A075582	001	Feb 23, 2001	May CAHN
AB		SENORES PHARMS	50MG	A215787	001	Mar 15, 2023	Mar NEWA

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB		AMNEAL	3%	A200936	001	Oct 28, 2013	Feb CAHN

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AB		AUROLIFE PHARMA LLC	2%	A213040	001	Feb 03, 2023	Jan NEWA

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

AB		RUBICON	25MG	A216548	001	May 11, 2023	May NEWA
AB			50MG	A216548	002	May 11, 2023	May NEWA
AB			75MG	A216548	003	May 11, 2023	May NEWA

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

	@	AUROBINDO PHARMA USA	100MG	A076152	001	Dec 13, 2001	Apr CAHN

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB		ZYDUS PHARMS	50MG;0.2MG	A206771	001	Jun 12, 2023	Jun NEWA
AB			75MG;0.2MG	A206771	002	Jun 12, 2023	Jun NEWA

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

AB		COREPHARMA	10MG	A216639	001	Mar 24, 2023	Mar NEWA

INJECTABLE;INJECTION

BENTYL

AP	+!	ABBVIE	10MG/ML	N008370	001	Oct 15, 1984	Feb CAHN

BENTYL PRESERVATIVE FREE

AP	+!	ABBVIE	10MG/ML	N008370	002	Oct 15, 1984	Feb CAHN

DICYCLOMINE HYDROCHLORIDE

>D>	@	ATHENEX INC	10MG/ML	A212058	001	Apr 26, 2019	Jul CAHN
>A>	@	PRAXGEN PHARMS	10MG/ML	A212058	001	Apr 26, 2019	Jul CAHN

TABLET;ORAL

DICYCLOMINE HYDROCHLORIDE

AB		AUROBINDO PHARMA USA	20MG	A040317	001	Sep 07, 1999	Feb CMFD
>A> AB		BIONPHARMA	20MG	A217916	001	Aug 04, 2023	Jul NEWA
AB		TWI PHARMS	20MG	A216782	001	Jun 01, 2023	May NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

DIETHYLPROPION HYDROCHLORIDE

	!	LANNETT CO INC	75MG	A091680	001	Oct 24, 2011	Feb CTEC

DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

	@	AVONDALE PHARMS	0.05%	A075187	001	Mar 30, 1998	May CAHN

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

AB		AVONDALE PHARMS	0.05%	A075374	001	Apr 27, 1999	May CAHN

DIHYDROERGOTAMINE MESYLATE

SPRAY, METERED;NASAL

DIHYDROERGOTAMINE MESYLATE

AB		AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022	Apr CMFD
AB		RUBICON	0.5MG/SPRAY	A216881	001	Jun 22, 2023	Jun NEWA

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB1		TWI PHARMS	60MG	A217377	001	Mar 01, 2023	Feb NEWA
AB1			90MG	A217377	002	Mar 01, 2023	Feb NEWA
AB1			120MG	A217377	003	Mar 01, 2023	Feb NEWA

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP		EUGIA PHARMA	5MG/ML	A216552	001	Mar 29, 2023	Mar NEWA

TABLET, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB		AMTA	120MG	A216439	001	Mar 07, 2023	Feb NEWA
AB			180MG	A216439	002	Mar 07, 2023	Feb NEWA
AB			240MG	A216439	003	Mar 07, 2023	Feb NEWA
AB			300MG	A216439	004	Mar 07, 2023	Feb NEWA
AB			360MG	A216439	005	Mar 07, 2023	Feb NEWA
AB			420MG	A216439	006	Mar 07, 2023	Feb NEWA
AB		SCIEGEN PHARMS INC	120MG	A216327	001	Apr 06, 2023	Mar NEWA
AB			180MG	A216327	002	Apr 06, 2023	Mar NEWA
AB			240MG	A216327	003	Apr 06, 2023	Mar NEWA
AB			300MG	A216327	004	Apr 06, 2023	Mar NEWA
AB			360MG	A216327	005	Apr 06, 2023	Mar NEWA
AB			420MG	A216327	006	Apr 06, 2023	Mar NEWA

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

AB	SOLA PHARMS	120MG	A210436	001	Mar 26, 2021	Feb	CMFD
AB		240MG	A210436	002	Mar 26, 2021	Feb	CMFD

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+!	PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982	Apr	CRLD

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

@	FRESENIUS KABI USA	5MG/ML	A074956	001	Sep 30, 1998	Jun	DISC

TABLET;ORAL

DIPYRIDAMOLE

@	ANI PHARMS	25MG	A086944	002	Apr 16, 1991	Apr	DISC
@		50MG	A086944	001	Feb 25, 1992	Apr	DISC
@		75MG	A086944	003	Feb 25, 1992	Apr	DISC

DISULFIRAM

TABLET;ORAL

DISULFIRAM

@	DASH PHARMS	250MG	A203916	001	Mar 04, 2015	Feb	CAHN
@		500MG	A203916	002	Mar 04, 2015	Feb	CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

AB	CHARTWELL RX	EQ 125MG VALPROIC ACID	A077296	001	Jul 31, 2008	Jun	CAHN
AB		EQ 250MG VALPROIC ACID	A077296	002	Jul 31, 2008	Jun	CAHN
AB		EQ 500MG VALPROIC ACID	A077296	003	Jul 31, 2008	Jun	CAHN

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP	ALEMBIC	20MG/2ML (10MG/ML)	A215744	001	Feb 28, 2023	Feb	NEWA
AP		80MG/8ML (10MG/ML)	A215744	002	Feb 28, 2023	Feb	NEWA
AP		160MG/16ML (10MG/ML)	A215744	003	Feb 28, 2023	Feb	NEWA
AP	MYLAN LABS LTD	20MG/ML (20MG/ML)	A203892	001	May 11, 2023	Apr	NEWA
AP		80MG/4ML (20MG/ML)	A203892	002	May 11, 2023	Apr	NEWA

SOLUTION;INTRAVENOUS

DOCETAXEL

>A>	+ @ INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Jul	CAHN
>A>	+ @	80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Jul	CAHN
>A>	+ @	160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Jul	CAHN
>D>	+ @ MERIDIAN LABS	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Jul	CAHN
	+ @	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	May	DISC
>D>	+ @	80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Jul	CAHN
	+ @	80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	May	DISC
>D>	+ @	160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Jul	CAHN
	+ @	160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	May	DISC

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

@	RK PHARMA	0.125MG	A215323	001	Apr 14, 2022	Jun	CAHN
@		0.25MG	A215323	002	Apr 14, 2022	Jun	CAHN
@		0.5MG	A215323	003	Apr 14, 2022	Jun	CAHN

DONEPEZIL HYDROCHLORIDE

SOLUTION;ORAL

ARICEPT

+ @	EISAI INC	5MG/5ML	N021719	001	Oct 18, 2004	Jun	CRLD

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

+ @	B BRAUN	80MG/100ML	N019099	002	Oct 15, 1986	Apr DISC
+ @		320MG/100ML	N019099	004	Oct 15, 1986	Apr DISC

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

+ @	B BRAUN	40MG/100ML	N019099	001	Oct 15, 1986	Apr DISC
+ @		160MG/100ML	N019099	003	Oct 15, 1986	Apr DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COSOPT

AT1	+!	THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE	N020869	001	Apr 07, 1998	May CTEC

COSOPT PF

AT2	+!	THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012	May CTEC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT1		AKORN	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008	May CTEC
AT1			EQ 2% BASE;EQ 0.5% BASE	A203058	001	Sep 22, 2014	May CTEC
AT1		ALEMBIC	EQ 2% BASE;EQ 0.5% BASE	A213099	001	May 04, 2021	May CTEC
AT1		BAUSCH AND LOMB	EQ 2% BASE;EQ 0.5% BASE	A090037	001	Jul 14, 2009	May CTEC
AT1		EUGIA PHARMA	EQ 2% BASE;EQ 0.5% BASE	A207629	001	May 14, 2021	May CTEC
AT2			EQ 2% BASE;EQ 0.5% BASE	A207630	001	Jul 24, 2018	May CTEC
AT1		FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	May CTEC
AT1		GLAND PHARMA LTD	EQ 2% BASE;EQ 0.5% BASE	A215520	001	Sep 19, 2022	May CTEC
AT1		INDOCO	EQ 2% BASE;EQ 0.5% BASE	A202054	001	Sep 03, 2014	May CTEC
AT2		INGENUS PHARMS LLC	EQ 2% BASE;EQ 0.5% BASE	A217260	001	May 01, 2023	May CTEC
AT			EQ 2% BASE;EQ 0.5% BASE	A217260	001	May 01, 2023	Apr NEWA
AT1		MICRO LABS	EQ 2% BASE;EQ 0.5% BASE	A204777	001	May 28, 2020	May CTEC
AT2			EQ 2% BASE;EQ 0.5% BASE	A215936	001	Jan 25, 2022	May CTEC
AT1		SANDOZ	EQ 2% BASE;EQ 0.5% BASE	A078749	001	Nov 06, 2008	May CTEC
AT1			EQ 2% BASE;EQ 0.5% BASE	A090604	001	Nov 18, 2009	May CTEC
AT1		SOMERSET	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	May CTEC
AT1		TEVA PHARMS	EQ 2% BASE;EQ 0.5% BASE	A078704	001	Sep 28, 2009	May CTEC

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB		MICRO LABS	EQ 10MG BASE	A217688	001	Jun 27, 2023	Jun NEWA
AB			EQ 25MG BASE	A217688	002	Jun 27, 2023	Jun NEWA
AB			EQ 50MG BASE	A217688	003	Jun 27, 2023	Jun NEWA
AB			EQ 75MG BASE	A217688	004	Jun 27, 2023	Jun NEWA
AB			EQ 100MG BASE	A217688	005	Jun 27, 2023	Jun NEWA
AB		ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar CAHN
AB			EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar CAHN
AB			EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar CAHN
AB			EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar CAHN
AB			EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar CAHN
AB			EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar CAHN
AB		ZYDUS PHARMS	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar NEWA
AB			EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar NEWA
AB			EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar NEWA
AB			EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar NEWA
AB			EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar NEWA
AB			EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar NEWA

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

>D> AA	!	LANNETT CO INC	EQ 10MG BASE/ML	A074721	001	Dec 29, 1998	Jul CTEC
>A>	!		EQ 10MG BASE/ML	A074721	001	Dec 29, 1998	Jul CTEC
>D> AA		XTTRIUM LABS INC	EQ 10MG BASE/ML	A071918	001	Jul 20, 1988	Jul DISC
>A>	@		EQ 10MG BASE/ML	A071918	001	Jul 20, 1988	Jul DISC

CREAM;TOPICAL

DOXEPIN HYDROCHLORIDE

AB		TEVA PHARMS	5%	A215408	001	Feb 17, 2023	Feb NFTG

ZONALON

AB	+!	MYLAN	5%	N020126	001	Apr 01, 1994	Feb CFTG

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB		MSN	EQ 3MG BASE	A214823	001	Apr 03, 2023	Mar NEWA
AB			EQ 6MG BASE	A214823	002	Apr 03, 2023	Mar NEWA

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP	ALEMBIC	4MCG/2ML (2MCG/ML)	A215810	001	Jun 15, 2023	Jun NEWA

DOXYCYCLINE HYCLATE

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

AP	GLAND PHARMA LTD	EQ 100MG BASE/VIAL	A215583	001	Apr 12, 2023	Mar NEWA
	@ PAR STERILE PRODUCTS	EQ 100MG BASE/VIAL	A216690	001	Dec 07, 2022	Jun DISC

TABLET;ORAL

DOXYCYCLINE HYCLATE

	@ ORYZA PHARMS SHENZHN	EQ 100MG BASE	A213475	001	Mar 10, 2021	Feb CAHN

TABLET, DELAYED RELEASE;ORAL

DORYX

	+ @ MAYNE PHARMA	EQ 50MG BASE	N050795	006	Dec 19, 2014	Jun DISC
	+ @	EQ 100MG BASE	N050795	002	May 06, 2005	Jun DISC
>D> AB	+!	EQ 200MG BASE	N050795	005	Apr 11, 2013	Jul CHRS
>A> AB	+	EQ 200MG BASE	N050795	005	Apr 11, 2013	Jul CHRS

DORYX MPC

	+ @ MAYNE PHARMA	EQ 120MG BASE	N050795	008	May 20, 2016	Jun DISC

DOXYCYCLINE HYCLATE

	@ AUROBINDO PHARMA USA	EQ 150MG BASE	A091052	001	Feb 08, 2012	May CAHN
>D> AB	HERITAGE PHARMS	EQ 200MG BASE	A200856	004	Nov 13, 2018	Jul CHRS
>A> AB	!	EQ 200MG BASE	A200856	004	Nov 13, 2018	Jul CHRS

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

>A> AB	BIONPHARMA	10MG;10MG	A217000	001	Aug 04, 2023	Jul NEWA

DROPERIDOL

INJECTABLE;INJECTION

DROPERIDOL

>D> AP	AM REGENT	2.5MG/ML	A072123	001	Oct 24, 1988	Jul CTEC
>A>	!	2.5MG/ML	A072123	001	Oct 24, 1988	Jul CTEC
>D> AP	HIKMA	2.5MG/ML	A208197	001	Dec 14, 2017	Jul DISC
>A>	@	2.5MG/ML	A208197	001	Dec 14, 2017	Jul DISC
AP		2.5MG/ML	A208197	001	Dec 14, 2017	May CAHN
>D> AP	HOSPIRA	2.5MG/ML	A071981	001	Feb 29, 1988	Jul DISC
>A>	@	2.5MG/ML	A071981	001	Feb 29, 1988	Jul DISC
>D>	INAPSINE					
>D> AP	+! AKORN	2.5MG/ML	N016796	001		Jul DISC
>A>	+ @	2.5MG/ML	N016796	001		Jul DISC

DROSPIRENONE

TABLET, CHEWABLE;ORAL

DROSPIRENONE

	+ @ EXELTIS USA INC	3.5MG	N216285	001	Jun 29, 2022	Jun DISC

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

	@ CHARTWELL RX	100MG	A214217	001	May 05, 2022	May CAHN
	@	200MG	A214217	002	May 05, 2022	May CAHN
	@	300MG	A214217	003	May 05, 2022	May CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DRIZALMA SPRINKLE

	+ @ SUN PHARM	EQ 30MG BASE	N212516	002	Jul 19, 2019	Mar DISC
	+ @	EQ 40MG BASE	N212516	003	Jul 19, 2019	Jan DISC
	+ @	EQ 60MG BASE	N212516	004	Jul 19, 2019	Mar DISC

DULOXETINE HYDROCHLORIDE

AB	ZYDUS HLTHCARE	EQ 40MG BASE	A090739	004	Apr 18, 2023	Apr NEWA

DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM

POWDER;INTRAVENOUS

XACDURO (COPACKAGED)

+!	ENTASIS THERAP	EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL	N216974	001	May 23, 2023	Jun CMS1
+!		EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL	N216974	001	May 24, 2023	May NEWA

DYCLONINE HYDROCHLORIDE

SOLUTION;TOPICAL

DYCLOPRO

!	SEPTODONT	0.5%	A200480	001	Nov 20, 2018	May CAHN
!		1%	A200480	002	Nov 20, 2018	May CAHN

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

@	AUROBINDO PHARMA USA	1%	A210364	001	Apr 18, 2018	Apr CAHN
@	PAI HOLDINGS PHARM	1%	A076574	001	Dec 17, 2004	May DISC

EDETATE CALCIUM DISODIUM

INJECTABLE;INJECTION

CALCIUM DISODIUM VERSENATE

+ @	BAUSCH	200MG/ML	N008922	001		Mar DISC

EDETATE CALCIUM DISODIUM

!	CASPER PHARMA LLC	200MG/ML	A216435	001	May 03, 2023	Apr NFTG
		200MG/ML	A216435	001	May 03, 2023	Apr NFTG

EFAVIRENZ

CAPSULE;ORAL

EFAVIRENZ

	AUROBINDO PHARMA	50MG	A078064	001	Dec 15, 2017	Mar CTEC
!		200MG	A078064	003	Dec 15, 2017	Mar CHRS
		200MG	A078064	003	Dec 15, 2017	Mar CTEC

SUSTIVA

+ @	BRISTOL MYERS SQUIBB	50MG	N020972	001	Sep 17, 1998	Mar DISC
+ @		200MG	N020972	003	Sep 17, 1998	Mar DISC

ELACESTRANT DIHYDROCHLORIDE

TABLET;ORAL

ORSERDU

+	STEMLINE THERAP	EQ 86MG BASE	N217639	001	Jan 27, 2023	Jan NEWA
+!		EQ 345MG BASE	N217639	002	Jan 27, 2023	Jan NEWA

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

GRANULES;ORAL

TRIKAFTA (COPACKAGED)

+	VERTEX PHARMS INC	80MG, 60MG, 40MG;59.5MG	N217660	001	Apr 26, 2023	Apr NEWA
+!		100MG, 75MG, 50MG;75MG	N217660	002	Apr 26, 2023	Apr NEWA

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

ELIGLUSTAT TARTRATE

AB	ZENARA	EQ 84MG BASE	A212420	001	May 02, 2023	Apr NEWA

EMPAGLIFLOZIN

TABLET;ORAL

EMPAGLIFLOZIN

@	ZYDUS PHARMS	10MG	A212138	001	Aug 03, 2022	Jan DISC
@		25MG	A212138	002	Aug 03, 2022	Jan DISC

JARDIANCE

+	BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014	Jan CTEC
+!		25MG	N204629	002	Aug 01, 2014	Jan CTEC

EMTRICITABINE

CAPSULE;ORAL

EMTRICITABINE

AB	AUROBINDO PHARMA LTD	200MG	A079188	001	Mar 15, 2023	Mar NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

	@ APOTEX	200MG;300MG	A208740	001	Jun 16, 2021	Apr DISC
AB	AUROBINDO PHARMA LTD	100MG;150MG	A211640	001	Mar 09, 2023	Mar NEWA
AB		133MG;200MG	A211640	002	Mar 09, 2023	Mar NEWA
AB		167MG;250MG	A211640	003	Mar 09, 2023	Mar NEWA

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

	@ CHARTWELL RX	2.5MG	A075048	001	Aug 22, 2000	May CAHN
	@	5MG	A075048	002	Aug 22, 2000	May CAHN
	@	10MG	A075048	003	Aug 22, 2000	May CAHN
	@	20MG	A075048	004	Aug 22, 2000	May CAHN

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP	DR REDDYS	1.25MG/ML	A075578	001	Aug 22, 2000	Apr CMFD

ENOXAPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP	BE PHARMS	30MG/0.3ML (100MG/ML)	A214646	001	Jun 06, 2023	May NEWA
AP		40MG/0.4ML (100MG/ML)	A214646	002	Jun 06, 2023	May NEWA
AP		60MG/0.6ML (100MG/ML)	A214646	003	Jun 06, 2023	May NEWA
AP		80MG/0.8ML (100MG/ML)	A214646	004	Jun 06, 2023	May NEWA
AP		100MG/ML (100MG/ML)	A214646	005	Jun 06, 2023	May NEWA
AP		120MG/0.8ML (150MG/ML)	A214646	006	Jun 06, 2023	May NEWA
AP		150MG/ML (150MG/ML)	A214646	007	Jun 06, 2023	May NEWA
AP	GLAND	30MG/0.3ML (100MG/ML)	A078990	001	Sep 28, 2018	Jun CAHN
AP		40MG/0.4ML (100MG/ML)	A078990	002	Sep 28, 2018	Jun CAHN
AP		60MG/0.6ML (100MG/ML)	A078990	003	Sep 28, 2018	Jun CAHN
AP		80MG/0.8ML (100MG/ML)	A078990	004	Sep 28, 2018	Jun CAHN
AP		100MG/ML (100MG/ML)	A078990	005	Sep 28, 2018	Jun CAHN
AP		120MG/0.8ML (150MG/ML)	A078990	006	Sep 28, 2018	Jun CAHN
AP		150MG/ML (150MG/ML)	A078990	007	Sep 28, 2018	Jun CAHN
AP	SHENZHEN TECHDOW	30MG/0.3ML (100MG/ML)	A205660	001	Mar 15, 2023	Mar NEWA
AP		40MG/0.4ML (100MG/ML)	A205660	002	Mar 15, 2023	Mar NEWA
AP		60MG/0.6ML (100MG/ML)	A205660	003	Mar 15, 2023	Mar NEWA
AP		80MG/0.8ML (100MG/ML)	A205660	004	Mar 15, 2023	Mar NEWA
AP		100MG/ML (100MG/ML)	A205660	005	Mar 15, 2023	Mar NEWA
AP		120MG/0.8ML (150MG/ML)	A205660	006	Mar 15, 2023	Mar NEWA
AP		150MG/ML (150MG/ML)	A205660	007	Mar 15, 2023	Mar NEWA

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EPHEDRINE SULFATE

+!	OPERAND PHARMS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Jun CAHN
+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Jun CAHN
AP	SAGENT PHARMS INC	50MG/ML (50MG/ML)	A214528	001	Mar 09, 2023	Feb NEWA
AP	ZYDUS PHARMS	50MG/ML (50MG/ML)	A217276	001	May 16, 2023	May NEWA

EPINEPHRINE

SOLUTION;INTRAVENOUS

EPINEPHRINE

+!	BPI LABS	1MG/ML (1MG/ML)	N205029	003	May 12, 2023	Jun NEWA

EPINEPHRINE IN 0.9% SODIUM CHLORIDE

+!	PAR STERILE PRODUCTS	2MG/250ML (8MCG/ML)	N215875	001	Apr 21, 2023	Apr NEWA
+!		4MG/250ML (16MCG/ML)	N215875	002	Apr 21, 2023	Apr NEWA
+!		5MG/250ML (20MCG/ML)	N215875	003	Apr 21, 2023	Apr NEWA
+!		8MG/250ML (32MCG/ML)	N215875	004	Apr 21, 2023	Apr NEWA
+!		10MG/250ML (40MCG/ML)	N215875	005	Apr 21, 2023	Apr NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

!	HOSPIRA	0.01MG/ML;2%	A089646	001	Jun 21, 1988	Apr CTEC

XYLOCAINE W/ EPINEPHRINE

+!	FRESENIUS KABI USA	0.02MG/ML;2%	N006488	005		May CTEC

EPLERENONE

TABLET;ORAL

EPLERENONE

AB		ANNORA PHARMA	25MG	A213812	001	Jun 02, 2023	May NEWA
AB			50MG	A213812	002	Jun 02, 2023	May NEWA

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION

EPOPROSTENOL SODIUM

AP2	!	SUN PHARM	EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Feb CHRS

VELETRI

AP2	+	ACTELION	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CHRS

ERGOCALCIFEROL

CAPSULE;ORAL

DRISDOL

AA	+	VALIDUS PHARMS	50,000 IU	N003444	001		Feb CHRS

ERGOCALCIFEROL

AA		CHARTWELL RX	50,000 IU	A040833	001	May 20, 2009	Feb CAHN
AA	!	STRIDES PHARMA	50,000 IU	A090455	001	Aug 03, 2010	Feb CHRS

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

AB	!	ZYDUS PHARMS	EQ 150MG BASE	A213065	003	Apr 16, 2020	Apr CHRS

TARCEVA

	+ @	OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	Apr DISC
	+ @		EQ 100MG BASE	N021743	002	Nov 18, 2004	Apr DISC
	+ @		EQ 150MG BASE	N021743	003	Nov 18, 2004	Apr DISC

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

AP		SUN PHARM	EQ 1GM BASE/VIAL	A209145	001	May 02, 2023	Apr NEWA

ERTUGLIFLOZIN

TABLET;ORAL

ERTUGLIFLOZIN

>A>	@	AUROBINDO PHARMA LTD	5MG	A216947	001	Jul 13, 2023	Jul DISC
>A>	@		15MG	A216947	002	Jul 13, 2023	Jul DISC

STEGLATRO

>D>	+	MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Jul CTEC
>A>	+		5MG	N209803	001	Dec 19, 2017	Jul CTEC
>D>	+!		15MG	N209803	002	Dec 19, 2017	Jul CTEC
>A>	+!		15MG	N209803	002	Dec 19, 2017	Jul CTEC

ERYTHROMYCIN

GEL;TOPICAL

ERYTHROMYCIN

	@	PAI HOLDINGS PHARM	2%	A208154	001	Jul 19, 2017	May DISC

SOLUTION;TOPICAL

ERYTHROMYCIN

>D> AT		XTTRIUM LABS INC	2%	A062825	001	Oct 23, 1987	Jul DISC
>A>	@		2%	A062825	001	Oct 23, 1987	Jul DISC

TABLET;ORAL

ERYTHROMYCIN

AB		ARBOR PHARMS LLC	500MG	A061621	002		Jan CHRS
AB	!	CADILA PHARMS LTD	500MG	A213628	002	Jun 28, 2021	Jan CHRS
AB		ZYDUS	250MG	A212693	001	Mar 07, 2023	Feb NEWA
AB			500MG	A212693	002	Mar 07, 2023	Feb NEWA

ERYTHROMYCIN ETHYLSUCCINATE

TABLET;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

	@	AUROBINDO PHARMA USA	EQ 400MG BASE	A062847	001	Sep 14, 1988	Apr CAHN

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROMYCIN LACTOBIONATE

		@ EXELA PHARMA	EQ 500MG BASE/VIAL	A211086	001	Sep 17, 2020	May DISC

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

>A>	AA	CHARTWELL MOLECULAR	EQ 5MG BASE/5ML	A090477	001	Jun 12, 2013	Jul CAHN
>D>	AA	LANNETT CO INC	EQ 5MG BASE/5ML	A090477	001	Jun 12, 2013	Jul CAHN

LEXAPRO

	+	@ ABBVIE	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Jan CAHN

TABLET;ORAL

ESCITALOPRAM OXALATE

		@ DASH PHARMS	EQ 5MG BASE	A077550	001	May 14, 2015	Feb CAHN
		@	EQ 10MG BASE	A077550	002	May 14, 2015	Feb CAHN
		@	EQ 20MG BASE	A077550	003	May 14, 2015	Feb CAHN
	AB	JUBILANT CADISTA	EQ 5MG BASE	A202280	001	Sep 12, 2012	May CAHN
	AB		EQ 10MG BASE	A202280	002	Sep 12, 2012	May CAHN
	AB		EQ 20MG BASE	A202280	003	Sep 12, 2012	May CAHN

LEXAPRO

	AB	+ ABBVIE	EQ 5MG BASE	N021323	001	Aug 14, 2002	Jan CAHN
	AB	+	EQ 10MG BASE	N021323	002	Aug 14, 2002	Jan CAHN
	AB	+!	EQ 20MG BASE	N021323	003	Aug 14, 2002	Jan CAHN

ESLICARBAZEPINE ACETATE

TABLET;ORAL

APTIOM

>A>	AB	+ SUMITOMO PHARMA AM	200MG	N022416	001	Nov 08, 2013	Jul CAHN
>A>	AB	+	400MG	N022416	002	Nov 08, 2013	Jul CAHN
>A>	AB	+	600MG	N022416	003	Nov 08, 2013	Jul CAHN
>A>	AB	+!	800MG	N022416	004	Nov 08, 2013	Jul CAHN
>D>	AB	+ SUNOVION PHARMS INC	200MG	N022416	001	Nov 08, 2013	Jul CAHN
>D>	AB	+	400MG	N022416	002	Nov 08, 2013	Jul CAHN
>D>	AB	+	600MG	N022416	003	Nov 08, 2013	Jul CAHN
>D>	AB	+!	800MG	N022416	004	Nov 08, 2013	Jul CAHN

ESLICARBAZEPINE ACETATE

>A>	AB	HETERO LABS LTD V	200MG	A211186	001	Aug 03, 2023	Jul NEWA
>A>	AB		400MG	A211186	002	Aug 03, 2023	Jul NEWA
>A>	AB		600MG	A211186	003	Aug 03, 2023	Jul NEWA
>A>	AB		800MG	A211186	004	Aug 03, 2023	Jul NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

	AP	+! BAXTER HLTHCARE	2GM/100ML	N019386	005	Jan 27, 2003	Jan CTEC

BREVIBLOC IN PLASTIC CONTAINER

	AP	+! BAXTER HLTHCARE	1GM/100ML	N019386	004	Feb 16, 2001	Jan CTEC

ESMOLOL HYDROCHLORIDE

	AP	AMNEAL	1GM/100ML	A216603	001	Dec 13, 2022	Jan CPOT
	AP		2GM/100ML	A216603	002	Dec 13, 2022	Jan CPOT
	AP	EUGIA PHARMA	1GM/100ML	A216244	001	Mar 21, 2022	Jan CPOT
	AP		2GM/100ML	A216244	002	Mar 21, 2022	Jan CPOT
	AP	HQ SPCLT PHARMA	1GM/100ML	A214172	001	Dec 02, 2022	Jan CPOT
	AP		2GM/100ML	A214172	002	Dec 02, 2022	Jan CPOT
	AP	MYLAN LABS LTD	1GM/100ML	A206608	001	Jun 08, 2018	Jan CPOT
	AP		2GM/100ML	A206608	002	Jun 08, 2018	Jan CPOT
	AP	SAGENT PHARMS INC	1GM/100ML	A207107	001	Jun 08, 2018	Jan CPOT
	AP		2GM/100ML	A207107	002	Jun 08, 2018	Jan CPOT

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

	AB	PRINSTON INC	EQ 20MG BASE	A214920	001	Mar 28, 2023	Mar NEWA
	AB		EQ 40MG BASE	A214920	002	Mar 28, 2023	Mar NEWA

FOR SUSPENSION, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

	AB	ZYDUS PHARMS	EQ 20MG BASE/PACKET	A206055	001	Jun 07, 2023	May NEWA
	AB		EQ 40MG BASE/PACKET	A206055	002	Jun 07, 2023	May NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

	@ ACTAVIS LABS FL INC	EQ 20MG BASE;375MG	A204470	001	Aug 24, 2022	Feb DISC
	@	EQ 20MG BASE;500MG	A204470	002	Aug 24, 2022	Feb DISC

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP	EUGIA PHARMA	EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jan CHRS
	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	Apr CTEC

ESTRADIOL

CREAM;VAGINAL

ESTRADIOL

AB	PRASCO	0.01%	A212313	001	Jul 15, 2021	Jun CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL

ESTRADIOL

AB2	ZYDUS NOVELTECH INC	0.025MG/24HR	A202985	001	Mar 29, 2023	Mar NEWA
AB2		0.0375MG/24HR	A202985	002	Mar 29, 2023	Mar NEWA
AB2		0.05MG/24HR	A202985	003	Mar 29, 2023	Mar NEWA
AB		0.06MG/24HR	A202985	004	Mar 29, 2023	Mar NEWA
AB2		0.075MG/24HR	A202985	005	Mar 29, 2023	Mar NEWA
AB2		0.1MG/24HR	A202985	006	Mar 29, 2023	Mar NEWA
>D> AB2	ZYDUS PHARMS	0.025MG/24HR	A202985	001	Mar 29, 2023	Jul DISC
>A>	@	0.025MG/24HR	A202985	001	Mar 29, 2023	Jul DISC
AB2		0.025MG/24HR	A202985	001	Mar 29, 2023	Apr CAHN
>D> AB2		0.0375MG/24HR	A202985	002	Mar 29, 2023	Jul DISC
>A>	@	0.0375MG/24HR	A202985	002	Mar 29, 2023	Jul DISC
AB2		0.0375MG/24HR	A202985	002	Mar 29, 2023	Apr CAHN
>D> AB2		0.05MG/24HR	A202985	003	Mar 29, 2023	Jul DISC
>A>	@	0.05MG/24HR	A202985	003	Mar 29, 2023	Jul DISC
AB2		0.05MG/24HR	A202985	003	Mar 29, 2023	Apr CAHN
>D> AB		0.06MG/24HR	A202985	004	Mar 29, 2023	Jul DISC
>A>	@	0.06MG/24HR	A202985	004	Mar 29, 2023	Jul DISC
AB		0.06MG/24HR	A202985	004	Mar 29, 2023	Apr CAHN
>D> AB2		0.075MG/24HR	A202985	005	Mar 29, 2023	Jul DISC
>A>	@	0.075MG/24HR	A202985	005	Mar 29, 2023	Jul DISC
AB2		0.075MG/24HR	A202985	005	Mar 29, 2023	Apr CAHN
>D> AB2		0.1MG/24HR	A202985	006	Mar 29, 2023	Jul DISC
>A>	@	0.1MG/24HR	A202985	006	Mar 29, 2023	Jul DISC
AB2		0.1MG/24HR	A202985	006	Mar 29, 2023	Apr CAHN

INSERT;VAGINAL

IMVEXXY

+	MAYNE PHARMA	0.004MG	N208564	001	May 29, 2018	Jan CAHN
+!		0.01MG	N208564	002	May 29, 2018	Jan CAHN

SYSTEM;TRANSDERMAL

ESTRADIOL

AB	ZYDUS NOVELTECH INC	0.014MG/24HR	A204379	001	Apr 17, 2023	Apr NFTG
AB	ZYDUS PHARMS	0.014MG/24HR	A204379	001	Apr 17, 2023	May CAHN
AB1		0.025MG/24HR	A206241	001	Dec 01, 2022	May CAHN
AB1		0.0375MG/24HR	A206241	002	Dec 01, 2022	May CAHN
AB1		0.05MG/24HR	A206241	003	Dec 01, 2022	May CAHN
AB1		0.075MG/24HR	A206241	004	Dec 01, 2022	May CAHN
AB1		0.1MG/24HR	A206241	005	Dec 01, 2022	May CAHN

MENOSTAR

AB +!	BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004	Apr CFTG

VIVELLE

@	SANDOZ	0.025MG/24HR	N020323	005	Aug 16, 2000	May CAHN
@		0.0375MG/24HR	N020323	001	Oct 28, 1994	May CAHN
@		0.05MG/24HR	N020323	002	Oct 28, 1994	May CAHN
@		0.075MG/24HR	N020323	003	Oct 28, 1994	May CAHN
@		0.1MG/24HR	N020323	004	Oct 28, 1994	May CAHN

VIVELLE-DOT

AB1 +	SANDOZ	0.025MG/24HR	N020538	009	May 03, 2002	May CAHN
AB1 +		0.0375MG/24HR	N020538	005	Jan 08, 1999	May CAHN
AB1 +		0.05MG/24HR	N020538	006	Jan 08, 1999	May CAHN
AB1 +		0.075MG/24HR	N020538	007	Jan 08, 1999	May CAHN
AB1 +!		0.1MG/24HR	N020538	008	Jan 08, 1999	May CAHN

ESTRADIOL VALERATE

INJECTABLE;INJECTION

ESTRADIOL VALERATE

AO	XIROMED	10MG/ML	A216656	001	Apr 28, 2023	Apr NEWA
AO		20MG/ML	A216656	002	Apr 28, 2023	Apr NEWA
AO		40MG/ML	A216656	003	Apr 28, 2023	Apr NEWA

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB	AUROBINDO PHARMA LTD	0.5MG;0.1MG	A214729	001	Jun 30, 2023	Jun NEWA
AB		1MG;0.5MG	A214729	002	Jun 30, 2023	Jun NEWA

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

ENILLORING

AB	XIROMED	0.015MG/24HR;0.12MG/24HR	A211157	001	Jun 29, 2023	Jun NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

	@ AMNEAL PHARMS	0.02MG;0.1MG	A201108	001	Feb 05, 2014	Jan DISC
	@	0.03MG;0.15MG	A201095	001	Dec 08, 2014	Jan DISC
AB1	HETERO LABS	0.02MG;0.1MG	A212298	001	Feb 13, 2023	Feb NEWA
AB	LUPIN LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A200248	001	Nov 19, 2015	Jan CTEC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

RHUZDAH

	@ AUROBINDO PHARMA	0.035MG;0.4MG	A207585	001	Oct 11, 2022	Apr DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

HAILEY 24 FE

AB	! GLENMARK PHARMS LTD	0.02MG;1MG	A204847	001	Nov 17, 2017	Feb CTNA

MINASTRIN 24 FE

	+ @ APIL	0.02MG;1MG	N203667	001	May 08, 2013	Apr DISC

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	! GLENMARK PHARMS LTD	0.02MG;1MG	A210369	001	Dec 26, 2017	Apr CHRS

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

	@ AMNEAL PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A203870	001	Nov 12, 2015	Jan DISC
	@	0.035MG;0.25MG	A203865	001	Oct 27, 2015	Jun DISC

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

>A>	TURQOZ					
>A> AB	LUPIN LTD	0.03MG;0.3MG	A202980	001	Jul 31, 2023	Jul NEWA

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING;VAGINAL

ANNOVERA

	+! MAYNE PHARMA	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018	Jan CAHN

ETOPOSIDE

INJECTABLE;INJECTION

ETOPOSIDE

	@ DASH PHARMS	20MG/ML	A204927	001	Oct 31, 2017	Mar CAHN
	@ DASH PHARMS NATCO	20MG/ML	A203507	001	Nov 20, 2017	Feb CAHN

EVEROLIMUS

TABLET;ORAL

EVEROLIMUS

AB	TEVA PHARMS USA	10MG	A210050	004	Dec 09, 2019	Apr CMFD

EXEMESTANE

TABLET;ORAL

EXEMESTANE

	@ ALVOGEN	25MG	A200898	001	Jul 28, 2014	Feb DISC

EZETIMIBE

TABLET;ORAL

EZETIMIBE

	@ ORIENT PHARMA	10MG	A215693	001	Sep 13, 2022	Mar DISC

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB	ALKEM LABS LTD	40MG/5ML	A216400	001	May 15, 2023	May NEWA
AB	APPCO	40MG/5ML	A217655	001	Jun 16, 2023	Jun NEWA
AB	CARNEGIE	40MG/5ML	A217137	001	Jul 07, 2023	Jun NEWA
AB	LUPIN LTD	40MG/5ML	A090440	001	Jun 29, 2010	Jun CHRS
AB !	NOVITIUM PHARMA	40MG/5ML	A215043	001	Apr 20, 2021	Jun CHRS

INJECTABLE;INJECTION

FAMOTIDINE

	@ ZYDUS PHARMS	10MG/ML	A215828	001	Nov 22, 2022	Apr DISC

TABLET;ORAL

FAMOTIDINE

AB	ALKEM LABS LTD	20MG	A217375	001	Apr 24, 2023	Apr NEWA
AB		40MG	A217375	002	Apr 24, 2023	Apr NEWA
AB	VKT PHARMA	20MG	A215630	001	Jan 07, 2022	Jan CAHN
AB		40MG	A215630	002	Jan 07, 2022	Jan CAHN

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND FAMOTIDINE

AB	ASCENT PHARMS INC	26.6MG;800MG	A216814	001	Mar 15, 2023	Mar NEWA

FEBUXOSTAT

TABLET;ORAL

FEBUXOSTAT

	@ MYLAN	80MG	A205385	002	Jul 01, 2019	Jun DISC
AB	ZYDUS LIFESCIENCES	40MG	A205443	001	Jan 09, 2023	Jan CAHN
AB		80MG	A205443	002	Jan 09, 2023	Jan CAHN

FENFLURAMINE HYDROCHLORIDE

SOLUTION;ORAL

FINTEPLA

+!	UCB INC	EQ 2.2MG BASE/ML	N212102	001	Jun 25, 2020	Jun CAHN

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

+ @	LUPIN	90MG	N021695	005	Oct 18, 2013	Jun DISC

TABLET;ORAL

FENOFIBRATE

AB	CHARTWELL RX	54MG	A209660	001	Feb 11, 2019	Feb CAHN
AB		160MG	A209660	002	Feb 11, 2019	Feb CAHN

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

AB	MISEMER	EQ 200MG BASE	A215548	001	May 16, 2023	May NEWA
		EQ 300MG BASE	A215548	002	May 16, 2023	May NEWA
AB		EQ 400MG BASE	A215548	003	May 16, 2023	May NEWA

NALFON

AB +	XSPIRE PHARMA	EQ 200MG BASE	N017604	003		May CTEC

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

>D>	@ AVEVA	100MCG/HR	A077449	004	Oct 20, 2008	Jul CMFD
>A> AB		100MCG/HR	A077449	004	Oct 20, 2008	Jul CMFD
AB	ZYDUS NOVELTECH INC	100MCG/HR	A209655	008	Jan 24, 2023	Jan NEWA
	@ ZYDUS PHARMS	100MCG/HR	A209655	008	Jan 24, 2023	Jun DISC
AB		100MCG/HR	A209655	008	Jan 24, 2023	May CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL

		FENTANYL-12					
>D>		@ AVEVA	12.5MCG/HR	A077449	005	Sep 11, 2015	Jul CMFD
>A>	AB		12.5MCG/HR	A077449	005	Sep 11, 2015	Jul CMFD
	AB	ZYDUS NOVELTECH INC	12.5MCG/HR	A209655	001	Jan 24, 2023	Jan NEWA
		@ ZYDUS PHARMS	12.5MCG/HR	A209655	001	Jan 24, 2023	Jun DISC
	AB		12.5MCG/HR	A209655	001	Jan 24, 2023	May CAHN
		FENTANYL-25					
>D>		@ AVEVA	25MCG/HR	A077449	001	Oct 20, 2008	Jul CMFD
>A>	AB		25MCG/HR	A077449	001	Oct 20, 2008	Jul CMFD
	AB	ZYDUS NOVELTECH INC	25MCG/HR	A209655	002	Jan 24, 2023	Jan NEWA
		@ ZYDUS PHARMS	25MCG/HR	A209655	002	Jan 24, 2023	Jun DISC
	AB		25MCG/HR	A209655	002	Jan 24, 2023	May CAHN
		FENTANYL-37					
>D>		@ AVEVA	37.5MCG/HR	A077449	006	Dec 06, 2017	Jul CMFD
>A>	AB		37.5MCG/HR	A077449	006	Dec 06, 2017	Jul CMFD
	AB	ZYDUS NOVELTECH INC	37.5MCG/HR	A209655	003	Jan 24, 2023	Jan NEWA
		@ ZYDUS PHARMS	37.5MCG/HR	A209655	003	Jan 24, 2023	Jun DISC
	AB		37.5MCG/HR	A209655	003	Jan 24, 2023	May CAHN
		FENTANYL-50					
>D>		@ AVEVA	50MCG/HR	A077449	002	Oct 20, 2008	Jul CMFD
>A>	AB		50MCG/HR	A077449	002	Oct 20, 2008	Jul CMFD
	AB	ZYDUS NOVELTECH INC	50MCG/HR	A209655	004	Jan 24, 2023	Jan NEWA
		@ ZYDUS PHARMS	50MCG/HR	A209655	004	Jan 24, 2023	Jun DISC
	AB		50MCG/HR	A209655	004	Jan 24, 2023	May CAHN
		FENTANYL-62					
>D>		@ AVEVA	62.5MCG/HR	A077449	007	Dec 06, 2017	Jul CMFD
>A>	AB		62.5MCG/HR	A077449	007	Dec 06, 2017	Jul CMFD
	AB	ZYDUS NOVELTECH INC	62.5MCG/HR	A209655	005	Jan 24, 2023	Jan NEWA
		@ ZYDUS PHARMS	62.5MCG/HR	A209655	005	Jan 24, 2023	Jun DISC
	AB		62.5MCG/HR	A209655	005	Jan 24, 2023	May CAHN
		FENTANYL-75					
>D>		@ AVEVA	75MCG/HR	A077449	003	Oct 20, 2008	Jul CMFD
>A>	AB		75MCG/HR	A077449	003	Oct 20, 2008	Jul CMFD
	AB	ZYDUS NOVELTECH INC	75MCG/HR	A209655	006	Jan 24, 2023	Jan NEWA
		@ ZYDUS PHARMS	75MCG/HR	A209655	006	Jan 24, 2023	Jun DISC
	AB		75MCG/HR	A209655	006	Jan 24, 2023	May CAHN
		FENTANYL-87					
>D>		@ AVEVA	87.5MCG/HR	A077449	008	Dec 06, 2017	Jul CMFD
>A>	AB		87.5MCG/HR	A077449	008	Dec 06, 2017	Jul CMFD
>D>		MYLAN TECHNOLOGIES	87.5MCG/HR	A076258	008	Dec 29, 2014	Jul CTEC
>A>	AB		87.5MCG/HR	A076258	008	Dec 29, 2014	Jul CTEC
			87.5MCG/HR	A076258	008	Dec 29, 2014	Jun CTEC
	AB		87.5MCG/HR	A076258	008	Dec 29, 2014	Jan CTEC
	AB	ZYDUS NOVELTECH INC	87.5MCG/HR	A209655	007	Jan 24, 2023	Jan NEWA
		@ ZYDUS PHARMS	87.5MCG/HR	A209655	007	Jan 24, 2023	Jun DISC
	AB		87.5MCG/HR	A209655	007	Jan 24, 2023	May CAHN

FENTANYL CITRATE

INJECTABLE;INJECTION

		FENTANYL CITRATE					
	+!	HIKMA	EQ 0.025MG BASE/0.5ML	N019101	002	Jan 20, 2023	Jan NEWA
	AP +!		EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Jan CTNA

SOLUTION;INTRAVENOUS

		FENTANYL CITRATE					
	+ @	EXELA PHARMA	EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N215870	001	Feb 08, 2023	May DISC
	+!		EQ 2.5MG BASE/50ML (EQ 0.05MG BASE/ML)	N215870	001	Feb 08, 2023	Feb NEWA
	+ @		EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N215870	002	Feb 08, 2023	May DISC
	+!		EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N215870	002	Feb 08, 2023	Feb NEWA

TABLET;BUCCAL, SUBLINGUAL

		FENTANYL CITRATE					
	@	DR REDDYS LABS SA	EQ 0.1MG BASE	A206329	001	Aug 22, 2022	Apr CAHN
	@		EQ 0.2MG BASE	A206329	002	Aug 22, 2022	Apr CAHN
	@		EQ 0.3MG BASE	A206329	003	Aug 22, 2022	Apr CAHN
	@		EQ 0.4MG BASE	A206329	004	Aug 22, 2022	Apr CAHN
	@		EQ 0.6MG BASE	A206329	005	Aug 22, 2022	Apr CAHN
	@		EQ 0.8MG BASE	A206329	006	Aug 22, 2022	Apr CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

>D>	AB	ACCORD HLTHCARE	4MG	A205012	001	Jan 04, 2023	Jul DISC
>A>		@	4MG	A205012	001	Jan 04, 2023	Jul DISC
>D>	AB		8MG	A205012	002	Jan 04, 2023	Jul DISC
>A>		@	8MG	A205012	002	Jan 04, 2023	Jul DISC
>D>	AB	ACTAVIS LABS FL INC	4MG	A204868	001	Jan 04, 2023	Jul DISC
>A>		@	4MG	A204868	001	Jan 04, 2023	Jul DISC
>D>	AB		8MG	A204868	002	Jan 04, 2023	Jul DISC
>A>		@	8MG	A204868	002	Jan 04, 2023	Jul DISC
		@ LUPIN LTD	4MG	A204983	001	Jan 05, 2023	Feb DISC
		@	8MG	A204983	002	Jan 05, 2023	Feb DISC

FEZOLINETANT

TABLET;ORAL

VEOZAH

	+!	ASTELLAS	45MG	N216578	001	May 12, 2023	May NEWA

FINAFLOXACIN

SUSPENSION/DROPS;OTIC

XTORO

	+ @	FONSECA BIOSCIENCES	0.3%	N206307	001	Dec 17, 2014	Jan CAHN

FINASTERIDE; TADALAFIL

CAPSULE;ORAL

ENTADFI

>A>	+!	BLUE WATER BIOTECH	5MG;5MG	N215423	001	Dec 09, 2021	Jul CAHN
>D>	+!	VERU	5MG;5MG	N215423	001	Dec 09, 2021	Jul CAHN

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

AB		BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Jan CMFD
AB		BIONPHARMA	EQ 0.5MG BASE	A210252	001	May 24, 2023	May NEWA

FINGOLIMOD LAURYL SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

TASCENSO ODT

	+	CYCLE	EQ 0.25MG BASE	N214962	001	Dec 23, 2021	Jan CAHN
	+!		EQ 0.5MG BASE	N214962	002	Dec 09, 2022	Jan CAHN

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

		@ ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Jun DISC
AP2			50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Jan CTEC
AP1		AREVA PHARMS	50MG/2ML (25MG/ML)	A090724	001	Sep 27, 2010	Jan CTEC
AP1		FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan CTEC
AP			50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan CHRS
AP1		SAGENT PHARMS INC	50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Jan CTEC
	+ @	SANDOZ	50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007	Jun DISC
AP2	+!		50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007	Jan CTEC

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

		@ HIKMA	0.1MG	A216013	001	Oct 27, 2022	Apr DISC

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

		@ INVATECH	0.025%	A088045	001	Dec 16, 1982	Mar CAHN

IMPLANT;INTRAVITREAL

YUTIQ

	+!	ALIMERA SCIENCES INC	0.18MG	N210331	001	Oct 12, 2018	Jun CAHN

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

>A>	AT	NOVEL LABS INC	0.01%	A207345	001	Jul 31, 2023	Jul NEWA
>A>	AT		0.01%	A207347	001	Aug 07, 2023	Jul NEWA

```
        SOLUTION;TOPICAL
          FLUOCINOLONE ACETONIDE
AT          CHARTWELL RX          0.01%                          A209596  001  Dec 26, 2017   May CAHN

      FLUOCINONIDE
        CREAM;TOPICAL
          FLUOCINONIDE
AB1   !   AMNEAL                 0.05%                          A210554  001  Aug 21, 2018   Feb CHRS
      + @ TARO                   0.05%                          N019117  001  Jun 26, 1984   Feb DISC
        GEL;TOPICAL
          FLUOCINONIDE
          @ PAI HOLDINGS PHARM   0.05%                          A209030  001  Jun 19, 2018   May DISC
        OINTMENT;TOPICAL
          FLUOCINONIDE
AB          CHARTWELL RX          0.05%                          A207538  001  Jul 31, 2017   Apr CAHN
        SOLUTION;TOPICAL
          FLUOCINONIDE
AT          CHARTWELL RX          0.05%                          A209118  001  Apr 23, 2018   May CAHN
          @ PAI HOLDINGS PHARM   0.05%                          A207554  001  Mar 18, 2019   May DISC

      FLUOROMETHOLONE
        SUSPENSION/DROPS;OPHTHALMIC
          FML
      +!  ABBVIE                 0.1%                           N016851  002  Jul 28, 1982   Jan CAHN
          FML FORTE
      +!  ABBVIE                 0.25%                          N019216  001  Apr 23, 1986   Jan CAHN

      FLUOROURACIL
        INJECTABLE;INJECTION
          FLUOROURACIL
AP          ALEMBIC               2.5GM/50ML (50MG/ML)           A217295  001  Mar 03, 2023   Feb NEWA

      FLUOXETINE HYDROCHLORIDE
        SOLUTION;ORAL
          FLUOXETINE HYDROCHLORIDE
>A>       @ CHARTWELL MOLECULAR   EQ 20MG BASE/5ML               A076458  001  May 14, 2004   Jul CAHN
>D>       @ LANNETT CO INC        EQ 20MG BASE/5ML               A076458  001  May 14, 2004   Jul CAHN
AA          NOSTRUM LABS INC      EQ 20MG BASE/5ML               A075292  001  Feb 07, 2002   Mar CMFD
>D> AA      XTTRIUM LABS INC      EQ 20MG BASE/5ML               A075514  001  Aug 29, 2002   Jul DISC
>A>       @                       EQ 20MG BASE/5ML               A075514  001  Aug 29, 2002   Jul DISC
AA                                EQ 20MG BASE/5ML               A075514  001  Aug 29, 2002   Jan CAHN
        TABLET;ORAL
          FLUOXETINE HYDROCHLORIDE
          @ PIRAMAL HLTHCARE UK   EQ 10MG BASE                   A211444  001  Sep 13, 2022   Mar DISC
          @                       EQ 20MG BASE                   A211444  002  Sep 13, 2022   Mar DISC

      FLUPHENAZINE DECANOATE
        INJECTABLE;INJECTION
          FLUPHENAZINE DECANOATE
AO          GLAND PHARMA LTD      25MG/ML                        A215509  001  Mar 30, 2023   Mar NEWA

      FLUPHENAZINE HYDROCHLORIDE
        TABLET;ORAL
          FLUPHENAZINE HYDROCHLORIDE
          @ AJANTA PHARMA LTD     1MG                            A217410  001  Jan 05, 2023   Jun DISC
          @                       2.5MG                          A217410  002  Jan 05, 2023   Jun DISC
          @                       5MG                            A217410  003  Jan 05, 2023   Jun DISC
          @                       10MG                           A217410  004  Jan 05, 2023   Jun DISC
          @ PRASCO                1MG                            A089804  002  Aug 12, 1988   Apr DISC
          @                       2.5MG                          A089804  003  Aug 12, 1988   Apr DISC
          @                       5MG                            A089804  004  Aug 12, 1988   Apr DISC
          @                       10MG                           A089804  001  Aug 12, 1988   Apr DISC

      FLURANDRENOLIDE
        LOTION;TOPICAL
          CORDRAN
      + @ ALMIRALL                0.05%                          N013790  001                   May DISC
          FLURANDRENOLIDE
      !   PADAGIS ISRAEL          0.05%                          A207133  001  Aug 30, 2016   May CTEC
AT    !                           0.05%                          A207133  001  Aug 30, 2016   May CHRS
```

OINTMENT;TOPICAL
CORDRAN
+ @ ALMIRALL 0.05% N012806 001 May DISC
FLURANDRENOLIDE
! TELIGENT 0.05% A207851 001 Dec 30, 2016 May CTEC
AT ! 0.05% A207851 001 Dec 30, 2016 May CHRS

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE
POWDER;INHALATION
BREO ELLIPTA
+ GLAXO GRP LTD 0.05MG/INH;EQ 0.025MG BASE/INH N204275 003 May 12, 2023 May NEWA

FLUVOXAMINE MALEATE
TABLET;ORAL
LUVOX
AB + ANI PHARMS 25MG N021519 001 Dec 20, 2007 Jan CRLD
AB + 50MG N021519 002 Dec 20, 2007 Jan CRLD
AB + 100MG N021519 003 Dec 20, 2007 Jan CRLD

FOMEPIZOLE
INJECTABLE;INJECTION
FOMEPIZOLE
AP GLAND PHARMA LTD 1.5GM/1.5ML (1GM/ML) A216791 001 Jul 06, 2023 Jun NEWA

FORMOTEROL FUMARATE
SOLUTION;INHALATION
FORMOTEROL FUMARATE
AN MANKIND PHARMA 0.02MG/2ML A215883 001 Mar 22, 2023 Mar NEWA

FOSAPREPITANT DIMEGLUMINE
POWDER;INTRAVENOUS
FOSAPREPITANT DIMEGLUMINE
AP PIRAMAL CRITICAL EQ 150MG BASE/VIAL A214683 001 May 16, 2023 May NEWA

FOSCARNET SODIUM
INJECTABLE;INJECTION
FOSCARNET SODIUM
AP AVET LIFESCIENCES 2.4GM/100ML A213807 001 Jun 05, 2023 May NEWA

FOSPHENYTOIN SODIUM
INJECTABLE;INJECTION
FOSPHENYTOIN SODIUM
@ MYLAN LABS LTD EQ 50MG PHENYTOIN NA/ML A078736 001 Jun 08, 2010 Apr DISC

FROVATRIPTAN SUCCINATE
TABLET;ORAL
FROVATRIPTAN SUCCINATE
@ MYLAN EQ 2.5MG BASE A202931 001 Aug 28, 2014 Apr DISC

FULVESTRANT
SOLUTION;INTRAMUSCULAR
FULVESTRANT
AO EUGIA PHARMA 250MG/5ML (50MG/ML) A215169 001 Jun 30, 2023 Jun NEWA

FUROSEMIDE
SOLUTION;ORAL
FUROSEMIDE
@ XTTRIUM LABS INC 10MG/ML A070655 001 Oct 02, 1987 Jan CAHN
TABLET;ORAL
FUROSEMIDE
@ CHARTWELL RX 20MG N018413 001 Nov 30, 1983 Mar CAHN
@ 40MG N018413 002 Nov 30, 1983 Mar CAHN

GABAPENTIN
CAPSULE;ORAL
GABAPENTIN
AB LAURUS 100MG A217546 001 May 12, 2023 May NEWA
AB 300MG A217546 002 May 12, 2023 May NEWA
AB 400MG A217546 003 May 12, 2023 May NEWA

```
          SOLUTION;ORAL
            GABAPENTIN
    AA        RUBICON                250MG/5ML                          A216492  001  Jan 18, 2023   Jan NEWA
          TABLET;ORAL
            GABAPENTIN
            @ CHARTWELL RX           600MG                              A076120  001  Jan 27, 2006   May CAHN
            @                        800MG                              A076120  002  Jan 27, 2006   May CAHN
    AB        GRANULES               600MG                              A217116  001  Mar 28, 2023   Mar NEWA
    AB                               800MG                              A217116  002  Mar 28, 2023   Mar NEWA
>A> AB        GRAVITI PHARMS         600MG                              A217995  001  Jul 19, 2023   Jul NEWA
>A> AB                               800MG                              A217995  002  Jul 19, 2023   Jul NEWA

        GADOBUTROL
          SOLUTION;INTRAVENOUS
            GADOBUTROL
    AP        HAINAN POLY PHARM      4.5354GM/7.5ML (604.72MG/ML)       A217480  001  Mar 15, 2023   Mar NEWA
    AP                               9.0708GM/15ML (604.72MG/ML)        A217480  002  Mar 15, 2023   Mar NEWA

        GADOTERATE MEGLUMINE
          SOLUTION;INTRAVENOUS
            GADOTERATE MEGLUMINE
    AP        HENGRUI PHARMA         37.69GM/100ML (376.9MG/ML)         A215304  005  Apr 15, 2022   Feb CMS1

        GALANTAMINE HYDROBROMIDE
          CAPSULE, EXTENDED RELEASE;ORAL
            GALANTAMINE HYDROBROMIDE
>D> AB        AUROBINDO PHARMA       EQ 8MG BASE                        A204895  001  Aug 05, 2016   Jul CHRS
>A> AB    !                          EQ 8MG BASE                        A204895  001  Aug 05, 2016   Jul CHRS
>D>         RAZADYNE ER
>D> AB    +!  JANSSEN PHARMS         EQ 8MG BASE                        N021615  001  Apr 01, 2005   Jul DISC
>A>       + @                        EQ 8MG BASE                        N021615  001  Apr 01, 2005   Jul DISC
>D> AB    +                          EQ 16MG BASE                       N021615  002  Apr 01, 2005   Jul DISC
>A>       + @                        EQ 16MG BASE                       N021615  002  Apr 01, 2005   Jul DISC
>D> AB    +                          EQ 24MG BASE                       N021615  003  Apr 01, 2005   Jul DISC
>A>       + @                        EQ 24MG BASE                       N021615  003  Apr 01, 2005   Jul DISC

        GANIRELIX ACETATE
          INJECTABLE;INJECTION
            GANIRELIX ACETATE
    AP        GLAND PHARMA LTD       250MCG/0.5ML                       A215658  001  Feb 28, 2023   Feb NEWA
    AP    +!  ORGANON USA ORGANON    250MCG/0.5ML                       N021057  001  Jul 29, 1999   May CAHN

        GATIFLOXACIN
          SOLUTION/DROPS;OPHTHALMIC
            ZYMAR
          + @ ALLERGAN               0.3%                               N021493  001  Mar 28, 2003   Mar DISC
            ZYMAXID
    AT    +!  ABBVIE                 0.5%                               N022548  001  May 18, 2010   Jan CAHN

        GEFITINIB
          TABLET;ORAL
            GEFITINIB
    AB        ACTAVIS LABS FL INC    250MG                              A208913  001  Apr 26, 2023   Apr NEWA
    AB        NATCO                  250MG                              A212827  001  May 31, 2023   May NEWA
    AB        QILU PHARM HAINAN      250MG                              A211591  001  Feb 13, 2023   Feb NEWA

        GEMCITABINE HYDROCHLORIDE
          INJECTABLE;INJECTION
            GEMCITABINE HYDROCHLORIDE
    AP        HIKMA                  200MG/5.26ML (38MG/ML)             A213175  001  Mar 07, 2023   Feb NEWA
    AP                               1GM/26.3ML (38MG/ML)               A213175  002  Mar 07, 2023   Feb NEWA
    AP                               2GM/52.6ML (38MG/ML)               A213175  003  Mar 07, 2023   Feb NEWA
    AP        NOVAST LABS            200MG/5.26ML (38MG/ML)             A210383  001  Feb 14, 2019   Jun CMFD
    AP                               1GM/26.3ML (38MG/ML)               A210383  002  Feb 14, 2019   Jun CMFD
    AP                               2GM/52.6ML (38MG/ML)               A210383  003  Feb 14, 2019   Jun CMFD
          SOLUTION;INTRAVENOUS
>D>         INFUGEM
>D>       +!  SUN PHARM              EQ 1200MG BASE/120ML (EQ 10MG      N208313  001  Jul 16, 2018   Jul DISC
                                     BASE/ML)
>A>       + @                        EQ 1200MG BASE/120ML (EQ 10MG      N208313  001  Jul 16, 2018   Jul DISC
                                     BASE/ML)
>D>       +!                         EQ 1300MG BASE/130ML (EQ 10MG      N208313  002  Jul 16, 2018   Jul DISC
```

		SOLUTION;INTRAVENOUS					
>D>		INFUGEM					
			BASE/ML)				
>A>	+ @		EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N208313	002	Jul 16, 2018	Jul DISC
>D>	+!		EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313	003	Jul 16, 2018	Jul DISC
>A>	+ @		EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313	003	Jul 16, 2018	Jul DISC
>D>	+!		EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313	004	Jul 16, 2018	Jul DISC
>A>	+ @		EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313	004	Jul 16, 2018	Jul DISC
>D>	+!		EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313	005	Jul 16, 2018	Jul DISC
>A>	+ @		EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313	005	Jul 16, 2018	Jul DISC
>D>	+!		EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313	006	Jul 16, 2018	Jul DISC
>A>	+ @		EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313	006	Jul 16, 2018	Jul DISC
>D>	+!		EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313	007	Jul 16, 2018	Jul DISC
>A>	+ @		EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313	007	Jul 16, 2018	Jul DISC
>D>	+!		EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313	008	Jul 16, 2018	Jul DISC
>A>	+ @		EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313	008	Jul 16, 2018	Jul DISC
>D>	+!		EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313	009	Jul 16, 2018	Jul DISC
>A>	+ @		EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313	009	Jul 16, 2018	Jul DISC
>D>	+!		EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313	010	Jul 16, 2018	Jul DISC
>A>	+ @		EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313	010	Jul 16, 2018	Jul DISC
		GENTAMICIN SULFATE					
		OINTMENT;OPHTHALMIC					
		GENTAMICIN SULFATE					
	@	AKORN	EQ 0.3% BASE	A064093	001	Aug 31, 1995	Feb DISC
	!	FERA PHARMS LLC	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb CTEC
AT	!		EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb CHRS
		OINTMENT;TOPICAL					
		GENTAMICIN SULFATE					
	@	PAI HOLDINGS PHARM	EQ 0.1% BASE	A209233	001	Dec 31, 2018	May DISC
		SOLUTION/DROPS;OPHTHALMIC					
		GENOPTIC					
	@	ALLERGAN	EQ 0.3% BASE	A062452	001	Oct 10, 1984	Feb DISC
		GENTAK					
	@	AKORN	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Feb DISC
		GENTAMICIN SULFATE					
AT	!	SANDOZ	EQ 0.3% BASE	A062196	001		Feb CHRS
		GENTAMICIN SULFATE; PREDNISOLONE ACETATE					
		OINTMENT;OPHTHALMIC					
		PRED-G					
	+ @	ALLERGAN	EQ 0.3% BASE;0.6%	N050612	001	Dec 01, 1989	Jan DISC
		GLATIRAMER ACETATE					
		FOR SOLUTION;SUBCUTANEOUS					
		COPAXONE					
	+ @	TEVA PHARMS USA	20MG/VIAL	N020622	001	Dec 20, 1996	Jun CRLD
		GLIPIZIDE; METFORMIN HYDROCHLORIDE					
		TABLET;ORAL					
		GLIPIZIDE AND METFORMIN HYDROCHLORIDE					
	@	DASH PHARMS	2.5MG;250MG	A078083	001	Apr 12, 2007	Feb CAHN
	@		2.5MG;500MG	A078083	002	Apr 12, 2007	Feb CAHN
	@		5MG;500MG	A078083	003	Apr 12, 2007	Feb CAHN

GLUCAGON

SOLUTION;SUBCUTANEOUS

GVOKE KIT

	+!	XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	005	Aug 20, 2021	May NEWA

GVOKE PFS

	+ @	XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	001	Sep 10, 2019	Jan DISC

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

RAVICTI

	+!	HORIZON THERAP US	1.1GM/ML	N203284	001	Feb 01, 2013	Jan CAHN

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

	@	LUPIN LTD	0.2MG/ML	A213655	001	Feb 07, 2023	Apr DISC
AP			0.2MG/ML	A213655	001	Feb 07, 2023	Jan NEWA
AP		MANKIND PHARMA	0.2MG/ML	A217354	001	Feb 27, 2023	Feb NEWA

SOLUTION;INHALATION

LONHALA MAGNAIR KIT

>A>	+ @	SUMITOMO PHARMA AM	25MCG/ML	N208437	001	Dec 05, 2017	Jul CAHN
>D>	+!	SUNOVION RESP	25MCG/ML	N208437	001	Dec 05, 2017	Jul CAHN

TABLET;ORAL

GLYCOPYRROLATE

AA		ALEMBIC	1MG	A203657	001	Nov 30, 2018	Feb CAHN
AA			2MG	A203657	002	Nov 30, 2018	Feb CAHN
AA		AUROBINDO PHARMA	1MG	A202675	001	Apr 15, 2013	Jan CAHN
AA			2MG	A202675	002	Oct 30, 2018	Jan CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

DARTISLA ODT

	+ @	EDENBRIDGE PHARMS	1.7MG	N215019	001	Dec 16, 2021	Jun DISC

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

PREVDUO

	+!	SLAYBACK PHARMA LLC	0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML)	N216903	001	Feb 23, 2023	Feb NEWA

GRANISETRON HYDROCHLORIDE

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

	@	AUROBINDO PHARMA USA	EQ 1MG BASE	A078725	001	Jan 30, 2008	May CAHN

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AB		AJANTA PHARMA LTD	EQ 1MG BASE	A217293	001	Apr 27, 2023	Apr NEWA
AB			EQ 2MG BASE	A217293	002	Apr 27, 2023	Apr NEWA
>D>	@	AUROBINDO PHARMA USA	EQ 1MG BASE	A074796	001	Jan 27, 1997	Jul CMFD
>A> AB			EQ 1MG BASE	A074796	001	Jan 27, 1997	Jul CMFD
>D>	@		EQ 2MG BASE	A074796	002	Jan 27, 1997	Jul CMFD
>A> AB			EQ 2MG BASE	A074796	002	Jan 27, 1997	Jul CMFD

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

>A> AB		ALEMBIC	EQ 1MG BASE	A217269	001	Aug 07, 2023	Jul NEWA
>A> AB			EQ 2MG BASE	A217269	002	Aug 07, 2023	Jul NEWA
>A> AB			EQ 3MG BASE	A217269	003	Aug 07, 2023	Jul NEWA
>A> AB			EQ 4MG BASE	A217269	004	Aug 07, 2023	Jul NEWA

HALCINONIDE

CREAM;TOPICAL

HALCINONIDE

AB		CHARTWELL RX	0.1%	A214723	001	Sep 08, 2021	May CAHN

HALOBETASOL PROPIONATE

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

	@	PAI HOLDINGS PHARM	0.05%	A209978	001	Mar 20, 2018	May DISC

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

	@	ACTAVIS GROUP	0.5MG	A200854	001	Jul 01, 2022	Jan DISC
	@		1MG	A200854	002	Jul 01, 2022	Jan DISC
	@		2MG	A200854	003	Jul 01, 2022	Jan DISC
	@		5MG	A200854	004	Jul 01, 2022	Jan DISC
	@		10MG	A200854	005	Jul 01, 2022	Jan DISC
	@		20MG	A200854	006	Jul 01, 2022	Jan DISC
AB		ZYDUS PHARMS USA	0.5MG	A077580	001	Jan 17, 2023	Jan NEWA
AB			1MG	A077580	002	Jan 17, 2023	Jan NEWA
AB			2MG	A077580	006	Jan 17, 2023	Jan NEWA

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

AO		MANKIND PHARMA	EQ 50MG BASE/ML	A216730	001	May 23, 2023	May NEWA
AO			EQ 100MG BASE/ML	A216730	002	May 23, 2023	May NEWA

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

AP		NANJING KING-FRIEND	5,000 UNITS/ML	A212061	001	Jul 15, 2020	Feb CMFD

HEPARIN SODIUM PRESERVATIVE FREE

AP		NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Feb CMFD

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

AP		EUGIA PHARMA	20MG/ML	A215147	001	Feb 13, 2023	Feb NEWA
	@	MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	May DISC

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA		HERITAGE PHARMS INC	10MG	A040858	001	Feb 26, 2010	May CMFD
AA			25MG	A040858	002	Feb 26, 2010	May CMFD
AA			50MG	A040858	003	Feb 26, 2010	May CMFD
AA			100MG	A040858	004	Feb 26, 2010	May CMFD

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

AB		HERITAGE PHARMS	12.5MG	A085182	003	May 02, 2023	Apr NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	!	INVAGEN PHARMS	12.5MG;20MG	A204058	002	May 23, 2017	Jun CHRS
AB	!		25MG;20MG	A204058	003	May 23, 2017	Jun CHRS

ZESTORETIC

AB	+	ALMATICA	12.5MG;20MG	N019888	001	Sep 20, 1990	Jun CHRS
AB	+		25MG;20MG	N019888	002	Jul 20, 1989	Jun CHRS

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB		MACLEODS PHARMS LTD	12.5MG;20MG	A204801	001	Jun 01, 2023	May NEWA
AB			12.5MG;40MG	A204801	002	Jun 01, 2023	May NEWA
AB			25MG;40MG	A204801	003	Jun 01, 2023	May NEWA
>D> AB		ZYDUS PHARMS	12.5MG;20MG	A206377	001	Feb 24, 2023	Jul DISC
>A>	@		12.5MG;20MG	A206377	001	Feb 24, 2023	Jul DISC
AB			12.5MG;20MG	A206377	001	Feb 24, 2023	Feb NEWA
>D> AB			12.5MG;40MG	A206377	002	Feb 24, 2023	Jul DISC
>A>	@		12.5MG;40MG	A206377	002	Feb 24, 2023	Jul DISC
AB			12.5MG;40MG	A206377	002	Feb 24, 2023	Feb NEWA
>D> AB			25MG;40MG	A206377	003	Feb 24, 2023	Jul DISC
>A>	@		25MG;40MG	A206377	003	Feb 24, 2023	Jul DISC
AB			25MG;40MG	A206377	003	Feb 24, 2023	Feb NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		APOTEX	12.5MG;EQ 10MG BASE	A091524	001	Mar 12, 2013	Jan CAHN
AB			12.5MG;EQ 20MG BASE	A091524	002	Mar 12, 2013	Jan CAHN
AB			25MG;EQ 20MG BASE	A091524	003	Mar 12, 2013	Jan CAHN
	@	CHARTWELL RX	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Apr CAHN
	@		12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Apr CAHN
	@		25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Apr CAHN

HYDROCORTISONE

TABLET;ORAL

HYDROCORTISONE

>A> AB		AUROBINDO PHARMA LTD	5MG	A214649	001	Jul 17, 2023	Jul NEWA
>A> AB			10MG	A214649	002	Jul 17, 2023	Jul NEWA
>A> AB			20MG	A214649	003	Jul 17, 2023	Jul NEWA

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDROMORPHONE HYDROCHLORIDE

AP		HIKMA	2MG/ML	A202159	001	Apr 27, 2018	May CAHN
		HOSPIRA INC	0.25MG/0.5ML	N200403	005	Mar 03, 2023	Mar NEWA
			4MG/ML	N200403	003	Dec 01, 2011	Apr CTEC

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

PAREMYD

	+ @	AKORN	1%;0.25%	N019261	001	Jan 30, 1992	Feb DISC

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

AB		CHARTWELL RX	200MG	A210543	001	Jul 06, 2018	May CAHN

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR

HYDROXYPROGESTERONE CAPROATE

>D>	!	ASPEN GLOBAL INC	1250MG/5ML (250MG/ML)	A200271	001	Aug 24, 2015	Jul DISC
>A>	@		1250MG/5ML (250MG/ML)	A200271	001	Aug 24, 2015	Jul DISC

HYDROXYPROPYL CELLULOSE

INSERT;OPHTHALMIC

LACRISERT

+!		BAUSCH	5MG	N018771	001		Jan CAHN
+!		BAUSCH AND LOMB INC	5MG	N018771	001		Jan CAHN

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDROXYZINE HYDROCHLORIDE

+!		AM REGENT	25MG/ML	A087408	001		Feb CRLD
+!			50MG/ML	A087408	002		Feb CRLD

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB		CHARTWELL RX	10MG	A040804	001	Jun 30, 2008	Jan CAHN
AB			25MG	A040804	002	Jun 30, 2008	Jan CAHN
AB			50MG	A040804	003	Jun 30, 2008	Jan CAHN

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB		HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar CTEC
AB			EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar CTEC

IBRUTINIB

CAPSULE;ORAL

IMBRUVICA

+		PHARMACYCLICS LLC	70MG	N205552	002	Dec 20, 2017	Jun CAHN
+!			140MG	N205552	001	Nov 13, 2013	Jun CAHN

```
          SUSPENSION;ORAL
            IMBRUVICA
          +!  PHARMACYCLICS LLC      70MG/ML                          N217003  001  Aug 24, 2022   Jun CAHN
          TABLET;ORAL
            IMBRUVICA
          +   PHARMACYCLICS LLC      140MG                            N210563  001  Feb 16, 2018   Jun CAHN
          +                          280MG                            N210563  002  Feb 16, 2018   Jun CAHN
          +                          420MG                            N210563  003  Feb 16, 2018   Jun CAHN
>D>       +!                         560MG                            N210563  004  Feb 16, 2018   Jul DISC
>A>       + @                        560MG                            N210563  004  Feb 16, 2018   Jul DISC
          +!                         560MG                            N210563  004  Feb 16, 2018   Jun CAHN

        ICOSAPENT ETHYL
          CAPSULE;ORAL
            ICOSAPENT ETHYL
    AB        DR REDDYS              500MG                            A209499  002  Mar 08, 2023   Feb NEWA
    AB        HIKMA                  500MG                            A209457  002  Mar 08, 2023   Feb NEWA
    AB        ZYDUS                  500MG                            A217656  001  Apr 20, 2023   Apr NEWA
    AB                               1GM                              A217656  002  Apr 20, 2023   Apr NEWA

        IMATINIB MESYLATE
          TABLET;ORAL
            IMATINIB MESYLATE
            @ BRECKENRIDGE           EQ 100MG BASE                    A205990  001  Feb 08, 2019   Mar DISC
            @                        EQ 400MG BASE                    A205990  002  Feb 08, 2019   Jun DISC
    AB        CHARTWELL RX           EQ 100MG BASE                    A208429  001  Jan 17, 2019   Jan CAHN
    AB                               EQ 400MG BASE                    A208429  002  Jan 17, 2019   Jan CAHN

        IMIQUIMOD
          CREAM;TOPICAL
            ALDARA
          + @ BAUSCH                 5%                               N020723  001  Feb 27, 1997   Feb DISC
            IMIQUIMOD
    AB    !   GLENMARK GENERICS      5%                               A201994  001  Mar 06, 2012   Feb CHRS

        INDAPAMIDE
          TABLET;ORAL
            INDAPAMIDE
            @ AUROBINDO PHARMA USA   1.25MG                           A075105  001  Jul 23, 1998   Apr CAHN
            @                        2.5MG                            A075105  002  Jul 23, 1998   Apr CAHN
>D>         @ RISING                 1.25MG                           A074461  002  Mar 26, 1997   Jul CMFD
>A> AB                               1.25MG                           A074461  002  Mar 26, 1997   Jul CMFD
>D>         @                        2.5MG                            A074461  001  Mar 27, 1996   Jul CMFD
>A> AB                               2.5MG                            A074461  001  Mar 27, 1996   Jul CMFD

        INDOMETHACIN
          CAPSULE;ORAL
            INDOMETHACIN
    AB        CHARTWELL MOLECULES    25MG                             N018829  002  Aug 06, 1984   Feb CMFD
    AB                               50MG                             N018829  001  Aug 06, 1984   Feb CMFD
          SUPPOSITORY;RECTAL
            INDOCIN
>D>       + @ EGALET                 50MG                             N017814  001  Aug 13, 1984   Jul CAHN
>A>       + @ ZYLA LIFE SCIENCES     50MG                             N017814  001  Aug 13, 1984   Jul CAHN
            INDOMETHACIN
>D>       !   COSETTE                50MG                             A073314  001  Aug 31, 1992   Jul CTEC
>A> AB    !                          50MG                             A073314  001  Aug 31, 1992   Jul CTEC
>A> AB        ZYDUS                  50MG                             A216184  001  Aug 02, 2023   Jul NEWA
          SUSPENSION;ORAL
            INDOCIN
          +!  ZYLA                   25MG/5ML                         N018332  001  Oct 10, 1985   Jun CAHN

        INFIGRATINIB PHOSPHATE
          CAPSULE;ORAL
            TRUSELTIQ
          + @ HELSINN HLTHCARE       25MG                             N214622  001  May 28, 2021   Apr DISC
          + @                        100MG                            N214622  002  May 28, 2021   Apr DISC
```

IOPAMIDOL

INJECTABLE;INJECTION

IOPAMIDOL

AP	HAINAN POLY	41%	A215382	001	Feb 27, 2023	Feb NEWA
AP		61%	A215382	002	Feb 27, 2023	Feb NEWA

ISOVUE-250

+	@ BRACCO	51%	N020327	002	Oct 12, 1994	Jun DISC

ISOVUE-M 200

AP	+! BRACCO	41%	N018735	001	Dec 31, 1985	Feb CTEC

ISOVUE-M 300

AP	+! BRACCO	61%	N018735	004	Dec 31, 1985	Feb CTEC

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL

IPRATROPIUM BROMIDE

@	AUROBINDO PHARMA USA	0.021MG/SPRAY	A075552	001	Mar 31, 2003	Apr CAHN
@		0.042MG/SPRAY	A075553	001	Mar 31, 2003	Apr CAHN

IRBESARTAN

TABLET;ORAL

IRBESARTAN

AB	UNICHEM	75MG	A203020	001	Dec 07, 2015	Jun CMFD
AB		150MG	A203020	002	Dec 07, 2015	Jun CMFD
AB		300MG	A203020	003	Dec 07, 2015	Jun CMFD

ISONIAZID

TABLET;ORAL

LANIAZID

@	CHARTWELL MOLECULAR	50MG	A080140	001		Feb CAHN
@		100MG	A080140	002		Feb CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE;INJECTION

ISOPROTERENOL HYDROCHLORIDE

@	AM REGENT	0.2MG/ML	A214775	001	Oct 19, 2022	Apr DISC
AP	HIKMA	0.2MG/ML	A211703	001	Apr 26, 2023	Apr NEWA
>D> AP	MYLAN LABS LTD	0.2MG/ML	A212573	001	Sep 06, 2022	Jul DISC
>A> @		0.2MG/ML	A212573	001	Sep 06, 2022	Jul DISC
AP	PENN LIFE	0.2MG/ML	A215542	001	Sep 20, 2022	May CAHN

ISUPREL

+	@ BAUSCH	0.2MG/ML	N010515	001		Jun DISC

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

@	SHANDONG	120MG	A214115	001	Apr 29, 2022	May DISC

ISOSULFAN BLUE

INJECTABLE;INJECTION

ISOSULFAN BLUE

AP	AM REGENT	1%	A210294	001	May 17, 2023	May NEWA

IVACAFTOR

GRANULE;ORAL

KALYDECO

+	VERTEX PHARMS INC	5.8MG/PACKET	N207925	004	May 03, 2023	May NEWA
+		13.4MG/PACKET	N207925	005	May 03, 2023	May NEWA

IVERMECTIN

CREAM;TOPICAL

IVERMECTIN

>D> @	ZYDUS	1%	A215210	001	Aug 02, 2022	Jul CMFD
>A> AB		1%	A215210	001	Aug 02, 2022	Jul CMFD
@		1%	A215210	001	Aug 02, 2022	Jan DISC

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

KETAMINE HYDROCHLORIDE

>D>	AP	FRESENIUS KABI USA	EQ 10MG BASE/ML	A215808	001	Jan 13, 2023	Jul DISC
>A>		@	EQ 10MG BASE/ML	A215808	001	Jan 13, 2023	Jul DISC
	AP		EQ 10MG BASE/ML	A215808	001	Jan 13, 2023	Jan NEWA
>D>	AP		EQ 50MG BASE/ML	A215808	002	Jan 13, 2023	Jul DISC
>A>		@	EQ 50MG BASE/ML	A215808	002	Jan 13, 2023	Jul DISC
	AP		EQ 50MG BASE/ML	A215808	002	Jan 13, 2023	Jan NEWA
	AP	GLAND PHARMA LTD	EQ 50MG BASE/ML	A216809	002	Jan 24, 2023	Jan NEWA
	AP		EQ 100MG BASE/ML	A216809	003	Jan 24, 2023	Jan NEWA

KETOCONAZOLE

TABLET;ORAL

KETOCONAZOLE

		@ AUROBINDO PHARMA USA	200MG	A075597	001	Dec 23, 1999	May CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

	AP	ASPIRO	15MG/ML	A217166	001	Jun 20, 2023	Jun NEWA
	AP		30MG/ML	A217166	002	Jun 20, 2023	Jun NEWA
	AP	CAPLIN	15MG/ML	A217789	001	May 10, 2023	Apr NEWA
	AP		30MG/ML	A217789	002	May 10, 2023	Apr NEWA

SOLUTION/DROPS;OPHTHALMIC

ACULAR

	AT	+! ABBVIE	0.5%	N019700	001	Nov 09, 1992	Jan CAHN

KETOROLAC TROMETHAMINE

		@ AKORN	0.5%	A078434	001	Nov 05, 2009	Jan DISC

TABLET;ORAL

KETOROLAC TROMETHAMINE

	AB	BIONPHARMA	10MG	A216759	001	Feb 23, 2023	Feb NEWA
	AB	LEADING	10MG	A215745	001	Feb 23, 2023	Feb NEWA

KETOTIFEN FUMARATE

DRUG-ELUTING CONTACT LENS;OPHTHALMIC

ACUVUE THERAVISION WITH KETOTIFEN

		+ @ JOHNSON JOHNSON VISN	EQ 19MCG BASE	N022388	001	Feb 25, 2022	May DISC

LACOSAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

MOTPOLY XR

		+ AUCTA	100MG	N216185	001	May 04, 2023	May NEWA
		+	150MG	N216185	002	May 04, 2023	May NEWA
		+!	200MG	N216185	003	May 04, 2023	May NEWA

SOLUTION;INTRAVENOUS

LACOSAMIDE

	AP	MSN	200MG/20ML (10MG/ML)	A215979	001	Feb 09, 2023	Feb NEWA

SOLUTION;ORAL

LACOSAMIDE

	AA	MEDLEY PHARMS	10MG/ML	A216461	001	Feb 06, 2023	Jan NEWA

TABLET;ORAL

LACOSAMIDE

		@ ACCORD HLTHCARE	50MG	A205011	001	Jul 12, 2022	Jan DISC
		@	100MG	A205011	002	Jul 12, 2022	Jan DISC
		@	150MG	A205011	003	Jul 12, 2022	Jan DISC
		@	200MG	A205011	004	Jul 12, 2022	Jan DISC
>D>	AB	ACTAVIS LABS FL INC	50MG	A204855	001	Jan 05, 2023	Jul DISC
>A>		@	50MG	A204855	001	Jan 05, 2023	Jul DISC
>D>	AB		100MG	A204855	002	Jan 05, 2023	Jul DISC
>A>		@	100MG	A204855	002	Jan 05, 2023	Jul DISC
>D>	AB		150MG	A204855	003	Jan 05, 2023	Jul DISC
>A>		@	150MG	A204855	003	Jan 05, 2023	Jul DISC
>D>	AB		200MG	A204855	004	Jan 05, 2023	Jul DISC
>A>		@	200MG	A204855	004	Jan 05, 2023	Jul DISC
		@ APOTEX	50MG	A214567	001	Sep 23, 2022	Mar DISC
		@	100MG	A214567	002	Sep 23, 2022	Mar DISC
		@	150MG	A214567	003	Sep 23, 2022	Mar DISC
		@	200MG	A214567	004	Sep 23, 2022	Mar DISC

LACTULOSE

SOLUTION;ORAL

LACTULOSE

AA	XTTRIUM LABS INC	10GM/15ML	A075911	001	Feb 21, 2002	Mar CMFD

SOLUTION;ORAL, RECTAL

LACTULOSE

AA	BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003	Feb CMFD

LAMIVUDINE

SOLUTION;ORAL

LAMIVUDINE

>A> AA	CHARTWELL MOLECULAR	10MG/ML	A203564	001	Oct 31, 2014	Jul CAHN
>D> AA	LANNETT CO INC	10MG/ML	A203564	001	Oct 31, 2014	Jul CAHN

TABLET;ORAL

LAMIVUDINE

@	AUROBINDO PHARMA USA	100MG	A204002	001	Dec 31, 2014	May CAHN

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TEMIXYS

+ @	CHARTWELL RX	300MG;300MG	N211284	001	Nov 16, 2018	Mar CAHN

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

@	CHARTWELL MOLECULAR	25MG	A077783	001	Nov 01, 2010	Jan CAHN
@		100MG	A077783	002	Nov 01, 2010	Jan CAHN
@		150MG	A077783	003	Nov 01, 2010	Jan CAHN
@		200MG	A077783	004	Nov 01, 2010	Jan CAHN

LANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

AB	AUROBINDO PHARMA LTD	15MG	A207167	001	Mar 28, 2023	Mar NEWA
AB		30MG	A207167	002	Mar 28, 2023	Mar NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

@	AKORN	0.005%	A090887	001	Jul 19, 2011	Jan DISC

LATANOPROST; NETARSUDIL DIMESYLATE

SOLUTION/DROPS;OPHTHALMIC

ROCKLATAN

+!	ALCON LABS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019	May CAHN

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

AB	APOTEX	2.5MG	A211022	005	Mar 07, 2023	Feb NEWA
AB		20MG	A211022	006	Mar 07, 2023	Feb NEWA
AB	ARROW INTL	2.5MG	A201452	005	Mar 06, 2023	Feb NEWA
AB		20MG	A201452	006	Mar 06, 2023	Feb NEWA
AB	CIPLA	2.5MG	A214618	001	Mar 06, 2023	Feb NEWA
AB		20MG	A210435	005	Mar 06, 2023	Feb NEWA
AB	EUGIA PHARMA	2.5MG	A213885	001	Mar 06, 2023	Feb NEWA
AB		5MG	A213885	002	Mar 06, 2023	Feb NEWA
AB		10MG	A213885	003	Mar 06, 2023	Feb NEWA
AB		15MG	A213885	004	Mar 06, 2023	Feb NEWA
AB		20MG	A213885	005	Mar 06, 2023	Feb NEWA
AB		25MG	A213885	006	Mar 06, 2023	Feb NEWA
AB	HETERO LABS LTD V	2.5MG	A212414	001	May 11, 2023	May NEWA
AB		5MG	A212414	002	May 11, 2023	May NEWA
AB		10MG	A212414	003	May 11, 2023	May NEWA
AB		15MG	A212414	004	May 11, 2023	May NEWA
AB		20MG	A212414	005	May 11, 2023	May NEWA
AB		25MG	A212414	006	May 11, 2023	May NEWA
AB	LOTUS PHARM CO LTD	2.5MG	A210480	005	Mar 06, 2023	Feb NEWA
AB		20MG	A210480	006	Mar 06, 2023	Feb NEWA
AB	MYLAN	2.5MG	A213912	005	Mar 06, 2023	Feb NEWA
AB		20MG	A213912	006	Mar 06, 2023	Feb NEWA

CAPSULE;ORAL
LENALIDOMIDE

	AB	SUN PHARM	2.5MG	A211846	005	Mar 06, 2023	Feb	NEWA
	AB		5MG	A211846	001	Feb 08, 2023	Jan	NEWA
	AB		10MG	A211846	002	Feb 08, 2023	Jan	NEWA
	AB		15MG	A211846	003	Feb 08, 2023	Jan	NEWA
	AB		20MG	A211846	006	Mar 06, 2023	Feb	NEWA
	AB		25MG	A211846	004	Feb 08, 2023	Jan	NEWA
	AB	TORRENT	10MG	A213405	001	Feb 17, 2023	Feb	NEWA
>A>	AB		20MG	A213405	003	Aug 03, 2023	Jul	NEWA
	AB		25MG	A213405	002	Feb 17, 2023	Feb	NEWA
	AB	ZYDUS PHARMS	2.5MG	A210154	005	Mar 06, 2023	Feb	NEWA
	AB		20MG	A210154	006	Mar 06, 2023	Feb	NEWA

LENIOLISIB PHOSPHATE

TABLET;ORAL
JOENJA

	+!	PHARMING	EQ 70MG BASE	N217759	001	Mar 24, 2023	Mar	NEWA

LETROZOLE

TABLET;ORAL
LETROZOLE

	@	CHARTWELL RX	2.5MG	A202716	001	May 16, 2013	Feb	CAHN

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION
LEUCOVORIN CALCIUM

	!	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Apr	CHRS
			EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Apr	CTEC
	!		EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Apr	CHRS
	AP	HAINAN POLY	EQ 50MG BASE/VIAL	A217021	001	Jul 10, 2023	Jun	NEWA
	AP		EQ 100MG BASE/VIAL	A217021	002	Jul 10, 2023	Jun	NEWA
	AP		EQ 200MG BASE/VIAL	A217021	003	Jul 10, 2023	Jun	NEWA
	AP		EQ 500MG BASE/VIAL	A217021	004	Jul 10, 2023	Jun	NEWA
>A>	AP	KINDOS	EQ 50MG BASE/VIAL	A216590	001	Jul 19, 2023	Jul	NEWA
>A>	AP		EQ 100MG BASE/VIAL	A216590	002	Jul 19, 2023	Jul	NEWA
>A>	AP		EQ 200MG BASE/VIAL	A216590	003	Jul 19, 2023	Jul	NEWA
>A>	AP		EQ 350MG BASE/VIAL	A216590	004	Jul 19, 2023	Jul	NEWA
>A>	AP		EQ 500MG BASE/VIAL	A216590	005	Jul 19, 2023	Jul	NEWA

LEUCOVORIN CALCIUM PRESERVATIVE FREE

	@	HIKMA	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Apr	DISC

LEUPROLIDE ACETATE

INJECTABLE;INJECTION
LEUPROLIDE ACETATE

	AP	RK PHARMA	1MG/0.2ML	A213829	001	Aug 13, 2021	Jun	CAHN

LUPRON DEPOT

>D>	+!	ABBVIE ENDOCRINE INC	7.5MG/VIAL	N019732	001	Jan 26, 1989	Jul	CPOT
>A>	+!		7.5MG	N019732	001	Jan 26, 1989	Jul	CPOT
>D>	+!		11.25MG/VIAL	N020708	001	Mar 07, 1997	Jul	CPOT
>A>	+!		11.25MG	N020708	001	Mar 07, 1997	Jul	CPOT
>D>	+		22.5MG/VIAL	N020517	001	Dec 22, 1995	Jul	CPOT
>A>	+		22.5MG	N020517	001	Dec 22, 1995	Jul	CPOT
>D>	+!		30MG/VIAL	N020517	002	May 30, 1997	Jul	CPOT
>A>	+!		30MG	N020517	002	May 30, 1997	Jul	CPOT
>D>	+!		45MG/VIAL	N020517	003	Jun 17, 2011	Jul	CPOT
>A>	+!		45MG	N020517	003	Jun 17, 2011	Jul	CPOT

POWDER;INTRAMUSCULAR
LUPRON DEPOT-PED KIT

	+!	ABBVIE ENDOCRINE INC	45MG	N020263	009	Apr 14, 2023	Apr	NEWA

POWDER;SUBCUTANEOUS
ELIGARD KIT

	+!	TOLMAR	7.5MG	N021343	001	Jan 23, 2002	Feb	CAHN
	+!		22.5MG	N021379	001	Jul 24, 2002	Feb	CAHN
	+!		30MG	N021488	001	Feb 13, 2003	Feb	CAHN
	+!		45MG	N021731	001	Dec 14, 2004	Feb	CAHN

LEVETIRACETAM

INJECTABLE;INTRAVENOUS

LEVETIRACETAM IN SODIUM CHLORIDE

AP	FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Jan NEWA
AP		1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Jan NEWA

SOLUTION;ORAL

LEVETIRACETAM

AA	ALEMBIC	100MG/ML	A203067	001	May 09, 2013	Feb CAHN
AA	BIONPHARMA	100MG/ML	A079120	001	Jan 16, 2009	Jun CAHN
AA	QUAGEN	100MG/ML	A090079	001	Apr 11, 2012	Feb CAHN
	@ XTTRIUM LABS INC	100MG/ML	A090028	001	Mar 03, 2010	Mar CAHN

TABLET;ORAL

LEVETIRACETAM

AB	GRANULES	250MG	A217878	001	Jun 13, 2023	Jun NEWA
AB		500MG	A217878	002	Jun 13, 2023	Jun NEWA
AB		750MG	A217878	003	Jun 13, 2023	Jun NEWA
AB		1GM	A217878	004	Jun 13, 2023	Jun NEWA
	@ MYLAN	250MG	A076919	001	Nov 04, 2008	Apr DISC

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

	@ AUROBINDO PHARMA USA	500MG	A200475	001	Dec 19, 2011	Apr CAHN
	@	750MG	A200475	002	Dec 19, 2011	Apr CAHN
	@	1GM	A200475	003	Dec 07, 2015	Apr CAHN
AB	OVERSEAS	500MG	A212688	002	May 05, 2023	Apr NEWA

LEVOFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

	@ AKORN	0.5%	A090268	001	Dec 20, 2010	Jan DISC
!	RISING	0.5%	A077700	001	Dec 20, 2010	Jan CTEC

LEVOLEUCOVORIN CALCIUM

SOLUTION;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

AP !	GLAND PHARMA LTD	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210892	002	Sep 14, 2018	May CTEC
AP	HAINAN POLY PHARM	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A217314	001	May 22, 2023	May NEWA
AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A217314	002	May 22, 2023	May NEWA

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

FETZIMA

+	ABBVIE	EQ 20MG BASE	N204168	001	Jul 25, 2013	Mar CTEC
AB +		EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan CAHN
+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Mar CTEC
AB +		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan CAHN
+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Mar CTEC
AB +		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan CAHN
+!		EQ 120MG BASE	N204168	004	Jul 25, 2013	Mar CTEC
AB +!		EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan CAHN

LEVOMILNACIPRAN HYDROCHLORIDE

	@ AUROBINDO PHARMA LTD	EQ 20MG BASE	A210826	001	Jan 06, 2023	Mar DISC
	@	EQ 40MG BASE	A210826	002	Jan 06, 2023	Mar DISC
	@	EQ 80MG BASE	A210826	003	Jan 06, 2023	Mar DISC
	@	EQ 120MG BASE	A210826	004	Jan 06, 2023	Mar DISC
AB	PRINSTON INC	EQ 20MG BASE	A210771	001	Mar 20, 2023	Mar NEWA
AB		EQ 40MG BASE	A210771	002	Mar 20, 2023	Mar NEWA
AB		EQ 80MG BASE	A210771	003	Mar 20, 2023	Mar NEWA
AB		EQ 120MG BASE	A210771	004	Mar 20, 2023	Mar NEWA

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

AB	HIKMA	2MG	A074278	001	Mar 31, 2000	Jan CMFD
AB !	NOVITIUM PHARMA	3MG	A213479	002	Jan 12, 2021	Apr CTEC
AB	SUN PHARM INDS INC	3MG	A213906	002	Apr 25, 2023	Apr NEWA

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

LEVOTHYROXINE SODIUM

	@ TEVA PHARMS USA INC	0.137MG	A211369	005	May 02, 2023	May DISC
AB		0.137MG	A211369	005	May 02, 2023	Apr NFTG
	@	0.175MG	A211369	006	May 02, 2023	May DISC
AB		0.175MG	A211369	006	May 02, 2023	Apr NFTG
	@	0.2MG	A211369	004	Nov 09, 2022	May DISC
	TIROSINT					
+	INSTITUT BIOCHIMIQUE	0.137MG	N021924	009	Oct 02, 2009	May CTEC
AB +		0.137MG	N021924	009	Oct 02, 2009	Apr CFTG
+		0.175MG	N021924	011	Apr 25, 2017	May CTEC
AB +		0.175MG	N021924	011	Apr 25, 2017	Apr CFTG
+!		0.2MG	N021924	012	Apr 25, 2017	May CTEC

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	ZYDUS PHARMS	100MCG/VIAL	A217066	001	Mar 24, 2023	Mar NEWA
AP		200MCG/VIAL	A217066	002	Mar 24, 2023	Mar NEWA
AP		500MCG/VIAL	A217066	003	Mar 24, 2023	Mar NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOTHYROXINE SODIUM

AB4	ASCENT PHARMS INC	0.025MG	A215259	001	Jan 18, 2023	Jan NEWA
AB4		0.05MG	A215259	002	Jan 18, 2023	Jan NEWA
AB4		0.075MG	A215259	003	Jan 18, 2023	Jan NEWA
AB4		0.088MG	A215259	004	Jan 18, 2023	Jan NEWA
AB4		0.1MG	A215259	005	Jan 18, 2023	Jan NEWA
AB4		0.112MG	A215259	006	Jan 18, 2023	Jan NEWA
AB4		0.125MG	A215259	007	Jan 18, 2023	Jan NEWA
AB4		0.137MG	A215259	008	Jan 18, 2023	Jan NEWA
AB4		0.15MG	A215259	009	Jan 18, 2023	Jan NEWA
AB4		0.175MG	A215259	010	Jan 18, 2023	Jan NEWA
AB4		0.2MG	A215259	011	Jan 18, 2023	Jan NEWA
AB4		0.3MG	A215259	012	Jan 18, 2023	Jan NEWA
AB2	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Jan CTEC
AB2		0.05MG	A211417	002	Dec 21, 2022	Jan CTEC
AB2		0.075MG	A211417	003	Dec 21, 2022	Jan CTEC
AB2		0.088MG	A211417	004	Dec 21, 2022	Jan CTEC
AB2		0.1MG	A211417	005	Dec 21, 2022	Jan CTEC
AB2		0.112MG	A211417	006	Dec 21, 2022	Jan CTEC
AB2		0.125MG	A211417	007	Dec 21, 2022	Jan CTEC
AB2		0.137MG	A211417	008	Dec 21, 2022	Jan CTEC
AB2		0.15MG	A211417	009	Dec 21, 2022	Jan CTEC
AB2		0.175MG	A211417	010	Dec 21, 2022	Jan CTEC
AB2		0.2MG	A211417	011	Dec 21, 2022	Jan CTEC
AB2		0.3MG	A211417	012	Dec 21, 2022	Jan CTEC

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

	@ PAI HOLDINGS PHARM	5%	A205318	001	Feb 01, 2016	May DISC

PATCH;TOPICAL

LIDOCAINE

AB	INST BIOCHIMIQUE SA	5%	A209190	001	Apr 30, 2020	Apr CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

AP	HUONS	2%	A212821	002	Jun 15, 2023	Jun NEWA
AP	MANKIND PHARMA	1%	A217692	001	Jun 16, 2023	Jun NEWA
AP		1%	A217693	001	Jul 11, 2023	Jun NEWA
AP		2%	A217692	002	Jun 16, 2023	Jun NEWA
AP		2%	A217693	002	Jul 11, 2023	Jun NEWA

JELLY;TOPICAL

GLYDO

AT !	SAGENT PHARMS INC	2%	A201094	001	Apr 28, 2014	Apr CHRS

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE

AT	RUBICON	2%	A216780	001	Mar 28, 2023	Mar NEWA

```
          SOLUTION;ORAL
            LIDOCAINE HYDROCHLORIDE VISCOUS
>A> AT        CHARTWELL MOLECULAR    2%                          A040708  001  Feb 27, 2007   Jul CAHN
>D> AT        LANNETT CO INC         2%                          A040708  001  Feb 27, 2007   Jul CAHN

        LIDOCAINE; PRILOCAINE
          CREAM;TOPICAL
            LIDOCAINE AND PRILOCAINE
            @ PAI HOLDINGS PHARM     2.5%;2.5%                   A205887  001  Jun 29, 2018   May DISC

        LIFITEGRAST
          SOLUTION/DROPS;OPHTHALMIC
>A>         LIFITEGRAST
>A> AT        MICRO LABS             5%                          A215081  001  Aug 04, 2023   Jul NFTG
            XIIDRA
>D>       +!  NOVARTIS               5%                          N208073  001  Jul 11, 2016   Jul CFTG
>A> AT    +!                         5%                          N208073  001  Jul 11, 2016   Jul CFTG

        LINACLOTIDE
          CAPSULE;ORAL
            LINACLOTIDE
            @ AUROBINDO PHARMA       145MCG                      A209611  001  Feb 07, 2023   Mar DISC
    AB                               145MCG                      A209611  001  Feb 07, 2023   Jan NEWA
            @                        290MCG                      A209611  002  Feb 07, 2023   Mar DISC
    AB                               290MCG                      A209611  002  Feb 07, 2023   Jan NEWA
            LINZESS
          +!  ABBVIE                 145MCG                      N202811  001  Aug 30, 2012   Mar CTEC
          +                          290MCG                      N202811  002  Aug 30, 2012   Mar CTEC
    AB    +!  ALLERGAN               145MCG                      N202811  001  Aug 30, 2012   Jan CTEC
    AB    +                          290MCG                      N202811  002  Aug 30, 2012   Jan CTEC

        LINAGLIPTIN
          TABLET;ORAL
            LINAGLIPTIN
>D> AB        ZYDUS PHARMS           5MG                         A208448  001  Mar 30, 2023   Jul DISC
>A>         @                        5MG                         A208448  001  Mar 30, 2023   Jul DISC
    AB                               5MG                         A208448  001  Mar 30, 2023   Mar NEWA

        LINAGLIPTIN; METFORMIN HYDROCHLORIDE
          TABLET;ORAL
            LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
>D> AB        ZYDUS PHARMS           2.5MG;500MG                 A208449  001  Mar 30, 2023   Jul DISC
>A>         @                        2.5MG;500MG                 A208449  001  Mar 30, 2023   Jul DISC
    AB                               2.5MG;500MG                 A208449  001  Mar 30, 2023   Mar NEWA
>D> AB                               2.5MG;850MG                 A208449  002  Mar 30, 2023   Jul DISC
>A>         @                        2.5MG;850MG                 A208449  002  Mar 30, 2023   Jul DISC
    AB                               2.5MG;850MG                 A208449  002  Mar 30, 2023   Mar NEWA
>D> AB                               2.5MG;1GM                   A208449  003  Mar 30, 2023   Jul DISC
>A>         @                        2.5MG;1GM                   A208449  003  Mar 30, 2023   Jul DISC
    AB                               2.5MG;1GM                   A208449  003  Mar 30, 2023   Mar NEWA

        LINCOMYCIN HYDROCHLORIDE
          INJECTABLE;INJECTION
            LINCOMYCIN HYDROCHLORIDE
>D>         @ ATHENEX INC            EQ 300MG BASE/ML            A212770  001  Mar 12, 2021   Jul CAHN
            @ HAINAN POLY            EQ 300MG BASE/ML            A216662  001  Dec 21, 2022   Jun DISC
>A>         @ PRAXGEN PHARMS         EQ 300MG BASE/ML            A212770  001  Mar 12, 2021   Jul CAHN

        LINEZOLID
          TABLET;ORAL
            LINEZOLID
    AB        CHARTWELL RX           600MG                       A210702  001  Apr 25, 2019   Mar CAHN

        LIOTHYRONINE SODIUM
          INJECTABLE;INJECTION
            LIOTHYRONINE SODIUM
          !   XGEN PHARMS            EQ 0.01MG BASE/ML           A076923  001  Aug 17, 2005   Jun CHRS
                                     EQ 0.01MG BASE/ML           A076923  001  Aug 17, 2005   Jun CTEC
            TRIOSTAT
          + @ PAR STERILE PRODUCTS   EQ 0.01MG BASE/ML           N020105  001  Dec 31, 1991   Jun DISC
```

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB	HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002	Mar	CMFD
AB		5MG	A075752	002	Jul 01, 2002	Mar	CMFD
AB		10MG	A075752	003	Jul 01, 2002	Mar	CMFD
AB		20MG	A075752	004	Jul 01, 2002	Mar	CMFD
AB		30MG	A075752	005	Jul 01, 2002	Mar	CMFD
AB		40MG	A075752	006	Jul 01, 2002	Mar	CMFD

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

AB	JUBILANT CADISTA	2MG	A217840	001	Jul 05, 2023	Jun	NEWA
AB	RUBICON	2MG	A216876	001	Jan 26, 2023	Jan	NEWA
AB	ZYDUS LIFESCIENCES	2MG	A217471	001	Mar 23, 2023	Apr	CAHN
AB	ZYDUS PHARMS	2MG	A217471	001	Mar 23, 2023	Mar	NEWA

LORAZEPAM

TABLET;ORAL

LORAZEPAM

@	AMNEAL PHARMS	0.5MG	A078826	001	Jun 23, 2010	May	DISC
@		1MG	A078826	002	Jun 23, 2010	May	DISC
@		2MG	A078826	003	Jun 23, 2010	May	DISC

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB	GRANULES	25MG	A215959	001	Feb 23, 2023	Feb	NEWA
AB		50MG	A215959	002	Feb 23, 2023	Feb	NEWA
AB		100MG	A215959	003	Feb 23, 2023	Feb	NEWA

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEPREDNOL ETABONATE

>A> AB	SUN PHARM	0.5%	A215384	001	Aug 09, 2023	Jul	NEWA

SUSPENSION/DROPS;OPHTHALMIC

ALREX

AB +!	BAUSCH AND LOMB	0.2%	N020803	001	Mar 09, 1998	Mar	CFTG

LOTEPREDNOL ETABONATE

>D> AB	AKORN	0.5%	A207609	001	Apr 17, 2019	Jul	CAHN
>A> AB	SENTISS	0.5%	A207609	001	Apr 17, 2019	Jul	CAHN

>A> LOTILANER

>A> SOLUTION/DROPS;OPHTHALMIC

>A> XDEMVY

>A> +!	TARSUS	0.25%	N217603	001	Jul 24, 2023	Jul	NEWA

LOVASTATIN

TABLET;ORAL

LOVASTATIN

@	AUROBINDO PHARMA USA	10MG	A075451	001	Dec 17, 2001	May	CAHN
@		10MG	A075935	001	Dec 17, 2001	Apr	CAHN
@		20MG	A075451	002	Dec 17, 2001	May	CAHN
@		20MG	A075935	002	Dec 17, 2001	Apr	CAHN
@		40MG	A075451	003	Dec 17, 2001	May	CAHN
@		40MG	A075935	003	Dec 17, 2001	Apr	CAHN

LUBIPROSTONE

CAPSULE;ORAL

LUBIPROSTONE

AB	AMNEAL	8MCG	A209450	001	Nov 30, 2021	Jan	CMFD
AB		24MCG	A209450	002	Nov 30, 2021	Jan	CMFD
AB	ZYDUS PHARMS	8MCG	A214131	001	Mar 23, 2023	Mar	NEWA
AB		24MCG	A214131	002	Mar 23, 2023	Mar	NEWA

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Feb	CMFD
AB		40MG	A208002	002	Jan 03, 2019	Feb	CMFD
AB		60MG	A208002	003	Jan 03, 2019	Feb	CMFD
AB		80MG	A208002	004	Jan 03, 2019	Feb	CMFD
AB		120MG	A208002	005	Jan 03, 2019	Feb	CMFD
AB	AUROBINDO PHARMA LTD	20MG	A208045	001	Mar 10, 2023	Mar	NEWA
AB		40MG	A208045	002	Mar 10, 2023	Mar	NEWA
AB		60MG	A208045	003	Mar 10, 2023	Mar	NEWA
AB		80MG	A208045	004	Mar 10, 2023	Mar	NEWA
AB		120MG	A208045	005	Mar 10, 2023	Mar	NEWA
	@ AVET LIFESCIENCES	120MG	A208058	005	Feb 28, 2023	Mar	DISC
AB		120MG	A208058	005	Feb 28, 2023	Feb	NEWA
AB	LUPIN LTD	20MG	A208031	001	Jan 03, 2019	Feb	CMFD
AB		40MG	A208031	002	Jan 03, 2019	Feb	CMFD
AB		60MG	A208031	003	Jan 03, 2019	Feb	CMFD
AB		80MG	A208031	004	Jan 03, 2019	Feb	CMFD
AB		120MG	A208031	005	Jan 03, 2019	Feb	CMFD
AB	MACLEODS PHARMS LTD	20MG	A212124	001	Jun 09, 2023	Jun	NEWA
AB		40MG	A212124	002	Jun 09, 2023	Jun	NEWA
AB		60MG	A212124	003	Jun 09, 2023	Jun	NEWA
AB		80MG	A212124	004	Jun 09, 2023	Jun	NEWA
AB		120MG	A212124	005	Jun 09, 2023	Jun	NEWA
AB	PIRAMAL HLTHCARE UK	20MG	A212091	001	Dec 28, 2020	Feb	CMFD
AB		40MG	A212091	002	Dec 28, 2020	Feb	CMFD
AB		60MG	A212091	003	Dec 28, 2020	Feb	CMFD
AB		80MG	A212091	004	Dec 28, 2020	Feb	CMFD
AB		120MG	A212091	005	Dec 28, 2020	Feb	CMFD
AB	TORRENT	20MG	A208055	001	Jan 03, 2019	Feb	CMFD
AB		40MG	A208055	002	Jan 03, 2019	Feb	CMFD
AB		80MG	A208055	003	Jan 03, 2019	Feb	CMFD
AB		120MG	A208055	004	Jan 03, 2019	Feb	CMFD

MACIMORELIN ACETATE

FOR SOLUTION;ORAL

MACRILEN

+ @	NOVO	EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017	May	DISC

MACITENTAN

TABLET;ORAL

MACITENTAN

	@ AUROBINDO PHARMA LTD	10MG	A211198	001	Apr 18, 2023	Apr	DISC
AB		10MG	A211198	001	Apr 18, 2023	Apr	NEWA

OPSUMIT

+!	ACTELION	10MG	N204410	001	Oct 18, 2013	Apr	CTEC
AB +!		10MG	N204410	001	Oct 18, 2013	Apr	CFTG

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

	@ NOVAST LABS	5%	A206716	001	Jul 31, 2017	May	DISC

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5

AP	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215370	001	Jun 29, 2022	Mar	CMFD

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4

AP	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215371	001	Jun 08, 2022	Mar	CMFD

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

AP +!	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	001		Mar	CTEC

PLASMA-LYTE A IN PLASTIC CONTAINER

AP +!	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	002	Nov 22, 1982	Mar	CTEC

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP		AMNEAL	2GM/50ML (40MG/ML)	A216597	001	Feb 15, 2023	Feb NEWA
AP			4GM/100ML (40MG/ML)	A216597	002	Feb 15, 2023	Feb NEWA

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

SUFLAVE

	+!	BRAINTREE LABS	0.9GM/BOT;178.7GM/BOT;1.12GM/BOT;0.5GM/BOT;7.3GM/BOT	N215344	001	Jun 15, 2023	Jun NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

AA		WILSHIRE PHARMS INC	12.5MG	A205136	001	Feb 22, 2019	May CAHN
AA			25MG	A205136	002	Feb 22, 2019	May CAHN
AA			50MG	A205136	003	Feb 22, 2019	May CAHN

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

	@	CHARTWELL RX	EQ 50MG BASE	A072262	001	Nov 29, 1988	Jan CAHN
	@		EQ 100MG BASE	A072263	001	Nov 29, 1988	Jan CAHN

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

AB		AMNEAL	150MG/ML	A215397	001	Jun 07, 2023	May NEWA
>D> AB		HIKMA	150MG/ML	A214309	001	Jan 05, 2023	Jul DISC
>A>	@		150MG/ML	A214309	001	Jan 05, 2023	Jul DISC

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGESTROL ACETATE

	@	BIONPHARMA	125MG/ML	A204688	001	Dec 01, 2017	Jun CAHN
	@	BRECKENRIDGE	125MG/ML	A204688	001	Dec 01, 2017	Jan DISC
>D> AB		XTTRIUM LABS INC	40MG/ML	A076721	001	Nov 01, 2004	Jul DISC
>A>	@		40MG/ML	A076721	001	Nov 01, 2004	Jul DISC
AB			40MG/ML	A076721	001	Nov 01, 2004	Jan CAHN

MELOXICAM

TABLET;ORAL

MELOXICAM

AB		ASCENT PHARMS INC	7.5MG	A217579	001	Jun 07, 2023	May NEWA
AB			15MG	A217579	002	Jun 07, 2023	May NEWA
AB		COREPHARMA	7.5MG	A077882	001	Jul 20, 2006	Feb CAHN
AB			15MG	A077882	002	Jul 20, 2006	Feb CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

	@	ANI PHARMS	28MG	A205365	004	Feb 28, 2020	Feb DISC
	@	XIAMEN LP PHARM CO	7MG	A213985	001	Oct 11, 2022	Apr DISC
	@		14MG	A213985	002	Oct 11, 2022	Apr DISC
	@		28MG	A213985	003	Oct 11, 2022	Apr DISC

NAMENDA XR

AB	+	ABBVIE	14MG	N022525	002	Jun 21, 2010	Feb CAHN
AB	+		21MG	N022525	003	Jun 21, 2010	Feb CAHN
AB	+!		28MG	N022525	004	Jun 21, 2010	Feb CAHN

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

	@	YILING	5MG	A212947	001	Apr 03, 2020	Mar CAHN
	@		10MG	A212947	002	Apr 03, 2020	Mar CAHN

NAMENDA

AB	+	ABBVIE	5MG	N021487	001	Oct 16, 2003	Feb CAHN
AB	+!		10MG	N021487	002	Oct 16, 2003	Feb CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

SCANDONEST PLAIN

	!	DEPROCO	3%	A088387	001	Oct 10, 1984	May CTEC

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

>D>		@ BROOKS STERISCIENCE	500MG/VIAL	A216154	001	Aug 18, 2022	Jul CMFD
>A>	AP		500MG/VIAL	A216154	001	Aug 18, 2022	Jul CMFD
		@	500MG/VIAL	A216154	001	Aug 18, 2022	Mar DISC
>D>		@	1GM/VIAL	A216154	002	Aug 18, 2022	Jul CMFD
>A>	AP		1GM/VIAL	A216154	002	Aug 18, 2022	Jul CMFD
		@	1GM/VIAL	A216154	002	Aug 18, 2022	Mar DISC

POWDER;INTRAVENOUS

MEROPENEM

>A>		+! HQ SPCLT PHARMA	2GM/VIAL	N215212	001	Jul 26, 2023	Jul NEWA

MESALAMINE

CAPSULE, DELAYED RELEASE;ORAL

DELZICOL

	AB	+! ABBVIE	400MG	N204412	001	Feb 01, 2013	Feb CAHN

CAPSULE, EXTENDED RELEASE;ORAL

MESALAMINE

	AB	AMTA	375MG	A217533	001	Jun 06, 2023	May NEWA
	AB	AUROBINDO PHARMA LTD	375MG	A214477	001	Mar 31, 2023	Mar NEWA

ENEMA;RECTAL

MESALAMINE

	AB	ENCUBE	4GM/60ML	A216941	001	May 30, 2023	May NEWA

SUPPOSITORY;RECTAL

CANASA

		@ ABBVIE	500MG	N021252	001	Jan 05, 2001	Feb CAHN
	AB	+!	1GM	N021252	002	Nov 05, 2004	Feb CAHN

TABLET, DELAYED RELEASE;ORAL

MESALAMINE

	AB	SINOTHERAPEUTICS INC	1.2GM	A217337	001	May 12, 2023	May NEWA

METAXALONE

TABLET;ORAL

METAXALONE

>D>	AB	AMNEAL PHARMS	800MG	A203399	001	Jun 21, 2013	Jul CHRS
>A>	AB	!	800MG	A203399	001	Jun 21, 2013	Jul CHRS
		+ @ PRIMUS PHARMS	640MG	N022503	001	Jun 01, 2015	Jun DISC
		+!	640MG	N022503	001	Jun 01, 2015	Feb CMFD

SKELAXIN

>D>	AB	+! KING PHARMS	800MG	N013217	003	Aug 30, 2002	Jul DISC
>A>		+ @	800MG	N013217	003	Aug 30, 2002	Jul DISC

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

	AB3	RK PHARMA	500MG	A215629	001	Jun 20, 2023	Jun CAHN
	AB3		1GM	A215629	002	Jun 20, 2023	Jun CAHN
	AB3	VGYAAN	500MG	A215629	001	Jun 20, 2023	Jun NEWA
	AB3		1GM	A215629	002	Jun 20, 2023	Jun NEWA

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

KOMBIGLYZE XR

>D>		+ ASTRAZENECA AB	500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010	Jul CFTG
>A>	AB	+	500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010	Jul CFTG
>D>		+	1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010	Jul CFTG
>A>	AB	+	1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010	Jul CFTG
>D>		+!	1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Jul CFTG
>A>	AB	+!	1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Jul CFTG

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

>A>	AB	DR REDDYS LABS SA	500MG;EQ 5MG BASE	A207678	001	Aug 09, 2023	Jul NEWA
>A>	AB		1GM;EQ 2.5MG BASE	A207678	002	Aug 09, 2023	Jul NEWA
>A>	AB		1GM;EQ 5MG BASE	A207678	003	Aug 09, 2023	Jul NEWA

TABLET, EXTENDED RELEASE;ORAL
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE

>A>	AB	MYLAN	500MG;EQ 5MG BASE	A205981	001	Jul 31, 2023	Jul NFTG
>A>	AB		1GM;EQ 2.5MG BASE	A205981	002	Jul 31, 2023	Jul NFTG
>A>	AB		1GM;EQ 5MG BASE	A205981	003	Jul 31, 2023	Jul NFTG
>A>	AB	SUN PHARM	500MG;EQ 5MG BASE	A206081	001	Jul 31, 2023	Jul NFTG
>A>	AB		1GM;EQ 2.5MG BASE	A206081	002	Jul 31, 2023	Jul NFTG
>A>	AB		1GM;EQ 5MG BASE	A206081	003	Jul 31, 2023	Jul NFTG

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL
JANUMET

+		MSD SUB MERCK	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007	Mar CAHN
+!			1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007	Mar CAHN

METHIMAZOLE

TABLET;ORAL
METHIMAZOLE

	AB	MACLEODS PHARMS LTD	5MG	A209827	001	May 24, 2023	May NEWA
	AB		10MG	A209827	002	May 24, 2023	May NEWA

METHOCARBAMOL

SOLUTION;IM-IV
METHOCARBAMOL

@		BAXTER HLTHCARE CORP	1GM/10ML (100MG/ML)	A215065	001	Jul 14, 2022	Feb DISC

TABLET;ORAL
METHOCARBAMOL

	AA	AUROBINDO PHARMA LTD	500MG	A213967	002	Feb 09, 2023	Feb NEWA
	AA		750MG	A213967	001	Aug 12, 2020	Feb CMFD
!	AB	AUSTARPHARMA LLC	1GM	A200958	003	Dec 06, 2021	Jun CTEC
	AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Feb CAHN
	AA		750MG	A203550	002	Feb 08, 2017	Feb CAHN
	AB	MIKART	1GM	A212707	001	Jun 12, 2023	Jun NEWA

METHOTREXATE

SOLUTION;ORAL
JYLAMVO

+ @		THERAKIND	2MG/ML	N212479	001	Nov 29, 2022	May DISC

METHOTREXATE SODIUM

TABLET;ORAL
METHOTREXATE SODIUM

>A>	AB	DAITO	EQ 2.5MG BASE	A213362	001	Aug 07, 2023	Jul NEWA

METHSUXIMIDE

CAPSULE;ORAL
CELONTIN

	AB	+! PARKE DAVIS	300MG	N010596	008		Apr CFTG

METHSUXIMIDE

	AB	NOVITIUM PHARMA	300MG	A217213	001	May 01, 2023	Apr NFTG

METHYLDOPA

TABLET;ORAL
METHYLDOPA

@		CHARTWELL RX	250MG	N018934	001	Jun 29, 1984	Jun DISC
			250MG	N018934	001	Jun 29, 1984	May CMFD
@			500MG	N018934	002	Jun 29, 1984	Jun DISC
!			500MG	N018934	002	Jun 29, 1984	May CMFD

METHYLERGONOVINE MALEATE

TABLET;ORAL
METHYLERGONOVINE MALEATE

!	AB	CHARTWELL RX	0.2MG	A091577	001	May 02, 2011	Jun CAHN

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

	AB	ALKEM LABS LTD	18MG	A214447	001	May 23, 2023	May NEWA
	AB		27MG	A214447	002	May 23, 2023	May NEWA
	AB		36MG	A214447	003	May 23, 2023	May NEWA
	AB		54MG	A214447	004	May 23, 2023	May NEWA
@		AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018	Jun DISC

TABLET, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

@		27MG	A207515	002	Feb 01, 2018	Jun DISC
@		36MG	A207515	003	Feb 01, 2018	Jun DISC
@		54MG	A207515	004	Feb 01, 2018	Jun DISC

METHYLPREDNISOLONE

TABLET;ORAL
MEDROL

+	PFIZER	2MG	N011153	002		Apr CTEC

METHYLPREDNISOLONE

@	CHARTWELL RX	2MG	A209097	001	Feb 22, 2019	May CAHN
@		4MG	A209097	002	Feb 22, 2019	May CAHN
@		8MG	A209097	003	Feb 22, 2019	May CAHN
@		16MG	A209097	004	Feb 22, 2019	May CAHN
@		32MG	A209097	005	Feb 22, 2019	May CAHN

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION
METHYLPREDNISOLONE ACETATE

AB	EUGIA PHARMA	40MG/ML	A211930	001	Apr 13, 2023	Apr NEWA
AB		80MG/ML	A211930	002	Apr 13, 2023	Apr NEWA
AB	PAR STERILE PRODUCTS	40MG/ML	A214297	001	Jan 21, 2022	Jun CMFD
AB	SLAYBACK PHARMA LLC	40MG/ML	A214870	002	May 10, 2023	Apr NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL
METOCLOPRAMIDE HYDROCHLORIDE

>D>	AA	PHARM ASSOC	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	Jul CHRS
>A>	AA	!	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	Jul CHRS
>D>	AA	! XTTRIUM LABS INC	EQ 5MG BASE/5ML	A074703	001	Oct 31, 1997	Jul DISC
>A>		@	EQ 5MG BASE/5ML	A074703	001	Oct 31, 1997	Jul DISC
	AA	!	EQ 5MG BASE/5ML	A074703	001	Oct 31, 1997	Jan CAHN

METOLAZONE

TABLET;ORAL
MYKROX

>A>		@ CHARTWELL MOLECULAR	0.5MG	N019532	001	Oct 30, 1987	Jul CAHN
>D>		@ LANNETT CO INC	0.5MG	N019532	001	Oct 30, 1987	Jul CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
METOPROLOL SUCCINATE

		@ ACCORD HLTHCARE	EQ 25MG TARTRATE	A215637	001	Oct 18, 2022	Apr DISC
		@	EQ 50MG TARTRATE	A215637	002	Oct 18, 2022	Apr DISC
		@	EQ 100MG TARTRATE	A215637	003	Oct 18, 2022	Apr DISC
		@	EQ 200MG TARTRATE	A215637	004	Oct 18, 2022	Apr DISC
>A>	AB	GRANULES	EQ 25MG TARTRATE	A216509	001	Aug 07, 2023	Jul NEWA
	AB		EQ 25MG TARTRATE	A216916	001	Jun 12, 2023	Jun NEWA
>A>	AB		EQ 50MG TARTRATE	A216509	002	Aug 07, 2023	Jul NEWA
	AB		EQ 50MG TARTRATE	A216916	002	Jun 12, 2023	Jun NEWA
>A>	AB		EQ 100MG TARTRATE	A216509	003	Aug 07, 2023	Jul NEWA
	AB		EQ 100MG TARTRATE	A216916	003	Jun 12, 2023	Jun NEWA
>A>	AB		EQ 200MG TARTRATE	A216509	004	Aug 07, 2023	Jul NEWA
	AB		EQ 200MG TARTRATE	A216916	004	Jun 12, 2023	Jun NEWA

METOPROLOL TARTRATE

INJECTABLE;INJECTION
METOPROLOL TARTRATE

@	HOSPIRA	1MG/ML	A075160	001	Jul 06, 1998	Jun DISC

TABLET;ORAL
METOPROLOL TARTRATE

AB	ZYDUS PHARMS	25MG	A212402	001	Apr 19, 2023	Apr NEWA
AB		50MG	A212402	002	Apr 19, 2023	Apr NEWA
AB		100MG	A212402	003	Apr 19, 2023	Apr NEWA

METRONIDAZOLE

CREAM;TOPICAL
METRONIDAZOLE

AB	ZYDUS LIFESCIENCES	0.75%	A217128	001	Apr 21, 2023	Apr NEWA

```
        GEL;TOPICAL
          METRONIDAZOLE
AB          COSETTE              1%                          A216692  001  Jan 23, 2023   Jan NEWA
          @ TOLMAR               1%                          A090903  001  Jul 22, 2011   Feb DISC
        GEL;VAGINAL
          METRONIDAZOLE
AB          COSETTE              0.75%                       A216323  001  Jul 12, 2023   Jun NEWA
          @ ENCUBE               0.75%                       A077264  001  Oct 31, 2006   Mar CAHN
AB                               0.75%                       A215610  001  Jun 16, 2023   Jun NEWA
        INJECTABLE;INJECTION
          METRONIDAZOLE IN PLASTIC CONTAINER
AP          AMNEAL               500MG/100ML                 A217665  001  May 24, 2023   Jun CMS1
        TABLET;ORAL
          METRONIDAZOLE
AB          ALEMBIC              250MG                       A208681  001  Jun 20, 2017   Feb CAHN
AB                               500MG                       A208681  002  Jun 20, 2017   Feb CAHN

      METRONIDAZOLE IN PLASTIC CONTAINER
        INJECTABLE;INJECTION
          METRONIDAZOLE IN PLASTIC CONTAINER
AP          AMNEAL               500MG/100ML                 A217665  001  May 24, 2023   May NEWA

      MEXILETINE HYDROCHLORIDE
        CAPSULE;ORAL
          MEXILETINE HYDROCHLORIDE
AB          LEADING              150MG                       A215876  001  Feb 27, 2023   Feb NEWA
AB                               200MG                       A215876  002  Feb 27, 2023   Feb NEWA
AB                               250MG                       A215876  003  Feb 27, 2023   Feb NEWA
AB          ZENARA               150MG                       A215315  001  Aug 26, 2022   Feb CAHN
AB                               200MG                       A215315  002  Aug 26, 2022   Feb CAHN
AB                               250MG                       A215315  003  Aug 26, 2022   Feb CAHN

      MIDAZOLAM
        SOLUTION;INTRAVENOUS
          MIDAZOLAM IN 0.9% SODIUM CHLORIDE
AP          HIKMA                50MG/50ML (1MG/ML)          A216159  001  Apr 17, 2023   Apr NFTG
AP                               100MG/100ML (1MG/ML)        A216159  002  Apr 17, 2023   Apr NFTG
AP    +!    INFORLIFE            50MG/50ML (1MG/ML)          N211844  001  Mar 22, 2021   Apr CFTG
AP    +!                         100MG/100ML (1MG/ML)        N211844  002  Mar 22, 2021   Apr CFTG

      MIGLUSTAT
        CAPSULE;ORAL
>D>       MIGLUSTAT
>D> AB      EDENBRIDGE PHARMS    100MG                       A209821  001  Aug 06, 2020   Jul CTNA
>A>       YARGESA
>A> AB      EDENBRIDGE PHARMS    100MG                       A209821  001  Aug 06, 2020   Jul CTNA

      MILNACIPRAN HYDROCHLORIDE
        TABLET;ORAL
          SAVELLA
        +   ABBVIE               12.5MG                      N022256  001  Jan 14, 2009   Jan CAHN
        +                        25MG                        N022256  002  Jan 14, 2009   Jan CAHN
        +!                       50MG                        N022256  003  Jan 14, 2009   Jan CAHN
        +                        100MG                       N022256  004  Jan 14, 2009   Jan CAHN

      MILRINONE LACTATE
        INJECTABLE;INJECTION
          MILRINONE LACTATE
AP          SHANDONG             EQ 1MG BASE/ML              A216373  001  Jan 23, 2023   Jan NEWA

      MINOCYCLINE HYDROCHLORIDE
        INJECTABLE;INJECTION
          MINOCIN
        +!  REMPEX               EQ 100MG BASE/VIAL          N050444  001                  May CTEC
        TABLET, EXTENDED RELEASE;ORAL
          MINOCYCLINE HYDROCHLORIDE
AB          ZYDUS PHARMS         EQ 55MG BASE                A203553  002  Jun 16, 2023   Jun NEWA
AB                               EQ 65MG BASE                A203553  003  Jun 16, 2023   Jun NEWA
AB                               EQ 115MG BASE               A203553  007  Jun 16, 2023   Jun NEWA
```

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

	@	ZYDUS PHARMS	25MG	A209488	001	Sep 29, 2022	Mar DISC
	@		50MG	A209488	002	Sep 29, 2022	Mar DISC

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

AB		PRASCO	7.5MG	A216751	001	Jan 18, 2023	Jan NEWA
AB			15MG	A216751	002	Jan 18, 2023	Jan NEWA
AB			30MG	A216751	003	Jan 18, 2023	Jan NEWA
AB			45MG	A216751	004	Jan 18, 2023	Jan NEWA

REMERON

AB	+!	ORGANON	15MG	N020415	001	Jun 14, 1996	Apr CAHN
AB	+		30MG	N020415	002	Jun 14, 1996	Apr CAHN
AB	+		30MG	N020415	002	Jun 14, 1996	May CAHN
	+ @		45MG	N020415	003	Mar 17, 1997	Apr CAHN
	+ @		45MG	N020415	003	Mar 17, 1997	May CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

REMERON SOLTAB

AB	+!	ORGANON USA ORGANON	15MG	N021208	001	Jan 12, 2001	May CAHN
AB	+		30MG	N021208	002	Jan 12, 2001	May CAHN
AB	+		45MG	N021208	003	Jan 12, 2001	May CAHN

MISOPROSTOL

TABLET;ORAL

MISOPROSTOL

	@	NOVEL LABS INC	0.1MG	A091667	001	Jul 25, 2012	Feb DISC
	@		0.2MG	A091667	002	Jul 25, 2012	Feb DISC

MODAFINIL

TABLET;ORAL

PROVIGIL

>D>	AB	+	CEPHALON	100MG	N020717	001	Dec 24, 1998	Jul CAHN
>A>	AB	+		100MG	N020717	001	Dec 24, 1998	Jul CAHN
>D>	AB	+!		200MG	N020717	002	Dec 24, 1998	Jul CAHN
>A>	AB	+!		200MG	N020717	002	Dec 24, 1998	Jul CAHN

MOMETASONE FUROATE

LOTION;TOPICAL

ELOCON

	+ @	ORGANON	0.1%	N019796	001	Mar 30, 1989	Mar DISC

MOMETASONE FUROATE

AB	!	PADAGIS ISRAEL	0.1%	A077180	001	Apr 06, 2005	Mar CHRS

MONTELUKAST SODIUM

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

AB		CHARTWELL MOLECULAR	EQ 4MG BASE	A207464	001	Dec 06, 2018	Jan CAHN
AB			EQ 5MG BASE	A207464	002	Dec 06, 2018	Jan CAHN

MORPHINE SULFATE

INJECTABLE;INJECTION

MORPHINE SULFATE

AP		HIKMA	2MG/ML	A211452	001	Jan 12, 2023	Jan NFTG
AP			4MG/ML	A211452	002	Jan 12, 2023	Jan NEWA
AP			8MG/ML	A211452	003	Jan 12, 2023	Jan NEWA
AP			10MG/ML	A211452	004	Jan 12, 2023	Jan NEWA
			15MG/ML	A211452	005	Jan 12, 2023	Jan NFTG
AP	+!	HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011	Jan CFTG

TABLET;ORAL

MORPHINE SULFATE

	@	DR REDDYS LABS SA	15MG	A207270	001	Jan 12, 2022	Apr CAHN
	@		30MG	A207270	002	Jan 12, 2022	Apr CAHN
	@	MAYNE PHARMA INC	15MG	A207270	001	Jan 12, 2022	Apr DISC
	@		30MG	A207270	002	Jan 12, 2022	Apr DISC

TABLET, EXTENDED RELEASE;ORAL

MORPHABOND ER

	+ @	OHEMO LIFE	15MG	N206544	001	Oct 02, 2015	Jun CAHN
	+ @		30MG	N206544	002	Oct 02, 2015	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL
MORPHABOND ER

	+ @		60MG	N206544	003	Oct 02, 2015	Jun CAHN
	+ @		100MG	N206544	004	Oct 02, 2015	Jun CAHN

MORPHINE SULFATE

	@	DR REDDYS LABS SA	15MG	A205386	001	Oct 28, 2016	Apr CAHN
	@		30MG	A205386	002	Oct 28, 2016	Apr CAHN
	@		60MG	A205386	003	Oct 28, 2016	Apr CAHN
	@		100MG	A205386	004	Oct 28, 2016	Apr CAHN
	@	MAYNE PHARMA INC	15MG	A205386	001	Oct 28, 2016	Apr DISC
	@		30MG	A205386	002	Oct 28, 2016	Apr DISC
	@		60MG	A205386	003	Oct 28, 2016	Apr DISC
	@		100MG	A205386	004	Oct 28, 2016	Apr DISC

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
MOXEZA

	+ @	HARROW EYE	EQ 0.5% BASE	N022428	001	Nov 19, 2010	Jun DISC
AT2	+!		EQ 0.5% BASE	N022428	001	Nov 19, 2010	May CAHN

MOXIFLOXACIN HYDROCHLORIDE

	@	AKORN	EQ 0.5% BASE	A202916	001	Nov 09, 2017	Jan DISC
	!	LUPIN LTD	EQ 0.5% BASE	A204079	001	May 28, 2015	Jun CHRS
			EQ 0.5% BASE	A204079	001	May 28, 2015	Jun CTEC

TABLET;ORAL
MOXIFLOXACIN HYDROCHLORIDE

AB		CHARTWELL RX	EQ 400MG BASE	A207285	001	Feb 13, 2017	Apr CAHN
AB		HETERO LABS LTD V	EQ 400MG BASE	A204836	001	Mar 02, 2023	Feb NEWA
	@	TORRENT	EQ 400MG BASE	A200160	001	Apr 03, 2014	Feb DISC

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP		BPI LABS	500MG/VIAL	A214283	001	Jun 01, 2023	May NEWA

NABUMETONE

TABLET;ORAL
NABUMETONE

	@	AUROBINDO PHARMA USA	500MG	A090516	001	Jul 12, 2010	Apr CAHN
	@		750MG	A090516	002	Jul 12, 2010	Apr CAHN

NADOLOL

TABLET;ORAL
NADOLOL

AB		ALEMBIC	20MG	A211763	001	Jun 02, 2023	May NEWA
AB			40MG	A211763	002	Jun 02, 2023	May NEWA
AB			80MG	A211763	003	Jun 02, 2023	May NEWA
AB		RK PHARMA	20MG	A212856	001	Sep 13, 2019	Jun CAHN
AB			40MG	A212856	002	Sep 13, 2019	Jun CAHN
AB			80MG	A212856	003	Sep 13, 2019	Jun CAHN

NAFCILLIN SODIUM

INJECTABLE;INJECTION
NAFCILLIN SODIUM

AP	!	EUGIA PHARMA SPECLTS	EQ 1GM BASE/VIAL	A091613	001	Dec 26, 2012	Jan CHRS
AP	!		EQ 2GM BASE/VIAL	A091613	002	Dec 26, 2012	Jan CHRS
AP	!		EQ 10GM BASE/VIAL	A091614	001	Dec 26, 2012	Jan CHRS
	@	SANDOZ	EQ 1GM BASE/VIAL	A062527	002	Aug 02, 1984	Jan DISC
	@		EQ 1GM BASE/VIAL	A062732	001	Dec 23, 1986	Jan DISC
	@		EQ 2GM BASE/VIAL	A062527	003	Aug 02, 1984	Jan DISC
	@		EQ 2GM BASE/VIAL	A062732	002	Dec 23, 1986	Jan DISC
	@		EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984	Jan DISC

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL
NAFTIFINE HYDROCHLORIDE

AB		AMNEAL	2%	A206960	001	Apr 10, 2017	Feb CAHN

GEL;TOPICAL
NAFTIFINE HYDROCHLORIDE

AB		AMNEAL	1%	A206165	001	Mar 20, 2019	Feb CAHN
AB		TARO	2%	A208201	001	Apr 10, 2019	Mar CMFD

NAFTIN

AB	+!	SEBELA IRELAND LTD	2%	N204286	001	Jun 27, 2013	May CTEC

```
          GEL;TOPICAL
            NAFTIN
          +!                        2%                                N204286  001  Jun 27, 2013   Feb CTEC

        NALMEFENE HYDROCHLORIDE
          SPRAY;NASAL
            OPVEE
          +!  INDIVIOR              EQ 2.7MG BASE/SPRAY               N217470  001  May 22, 2023   Jun CAHN
          +!  OPIANT PHARMS         EQ 2.7MG BASE/SPRAY               N217470  001  May 22, 2023   May NEWA

        NALOXEGOL OXALATE
          TABLET;ORAL
            MOVANTIK
          +   VALINOR               EQ 12.5MG BASE                    N204760  001  Sep 16, 2014   Feb CAHN
          +!                        EQ 25MG BASE                      N204760  002  Sep 16, 2014   Feb CAHN

        NALOXONE HYDROCHLORIDE
          INJECTABLE;INJECTION
            NALOXONE HYDROCHLORIDE
            @ PAR STERILE PRODUCTS  1MG/ML                            A215964  001  Jul 29, 2022   Jan DISC
          SPRAY, METERED;NASAL
            NALOXONE HYDROCHLORIDE
>D> AB        PADAGIS ISRAEL        4MG/SPRAY                         A211951  001  Jun 21, 2022   Jul CMKT
>D> AB        TEVA PHARMS USA       4MG/SPRAY                         A209522  001  Apr 19, 2019   Jul CTEC
>A>                                 4MG/SPRAY                         A209522  001  Apr 19, 2019   Jul CTEC
            REXTOVY
          +!  AMPHASTAR PHARMS INC  4MG/SPRAY                         N208969  001  Mar 07, 2023   Jun CTNA
          +!                        4MG/SPRAY                         N208969  001  Mar 07, 2023   Mar NEWA

        NALTREXONE
          FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
            NALTREXONE
    AP        TEVA PHARMS USA INC   380MG/VIAL                        A213195  001  Jul 06, 2023   Jun NFTG
            VIVITROL
    AP    +!  ALKERMES              380MG/VIAL                        N021897  001  Apr 13, 2006   Jun CFTG

        NAPROXEN
          TABLET, DELAYED RELEASE;ORAL
            NAPROXEN
            @ AUROBINDO PHARMA USA  375MG                             A075390  001  Apr 19, 2001   Apr CAHN
            @                       500MG                             A075390  002  Apr 19, 2001   Apr CAHN
    AB        TULEX PHARMS INC      375MG                             A216908  001  May 31, 2023   May NEWA
    AB                              500MG                             A216908  002  May 31, 2023   May NEWA

        NARATRIPTAN HYDROCHLORIDE
          TABLET;ORAL
            NARATRIPTAN
            @ AUROBINDO PHARMA USA  EQ 1MG BASE                       A202431  001  May 31, 2012   Apr CAHN
            @                       EQ 2.5MG BASE                     A202431  002  May 31, 2012   Apr CAHN

        NEBIVOLOL HYDROCHLORIDE
          TABLET;ORAL
            NEBIVOLOL HYDROCHLORIDE
    AB        BEXIMCO PHARMS USA    EQ 2.5MG BASE                     A216568  001  Mar 30, 2023   Mar NEWA
    AB                              EQ 5MG BASE                       A216568  002  Mar 30, 2023   Mar NEWA
    AB                              EQ 10MG BASE                      A216568  003  Mar 30, 2023   Mar NEWA
    AB                              EQ 20MG BASE                      A216568  004  Mar 30, 2023   Mar NEWA

        NEFAZODONE HYDROCHLORIDE
          TABLET;ORAL
            NEFAZODONE HYDROCHLORIDE
            @ AUROBINDO PHARMA USA  100MG                             A076129  002  Sep 16, 2003   Apr CAHN
            @                       150MG                             A076129  003  Sep 16, 2003   Apr CAHN
            @                       200MG                             A076129  004  Sep 16, 2003   Apr CAHN
            @                       250MG                             A076129  005  Sep 16, 2003   Apr CAHN
```

NELARABINE

INJECTABLE;INTRAVENOUS

ARRANON

AP	+!	SANDOZ	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	May CAHN

NELARABINE

AP		AMNEAL	250MG/50ML (5MG/ML)	A216346	001	Apr 04, 2023	Mar NEWA
AP		SHORLA	250MG/50ML (5MG/ML)	A214809	001	Mar 03, 2023	Feb NEWA

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP		HIKMA	5MG/10ML (0.5MG/ML)	A207042	001	Dec 28, 2015	May CAHN
AP			10MG/10ML (1MG/ML)	A207042	002	Dec 28, 2015	May CAHN
AP		SAGENT PHARMS INC	5MG/10ML (0.5MG/ML)	A216542	001	Feb 17, 2023	Feb NEWA
AP			10MG/10ML (1MG/ML)	A216542	002	Feb 17, 2023	Feb NEWA

NEPAFENAC

SUSPENSION/DROPS;OPHTHALMIC

ILEVRO

	+!	HARROW EYE	0.3%	N203491	001	Oct 16, 2012	May CAHN

NEVANAC

	+!	HARROW EYE	0.1%	N021862	001	Aug 19, 2005	May CAHN

NETARSUDIL MESYLATE

SOLUTION/DROPS;OPHTHALMIC

RHOPRESSA

	+!	ALCON LABS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017	May CAHN

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

>A> AB		SENORES PHARMS	20MG	A215377	001	Jul 17, 2023	Jul NEWA
>A> AB			30MG	A215377	002	Jul 17, 2023	Jul NEWA
AB		SQUARE PHARMS	20MG	A217555	001	May 03, 2023	Apr NEWA
AB			30MG	A217555	002	May 03, 2023	Apr NEWA

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

AP	+!	HIKMA INTL PHARMS	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008	Jun CTEC
AP		MICRO LABS	25MG/10ML (2.5MG/ML)	A216420	001	Jul 07, 2023	Jun NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

	@	PHARMADAX INC	30MG	A216019	001	Nov 18, 2022	Apr DISC
	@		60MG	A216019	002	Nov 18, 2022	Apr DISC

NIRAPARIB TOSYLATE

TABLET;ORAL

ZEJULA

	+	GLAXOSMITHKLINE	EQ 100MG BASE	N214876	001	Apr 26, 2023	Apr NEWA
	+		EQ 200MG BASE	N214876	002	Apr 26, 2023	Apr NEWA
	+!		EQ 300MG BASE	N214876	003	Apr 26, 2023	Apr NEWA

NIRMATRELVIR; RITONAVIR

TABLET;ORAL

PAXLOVID (COPACKAGED)

	+	PFIZER	150MG;100MG	N217188	001	May 25, 2023	May NEWA
	+!		300MG;100MG	N217188	002	May 25, 2023	May NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

AB		AMTA	8.5MG	A216606	001	Apr 10, 2023	Mar NEWA

NITISINONE

CAPSULE;ORAL

NITISINONE

AB		MEDUNIK	20MG	A212390	004	Apr 27, 2023	Apr NEWA
AB		ZENARA	2MG	A216201	001	May 25, 2023	May NEWA
AB			5MG	A216201	002	May 25, 2023	May NEWA
AB			10MG	A216201	003	May 25, 2023	May NEWA

```
          CAPSULE;ORAL
            NITISINONE
    AB                            20MG                              A216201  004  May 25, 2023   May NEWA

        NITRIC OXIDE
          GAS;INHALATION
            GENOSYL
          +!  VERO BIOTECH INC    800PPM                            N202860  001  Dec 20, 2019   Jan CAHN
            ULSPIRA
>A> AA        AIRGAS THERAP       800PPM                            A203144  001  Jul 27, 2023   Jul NEWA

        NITROFURANTOIN
          SUSPENSION;ORAL
            FURADANTIN
    AB    +   CASPER PHARMA LLC   25MG/5ML                          N009175  001                  Jun CHRS
          +!                      50MG/5ML                          N009175  002  Jun 09, 2023   Jun NEWA
            NITROFURANTOIN
    AB        AUROBINDO PHARMA    25MG/5ML                          A212607  001  May 11, 2023   May NEWA
    AB        NOVITIUM PHARMA     25MG/5ML                          A216385  001  Apr 14, 2023   Apr NEWA
          TABLET;ORAL
            FURALAN
>A>         @ CHARTWELL MOLECULAR 50MG                              A080017  001                  Jul CAHN
>A>         @                     100MG                             A080017  002                  Jul CAHN
>D>         @ LANNETT             50MG                              A080017  001                  Jul CAHN
>D>         @                     100MG                             A080017  002                  Jul CAHN

        NITROFURANTOIN, MACROCRYSTALLINE
          CAPSULE;ORAL
            NITROFURANTOIN
    AB        AUROBINDO PHARMA USA 50MG                             A074967  001  Jul 09, 1997   Apr CMFD
    AB                            100MG                             A074967  002  Jul 09, 1997   Apr CMFD
    AB                            100MG                             A077025  001  Aug 18, 2004   May CMFD
    AB        MANKIND PHARMA      25MG                              A217272  001  Mar 21, 2023   Mar NEWA
    AB                            50MG                              A217272  002  Mar 21, 2023   Mar NEWA
    AB                            100MG                             A217272  003  Mar 21, 2023   Mar NEWA

        NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE
          CAPSULE;ORAL
            NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
          @ ALVOGEN               75MG;25MG                         A215002  001  Jul 20, 2022   Jan DISC
    AB        AUROBINDO PHARMA    75MG;25MG                         A209225  001  Mar 30, 2023   Mar NEWA
    AB        MANKIND PHARMA      75MG;25MG                         A217357  001  Jul 11, 2023   Jun NEWA

        NITROGLYCERIN
          INJECTABLE;INJECTION
            NITROGLYCERIN IN DEXTROSE 5%
          +!  BAXTER HLTHCARE     10MG/100ML                        N019970  001  Dec 29, 1989   May CTEC
          +!                      20MG/100ML                        N019970  002  Dec 29, 1989   May CTEC
          +!                      40MG/100ML                        N019970  003  Dec 29, 1989   May CTEC
          OINTMENT;TRANSDERMAL
            NITROGLYCERIN
          +!  FOUGERA PHARMS INC  2%                                A087355  001  Jul 08, 1988   May CRLD

        NOREPINEPHRINE BITARTRATE
          SOLUTION;INTRAVENOUS
            NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
          + @ LONG GROVE PHARMS   EQ 4MG BASE/250 ML (EQ 16MCG      N214628  001  Oct 06, 2022   May CAHN
                                  BASE/ML)
          + @                     EQ 8MG BASE/250ML (EQ 32MCG       N214628  002  Oct 06, 2022   May CAHN
                                  BASE/ML)
          + @                     EQ 16MG BASE/250ML (EQ 64MCG      N214628  003  Oct 06, 2022   May CAHN
                                  BASE/ML)
          + @ NEVAKAR INJECTABLES EQ 4MG BASE/250 ML (EQ 16MCG      N214628  001  Oct 06, 2022   Apr DISC
                                  BASE/ML)
          + @                     EQ 8MG BASE/250ML (EQ 32MCG       N214628  002  Oct 06, 2022   Apr DISC
                                  BASE/ML)
          + @                     EQ 16MG BASE/250ML (EQ 64MCG      N214628  003  Oct 06, 2022   Apr DISC
                                  BASE/ML)
```

NORGESTREL

TABLET;ORAL

OPILL

>D>	+ @	LABORATOIRE HRA	0.075MG	N017031	001		Jul CMKT

NYSTATIN

OINTMENT;TOPICAL

NYSTATIN

	@	TORRENT	100,000 UNITS/GM	A211838	001	Jan 28, 2019	Mar DISC

SUSPENSION;ORAL

NILSTAT

	+ @	CHARTWELL MOLECULES	100,000 UNITS/ML	N050299	001		Apr CAHN

OBETICHOLIC ACID

TABLET;ORAL

OBETICHOLIC ACID

AB		APOTEX	5MG	A214862	001	May 30, 2023	May NFTG
AB			10MG	A214862	002	May 30, 2023	May NFTG
AB		LUPIN LTD	5MG	A214980	001	May 30, 2023	May NFTG
AB			10MG	A214980	002	May 30, 2023	May NFTG
	@	MSN	5MG	A215017	001	May 30, 2023	Jun DISC
AB			5MG	A215017	001	May 30, 2023	May NFTG
	@		10MG	A215017	002	May 30, 2023	Jun DISC
AB			10MG	A215017	002	May 30, 2023	May NFTG

OCALIVA

AB	+	INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016	May CFTG
AB	+!		10MG	N207999	002	May 27, 2016	May CFTG

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AP		GLAND PHARMA LTD	EQ 0.1MG BASE/ML	A216839	002	Jun 22, 2023	Jun NEWA
AP			EQ 0.2MG BASE/ML	A216807	001	Jun 13, 2023	Jun NEWA
AP			EQ 0.5MG BASE/ML	A216839	001	Jun 22, 2023	Jun NEWA
AP			EQ 1MG BASE/ML	A216807	002	Jun 13, 2023	Jun NEWA

OLANZAPINE

INJECTABLE;INTRAMUSCULAR

OLANZAPINE

AP		ASPIRO	10MG/VIAL	A217466	001	Mar 22, 2023	Mar NEWA

TABLET;ORAL

OLANZAPINE

AB		CADILA PHARMS LTD	2.5MG	A210022	001	Feb 24, 2023	Feb NEWA
AB			5MG	A210022	002	Feb 24, 2023	Feb NEWA
AB			7.5MG	A210022	003	Feb 24, 2023	Feb NEWA
AB			10MG	A210022	004	Feb 24, 2023	Feb NEWA
AB			15MG	A210022	005	Feb 24, 2023	Feb NEWA
AB			20MG	A210022	006	Feb 24, 2023	Feb NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB		HISUN PHARM HANGZHOU	5MG	A206892	001	Dec 31, 2020	Apr CMFD
AB			10MG	A206892	002	Dec 31, 2020	Apr CMFD
AB			15MG	A206892	003	Dec 31, 2020	Apr CMFD
AB			20MG	A206892	004	Dec 31, 2020	Apr CMFD
>D> AB		ZYDUS PHARMS	5MG	A202889	001	Mar 09, 2023	Jul DISC
>A>	@		5MG	A202889	001	Mar 09, 2023	Jul DISC
AB			5MG	A202889	001	Mar 09, 2023	Mar NEWA
>D> AB			10MG	A202889	002	Mar 09, 2023	Jul DISC
>A>	@		10MG	A202889	002	Mar 09, 2023	Jul DISC
AB			10MG	A202889	002	Mar 09, 2023	Mar NEWA
>D> AB			15MG	A202889	003	Mar 09, 2023	Jul DISC
>A>	@		15MG	A202889	003	Mar 09, 2023	Jul DISC
AB			15MG	A202889	003	Mar 09, 2023	Mar NEWA
>D> AB			20MG	A202889	004	Mar 09, 2023	Jul DISC
>A>	@		20MG	A202889	004	Mar 09, 2023	Jul DISC
AB			20MG	A202889	004	Mar 09, 2023	Mar NEWA

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB		AMNEAL	5MG	A207480	001	Jul 11, 2023	Jun NEWA
AB			20MG	A207480	002	Jul 11, 2023	Jun NEWA
AB			40MG	A207480	003	Jul 11, 2023	Jun NEWA
AB		MSN	5MG	A217399	001	Jan 18, 2023	Jan NEWA
AB			20MG	A217399	002	Jan 18, 2023	Jan NEWA
AB			40MG	A217399	003	Jan 18, 2023	Jan NEWA

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

AB	!	AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020	May CHRS

PATANASE

	+ @	NOVARTIS	0.665MG/SPRAY	N021861	001	Apr 15, 2008	May DISC

OMAVELOXOLONE

CAPSULE;ORAL

SKYCLARYS

	+!	REATA PHARMS	50MG	N216718	001	Feb 28, 2023	Feb NEWA

OMIDENEPAG ISOPROPYL

SOLUTION;OPHTHALMIC

OMLONTI

	+ @	SANTEN	0.002%	N215092	001	Sep 22, 2022	May DISC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

	!	CHARTWELL MOLECULES	16MG	A077406	001	Dec 26, 2006	Mar CHRS
	!		24MG	A077406	002	Dec 26, 2006	Mar CHRS

ZOFRAN ODT

	+ @	SANDOZ	4MG	N020781	001	Jan 27, 1999	May CAHN
	+ @		8MG	N020781	002	Jan 27, 1999	May CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ZOFRAN

	+ @	SANDOZ	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	May CAHN

ZOFRAN PRESERVATIVE FREE

	+ @	SANDOZ	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	May CAHN

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

>A> AA		CHARTWELL MOLECULAR	EQ 4MG BASE/5ML	A091342	001	Jan 27, 2011	Jul CAHN
>D> AA		LANNETT CO INC	EQ 4MG BASE/5ML	A091342	001	Jan 27, 2011	Jul CAHN

ZOFRAN

	+ @	SANDOZ	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	May CAHN

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

	!	CHARTWELL MOLECULES	EQ 24MG BASE	A077303	004	Jun 25, 2007	Feb CTEC

ZOFRAN

	+ @	SANDOZ	EQ 4MG BASE	N020103	001	Dec 31, 1992	May CAHN
	+ @		EQ 8MG BASE	N020103	002	Dec 31, 1992	May CAHN
	+ @		EQ 24MG BASE	N020103	003	Aug 27, 1999	May CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL

ORPHENADRINE CITRATE

AB		RISING	100MG	A040249	001	Jan 29, 1999	Jan CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

	@	ACCORD HLTHCARE	EQ 30MG BASE	A214726	001	Jul 25, 2022	Feb DISC
	@		EQ 45MG BASE	A214726	002	Jul 25, 2022	Feb DISC
	@		EQ 75MG BASE	A214726	003	Jul 25, 2022	Feb DISC
AB		SUNSHINE	EQ 30MG BASE	A212739	001	Mar 04, 2020	Jun CMFD
AB			EQ 45MG BASE	A212739	002	Mar 04, 2020	Jun CMFD
AB			EQ 75MG BASE	A212739	003	Mar 04, 2020	Jun CMFD

```
          FOR SUSPENSION;ORAL
            OSELTAMIVIR PHOSPHATE
    AB        EPIC PHARMA LLC       EQ 6MG BASE/ML                    A215538  001  Feb 14, 2023   Feb NEWA

        OSILODROSTAT PHOSPHATE
          TABLET;ORAL
            ISTURISA
>D>       +!  RECORDATI RARE        EQ 10MG BASE                      N212801  003  Mar 06, 2020   Jul DISC
>A>       + @                       EQ 10MG BASE                      N212801  003  Mar 06, 2020   Jul DISC

        OXCARBAZEPINE
          SUSPENSION;ORAL
            OXCARBAZEPINE
    AB        CHARTWELL RX          300MG/5ML                         A212428  001  Jun 21, 2021   May CAHN
          TABLET;ORAL
            OXCARBAZEPINE
    AB        ZYDUS                 150MG                             A211747  001  Jul 03, 2023   Jun NEWA
    AB                              300MG                             A211747  002  Jul 03, 2023   Jun NEWA
    AB                              600MG                             A211747  003  Jul 03, 2023   Jun NEWA
          TABLET, EXTENDED RELEASE;ORAL
>A>         OXCARBAZEPINE
>A> AB      APOTEX                150MG                             A213369  001  Jul 13, 2023   Jul NFTG
>A> AB                            300MG                             A213369  002  Jul 13, 2023   Jul NFTG
>A> AB                            600MG                             A213369  003  Jul 13, 2023   Jul NFTG
            OXTELLAR XR
>D>       +   SUPERNUS PHARMS     150MG                             N202810  001  Oct 19, 2012   Jul CFTG
>A> AB    +                       150MG                             N202810  001  Oct 19, 2012   Jul CFTG
>D>       +                       300MG                             N202810  002  Oct 19, 2012   Jul CFTG
>A> AB    +                       300MG                             N202810  002  Oct 19, 2012   Jul CFTG
>D>       +!                      600MG                             N202810  003  Oct 19, 2012   Jul CFTG
>A> AB    +!                      600MG                             N202810  003  Oct 19, 2012   Jul CFTG

        OXYBUTYNIN CHLORIDE
          GEL;TRANSDERMAL
            GELNIQUE
          +!  ABBVIE                10% (100MG/PACKET)                N022204  001  Jan 27, 2009   Apr CAHN
          SYRUP;ORAL
            OXYBUTYNIN CHLORIDE
    AA        CHARTWELL RX          5MG/5ML                           A075039  001  Jan 29, 1999   Mar CMFD
            @ XTTRIUM LABS INC      5MG/5ML                           A074868  001  Feb 12, 1997   Mar CAHN
          TABLET;ORAL
            OXYBUTYNIN CHLORIDE
          !   APPCO                 2.5MG                             A209025  002  Feb 07, 2023   Jan NFTG
    AB        AVET LIFESCIENCES     5MG                               A211682  001  May 10, 2019   Jun CTEC

        OXYCODONE HYDROCHLORIDE
          CAPSULE;ORAL
            OXYCODONE HYDROCHLORIDE
            @ DR REDDYS LABS SA     5MG                               A203107  001  Jul 26, 2012   Apr CAHN
            @ MAYNE PHARMA INC      5MG                               A203107  001  Jul 26, 2012   Apr DISC
          SOLUTION;ORAL
            OXYCODONE HYDROCHLORIDE
            @ DR REDDYS LABS SA     100MG/5ML                         A204092  001  Jun 05, 2014   Apr CAHN
            @ MAYNE PHARMA INC      100MG/5ML                         A204092  001  Jun 05, 2014   Apr DISC
          TABLET;ORAL
            OXYCODONE HYDROCHLORIDE
            @ DR REDDYS LABS SA     5MG                               A091313  001  Feb 18, 2011   Apr CAHN
            @                       10MG                              A091313  004  Apr 29, 2016   Apr CAHN
            @                       15MG                              A091313  002  Feb 18, 2011   Apr CAHN
            @                       20MG                              A091313  005  Apr 29, 2016   Apr CAHN
            @                       30MG                              A091313  003  Feb 18, 2011   Apr CAHN

        PACLITAXEL
          INJECTABLE;INJECTION
            PACLITAXEL
            @ DASH PHARMS           6MG/ML                            A091540  001  Sep 29, 2011   Feb CAHN
          POWDER;INTRAVENOUS
            PACLITAXEL
          +!  AM REGENT             100MG/VIAL                        N211875  001  Jul 27, 2022   Apr CAHN
          +!  TEVA PHARMS INC       100MG/VIAL                        N216338  001  May 11, 2023   May NEWA
```

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

	@	CIPLA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206396	001	Sep 19, 2018	Feb DISC
	@	INGENUS PHARMS LLC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	Feb DISC

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

AP2		DR REDDYS	30MG/10ML (3MG/ML)	A078156	001	Aug 19, 2008	May CTEC
AP2			90MG/10ML (9MG/ML)	A078156	003	Aug 19, 2008	May CTEC
AP1	+!	HIKMA	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	May CTEC
AP1	+!		90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	May CTEC
AP2		HOSPIRA	30MG/10ML (3MG/ML)	A075841	001	Jun 27, 2002	May CTEC
AP			30MG/10ML (3MG/ML)	A075841	001	Jun 27, 2002	Apr CHRS
AP2			90MG/10ML (9MG/ML)	A075841	003	Jun 27, 2002	May CTEC
AP			90MG/10ML (9MG/ML)	A075841	003	Jun 27, 2002	Apr CHRS
AP2		MYLAN LABS LTD	30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	May CTEC
AP2			90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	May CTEC
AP1		SAGENT PHARMS INC	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	May CTEC
AP1			90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	May CTEC

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB		AJANTA PHARMA LTD	EQ 40MG BASE	A217416	001	Feb 09, 2023	Feb NEWA
AB		DEXCEL	EQ 40MG BASE	A216247	001	Jun 16, 2023	Jun NEWA

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

	@	EPIC PHARMA LLC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan CAHN
	@		EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan CAHN
	@		EQ 37.5MG BASE	A213612	003	May 26, 2022	Jan CAHN

PAROXETINE MESYLATE

TABLET;ORAL

PEXEVA

+	@	SEBELA IRELAND LTD	EQ 10MG BASE	N021299	001	Jul 03, 2003	May DISC
+	@		EQ 20MG BASE	N021299	002	Jul 03, 2003	May DISC
+	@		EQ 30MG BASE	N021299	003	Jul 03, 2003	May DISC

PEGCETACOPLAN

SOLUTION;INTRAVITREAL

SYFOVRE

+!		APELLIS PHARMS	15MG/0.1ML (15MG/0.1ML)	N217171	001	Feb 17, 2023	Feb NEWA

PEMETREXED DISODIUM

POWDER;INTRAVENOUS

PEMETREXED DISODIUM

	@	AMNEAL	EQ 100MG BASE/VIAL	A210047	002	May 08, 2023	Jun DISC
AP			EQ 100MG BASE/VIAL	A210047	002	May 08, 2023	Apr NEWA
	@		EQ 500MG BASE/VIAL	A210047	001	Aug 04, 2022	Jun DISC
AP		MEITHEAL	EQ 100MG BASE/VIAL	A215479	001	Dec 13, 2022	Jan CAHN
AP			EQ 500MG BASE/VIAL	A215479	002	Dec 13, 2022	Jan CAHN
AP			EQ 750MG BASE/VIAL	A215479	003	Dec 13, 2022	Jan CAHN
AP			EQ 1GM BASE/VIAL	A215479	004	Dec 13, 2022	Jan CAHN
	@	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203628	001	Mar 10, 2023	Mar DISC
AP			EQ 500MG BASE/VIAL	A203628	001	Mar 10, 2023	Mar NEWA

SOLUTION;INTRAVENOUS

PEMETREXED

+!		SHILPA	EQ 100MG/10ML BASE (10MG/ML)	N215179	001	May 22, 2023	May NEWA
+!			EQ 500MG/50ML BASE (10MG/ML)	N215179	002	May 22, 2023	May NEWA
+!			EQ 1GM/100ML BASE (10MG/ML)	N215179	003	May 22, 2023	May NEWA

PEMETREXED DISODIUM

+!		SANDOZ	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214657	001	May 26, 2022	Jan CMS1

PENCICLOVIR

CREAM;TOPICAL

PENCICLOVIR

>A>	AB	TORRENT	1%	A216981	001	Aug 07, 2023	Jul NEWA

PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION

PENTAMIDINE ISETHIONATE

	AN	X-GEN PHARMS INC	300MG/VIAL	A206983	001	Jan 20, 2023	Jan NEWA

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION

PENTOBARBITAL SODIUM

>D>	AP	ATHENEX	50MG/ML	A206677	001	Nov 27, 2017	Jul CAHN
>A>	AP	PRAXGEN PHARMS	50MG/ML	A206677	001	Nov 27, 2017	Jul CAHN

PERAMPANEL

SUSPENSION;ORAL

FYCOMPA

	+!	CATALYST PHARMS	0.5MG/ML	N208277	001	Apr 29, 2016	Feb CAHN

TABLET;ORAL

FYCOMPA

	+	CATALYST PHARMS	2MG	N202834	001	Oct 22, 2012	Feb CAHN
	+		4MG	N202834	002	Oct 22, 2012	Feb CAHN
	+		6MG	N202834	003	Oct 22, 2012	Feb CAHN
	+		8MG	N202834	004	Oct 22, 2012	Feb CAHN
	+		10MG	N202834	005	Oct 22, 2012	Feb CAHN
	+!		12MG	N202834	006	Oct 22, 2012	Feb CAHN

PERFLUOROHEXYLOCTANE

SOLUTION/DROPS;OPHTHALMIC

MIEBO

	+!	BAUSCH AND LOMB INC	1.338GM/ML	N216675	001	May 18, 2023	May NEWA

PERMETHRIN

CREAM;TOPICAL

PERMETHRIN

>A>	AB	DR REDDYS LABS EU	5%	A209732	001	Aug 01, 2023	Jul NEWA

PEXIDARTINIB HYDROCHLORIDE

CAPSULE;ORAL

TURALIO

	+ @	DAIICHI SANKYO INC	EQ 200MG BASE	N211810	001	Aug 02, 2019	Jun DISC

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

	AB	AUROBINDO PHARMA	10MG	A215600	001	May 08, 2023	Apr NEWA
	AB	RISING	10MG	A204551	001	Jun 20, 2023	Jun NEWA

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

	@	LANNETT	15MG	A087022	002	Jan 20, 2012	Feb DISC
	@		30MG	A087022	001	Feb 03, 1983	Feb DISC

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

IMMPHENTIV

	+!	HIKMA	0.5MG/5ML (0.1MG/ML)	N203826	004	Mar 09, 2023	May CAHN
	+!		0.5MG/5ML (0.1MG/ML)	N203826	004	Mar 09, 2023	Mar NEWA
	+!		1MG/10ML (0.1MG/ML)	N203826	005	Mar 09, 2023	May CAHN
	+!		1MG/10ML (0.1MG/ML)	N203826	005	Mar 09, 2023	Mar NEWA

PHENYLEPHRINE HYDROCHLORIDE

AP2		AVET LIFESCIENCES	10MG/ML (10MG/ML)	A209968	001	Feb 28, 2023	Feb NEWA
AP2		BE PHARMS	10MG/ML (10MG/ML)	A217521	001	Jun 26, 2023	Jun NEWA
AP2			50MG/5ML (10MG/ML)	A217521	002	Jun 26, 2023	Jun NEWA
AP2			100MG/10ML (10MG/ML)	A217521	003	Jun 26, 2023	Jun NEWA
AP2	+!	HIKMA	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	May CAHN
	+!		50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	Jun CTEC
AP2	+!		50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	May CAHN

		SOLUTION;INTRAVENOUS						
		PHENYLEPHRINE HYDROCHLORIDE						
		+!		100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	Jun CTEC
	AP2	+!		100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	May CAHN
		SOLUTION/DROPS;OPHTHALMIC						
		PHENYLEPHRINE HYDROCHLORIDE						
>D>	AT	+!	AKORN	2.5%	N207926	001	Jan 15, 2015	Jul CAHN
>D>	AT	+!		10%	N207926	002	Jan 15, 2015	Jul CAHN
>A>	AT	+	ALCON	2.5%	N207926	001	Jan 15, 2015	Jul CAHN
>A>	AT	+		10%	N207926	002	Jan 15, 2015	Jul CAHN
>D>	AT		MANKIND PHARMA	2.5%	A216859	001	Sep 29, 2022	Jul CHRS
>A>	AT	!		2.5%	A216859	001	Sep 29, 2022	Jul CHRS
>D>	AT			10%	A216496	001	Jan 11, 2023	Jul CHRS
>A>	AT	!		10%	A216496	001	Jan 11, 2023	Jul CHRS
		PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE						
		SYRUP;ORAL						
		PROMETHAZINE VC PLAIN						
		@	XTTRIUM LABS INC	5MG/5ML;6.25MG/5ML	A088897	001	Jan 04, 1985	Jan CAHN
		PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE						
		SPRAY, METERED;OPHTHALMIC						
		MYDCOMBI						
		+!	EYENOVIA	2.5%;1%	N215352	001	May 05, 2023	May NEWA
		PHENYTOIN SODIUM						
		CAPSULE;ORAL						
		DIPHENYLAN SODIUM						
>A>		@	CHARTWELL MOLECULAR	30MG PROMPT	A080857	001		Jul CAHN
>A>		@		100MG PROMPT	A080857	002		Jul CAHN
>D>		@	LANNETT	30MG PROMPT	A080857	001		Jul CAHN
>D>		@		100MG PROMPT	A080857	002		Jul CAHN
		EXTENDED PHENYTOIN SODIUM						
		@	MYLAN	100MG EXTENDED	A040298	001	Dec 28, 1998	Mar DISC
		@	UNICHEM	100MG EXTENDED	A213834	001	Oct 13, 2022	Apr DISC
		PHYTONADIONE						
		TABLET;ORAL						
		MEPHYTON						
		+ @	BAUSCH	5MG	N010104	003		Feb DISC
		PHYTONADIONE						
>A>	AB		SCIEGEN PHARMS INC	5MG	A213329	001	Jul 28, 2023	Jul NEWA
	AB	!	ZYDUS	5MG	A210189	001	Feb 20, 2019	Feb CHRS
		PIPERACILLIN SODIUM; TAZOBACTAM SODIUM						
		INJECTABLE;INJECTION						
		PIPERACILLIN AND TAZOBACTAM						
	AP		SHANDONG	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A204959	001	Aug 10, 2018	Apr CAHN
	AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A204959	002	Aug 10, 2018	Apr CAHN
	AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A204959	003	Aug 10, 2018	Apr CAHN
	AP			EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A217243	001	Apr 14, 2023	Apr NEWA
		ZOSYN IN PLASTIC CONTAINER						
		+!	BAXTER HLTHCARE CORP	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998	Mar CAHN
		+!		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998	Mar CAHN
		+!		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998	Mar CAHN
		PIRFENIDONE						
		CAPSULE;ORAL						
		PIRFENIDONE						
	AB		APOTEX	267MG	A212687	001	Jun 09, 2023	Jun NEWA
		TABLET;ORAL						
		PIRFENIDONE						
	AB		APOTEX	267MG	A212709	001	May 31, 2023	May NEWA
	AB			801MG	A212709	002	May 31, 2023	May NEWA

PIRTOBRUTINIB

TABLET;ORAL

JAYPIRCA

		+	LOXO ONCOL	50MG	N216059	001	Jan 27, 2023	Jan NEWA
		+!		100MG	N216059	002	Jan 27, 2023	Jan NEWA

PITAVASTATIN CALCIUM

TABLET;ORAL

PITAVASTATIN CALCIUM

	AB		ZYDUS PHARMS	EQ 1MG BASE	A206047	001	Feb 22, 2023	Feb NEWA
	AB			EQ 2MG BASE	A206047	002	Feb 22, 2023	Feb NEWA
	AB			EQ 4MG BASE	A206047	003	Feb 22, 2023	Feb NEWA

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

MOZOBIL

>D>		+!	GENZYME	24MG/1.2ML (20MG/ML)	N022311	001	Dec 15, 2008	Jul CFTG
>A>	AP	+!		24MG/1.2ML (20MG/ML)	N022311	001	Dec 15, 2008	Jul CFTG

>A> PLERIXAFOR

>A>	AP		AMNEAL	24MG/1.2ML (20MG/ML)	A215334	001	Jul 24, 2023	Jul NFTG
>A>	AP		DR REDDYS	24MG/1.2ML (20MG/ML)	A205182	001	Jul 24, 2023	Jul NFTG
>A>	AP		EUGIA PHARMA	24MG/1.2ML (20MG/ML)	A213672	001	Jul 24, 2023	Jul NFTG
>A>	AP		KINDOS	24MG/1.2ML (20MG/ML)	A215698	001	Jul 24, 2023	Jul NFTG
>A>	AP		MSN	24MG/1.2ML (20MG/ML)	A211901	001	Jul 24, 2023	Jul NFTG
>A>	AP		TEVA PHARMS USA INC	24MG/1.2ML (20MG/ML)	A205197	001	Jul 24, 2023	Jul NFTG
>A>	AP		ZYDUS PHARMS	24MG/1.2ML (20MG/ML)	A208980	001	Jul 26, 2023	Jul NEWA

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

POLYTRIM

		+ @	ALLERGAN	10,000 UNITS/ML;EQ 1MG BASE/ML	N050567	001	Oct 20, 1988	Feb DISC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

	AT	!	SANDOZ	10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Feb CHRS

POMALIDOMIDE

CAPSULE;ORAL

POMALYST

		+	BRISTOL	1MG	N204026	001	Feb 08, 2013	Jan CAHN
		+		2MG	N204026	002	Feb 08, 2013	Jan CAHN
		+		3MG	N204026	003	Feb 08, 2013	Jan CAHN
		+!		4MG	N204026	004	Feb 08, 2013	Jan CAHN

PONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

>D>		+	TAKEDA PHARMS USA	EQ 15MG BASE	N203469	001	Dec 14, 2012	Jul CFTG
>A>	AB	+		EQ 15MG BASE	N203469	001	Dec 14, 2012	Jul CFTG
>D>		+!		EQ 45MG BASE	N203469	002	Dec 14, 2012	Jul CFTG
>A>	AB	+!		EQ 45MG BASE	N203469	002	Dec 14, 2012	Jul CFTG

PONATINIB HYDROCHLORIDE

>A>	AB		APOTEX	EQ 15MG BASE	A215893	001	Jul 14, 2023	Jul NFTG
>A>	AB			EQ 45MG BASE	A215893	002	Jul 14, 2023	Jul NFTG

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL

POSACONAZOLE

		@	ACTAVIS LABS FL INC	100MG	A207355	001	Nov 30, 2022	May DISC
>D>	AB		WELDING	100MG	A216326	001	Jun 20, 2023	Jul CAHN
	AB			100MG	A216326	001	Jun 20, 2023	Jun NEWA
>A>	AB		WESTMINSTER PHARMS	100MG	A216326	001	Jun 20, 2023	Jul CAHN

POTASSIUM ACETATE

INJECTABLE;INJECTION

POTASSIUM ACETATE

	AP		EXELA PHARMA	2MEQ/ML	A212692	001	Oct 20, 2021	Feb CMFD

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

>A>		@	CHARTWELL MOLECULAR	8MEQ	A204210	001	Mar 28, 2016	Jul CAHN
>A>		@		10MEQ	A204210	002	Mar 28, 2016	Jul CAHN
>D>		@	LANNETT CO INC	8MEQ	A204210	001	Mar 28, 2016	Jul CAHN
>D>		@		10MEQ	A204210	002	Mar 28, 2016	Jul CAHN

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

>D>		@	GRANULES	20MEQ	A213467	001	Jan 27, 2022	Jul CMFD
>A>	AA			20MEQ	A213467	001	Jan 27, 2022	Jul CMFD
	AA		NOVITIUM PHARMA	20MEQ	A212816	001	Jul 12, 2023	Jun NEWA

SOLUTION;ORAL

POTASSIUM CHLORIDE

	AA		BELCHER	20MEQ/15ML	A216156	001	Mar 07, 2023	Feb NEWA
	AA			40MEQ/15ML	A216156	002	Mar 07, 2023	Feb NEWA
		@	STRIDES PHARMA	40MEQ/15ML	A211665	001	Nov 17, 2022	May DISC

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

	AB1		RUBICON	10MEQ	A216321	001	Jun 16, 2023	Jun NEWA
	AB1			15MEQ	A216321	002	Jun 16, 2023	Jun NEWA
	AB1			20MEQ	A216321	003	Jun 16, 2023	Jun NEWA
	AB3		TWI PHARMS	10MEQ	A209688	001	Jan 12, 2018	Apr CAHN
	AB3	!		20MEQ	A209688	002	Jan 12, 2018	Apr CAHN
	AB3	!	VITRUVIAS THERAP	20MEQ	A209688	002	Jan 12, 2018	Feb CHRS

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

PRASUGREL

	AB		AMNEAL PHARMS	EQ 5MG BASE	A205913	001	Jun 19, 2018	Mar CTEC
	AB			EQ 10MG BASE	A205913	002	Jun 19, 2018	Mar CTEC
		@	LUPIN LTD	EQ 5MG BASE	A205930	001	Jan 09, 2023	Feb DISC
		@		EQ 10MG BASE	A205930	002	Jan 09, 2023	Feb DISC

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

	AB		CHARTWELL RX	10MG	A077917	001	Jan 08, 2008	May CAHN
	AB			20MG	A077917	002	Jan 08, 2008	May CAHN
	AB			40MG	A077917	003	Jan 08, 2008	May CAHN
	AB			80MG	A077917	004	Jan 08, 2008	May CAHN

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

	AB		ALEMBIC	EQ 1MG BASE	A217268	001	Mar 06, 2023	Feb NEWA
	AB			EQ 2MG BASE	A217268	002	Mar 06, 2023	Feb NEWA
	AB			EQ 5MG BASE	A217268	003	Mar 06, 2023	Feb NEWA
	AB		AUROBINDO PHARMA LTD	EQ 1MG BASE	A213052	001	Mar 31, 2023	Mar NEWA
	AB			EQ 2MG BASE	A213052	002	Mar 31, 2023	Mar NEWA
	AB			EQ 5MG BASE	A213052	003	Mar 31, 2023	Mar NEWA

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

	AA		AKORN	15MG/5ML	A040401	001	Feb 27, 2003	Jun CHRS
	AA	!	CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Jun CHRS
>D>	AA		XTTRIUM LABS INC	15MG/5ML	A040313	001	Sep 10, 2003	Jul DISC
>A>		@		15MG/5ML	A040313	001	Sep 10, 2003	Jul DISC
	AA			15MG/5ML	A040313	001	Sep 10, 2003	Jan CAHN

TABLET;ORAL

PREDNISOLONE

	AB		AUROBINDO PHARMA LTD	5MG	A215673	001	Mar 17, 2023	Mar NEWA
	BX		CHARTWELL MOLECULAR	5MG	A080531	002		May CMFD
	AB	+!	WATSON LABS	5MG	A080354	001		Mar CTEC

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

PRED FORTE

AB	+!	ABBVIE	1%	N017011	001			Jan CAHN

PRED MILD

	+!	ABBVIE	0.12%	N017100	001			Feb CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA		EDENBRIDGE PHARMS	EQ 15MG BASE/5ML	A203559	003	Feb 06, 2023		Jan NEWA
AA			EQ 15MG BASE/5ML	A203559	003	Feb 06, 2023		Jan NEWA
AA			EQ 25MG BASE/5ML	A203559	004	Feb 06, 2023		Jan NEWA
AA			EQ 25MG BASE/5ML	A203559	004	Feb 06, 2023		Jan NEWA
AA	!	MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010		Jan CTEC
>D> AA		PHARM ASSOC	EQ 15MG BASE/5ML	A076913	001	Apr 25, 2005		Jul CHRS
>A> AA	!		EQ 15MG BASE/5ML	A076913	001	Apr 25, 2005		Jul CHRS
>D> AA		XTTRIUM LABS INC	EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002		Jul DISC
>A>	@		EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002		Jul DISC
AA			EQ 5MG BASE/5ML	A075099	001	Jun 28, 2002		Jan CAHN
>D> AA	!		EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004		Jul DISC
>A>	@		EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004		Jul DISC
AA	!		EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004		Jan CAHN

PREDNISONE

SOLUTION;ORAL

PREDNISONE

	@	XTTRIUM LABS INC	5MG/5ML	A089726	001	Aug 02, 1988		Jan CAHN

TABLET;ORAL

PREDNISONE

AB	+!	HIKMA	2.5MG	A087801	001	Apr 22, 1982		Jan CRLD
AB	+!		5MG	A080352	001			Jan CRLD
AB	+!		50MG	A084283	001			Jan CRLD
AB		JUBILANT CADISTA	2.5MG	A040362	004	Apr 17, 2023		Apr NEWA
AB			50MG	A040362	005	Apr 17, 2023		Apr NEWA

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB		ACI	25MG	A215755	001	Apr 26, 2023		Apr NEWA
AB			50MG	A215755	002	Apr 26, 2023		Apr NEWA
AB			75MG	A215755	003	Apr 26, 2023		Apr NEWA
AB			100MG	A215755	004	Apr 26, 2023		Apr NEWA
AB			150MG	A215755	005	Apr 26, 2023		Apr NEWA
AB			200MG	A215755	006	Apr 26, 2023		Apr NEWA
AB			225MG	A215755	007	Apr 26, 2023		Apr NEWA
AB			300MG	A215755	008	Apr 26, 2023		Apr NEWA
AB		AUROBINDO PHARMA	25MG	A205321	001	Mar 29, 2023		Mar NEWA
AB			50MG	A205321	002	Mar 29, 2023		Mar NEWA
AB			75MG	A205321	003	Mar 29, 2023		Mar NEWA
AB			100MG	A205321	004	Mar 29, 2023		Mar NEWA
AB			150MG	A205321	005	Mar 29, 2023		Mar NEWA
AB			200MG	A205321	006	Mar 29, 2023		Mar NEWA
AB			225MG	A205321	007	Mar 29, 2023		Mar NEWA
AB			300MG	A205321	008	Mar 29, 2023		Mar NEWA
AB		CADILA PHARMS LTD	25MG	A206452	001	Jul 12, 2023		Jun NEWA
AB			50MG	A206452	002	Jul 12, 2023		Jun NEWA
AB			75MG	A206452	003	Jul 12, 2023		Jun NEWA
AB			100MG	A206452	004	Jul 12, 2023		Jun NEWA
AB			150MG	A206452	005	Jul 12, 2023		Jun NEWA
AB			200MG	A206452	006	Jul 12, 2023		Jun NEWA
AB			225MG	A206452	007	Jul 12, 2023		Jun NEWA
AB			300MG	A206452	008	Jul 12, 2023		Jun NEWA
AB		CHARTWELL RX	50MG	A212865	001	Mar 20, 2020		Mar CAHN
AB			75MG	A212865	002	Mar 20, 2020		Mar CAHN
AB			100MG	A212865	003	Mar 20, 2020		Mar CAHN
AB			150MG	A212865	004	Mar 20, 2020		Mar CAHN
AB		YILING	75MG	A210891	001	Sep 30, 2019		Mar CAHN
AB			300MG	A210891	002	Sep 30, 2019		Mar CAHN
	@	ZYDUS PHARMS	25MG	A206752	001	Dec 09, 2022		May DISC
	@		50MG	A206752	002	Dec 09, 2022		May DISC
	@		75MG	A206752	003	Dec 09, 2022		May DISC

```
          CAPSULE;ORAL
            PREGABALIN
            @                       100MG                           A206752  004  Dec 09, 2022   May DISC
            @                       150MG                           A206752  005  Dec 09, 2022   May DISC
            @                       200MG                           A206752  006  Dec 09, 2022   May DISC
            @                       225MG                           A206752  007  Dec 09, 2022   May DISC
            @                       300MG                           A206752  008  Dec 09, 2022   May DISC
          SOLUTION;ORAL
            PREGABALIN
     AA       PATRIN                 20MG/ML                         A212604  001  Feb 18, 2022   Jan CAHN
          TABLET, EXTENDED RELEASE;ORAL
            PREGABALIN
            @ SCIEGEN PHARMS INC    82.5MG                          A215675  001  Sep 14, 2022   May DISC
            @                       165MG                           A215675  002  Sep 14, 2022   May DISC
            @                       330MG                           A215675  003  Sep 14, 2022   May DISC
     AB       SINOTHERAPEUTICS INC  82.5MG                          A214496  001  Jun 01, 2023   May NEWA
     AB                             165MG                           A214496  002  Jun 01, 2023   May NEWA
     AB                             330MG                           A214496  003  Jun 01, 2023   May NEWA
            @ ZYDUS PHARMS          82.5MG                          A215577  001  Aug 26, 2022   Jan DISC
            @                       165MG                           A215577  002  Aug 26, 2022   Jan DISC
            @                       330MG                           A215577  003  Aug 26, 2022   Jan DISC

        PRIMIDONE
          TABLET;ORAL
            PRIMIDONE
              RUBICON               125MG                           A214896  003  Dec 28, 2022   May CTEC

        PROCAINAMIDE HYDROCHLORIDE
          INJECTABLE;INJECTION
            PROCAINAMIDE HYDROCHLORIDE
     AP   !   HOSPIRA               500MG/ML                        A089070  001  Feb 12, 1986   Feb CTEC

        PROCHLORPERAZINE EDISYLATE
          INJECTABLE;INJECTION
            PROCHLORPERAZINE EDISYLATE
>D> AP       ATHENEX INC            EQ 5MG BASE/ML                  A040540  001  May 28, 2004   Jul CAHN
>A> AP       SAGENT                 EQ 5MG BASE/ML                  A040540  001  May 28, 2004   Jul CAHN

        PROCHLORPERAZINE MALEATE
          TABLET;ORAL
            PROCHLORPERAZINE MALEATE
     AB       AMNEAL                 EQ 5MG BASE                     A216598  001  Apr 17, 2023   Apr NEWA
     AB                              EQ 10MG BASE                    A216598  002  Apr 17, 2023   Apr NEWA
     AB       BIONPHARMA             EQ 5MG BASE                     A217478  001  Apr 04, 2023   Mar NEWA
     AB                              EQ 10MG BASE                    A217478  002  Apr 04, 2023   Mar NEWA
     AB       GLENMARK PHARMS LTD    EQ 5MG BASE                     A216595  001  Mar 17, 2023   Mar NEWA
     AB                              EQ 10MG BASE                    A216595  002  Mar 17, 2023   Mar NEWA

        PROMETHAZINE HYDROCHLORIDE
          SYRUP;ORAL
            PROMETHAZINE HYDROCHLORIDE
            @ AMNEAL PHARMS         6.25MG/5ML                      A040882  001  Dec 30, 2009   Jun DISC
          TABLET;ORAL
            PROMETHAZINE HYDROCHLORIDE
            @ AUROBINDO PHARMA USA  12.5MG                          A091054  001  Aug 30, 2011   Apr CAHN
            @                       25MG                            A091054  002  Aug 30, 2011   Apr CAHN
            @                       50MG                            A091054  003  Aug 30, 2011   Apr CAHN

        PROPAFENONE HYDROCHLORIDE
          CAPSULE, EXTENDED RELEASE;ORAL
            PROPAFENONE HYDROCHLORIDE
     AB       AUROBINDO PHARMA LTD  225MG                           A213096  001  Feb 21, 2023   Feb NEWA
     AB                             325MG                           A213096  002  Feb 21, 2023   Feb NEWA
     AB                             425MG                           A213096  003  Feb 21, 2023   Feb NEWA

        PROPARACAINE HYDROCHLORIDE
          SOLUTION/DROPS;OPHTHALMIC
            PROPARACAINE HYDROCHLORIDE
>D> AT   !   AKORN                 0.5%                            A040277  001  Mar 16, 2000   Jul CHRS
>A> AT                             0.5%                            A040277  001  Mar 16, 2000   Jul CHRS
>D> AT       BAUSCH AND LOMB       0.5%                            A040074  001  Sep 29, 1995   Jul CHRS
>A> AT   !                         0.5%                            A040074  001  Sep 29, 1995   Jul CHRS
```

PROPOFOL

INJECTABLE;INJECTION

PROPOFOL

AB		AVET LIFESCIENCES	10MG/ML	A206408	001	Oct 12, 2021	Jan CAHN

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

AB	!	IMPAX LABS INC	80MG	A071976	001	Apr 06, 1988	Jun CHRS
AB		WATSON LABS	80MG	A070178	001	May 13, 1986	Jun CHRS

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

AB	+!	DAVA PHARMS INC	50MG	N006188	001		Apr CTEC
AB		MACLEODS PHARMS LTD	50MG	A208867	001	May 10, 2023	Apr NEWA

QUININE SULFATE

CAPSULE;ORAL

QUININE SULFATE

	@	AUROBINDO PHARMA USA	324MG	A202581	001	Dec 14, 2012	May CAHN

>A> QUIZARTINIB DIHYDROCHLORIDE

>A> TABLET;ORAL

>A> VANFLYTA

>A>	+	DAIICHI SANKYO INC	EQ 17.7MG BASE	N216993	001	Jul 20, 2023	Jul NEWA
>A>	+!		EQ 26.5MG BASE	N216993	002	Jul 20, 2023	Jul NEWA

RAMELTEON

TABLET;ORAL

RAMELTEON

AB		AUROBINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023	Jun NEWA
AB		INNOGENIX	8MG	A215435	001	Aug 24, 2022	May CMFD
	@		8MG	A215435	001	Aug 24, 2022	Mar DISC
AB			8MG	A215435	001	Aug 24, 2022	Jan CAHN
AB		MICRO LABS	8MG	A215243	001	Feb 09, 2023	Feb NEWA

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

AB		COREPHARMA	1.25MG	A079116	001	Jun 20, 2008	Feb CAHN
AB			2.5MG	A079116	002	Jun 20, 2008	Feb CAHN
AB			5MG	A079116	003	Jun 20, 2008	Feb CAHN
AB			10MG	A079116	004	Jun 20, 2008	Feb CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

	@	HIKMA	EQ 25MG BASE/ML	A074777	001	Mar 02, 2005	May DISC
	@		EQ 25MG BASE/ML	A077458	001	Feb 16, 2006	May DISC
	@	ZYDUS PHARMS USA INC	EQ 25MG BASE/ML	A091534	001	Feb 22, 2013	May DISC

ZANTAC

	+ @	PAI HOLDINGS PHARM	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	May DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

	+ @	GILEAD	500MG	N021526	002	Jan 27, 2006	Jan DISC
	+ @		1GM	N021526	001	Feb 12, 2007	Jan DISC

RANOLAZINE

>A> AB		PIRAMAL HLTHCARE UK	500MG	A213085	001	Jul 25, 2023	Jul NEWA
>A> AB			1GM	A213085	002	Jul 25, 2023	Jul NEWA
AB	!	SUN PHARM	1GM	A211707	002	May 28, 2019	Jan CHRS
AB		UNICHEM	500MG	A213083	001	Mar 16, 2023	Mar NEWA
AB			1GM	A213083	002	Mar 16, 2023	Mar NEWA

REGADENOSON

SOLUTION;INTRAVENOUS

REGADENOSON

AP	BAXTER HLTHCARE CORP	0.4MG/5ML (0.08MG/ML)	A217455	001	May 23, 2023	May NEWA
AP	HIKMA	0.4MG/5ML (0.08MG/ML)	A215827	001	Feb 02, 2023	Jan NEWA
AP	IMS LTD	0.4MG/5ML (0.08MG/ML)	A214252	001	May 23, 2022	Apr CMFD

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB	MACLEODS PHARMS LTD	0.5MG	A207209	001	Mar 22, 2023	Mar NEWA
AB		1MG	A207209	002	Mar 22, 2023	Mar NEWA
AB		2MG	A207209	003	Mar 22, 2023	Mar NEWA

REZAFUNGIN ACETATE

POWDER;INTRAVENOUS

REZZAYO

+!	CIDARA THERAPS	EQ 200MG BASE/VIAL	N217417	001	Mar 22, 2023	Mar NEWA

RIBOFLAVIN 5'-PHOSPHATE

SOLUTION/DROPS;OPHTHALMIC

PHOTREXA

+!	GLAUKOS	0.146%	N203324	001	Apr 15, 2016	Jun CAIN

PHOTREXA VISCOUS IN DEXTRAN 20%

+!	GLAUKOS	0.146%	N203324	002	Apr 15, 2016	Jun CAIN

RIMEGEPANT SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

NURTEC ODT

+!	PFIZER	EQ 75MG BASE	N212728	001	Feb 27, 2020	Feb CAHN

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

RYKINDO

+!	SHANDONG LUYE	12.5MG	N212849	001	Jan 13, 2023	Jan NEWA
+!		25MG	N212849	002	Jan 13, 2023	Jan NEWA
+!		37.5MG	N212849	003	Jan 13, 2023	Jan NEWA
+!		50MG	N212849	004	Jan 13, 2023	Jan NEWA

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

UZEDY

+	TEVA	50MG/0.14ML (50MG/0.14ML)	N213586	001	Apr 28, 2023	Apr NEWA
+		75MG/0.21ML (75MG/0.21ML)	N213586	002	Apr 28, 2023	Apr NEWA
+		100MG/0.28ML (100MG/0.28ML)	N213586	003	Apr 28, 2023	Apr NEWA
+		125MG/0.35ML (125MG/0.35ML)	N213586	004	Apr 28, 2023	Apr NEWA
+		150MG/0.42ML (150MG/0.42ML)	N213586	005	Apr 28, 2023	Apr NEWA
+		200MG/0.56ML (200MG/0.56ML)	N213586	006	Apr 28, 2023	Apr NEWA
+!		250MG/0.7ML (250MG/0.7ML)	N213586	007	Apr 28, 2023	Apr NEWA

TABLET;ORAL

RISPERIDONE

@	DASH PHARMS	0.25MG	A076288	001	Sep 15, 2008	Feb CAHN
@		0.5MG	A076288	002	Sep 15, 2008	Feb CAHN
@		1MG	A076288	003	Sep 15, 2008	Feb CAHN
@		2MG	A076288	004	Sep 15, 2008	Feb CAHN
@		3MG	A076288	005	Sep 15, 2008	Feb CAHN
@		4MG	A076288	006	Sep 15, 2008	Feb CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

@	DASH PHARMS	0.25MG	A091537	006	Feb 12, 2013	Feb CAHN
@		0.5MG	A091537	001	Mar 30, 2011	Feb CAHN
@		1MG	A091537	002	Mar 30, 2011	Feb CAHN
@		2MG	A091537	003	Mar 30, 2011	Feb CAHN
@		3MG	A091537	004	Mar 30, 2011	Feb CAHN
@		4MG	A091537	005	Mar 30, 2011	Feb CAHN

RITLECITINIB TOSYLATE

CAPSULE;ORAL

LITFULO

+!	PFIZER	EQ 50MG BASE	N215830	001	Jun 23, 2023	Jun NEWA

RITONAVIR

SOLUTION;ORAL

NORVIR

	+ @	ABBVIE	80MG/ML	N020659	001	Mar 01, 1996	Feb DISC

RIZATRIPTAN BENZOATE

FILM;ORAL

RIZAFILM

	+!	INTELGENX CORP	EQ 10MG BASE	N205394	001	Apr 14, 2023	Apr NEWA

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB		CHARTWELL RX	EQ 5MG BASE	A077526	001	Mar 26, 2013	May CAHN
AB			EQ 10MG BASE	A077526	002	Mar 26, 2013	May CAHN

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP		CAPLIN	50MG/5ML (10MG/ML)	A216234	001	Mar 02, 2023	Feb NEWA
AP			100MG/10ML (10MG/ML)	A216234	002	Mar 02, 2023	Feb NEWA
AP		HIKMA	50MG/5ML (10MG/ML)	A217034	001	May 24, 2023	May NEWA

ROFLUMILAST

TABLET;ORAL

ROFLUMILAST

AB		ALKEM LABS LTD	250MCG	A212490	001	Apr 18, 2023	Apr NEWA
AB			500MCG	A212490	002	Apr 18, 2023	Apr NEWA
AB		AUROBINDO PHARMA LTD	500MCG	A213298	001	Apr 17, 2023	Apr NEWA
AB		HETERO LABS LTD III	250MCG	A208213	002	Apr 18, 2023	Apr NEWA
AB		MICRO LABS	250MCG	A208180	002	Apr 18, 2023	Apr NEWA
AB		STRIDES PHARMA	250MCG	A208247	002	Jun 20, 2023	Jun NEWA
AB		ZYDUS PHARMS	250MCG	A208303	002	Apr 18, 2023	Apr NEWA

ROMIDEPSIN

POWDER;INTRAVENOUS

ISTODAX

>A> AP	+!	BRISTOL-MYERS	10MG/VIAL	N022393	001	Nov 05, 2009	Jul CAHN
>D> AP	+!	CELGENE	10MG/VIAL	N022393	001	Nov 05, 2009	Jul CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB		CHARTWELL RX	EQ 0.25MG BASE	A079050	001	May 29, 2008	Jun CAHN
AB			EQ 0.5MG BASE	A079050	002	May 29, 2008	Jun CAHN
AB			EQ 1MG BASE	A079050	003	May 29, 2008	Jun CAHN
AB			EQ 2MG BASE	A079050	004	May 29, 2008	Jun CAHN
AB			EQ 3MG BASE	A079050	005	May 29, 2008	Jun CAHN
AB			EQ 4MG BASE	A079050	006	May 29, 2008	Jun CAHN
AB			EQ 5MG BASE	A079050	007	May 29, 2008	Jun CAHN
	@	MYLAN	EQ 0.25MG BASE	A078881	001	May 05, 2008	May DISC
	@		EQ 0.5MG BASE	A078881	002	May 05, 2008	May DISC
	@		EQ 1MG BASE	A078881	003	May 05, 2008	May DISC
	@		EQ 2MG BASE	A078881	004	May 05, 2008	May DISC
	@		EQ 3MG BASE	A078881	005	May 05, 2008	May DISC
	@		EQ 4MG BASE	A078881	006	May 05, 2008	May DISC
	@		EQ 5MG BASE	A078881	007	May 19, 2008	Mar DISC

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

AB		CHARTWELL RX	EQ 2MG BASE	A091395	001	Aug 27, 2012	Jun CAHN
AB			EQ 4MG BASE	A091395	002	Aug 27, 2012	Jun CAHN
AB			EQ 6MG BASE	A091395	003	Aug 27, 2012	Jun CAHN
AB			EQ 8MG BASE	A091395	004	Aug 27, 2012	Jun CAHN
AB			EQ 12MG BASE	A091395	005	Aug 27, 2012	Jun CAHN

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP		AMNEAL	200MG/100ML (2MG/ML)	A216605	001	Mar 08, 2023	Feb NEWA
AP			400MG/200ML (2MG/ML)	A216605	002	Mar 08, 2023	Feb NEWA
AP			500MG/100ML (5MG/ML)	A216605	003	Mar 07, 2023	Feb NEWA
AP			1GM/200ML (5MG/ML)	A216605	004	Mar 07, 2023	Feb NEWA

ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDIA

	+ @	WOODWARD	EQ 2MG BASE	N021071	002	May 25, 1999	Jun DISC
	+ @		EQ 4MG BASE	N021071	003	May 25, 1999	Jun DISC

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

>D>	@	UMEDICA LABS PVT LTD	EQ 5MG BASE	A207626	001	Apr 09, 2019	Jul CMFD
>A> AB			EQ 5MG BASE	A207626	001	Apr 09, 2019	Jul CMFD
>D>	@		EQ 10MG BASE	A207626	002	Apr 09, 2019	Jul CMFD
>A> AB			EQ 10MG BASE	A207626	002	Apr 09, 2019	Jul CMFD
>D>	@		EQ 20MG BASE	A207626	003	Apr 09, 2019	Jul CMFD
>A> AB			EQ 20MG BASE	A207626	003	Apr 09, 2019	Jul CMFD
>D>	@		EQ 40MG BASE	A207626	004	Apr 09, 2019	Jul CMFD
>A> AB			EQ 40MG BASE	A207626	004	Apr 09, 2019	Jul CMFD

RUCAPARIB CAMSYLATE

TABLET;ORAL

RUBRACA

	+	ZR PHARMA	EQ 200MG BASE	N209115	001	Dec 19, 2016	May CAHN
	+		EQ 250MG BASE	N209115	003	May 01, 2017	May CAHN
	+!		EQ 300MG BASE	N209115	002	Dec 19, 2016	May CAHN

RUFINAMIDE

SUSPENSION;ORAL

RUFINAMIDE

AB		CHARTWELL RX	40MG/ML	A214009	001	Nov 07, 2022	May CAHN

TABLET;ORAL

RUFINAMIDE

AB		AUROBINDO PHARMA	200MG	A217230	001	Jun 16, 2023	Jun NEWA
AB			400MG	A217230	002	Jun 16, 2023	Jun NEWA
AB		MICRO LABS	200MG	A216688	001	May 15, 2023	May NEWA
AB			400MG	A216688	002	May 15, 2023	May NEWA

SAFINAMIDE MESYLATE

TABLET;ORAL

SAFINAMIDE MESYLATE

	@	AUROBINDO PHARMA	EQ 50MG BASE	A215902	001	Jun 14, 2023	Jun DISC
AB			EQ 50MG BASE	A215902	001	Jun 14, 2023	Jun NFTG
	@		EQ 100MG BASE	A215902	002	Jun 14, 2023	Jun DISC
AB			EQ 100MG BASE	A215902	002	Jun 14, 2023	Jun NFTG

XADAGO

	+	MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017	Jun CTEC
AB	+		EQ 50MG BASE	N207145	001	Mar 21, 2017	Jun CFTG
	+!		EQ 100MG BASE	N207145	002	Mar 21, 2017	Jun CTEC
AB	+!		EQ 100MG BASE	N207145	002	Mar 21, 2017	Jun CFTG

SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

ONGLYZA

>D>	+	ASTRAZENECA AB	EQ 2.5MG BASE	N022350	001	Jul 31, 2009	Jul CFTG
>A> AB	+		EQ 2.5MG BASE	N022350	001	Jul 31, 2009	Jul CFTG
>D>	+!		EQ 5MG BASE	N022350	002	Jul 31, 2009	Jul CFTG
>A> AB	+!		EQ 5MG BASE	N022350	002	Jul 31, 2009	Jul CFTG
>A>		SAXAGLIPTIN					
>A> AB		AMNEAL	EQ 2.5MG BASE	A205941	001	Jul 31, 2023	Jul NFTG
>A> AB			EQ 5MG BASE	A205941	002	Jul 31, 2023	Jul NFTG
>A> AB		AUROBINDO PHARMA	EQ 2.5MG BASE	A205972	001	Jul 31, 2023	Jul NFTG
>A> AB			EQ 5MG BASE	A205972	002	Jul 31, 2023	Jul NFTG
>A> AB		GLENMARK PHARMS LTD	EQ 2.5MG BASE	A205994	001	Jul 31, 2023	Jul NFTG
>A> AB			EQ 5MG BASE	A205994	002	Jul 31, 2023	Jul NFTG
>A> AB		MYLAN	EQ 2.5MG BASE	A205980	001	Jul 31, 2023	Jul NFTG
>A> AB			EQ 5MG BASE	A205980	002	Jul 31, 2023	Jul NFTG
>A> AB		SUN PHARM	EQ 2.5MG BASE	A206078	001	Jul 31, 2023	Jul NFTG
>A> AB			EQ 5MG BASE	A206078	002	Jul 31, 2023	Jul NFTG

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

	@	DASH PHARMS NATCO	5MG	A074866	001	Nov 26, 1997	Mar CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL

SELENIUM SULFIDE

	@	XTTRIUM LABS INC	2.5%	A088228	001	Sep 01, 1983	Mar CAHN

SELEXIPAG

TABLET;ORAL

SELEXIPAG

	@	ZYDUS	0.2MG	A214302	001	Dec 21, 2022	May DISC
	@		0.4MG	A214302	002	Dec 21, 2022	May DISC
	@		0.6MG	A214302	003	Dec 21, 2022	May DISC
	@		0.8MG	A214302	004	Dec 21, 2022	May DISC
	@		1MG	A214302	005	Dec 21, 2022	May DISC
	@		1.2MG	A214302	006	Dec 21, 2022	May DISC
	@		1.4MG	A214302	007	Dec 21, 2022	May DISC
	@		1.6MG	A214302	008	Dec 21, 2022	May DISC
		UPTRAVI					
	+	ACTELION	0.2MG	N207947	001	Dec 21, 2015	May CTEC
	+!		0.4MG	N207947	002	Dec 21, 2015	May CTEC
	+		0.6MG	N207947	003	Dec 21, 2015	May CTEC
	+		0.8MG	N207947	004	Dec 21, 2015	May CTEC
	+		1MG	N207947	005	Dec 21, 2015	May CTEC
	+		1.2MG	N207947	006	Dec 21, 2015	May CTEC
	+		1.4MG	N207947	007	Dec 21, 2015	May CTEC
	+		1.6MG	N207947	008	Dec 21, 2015	May CTEC

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

AB		HERITAGE PHARMA AVET	EQ 25MG BASE	A076465	001	Aug 11, 2006	Mar CMFD
AB			EQ 50MG BASE	A076465	002	Aug 11, 2006	Mar CMFD
AB			EQ 100MG BASE	A076465	003	Aug 11, 2006	Mar CMFD
	@	ZYDUS	EQ 25MG BASE	A077106	001	Feb 06, 2007	May CAHN
	@		EQ 50MG BASE	A077106	002	Feb 06, 2007	May CAHN
	@		EQ 100MG BASE	A077106	003	Feb 06, 2007	May CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

AB		HANGZHOU ANPRIME	800MG/PACKET	A217319	001	Mar 02, 2023	Feb NEWA
AB			2.4GM/PACKET	A217319	002	Mar 02, 2023	Feb NEWA

TABLET;ORAL

SEVELAMER CARBONATE

AB		MACLEODS PHARMS LTD	800MG	A206100	001	Apr 19, 2023	Apr NEWA

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

SEVELAMER HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	400MG	A212599	001	Jul 11, 2023	Jun NEWA
AB			800MG	A212599	002	Jul 11, 2023	Jun NEWA
AB		MACLEODS PHARMS LTD	400MG	A206883	001	May 26, 2023	May NEWA
AB			800MG	A206883	002	May 26, 2023	May NEWA

SILDENAFIL CITRATE

SUSPENSION;ORAL

LIQREV

	+!	CMP DEV LLC	EQ 10MG BASE/ML	N214952	001	Apr 28, 2023	Apr NEWA

TABLET;ORAL

SILDENAFIL CITRATE

AB		MACLEODS PHARMS LTD	EQ 25MG BASE	A202255	001	Apr 19, 2023	Apr NEWA
AB			EQ 50MG BASE	A202255	002	Apr 19, 2023	Apr NEWA
AB			EQ 100MG BASE	A202255	003	Apr 19, 2023	Apr NEWA

SILODOSIN

CAPSULE;ORAL

SILODOSIN

@	ZYDUS PHARMS	4MG	A204816	001	Dec 08, 2022	May DISC
@		8MG	A204816	002	Dec 08, 2022	May DISC

SIPONIMOD

TABLET;ORAL

MAYZENT

+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	May CAIN
+		EQ 1MG BASE	N209884	003	Aug 24, 2021	May CAIN
+!		EQ 2MG BASE	N209884	002	Mar 26, 2019	May CAIN

SIROLIMUS

SOLUTION;ORAL

SIROLIMUS

AA	MSN	1MG/ML	A216728	001	Jan 19, 2023	Jan NEWA

TABLET;ORAL

SIROLIMUS

AB	ZYDUS PHARMS	1MG	A201676	001	Feb 15, 2023	Feb NEWA
AB		2MG	A201676	002	Feb 15, 2023	Feb NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;INTRAVENOUS

SODIUM PHENYLACETATE AND SODIUM BENZOATE

>D> +!	MAIA PHARMS INC	10%;10% (2GM/20ML;2GM/20ML)	N215025	001	Jun 10, 2021	Jul CFTG
>A> AP +!		10%;10% (2GM/20ML;2GM/20ML)	N215025	001	Jun 10, 2021	Jul CFTG
>A> AP	NAVINTA LLC	10%;10% (2GM/20ML; 2GM/20ML)	A217526	001	Jul 14, 2023	Jul NFTG

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE

AP	OMNIVIUM PHARMS	1MEQ/ML	A216364	001	Jun 15, 2023	Jun NEWA
AP	STERISCIENCE	1MEQ/ML	A217594	001	Jun 28, 2023	Jun NEWA

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9%

+	B BRAUN	9MG/ML	N019635	005	Aug 08, 2016	Mar CPOT

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ @	LIEBEL-FLARSHEIM	450MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Mar CPOT
+		1.125GM/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Mar CPOT

SODIUM CHLORIDE 0.9% IN PLASTIC THERMOJECT KIT FOR CARDIAC OUTPUT USE

+ @	ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984	Jun CTNA

SODIUM CHLORIDE 23.4%

AP	FRESENIUS KABI USA	234MG/ML	A212248	001	Apr 28, 2021	Jun CTEC
AP		234MG/ML	A217796	001	Jul 11, 2023	Jun NEWA

SOLUTION;INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	ABRAXIS PHARM	9MG/ML	A088909	001	Feb 07, 1985	Jun CDFR
@		90MG/10ML (9MG/ML)	A088909	002	May 15, 1985	Jun CMS1
@		270MG/30ML (9MG/ML)	A088909	001	Feb 07, 1985	Jun CPOT
AP	FRESENIUS KABI USA	9MG/ML	A088911	001	Feb 07, 1985	Jun CDFR
AP		90MG/10ML (9MG/ML)	A088911	002	May 17, 1985	Jun CMS1
AP		270MG/30ML (9MG/ML)	A088911	001	Feb 07, 1985	Jun CPOT
AP +!	HOSPIRA	9MG/ML	N018800	001	Oct 29, 1982	Jun CDFR
AP +!		90MG/10ML (9MG/ML)	N018800	001	Oct 29, 1982	Jun CPOT
AP +!		180MG/20ML (9MG/ML)	N018800	002	Oct 29, 1982	Jun CMS1
AP +!		270MG/30ML (9MG/ML)	N018800	003	Oct 29, 1982	Jun CMS1

SODIUM CHLORIDE 0.9%

+	B BRAUN	9MG/ML	N019635	005	Aug 08, 2016	Jun CDFR
+		90MG/10ML (9MG/ML)	N019635	005	Aug 08, 2016	Jun CPOT
	HIKMA	9MG/ML	A201833	001	Sep 24, 2013	Jun CDFR
AP		9MG/ML	A201850	001	Jan 20, 2012	Jun CDFR
		18MG/2ML (9MG/ML)	A201833	001	Sep 24, 2013	Jun CPOT
AP		90MG/10ML (9MG/ML)	A201833	002	Jan 07, 2015	Jun CMS1
AP		90MG/10ML (9MG/ML)	A201850	001	Jan 20, 2012	Jun CPOT
AP	SPECTRA MDCL DEVICES	9MG/ML	A206171	001	Jul 21, 2017	Jun CDFR
AP		45MG/5ML (9MG/ML)	A206171	001	Jul 21, 2017	Jun CPOT
AP		90MG/10ML (9MG/ML)	A206171	002	Jul 21, 2017	Jun CMS1

```
          SOLUTION;INJECTION
            SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
            @ ABBOTT                 9MG/ML                          N019218  001  Jul 13, 1984   Jun CDFR
            @                        90MG/10ML (9MG/ML)              N019218  001  Jul 13, 1984   Jun CPOT
            @                        180MG/20ML (9MG/ML)             N019218  002  Apr 30, 1985   Jun CMS1
    AP    +!  BAXTER HLTHCARE        9MG/ML                          N016677  004  Oct 30, 1985   Jun CDFR
    AP    +                          9MG/ML                          N020178  002  Dec 07, 1992   Jun CDFR
          +!                         225MG/25ML (9MG/ML)             N016677  004  Oct 30, 1985   Jun CTEC
    AP    +!                         225MG/25ML (9MG/ML)             N016677  004  Oct 30, 1985   Jun CPOT
    AP    +!                         450MG/50ML (9MG/ML)             N016677  003                 Jun CMS1
    AP    +                          450MG/50ML (9MG/ML)             N020178  002  Dec 07, 1992   Jun CPOT
    AP    +!                         900MG/100ML                     N016677  001                 Jun CDFR
    AP    +!                         900MG/100ML                     N020178  001  Dec 07, 1992   Jun CDFR
    AP    !   FRESENIUS KABI USA     9MG/ML                          A088912  001  Jan 10, 1985   Jun CDFR
          !                          18MG/2ML (9MG/ML)               A088912  004  Nov 29, 1985   Jun CMS1
    AP    !                          90MG/10ML (9MG/ML)              A088912  001  Jan 10, 1985   Jun CPOT
    AP    !                          180MG/20ML (9MG/ML)             A088912  002  Jan 10, 1985   Jun CMS1
    AP    !                          270MG/30ML (9MG/ML)             A088912  003  Jan 10, 1985   Jun CMS1
    AP    +!  HOSPIRA                90MG/10ML (9MG/ML)              N018803  001  Oct 29, 1982   Jun CPOT
    AP    +!                         9MG/ML                          N018803  001  Oct 29, 1982   Jun CDFR
    AP    +                          9MG/ML                          N019465  002  Jul 15, 1985   Jun CDFR
          + @                        18MG/2ML (9MG/ML)               N018803  004  Jan 22, 2015   Jun CMS1
          + @                        27MG/3ML (9MG/ML)               N018803  005  Jan 22, 2015   Jun CMS1
          + @                        45MG/5ML (9MG/ML)               N018803  006  Jan 22, 2015   Jun CMS1
    AP    +!                         180MG/20ML (9MG/ML)             N018803  002  Oct 29, 1982   Jun CMS1
    AP    +!                         450MG/50ML (9MG/ML)             N018803  003  Oct 29, 1982   Jun CMS1
    AP    +                          450MG/50ML (9MG/ML)             N019465  002  Jul 15, 1985   Jun CPOT
    AP    +!                         900MG/100ML                     N019465  001  Jul 15, 1985   Jun CDFR
          + @ ICU MEDICAL INC        45MG/5ML (9MG/ML)               N019217  002  Nov 18, 1998   Jun CMS1
          + @                        90MG/10ML (9MG/ML)              N019217  003  Nov 18, 1998   Jun CMS1
          + @                        360MG/40ML (9MG/ML)             N019217  004  Apr 01, 1999   Jun CMS1
            @ JUBILANT CADISTA       9MG/ML                          A203352  001  May 18, 2016   Jun CDFR
            @                        27MG/3ML (9MG/ML)               A203352  002  May 18, 2016   Jun CMS1
            @                        90MG/10ML (9MG/ML)              A203352  001  May 18, 2016   Jun CPOT
            @ MILES                  450MG/50ML (9MG/ML)             N018502  002                 Jun CMS1
            @                        900MG/100ML                     N018502  001                 Jun CDFR
    AP        NEPHRON                9MG/ML                          A211968  001  Apr 23, 2020   Jun CDFR
    AP                               450MG/50ML (9MG/ML)             A211968  001  Apr 23, 2020   Jun CPOT
    AP                               900MG/100ML                     A211968  002  Apr 23, 2020   Jun CMS1
    AP    !   TARO                   9MG/ML                          A077407  001  Aug 11, 2006   Jun CDFR
    AP    !                          45MG/5ML (9MG/ML)               A077407  001  Aug 11, 2006   Jun CPOT
    AP    !                          90MG/10ML (9MG/ML)              A077407  002  Aug 11, 2006   Jun CMS1
            SODIUM CHLORIDE 0.9% IN PLASTIC THERMOJECT KIT FOR CARDIAC OUTPUT USE
          + @ ICU MEDICAL INC        9MG/ML                          N019217  001  Jul 13, 1984   Jun CDFR
          + @                        90MG/10ML (9MG/ML)              N019217  001  Jul 13, 1984   Jun CPOT

        SODIUM OXYBATE
          FOR SUSPENSION, EXTENDED RELEASE;ORAL
            LUMRYZ
          +!  AVADEL CNS             4.5GM/PACKET                    N214755  001  May 01, 2023   Jun CHRS
          +                          4.5GM/PACKET                    N214755  001  May 01, 2023   May NEWA
          +                          6GM/PACKET                      N214755  002  May 01, 2023   May NEWA
          +                          7.5GM/PACKET                    N214755  003  May 01, 2023   May NEWA
          +                          9GM/PACKET                      N214755  004  May 01, 2023   May NEWA

        SODIUM PHENYLBUTYRATE
          POWDER;ORAL
            BUPHENYL
    AB    +!  HORIZON THERAP US      3GM/TEASPOONFUL                 N020573  001  Apr 30, 1996   Jan CAHN
          TABLET;ORAL
            BUPHENYL
    AB    +!  HORIZON THERAP US      500MG                           N020572  001  May 13, 1996   Jan CAHN

        SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
          TABLET;ORAL
            MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE
>D> AB        NOVEL LABS INC         0.398GM;1.102GM                 A079247  001  Dec 30, 2011   Jul CTEC
>A>       !                          0.398GM;1.102GM                 A079247  001  Dec 30, 2011   Jul CTEC
>D>         OSMOPREP
>D> AB    +!  SALIX PHARMS           0.398GM;1.102GM                 N021892  001  Mar 16, 2006   Jul DISC
>A>       + @                        0.398GM;1.102GM                 N021892  001  Mar 16, 2006   Jul DISC
```

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE;INJECTION
SODIUM PHOSPHATES

AP	!	FRESENIUS KABI USA	142MG/ML;276MG/ML	A209997	001	Mar 30, 2022	Mar CHRS

SOLIFENACIN SUCCINATE

TABLET;ORAL
SOLIFENACIN SUCCINATE

AB		CHARTWELL RX	5MG	A210582	001	May 20, 2019	May CAHN
AB			10MG	A210582	002	May 20, 2019	May CAHN
>D> AB		CIPLA	5MG	A209839	001	May 20, 2019	Jul DISC
>A>	@		5MG	A209839	001	May 20, 2019	Jul DISC
>D> AB			10MG	A209839	002	May 20, 2019	Jul DISC
>A>	@		10MG	A209839	002	May 20, 2019	Jul DISC
AB		LANNETT CO INC	5MG	A211622	001	Jun 06, 2023	May NEWA
AB			10MG	A211622	002	Jun 06, 2023	May NEWA

SORAFENIB TOSYLATE

TABLET;ORAL
SORAFENIB TOSYLATE

AB		TORRENT	EQ 200MG BASE	A217095	001	Apr 12, 2023	Mar NEWA

SOTAGLIFLOZIN

TABLET;ORAL
INPEFA

	+	LEXICON PHARMS INC	200MG	N216203	001	May 26, 2023	May NEWA
	+!		400MG	N216203	002	May 26, 2023	May NEWA

SOTALOL HYDROCHLORIDE

TABLET;ORAL
SOTALOL HYDROCHLORIDE

>D>	@	AUROBINDO PHARMA USA	80MG	A077616	001	Feb 07, 2007	Jul CMFD
>A> AB			80MG	A077616	001	Feb 07, 2007	Jul CMFD
>D>	@		120MG	A077616	002	Feb 07, 2007	Jul CMFD
>A> AB			120MG	A077616	002	Feb 07, 2007	Jul CMFD
>D>	@		160MG	A077616	003	Feb 07, 2007	Jul CMFD
>A> AB			160MG	A077616	003	Feb 07, 2007	Jul CMFD

SOTORASIB

TABLET;ORAL
LUMAKRAS

	+	AMGEN INC	120MG	N214665	001	May 28, 2021	Mar CHRS
	+!		320MG	N214665	002	Jan 20, 2023	Mar CHRS
	+		320MG	N214665	002	Jan 20, 2023	Feb NEWA

SPARSENTAN

TABLET;ORAL
FILSPARI

	+	TRAVERE	200MG	N216403	001	Feb 17, 2023	Feb NEWA
	+!		400MG	N216403	002	Feb 17, 2023	Feb NEWA

STERILE WATER FOR INJECTION

LIQUID;N/A
STERILE WATER FOR INJECTION

AP		HIKMA	100%	A212735	001	Jan 31, 2023	Jan NEWA
AP	+!	HOSPIRA	100% (20ML)	N018801	003	Oct 27, 1982	Jun CFTG
	+ @		100% (5.2ML)	N018801	006	May 02, 2023	Jun DISC
	+!		100% (5.2ML)	N018801	006	May 02, 2023	May NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION
SUCCINYLCHOLINE CHLORIDE

	@	BRECKENRIDGE	20MG/ML	A212638	001	Oct 09, 2019	Apr DISC

SUCRALFATE

TABLET;ORAL
SUCRALFATE

AB		ZYDUS LIFESCIENCES	1GM	A215705	001	May 03, 2023	Apr NEWA

SUFENTANIL CITRATE

TABLET;SUBLINGUAL

DSUVIA

		+!	VERTICAL PHARMS	EQ 0.03MG BASE	N209128	001	Nov 02, 2018	Apr CAHN

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS

BRIDION

>A>	AP	+	MSD SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jul CAHN
>A>	AP	+!		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jul CAHN
>D>	AP	+	ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jul CAHN
	AP	+		EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jun CFTG
>D>	AP	+!		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jul CAHN
	AP	+!		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jun CFTG

SUGAMMADEX SODIUM

	AP		ASPIRO	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214337	001	Jun 09, 2023	Jun NFTG
	AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214337	002	Jun 09, 2023	Jun NFTG
	AP		MYLAN	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A213915	001	Jun 15, 2023	Jun NEWA
	AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A213915	002	Jun 15, 2023	Jun NEWA
	AP		SANDOZ	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214311	001	Jun 23, 2023	Jun NEWA
	AP			EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214311	002	Jun 23, 2023	Jun NEWA

SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM

		@	AKORN	10%	A040215	001	May 25, 1999	Jan DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>A>	AB		CHARTWELL MOLECULAR	200MG/5ML;40MG/5ML	A077785	001	Jan 24, 2007	Jul CAHN
>D>	AB		LANNETT CO INC	200MG/5ML;40MG/5ML	A077785	001	Jan 24, 2007	Jul CAHN

SULINDAC

TABLET;ORAL

SULINDAC

		@	CHARTWELL RX	150MG	A072712	001	Aug 30, 1991	Jan CAHN
		@		200MG	A072713	001	Aug 30, 1991	Jan CAHN

SUMATRIPTAN

SPRAY;NASAL

TOSYMRA

>A>		+!	TONIX MEDS	10MG/SPRAY	N210884	001	Jan 25, 2019	Jul CAHN
>D>		+!	UPSHER SMITH LABS	10MG/SPRAY	N210884	001	Jan 25, 2019	Jul CAHN

SUMATRIPTAN SUCCINATE

SOLUTION;SUBCUTANEOUS

ZEMBRACE SYMTOUCH

>A>		+	TONIX MEDS	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jul CAHN
>D>		+	UPSHER SMITH LABS	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jul CAHN

TACROLIMUS

CAPSULE;ORAL

TACROLIMUS

	AB		HANGZHOU ZHONGMEI	EQ 0.5MG BASE	A210929	001	Apr 17, 2023	Apr NEWA
	AB			EQ 1MG BASE	A210929	002	Apr 17, 2023	Apr NEWA
	AB			EQ 5MG BASE	A210929	003	Apr 17, 2023	Apr NEWA

TADALAFIL

TABLET;ORAL

ALYQ

	@	TEVA PHARMS INC	20MG	A216932	001	Oct 12, 2022	Apr DISC

TADALAFIL

AB2		CHARTWELL RX	20MG	A210572	001	Feb 05, 2019	May CAHN
AB1		NOVITIUM PHARMA	5MG	A215949	001	Mar 03, 2023	Feb NEWA
AB1			10MG	A215949	002	Mar 03, 2023	Feb NEWA
AB1			20MG	A215949	003	Mar 03, 2023	Feb NEWA
AB1		UNICHEM	2.5MG	A209250	001	Mar 26, 2019	Jan CTEC
AB1			5MG	A209250	002	Mar 26, 2019	Jan CTEC
AB1			10MG	A209250	003	Mar 26, 2019	Jan CTEC
AB1			20MG	A209250	004	Mar 26, 2019	Jan CTEC
AB2		ZYDUS PHARMS	20MG	A212515	001	Jun 06, 2023	May NEWA

TALAZOPARIB TOSYLATE

CAPSULE;ORAL

TALZENNA

>A>	+	PFIZER	EQ 0.1MG BASE	N211651	005	Jun 20, 2023	Jul NEWA
>A>	+		EQ 0.35MG BASE	N211651	006	Jun 20, 2023	Jul NEWA

TAMOXIFEN CITRATE

SOLUTION;ORAL

SOLTAMOX

	+!	MAYNE PHARMA COMMRCL	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Feb CAHN

TASIMELTEON

CAPSULE;ORAL

TASIMELTEON

AB		APOTEX	20MG	A211607	001	Dec 20, 2022	Jan CAHN
AB		MSN	20MG	A211654	001	Jan 12, 2023	Jan NEWA

TAVABOROLE

SOLUTION;TOPICAL

TAVABOROLE

AB		ZYDUS LIFESCIENCES	5%	A212294	001	Apr 10, 2023	Mar NEWA

TAZAROTENE

GEL;TOPICAL

TAZAROTENE

AB		PADAGIS ISRAEL	0.05%	A213079	001	Apr 25, 2023	Apr NEWA
AB			0.1%	A213079	002	Apr 25, 2023	Apr NEWA
AB		SOLARIS PHARMA CORP	0.05%	A213644	001	Mar 20, 2023	Mar NEWA
AB			0.1%	A213644	002	Mar 20, 2023	Mar NEWA

TECHNETIUM TC-99M MERTIATIDE KIT

POWDER;INTRAVENOUS

TECHNETIUM TC 99M MERTIATIDE KIT

	+!	JUBILANT DRAXIMAGE	N/A	N216820	001	Jan 30, 2023	Jan NEWA

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB		CHARTWELL RX	20MG	A078710	001	Jan 08, 2014	May CAHN
AB			40MG	A078710	002	Jan 08, 2014	May CAHN
AB			80MG	A078710	003	Jan 08, 2014	May CAHN

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

>A>	@	CHARTWELL MOLECULAR	5MG	A203898	001	Feb 10, 2016	Jul CAHN
>A>	@		20MG	A203898	002	Feb 10, 2016	Jul CAHN
>A>	@		100MG	A203898	003	Feb 10, 2016	Jul CAHN
>A>	@		140MG	A203898	004	Feb 10, 2016	Jul CAHN
>A>	@		180MG	A203898	005	Feb 10, 2016	Jul CAHN
>A>	@		250MG	A203898	006	Feb 10, 2016	Jul CAHN
>D>	@	LANNETT CO INC	5MG	A203898	001	Feb 10, 2016	Jul CAHN
>D>	@		20MG	A203898	002	Feb 10, 2016	Jul CAHN
>D>	@		100MG	A203898	003	Feb 10, 2016	Jul CAHN
>D>	@		140MG	A203898	004	Feb 10, 2016	Jul CAHN
>D>	@		180MG	A203898	005	Feb 10, 2016	Jul CAHN

```
          CAPSULE;ORAL
            TEMOZOLOMIDE
>D>         @                        250MG                              A203898  006  Feb 10, 2016   Jul CAHN

        TENOFOVIR ALAFENAMIDE FUMARATE
          TABLET;ORAL
            TENOFOVIR ALAFENAMIDE
    AB        LUPIN LTD              EQ 25MG BASE                       A214226  001  Mar 30, 2023   Mar NFTG
            VEMLIDY
    AB    +!  GILEAD SCIENCES INC    EQ 25MG BASE                       N208464  001  Nov 10, 2016   Mar CFTG

        TENOFOVIR DISOPROXIL FUMARATE
          TABLET;ORAL
            TENOFOVIR DISOPROXIL FUMARATE
    AB        REYOUNG PHARM          300MG                              A211337  001  Mar 02, 2023   Feb NEWA

        TERAZOSIN HYDROCHLORIDE
          CAPSULE;ORAL
            TERAZOSIN HYDROCHLORIDE
            @ BIONPHARMA             EQ 1MG BASE                        A075667  001  Jul 28, 2000   Apr CAHN
            @                        EQ 2MG BASE                        A075667  002  Jul 28, 2000   Apr CAHN
            @                        EQ 5MG BASE                        A075667  003  Jul 28, 2000   Apr CAHN
            @                        EQ 10MG BASE                       A075667  004  Jul 28, 2000   Apr CAHN
          TABLET;ORAL
            TERAZOSIN HYDROCHLORIDE
            @ CHARTWELL RX           EQ 1MG BASE                        A074657  001  Apr 28, 2000   May CAHN
            @                        EQ 2MG BASE                        A074657  002  Apr 28, 2000   May CAHN
            @                        EQ 5MG BASE                        A074657  003  Apr 28, 2000   May CAHN
            @                        EQ 10MG BASE                       A074657  004  Apr 28, 2000   May CAHN

        TERIFLUNOMIDE
          TABLET;ORAL
            TERIFLUNOMIDE
    AB        AMNEAL PHARMS CO       7MG                                A209613  001  Sep 28, 2018   Feb CMFD
    AB                               14MG                               A209613  002  Sep 28, 2018   Feb CMFD
    AB        APOTEX                 7MG                                A209601  001  Nov 02, 2018   Jan CMFD
    AB                               14MG                               A209601  002  Nov 02, 2018   Jan CMFD
    AB        AUROBINDO PHARMA       7MG                                A209638  001  Oct 26, 2018   Jan CMFD
    AB                               14MG                               A209638  002  Oct 26, 2018   Jan CMFD
    AB        BIOCON PHARMA          7MG                                A209639  001  Mar 13, 2023   Mar NEWA
    AB                               14MG                               A209639  002  Mar 13, 2023   Mar NEWA
    AB        HETERO LABS LTD V      7MG                                A209598  001  Mar 13, 2023   Mar NEWA
    AB                               14MG                               A209598  002  Mar 13, 2023   Mar NEWA
    AB        MSN                    7MG                                A209623  001  Apr 24, 2019   Feb CMFD
    AB                               14MG                               A209623  002  Apr 24, 2019   Feb CMFD
    AB        MYLAN                  7MG                                A209702  001  Feb 28, 2020   Feb CMFD
    AB                               14MG                               A209702  002  Feb 28, 2020   Feb CMFD
    AB        NATCO                  7MG                                A209555  001  May 15, 2023   May NEWA
    AB                               14MG                               A209555  002  May 15, 2023   May NEWA
    AB        SOLA PHARMS            14MG                               A209677  001  Jun 17, 2020   Feb CMFD
    AB        TEVA PHARMS USA        7MG                                A209700  001  Sep 04, 2018   Feb CMFD
    AB                               14MG                               A209700  002  Sep 04, 2018   Feb CMFD
    AB        ZYDUS PHARMS           7MG                                A209668  001  Nov 30, 2018   Jan CMFD
    AB                               14MG                               A209668  002  Nov 30, 2018   Jan CMFD

        TESTOSTERONE
          GEL, METERED;NASAL
            NATESTO
          +!  ACERUS                 5.5MG/0.122GM ACTUATION            N205488  001  May 28, 2014   Jan CHRS
          +                          5.5MG/0.122GM ACTUATION            N205488  001  May 28, 2014   Jan CRLD
          GEL, METERED;TRANSDERMAL
            ANDROGEL
    AB    +!  BESINS HLTHCARE        1.62% (20.25MG/1.25GM ACTUATION)   N022309  001  Apr 29, 2011   Feb CAHN
          + @                        12.5MG/1.25GM ACTUATION            N021015  003  Sep 26, 2003   Feb CAHN
            TESTOSTERONE
    AB        ENCUBE                 1.62% (20.25MG/1.25GM ACTUATION)   A208620  001  Apr 10, 2019   Jan CAHN
```

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

TESTOSTERONE CYPIONATE

AO	XIROMED	100MG/ML	A215351	001	Apr 13, 2023	Mar NEWA
AO		200MG/ML	A215351	002	Apr 13, 2023	Mar NEWA

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

AB	CHARTWELL RX	12.5MG	A210544	001	Apr 20, 2018	May CAHN
AB		25MG	A210544	002	Apr 20, 2018	May CAHN
@	SUN PHARM	12.5MG	A206129	001	Aug 17, 2015	Jan DISC
@		25MG	A206129	002	Aug 17, 2015	Jan DISC

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

TETRACYCLINE HYDROCHLORIDE

@	AUROBINDO PHARMA USA	250MG	A060783	001		Apr CAHN
@		500MG	A060783	002		Apr CAHN

THALIDOMIDE

CAPSULE;ORAL

THALIDOMIDE

AB	NATCO	150MG	A213267	001	Apr 27, 2023	Apr NFTG

THALOMID

AB +	CELGENE	150MG	N020785	004	Jan 10, 2007	Apr CFTG

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

AB	AMNEAL	300MG	A216276	001	Mar 20, 2023	Mar NEWA
AB		450MG	A216276	002	Mar 20, 2023	Mar NEWA
AB	BIONPHARMA	300MG	A216300	001	Apr 26, 2023	Apr NEWA
AB		450MG	A216300	002	Apr 26, 2023	Apr NEWA
AB	LEADING	300MG	A214950	001	Jan 30, 2023	Jan NEWA
AB		450MG	A214950	002	Jan 30, 2023	Jan NEWA
AB	RHODES PHARMS	300MG	A214113	001	May 11, 2023	May NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

AP	CAPLIN	100MG/ML	A215692	001	Mar 06, 2023	Feb NEWA
AP	DR REDDYS	100MG/ML	A080571	001		Mar CMFD
!		200MG/ML	A080571	002		Mar CMFD

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

@	CHARTWELL RX	10MG	A088131	001	Aug 30, 1983	Jan CAHN
@		15MG	A088132	001	Aug 30, 1983	Jan CAHN
@		25MG	A088133	001	Aug 30, 1983	Jan CAHN
@		50MG	A088134	001	Aug 30, 1983	Jan CAHN
@		100MG	A088135	001	Nov 20, 1984	Jan CAHN
@		150MG	A088136	001	Sep 17, 1986	Jan CAHN
@		200MG	A088137	001	Sep 17, 1986	Jan CAHN

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA

AP	PENN LIFE	15MG/VIAL	A208242	001	Jan 10, 2020	May CAHN

THIOTHIXENE

CAPSULE;ORAL

THIOTHIXENE

AB	RISING	1MG	A071093	002	Jun 23, 1987	Feb CAHN
AB		2MG	A071093	003	Jun 23, 1987	Feb CAHN
AB		5MG	A071093	004	Jun 23, 1987	Feb CAHN
AB		10MG	A071093	001	Jun 23, 1987	Feb CAHN

TICAGRELOR

TABLET;ORAL

TICAGRELOR

AB	ALKEM LABS LTD	90MG	A208567	001	Apr 21, 2023	Apr NEWA

TIMOLOL

SOLUTION/DROPS;OPHTHALMIC

BETIMOL

+!	THEA PHARMA	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Jan CTEC
+!		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Jan CTEC

TIMOLOL

@	AKORN	EQ 0.25% BASE	A205309	001	Sep 30, 2016	Jan DISC
@		EQ 0.5% BASE	A205309	002	Sep 30, 2016	Jan DISC

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AB	EUGIA PHARMA	EQ 0.5% BASE	A213540	001	Mar 23, 2023	Mar NEWA
AB	GLAND PHARMA LTD	EQ 0.5% BASE	A214645	002	Feb 14, 2023	Feb NEWA

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

@	AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Jan DISC
AT1	MICRO LABS	EQ 0.25% BASE	A217343	001	May 26, 2023	May NEWA
AT1		EQ 0.5% BASE	A217343	002	May 26, 2023	May NEWA
AT3	SENTISS PHARMA	EQ 0.5% BASE	A217195	001	May 08, 2023	Apr NEWA

TINIDAZOLE

TABLET;ORAL

TINIDAZOLE

AB	CHARTWELL RX	250MG	A202044	001	Apr 30, 2012	Apr CAHN
AB		500MG	A202044	002	Apr 30, 2012	Apr CAHN

TIOPRONIN

TABLET, DELAYED RELEASE;ORAL

THIOLA EC

+	MISSION PHARMACAL CO	100MG	N211843	001	Jun 28, 2019	Apr CTEC
AB +		100MG	N211843	001	Jun 28, 2019	Feb CFTG
+!		300MG	N211843	002	Jun 28, 2019	Apr CTEC
AB +!		300MG	N211843	002	Jun 28, 2019	Feb CFTG

TIOPRONIN

@	PAR PHARM	100MG	A217219	001	Feb 24, 2023	Apr DISC
AB		100MG	A217219	001	Feb 24, 2023	Feb NFTG
@		300MG	A217219	002	Feb 24, 2023	Apr DISC
AB		300MG	A217219	002	Feb 24, 2023	Feb NFTG

TIOTROPIUM BROMIDE

POWDER;INHALATION

SPIRIVA

AB +!	BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH	N021395	001	Jan 30, 2004	Jun CFTG

TIOTROPIUM BROMIDE

AB	LUPIN	EQ 0.018MG BASE/INH	A211287	001	Jun 20, 2023	Jun NFTG

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

TABLET;ORAL

LONSURF

AB +	TAIHO ONCOLOGY	EQ 6.14MG BASE;15MG	N207981	001	Sep 22, 2015	Jun CFTG
AB +!		EQ 8.19MG BASE;20MG	N207981	002	Sep 22, 2015	Jun CFTG

TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE

AB	NATCO	EQ 6.14MG BASE;15MG	A214008	001	Jun 13, 2023	Jun NFTG
AB		EQ 8.19MG BASE;20MG	A214008	002	Jun 13, 2023	Jun NFTG

TIROFIBAN HYDROCHLORIDE

SOLUTION;INTRAVENOUS

AGGRASTAT

AP +	MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002	Jan CFTG

TIROFIBAN HYDROCHLORIDE

AP	EUGIA PHARMA	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	A216379	001	May 01, 2023	Apr NEWA
AP		EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	A216379	002	May 01, 2023	Apr NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

ZANAFLEX

>D>	AB	+	LEGACY PHARMA	EQ 2MG BASE	N021447	001	Aug 29, 2002	Jul CAHN
>D>	AB	+		EQ 4MG BASE	N021447	002	Aug 29, 2002	Jul CAHN
>D>	AB	+!		EQ 6MG BASE	N021447	003	Aug 29, 2002	Jul CAHN
>A>	AB	+	LEGACY PHARMA USA	EQ 2MG BASE	N021447	001	Aug 29, 2002	Jul CAHN
>A>	AB	+		EQ 4MG BASE	N021447	002	Aug 29, 2002	Jul CAHN
>A>	AB	+!		EQ 6MG BASE	N021447	003	Aug 29, 2002	Jul CAHN

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

		@	AUROBINDO PHARMA USA	EQ 2MG BASE	A076282	001	Dec 16, 2003	Apr CAHN
		@		EQ 4MG BASE	A076282	002	Dec 16, 2003	Apr CAHN

ZANAFLEX

>D>		+ @	LEGACY PHARMA	EQ 2MG BASE	N020397	002	Feb 04, 2000	Jul CAHN
>D>	AB	+!		EQ 4MG BASE	N020397	001	Nov 27, 1996	Jul CAHN
>A>		+ @	LEGACY PHARMA USA	EQ 2MG BASE	N020397	002	Feb 04, 2000	Jul CAHN
>A>	AB	+!		EQ 4MG BASE	N020397	001	Nov 27, 1996	Jul CAHN

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

	AN		MANKIND PHARMA	300MG/5ML	A214478	001	Jun 30, 2023	Jun NEWA
>A>	AN		MICRO LABS	300MG/5ML	A217344	001	Jul 27, 2023	Jul NEWA

SOLUTION/DROPS;OPHTHALMIC

AKTOB

		@	AKORN	0.3%	A064096	001	Jan 31, 1996	Feb DISC

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

	AP		EUGIA PHARMA	EQ 1.2GM BASE/VIAL	A217519	001	Jun 21, 2023	Jun NEWA
	AP		HAINAN POLY	EQ 1.2GM BASE/VIAL	A217029	001	Feb 01, 2023	Jan NEWA

TOFACITINIB CITRATE

TABLET;ORAL

TOFACITINIB CITRATE

		@	MICRO LABS	EQ 5MG BASE	A209738	001	Mar 13, 2023	Mar DISC
	AB			EQ 5MG BASE	A209738	001	Mar 13, 2023	Mar NFTG
	AB		ZYDUS PHARMS	EQ 5MG BASE	A209829	001	Mar 13, 2023	Mar NEWA

XELJANZ

	AB	+	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	Mar CFTG

TOFERSEN

SOLUTION;INTRATHECAL

QALSODY

		+!	BIOGEN MA	100MG/15ML (6.7MG/ML)	N215887	001	Apr 25, 2023	Apr NEWA

TOLMETIN SODIUM

CAPSULE;ORAL

TOLMETIN SODIUM

>D>		@	RISING	EQ 400MG BASE	A073393	001	May 27, 1993	Jul CMFD
>A>				EQ 400MG BASE	A073393	001	May 27, 1993	Jul CMFD

TABLET;ORAL

TOLMETIN SODIUM

		!	RISING	EQ 600MG BASE	A074473	001	Aug 30, 1994	May CMFD

TOLVAPTAN

TABLET;ORAL

TOLVAPTAN

	AB		MSN	15MG	A216949	001	Jun 21, 2023	Jun NEWA
	AB			30MG	A216949	002	Jun 21, 2023	Jun NEWA

TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE

	AB1		ACTAVIS LABS FL	25MG	A206210	001	Mar 10, 2023	Mar NEWA
	AB1			50MG	A206210	002	Mar 10, 2023	Mar NEWA
	AB1			100MG	A206210	003	Mar 10, 2023	Mar NEWA
	AB1			200MG	A206210	004	Mar 10, 2023	Mar NEWA
	AB1		ALKEM LABS LTD	25MG	A217248	001	Jun 20, 2023	Jun NEWA

CAPSULE, EXTENDED RELEASE;ORAL
TOPIRAMATE

AB1		50MG	A217248	002	Jun 20, 2023	Jun NEWA
AB1		100MG	A217248	003	Jun 20, 2023	Jun NEWA
AB1		200MG	A217248	004	Jun 20, 2023	Jun NEWA
AB1	PAR PHARM	25MG	A205976	002	May 04, 2023	Apr NEWA
AB1		50MG	A205976	003	May 04, 2023	Apr NEWA
AB1		100MG	A205976	004	May 04, 2023	Apr NEWA
AB1		200MG	A205976	001	Mar 01, 2023	Feb NEWA
AB1	ZYDUS	25MG	A207382	001	Nov 24, 2017	Jan CAHN
AB2		25MG	A208949	001	Nov 29, 2022	Jan CAHN
AB1		50MG	A207382	002	Nov 24, 2017	Jan CAHN
AB2		50MG	A208949	002	Nov 29, 2022	Jan CAHN
AB1		100MG	A207382	003	Nov 24, 2017	Jan CAHN
AB2		100MG	A208949	003	Nov 29, 2022	Jan CAHN
AB2		150MG	A208949	004	Nov 29, 2022	Jan CAHN
AB2		200MG	A208949	005	Nov 29, 2022	Jan CAHN
	TROKENDI XR					
AB1	+! SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013	Jan CFTG

TOPOTECAN HYDROCHLORIDE

CAPSULE;ORAL
HYCAMTIN

	+ SANDOZ	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	May CAHN
	+!	EQ 1MG BASE	N020981	002	Oct 11, 2007	May CAHN

INJECTABLE;INJECTION
HYCAMTIN

AP	+! SANDOZ	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	May CAHN

SOLUTION;INTRAVENOUS
TOPOTECAN HYDROCHLORIDE

	@ DASH PHARMS	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar CAHN

TORSEMIDE

TABLET;ORAL
SOAANZ

	+ @ SARFE PHARMS	20MG	N213218	001	Jun 14, 2021	Jun DISC
	+ @	60MG	N213218	002	Jun 14, 2021	Jun DISC

TRAMETINIB DIMETHYL SULFOXIDE

SOLUTION;ORAL
MEKINIST

	+! NOVARTIS	EQ 0.05MG BASE/ML	N217513	001	Mar 16, 2023	Mar NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL
TRAZODONE HYDROCHLORIDE

AB	AUROBINDO PHARMA	50MG	A204852	001	Feb 05, 2020	Jan CAHN
AB		100MG	A204852	002	Feb 05, 2020	Jan CAHN
AB		150MG	A204852	003	Feb 05, 2020	Jan CAHN
AB		300MG	A204852	004	Feb 05, 2020	Jan CAHN

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS
TREPROSTINIL

AP	DR REDDYS	1MG/ML	A210214	001	May 22, 2020	Feb CMFD
AP		2.5MG/ML	A210214	002	May 22, 2020	Feb CMFD
AP		5MG/ML	A210214	003	May 22, 2020	Feb CMFD
AP		10MG/ML	A210214	004	May 22, 2020	Feb CMFD

TRETINOIN

CREAM;TOPICAL
RETIN-A

AB	+! BAUSCH	0.025%	N019049	001	Sep 16, 1988	Jan CAHN

GEL;TOPICAL
AVITA

	@ MYLAN	0.025%	N020400	001	Jan 29, 1998	May DISC

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	CHARTWELL RX	0.025%	A208763	001	Feb 01, 2017	May CAHN
AT		0.1%	A208763	002	Feb 01, 2017	May CAHN
AT		0.5%	A208763	003	Feb 01, 2017	May CAHN

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	CHARTWELL RX	0.05%	A214532	001	Jan 27, 2023	May CAHN
AT		0.1%	A207365	001	Oct 12, 2018	Apr CAHN
AT	GLASSHOUSE PHARMS	0.05%	A214532	001	Jan 27, 2023	Jan NEWA

SPRAY;TOPICAL

KENALOG

+ @	SUN PHARM INDS INC	0.147MG/GM	N012104	001		Jun DISC

TRIAMCINOLONE ACETONIDE

AT !	PADAGIS ISRAEL	0.147MG/GM	A205782	001	Apr 13, 2015	Jun CHRS

TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE

@	EYWA	50MG	A214768	001	Jul 06, 2022	Jan DISC
@		100MG	A214768	002	Jul 06, 2022	Jan DISC

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

AB	MSN	250MG	A211134	001	May 22, 2019	Mar CTEC

TROFINETIDE

SOLUTION;ORAL

DAYBUE

+!	ACADIA PHARMS INC	200MG/ML	N217026	001	Mar 10, 2023	Mar NEWA

UBROGEPANT

TABLET;ORAL

UBRELVY

+	ABBVIE	50MG	N211765	001	Dec 23, 2019	Jan CAHN
+!		100MG	N211765	002	Dec 23, 2019	Jan CAHN

URIDINE TRIACETATE

GRANULE;ORAL

VISTOGARD

>A> +!	BTG INTL	10GM/PACKET	N208159	001	Dec 11, 2015	Jul CAHN
>D> +!	WELLSTAT THERAP	10GM/PACKET	N208159	001	Dec 11, 2015	Jul CAHN

XURIDEN

>A> +!	BTG INTL	2GM/PACKET	N208169	001	Sep 04, 2015	Jul CAHN
>D> +!	WELLSTAT THERAP	2GM/PACKET	N208169	001	Sep 04, 2015	Jul CAHN

URSODIOL

CAPSULE;ORAL

URSODIOL

@	MYLAN	300MG	A090530	001	Feb 17, 2010	Jan DISC
AB	RK PHARMA	300MG	A214329	001	Jul 28, 2021	Jun CAHN
AB	VGYAAN	300MG	A214329	001	Jul 28, 2021	Apr CMFD

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	CHARTWELL RX	EQ 500MG BASE	A090216	001	May 24, 2010	Jan CAHN
AB		EQ 1GM BASE	A090216	002	May 24, 2010	Jan CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALCYTE

AB +!	CHEPLAPHARM	50MG/ML	N022257	001	Aug 28, 2009	Mar CAHN

VALGANCICLOVIR HYDROCHLORIDE

AB	APPCO	50MG/ML	A216317	001	Apr 11, 2023	Mar NEWA

TABLET;ORAL

VALCYTE

AB +!	CHEPLAPHARM	EQ 450MG BASE	N021304	001	Mar 29, 2001	Mar CAHN

VALPROIC ACID

SYRUP;ORAL

VALPROIC ACID

	AA	QUAGEN	250MG/5ML	A090517	001	May 28, 2010	Apr CAHN
	@	XTTRIUM LABS INC	250MG/5ML	A070868	001	Jul 01, 1986	Mar CAHN

VALSARTAN

SOLUTION;ORAL

VALSARTAN

	!	NOVITIUM PHARMA	20MG/5ML	A214102	001	Nov 02, 2021	Jan CHRS

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION;ORAL

VANCOCIN HYDROCHLORIDE

AA	!	ANI PHARMS	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983	Jun CTEC

VANCOMYCIN HYDROCHLORIDE

AA		AMNEAL	EQ 250MG BASE/5ML	A215338	001	Jun 23, 2023	Jun NEWA

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

AP		GLAND PHARMA LTD	EQ 5GM BASE/VIAL	A205694	003	Jun 06, 2023	May NEWA
AP			EQ 10GM BASE/VIAL	A205694	004	Jun 06, 2023	May NEWA
AP		HIKMA	EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020	Jan CMFD

POWDER;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

>A>	AP	EUGIA PHARMA	EQ 1.25GM BASE/VIAL	A217401	001	Aug 04, 2023	Jul NEWA
>A>	AP		EQ 1.5GM BASE/VIAL	A217401	002	Aug 04, 2023	Jul NEWA
	AP	HIKMA	EQ 1.25GM BASE/VIAL	A217489	001	Jun 29, 2023	Jun NFTG
	AP		EQ 1.5GM BASE/VIAL	A217489	002	Jun 29, 2023	Jun NFTG
	AP	+! MYLAN LABS LTD	EQ 1.25GM BASE/VIAL	N209481	003	Jul 10, 2018	Jun CFTG
	AP	+!	EQ 1.5GM BASE/VIAL	N209481	004	Jul 10, 2018	Jun CFTG

POWDER;INTRAVENOUS, ORAL

VANCOMYCIN HYDROCHLORIDE

	+!	ZHEJIANG NOVUS PHARM	EQ 500MG BASE/VIAL	N210274	001	Jan 20, 2023	Jan NEWA
	+!		EQ 1GM BASE/VIAL	N210274	002	Jan 20, 2023	Jan NEWA
	+!		EQ 5GM BASE/VIAL	N210274	003	Jan 20, 2023	Jan NEWA
	+!		EQ 10GM BASE/VIAL	N210274	004	Jan 20, 2023	Jan NEWA

VARENICLINE TARTRATE

TABLET;ORAL

VARENICLINE TARTRATE

	AB	APOTEX	EQ 0.5MG BASE	A201962	001	Jan 25, 2023	Jan NEWA
	AB		EQ 1MG BASE	A201962	002	Jan 25, 2023	Jan NEWA
>A>	AB	MANKIND PHARMA	EQ 0.5MG BASE	A214255	001	Aug 01, 2023	Jul NEWA
>A>	AB		EQ 1MG BASE	A214255	002	Aug 01, 2023	Jul NEWA
>A>	AB	MEDLEY PHARMS	EQ 0.5MG BASE	A217151	001	Jul 25, 2023	Jul NEWA
>A>	AB		EQ 1MG BASE	A217151	002	Jul 25, 2023	Jul NEWA
	AB	PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Jan CTEC
	AB	!	EQ 1MG BASE	A201785	002	Aug 11, 2021	Jan CTEC
	AB	ZYDUS	EQ 0.5MG BASE	A216723	001	Jun 12, 2023	Jun CAHN
	AB		EQ 1MG BASE	A216723	002	Jun 12, 2023	Jun CAHN
	AB	ZYDUS PHARMS	EQ 0.5MG BASE	A216723	001	Jun 12, 2023	Jun NEWA
	AB		EQ 1MG BASE	A216723	002	Jun 12, 2023	Jun NEWA

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOPRESSIN

>A>	+!	AM REGENT	200UNITS/10ML (20UNITS/ML)	N212593	002	Jun 09, 2023	Jul NEWA
	AP	FRESENIUS KABI USA	20UNITS/ML (20UNITS/ML)	A213206	001	May 26, 2023	May NEWA

VASOSTRICT

	+!	PAR STERILE PRODUCTS	50UNITS/50ML (1UNITS/ML)	N204485	006	Apr 12, 2023	Apr NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

	AB	GRANULES	EQ 37.5MG BASE	A217390	001	May 18, 2023	May NEWA
	AB		EQ 75MG BASE	A217390	002	May 18, 2023	May NEWA
	AB		EQ 150MG BASE	A217390	003	May 18, 2023	May NEWA
	AB	NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	Mar NEWA
	AB		EQ 75MG BASE	A200430	002	Apr 04, 2023	Mar NEWA
	AB		EQ 150MG BASE	A200430	003	Apr 04, 2023	Mar NEWA

		TABLET;ORAL					
		VENLAFAXINE HYDROCHLORIDE					
		@ CHARTWELL RX	EQ 25MG BASE	A077515	001	Jun 13, 2008	Jan CAHN
		@	EQ 37.5MG BASE	A077515	002	Jun 13, 2008	Jan CAHN
		@	EQ 50MG BASE	A077515	003	Jun 13, 2008	Jan CAHN
		@	EQ 75MG BASE	A077515	004	Jun 13, 2008	Jan CAHN
		@	EQ 100MG BASE	A077515	005	Jun 13, 2008	Jan CAHN
		TABLET, EXTENDED RELEASE;ORAL					
		VENLAFAXINE HYDROCHLORIDE					
	AB	AJANTA PHARMA LTD	EQ 37.5MG BASE	A214691	001	Apr 12, 2023	Mar NEWA
	AB		EQ 75MG BASE	A214691	002	Apr 12, 2023	Mar NEWA
	AB		EQ 150MG BASE	A214691	003	Apr 12, 2023	Mar NEWA
	AB		EQ 225MG BASE	A214691	004	Apr 12, 2023	Mar NEWA
		VERAPAMIL HYDROCHLORIDE					
		TABLET, EXTENDED RELEASE;ORAL					
		CALAN SR					
	+	@ PFIZER	120MG	N019152	003	Mar 06, 1991	Mar DISC
	+	@	240MG	N019152	001	Dec 16, 1986	Mar DISC
		VERAPAMIL HYDROCHLORIDE					
	AB	CADILA PHARMS LTD	120MG	A206173	003	Nov 14, 2022	Mar NEWA
	AB	! GLENMARK GENERICS	120MG	A090700	001	Aug 03, 2011	Mar CHRS
	AB	!	240MG	A078906	001	Sep 17, 2009	Mar CHRS
		VIGABATRIN					
		FOR SOLUTION;ORAL					
		VIGABATRIN					
		@ ACCORD HLTHCARE	500MG/PACKET	A214425	001	Nov 13, 2020	Mar DISC
		@ CHARTWELL RX	500MG/PACKET	A211790	001	Mar 10, 2022	May CAHN
>D>	AA	ZYDUS	500MG/PACKET	A214671	001	Mar 02, 2023	Jul DISC
>A>		@	500MG/PACKET	A214671	001	Mar 02, 2023	Jul DISC
	AA		500MG/PACKET	A214671	001	Mar 02, 2023	Feb NEWA
		TABLET;ORAL					
		VIGABATRIN					
	AB	PROPEL PHARMA	500MG	A215519	001	Apr 28, 2023	Apr NEWA
	AB	ZENARA	500MG	A214749	001	Jun 29, 2023	Jun NEWA
		VILAZODONE HYDROCHLORIDE					
		TABLET;ORAL					
		VIIBRYD					
	AB	+! ABBVIE	10MG	N022567	001	Jan 21, 2011	Jan CAHN
	AB	+	20MG	N022567	002	Jan 21, 2011	Jan CAHN
	AB	+	40MG	N022567	003	Jan 21, 2011	Jan CAHN
		VILAZODONE HYDROCHLORIDE					
	AB	APOTEX	10MG	A208228	001	Jul 07, 2023	Jun NEWA
	AB		20MG	A208228	002	Jul 07, 2023	Jun NEWA
	AB		40MG	A208228	003	Jul 07, 2023	Jun NEWA
		VORICONAZOLE					
		INJECTABLE;INTRAVENOUS					
		VORICONAZOLE					
	AP	UBI	200MG/VIAL	A211264	001	Mar 09, 2023	Mar NEWA
	AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Mar CDFR
		TABLET;ORAL					
		VORICONAZOLE					
	AB	CHARTWELL RX	50MG	A207371	001	May 24, 2016	Apr CAHN
	AB		200MG	A207371	002	May 24, 2016	Apr CAHN
		VUTRISIRAN SODIUM					
		SOLUTION;SUBCUTANEOUS					
		AMVUTTRA					
	+!	ALNYLAM PHARMS INC	EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)	N215515	001	Jun 13, 2022	Feb CPOT
	+!		25MG/0.5ML (25MG/0.5ML)	N215515	001	Jun 13, 2022	Feb CAIN
		WARFARIN SODIUM					
		TABLET;ORAL					
		WARFARIN SODIUM					
		@ AUROBINDO PHARMA USA	1MG	A040415	001	Sep 27, 2004	May CAHN
		@	2MG	A040415	002	Sep 27, 2004	May CAHN
		@	2.5MG	A040415	003	Sep 29, 2004	May CAHN
		@	3MG	A040415	004	Sep 27, 2004	May CAHN

```
        TABLET;ORAL
          WARFARIN SODIUM
          @                       4MG                              A040415  005  Sep 27, 2004   May CAHN
          @                       5MG                              A040415  006  Sep 27, 2004   May CAHN
          @                       6MG                              A040415  007  Sep 27, 2004   May CAHN
          @                       7.5MG                            A040415  008  Sep 27, 2004   May CAHN
          @                       10MG                             A040415  009  Sep 27, 2004   May CAHN

      XENON XE-129 HYPERPOLARIZED
        GAS;INHALATION
          XENOVIEW
        +!  POLAREAN              N/A                              N214375  001  Dec 23, 2022   Jan NEWA

      ZAVEGEPANT HYDROCHLORIDE
        SPRAY, METERED;NASAL
          ZAVZPRET
        +!  PFIZER                EQ 10MG BASE/SPRAY               N216386  001  Mar 09, 2023   Mar NEWA

      ZILEUTON
        TABLET, EXTENDED RELEASE;ORAL
          ZILEUTON
    AB  !   RISING                600MG                            A204929  001  Mar 17, 2017   Jan CHRS
          ZYFLO CR
        + @ CHIESI                600MG                            N022052  001  May 30, 2007   Jan DISC

      ZINC SULFATE
        SOLUTION;INTRAVENOUS
          ZINC SULFATE
    AP        FRESENIUS KABI USA  EQ 10MG BASE/10ML (EQ 1MG BASE/ML)  A216145  001  Dec 27, 2022   May CAIN
    AP                            EQ 25MG BASE/5ML (EQ 5MG BASE/ML)   A216145  002  Dec 27, 2022   May CAIN
    AP                            EQ 30MG BASE/10ML (EQ 3MG BASE/ML)  A216145  003  Dec 27, 2022   May CAIN

      ZOLEDRONIC ACID
        INJECTABLE;INTRAVENOUS
          RECLAST
    AP  +!  SANDOZ                EQ 5MG BASE/100ML                N021817  001  Apr 16, 2007   May CAHN
          ZOLEDRONIC ACID
>D> AP        BRECKENRIDGE        EQ 4MG BASE/5ML                  A202571  001  May 07, 2013   Jul CAHN
>D> AP                            EQ 5MG BASE/100ML                A202163  001  Aug 05, 2013   Jul CAHN
>D> AP        INFORLIFE           EQ 4MG BASE/100ML                N203231  001  Aug 02, 2013   Jul CRLD
>A> AP  +                         EQ 4MG BASE/100ML                N203231  001  Aug 02, 2013   Jul CRLD
        @ INGENUS PHARMS LLC      EQ 4MG BASE/5ML                  A208968  001  Feb 19, 2020   Jun DISC
>A> AP        PII                 EQ 4MG BASE/5ML                  A202571  001  May 07, 2013   Jul CAHN
>A> AP                            EQ 5MG BASE/100ML                A202163  001  Aug 05, 2013   Jul CAHN

      ZOLMITRIPTAN
        SPRAY;NASAL
          ZOMIG
    AB  +   AMNEAL                2.5MG/SPRAY                      N021450  003  Sep 16, 2013   Jan CAHN
    AB  +!                        5MG/SPRAY                        N021450  004  Sep 30, 2003   Jan CAHN
        TABLET;ORAL
          ZOLMITRIPTAN
    AB  !   AJANTA PHARMA LTD     5MG                              A204041  002  May 20, 2016   Jun CHRS
          ZOMIG
        + @ IPR                   2.5MG                            N020768  001  Nov 25, 1997   Jun DISC
        + @                       5MG                              N020768  002  Nov 25, 1997   Jun DISC
        TABLET, ORALLY DISINTEGRATING;ORAL
          ZOLMITRIPTAN
    AB  !   ZYDUS PHARMS USA INC  5MG                              A202890  002  May 15, 2013   Jun CHRS
          ZOMIG-ZMT
        + @ ASTRAZENECA           2.5MG                            N021231  001  Feb 13, 2001   Jun DISC
        + @                       5MG                              N021231  002  Sep 17, 2001   Jun DISC

      ZOLPIDEM TARTRATE
        CAPSULE;ORAL
          ZOLPIDEM TARTRATE
        +!  ALMATICA              7.5MG                            N215721  001  May 09, 2023   May NEWA
        TABLET, EXTENDED RELEASE;ORAL
          ZOLPIDEM TARTRATE
          @ ANCHEN PHARMS         6.25MG                           A078148  002  Apr 14, 2011   May DISC
          @                       12.5MG                           A078148  001  Dec 03, 2010   May DISC
```

ACETAMINOPHEN; ASPIRIN; CAFFEINE

	TABLET;ORAL						
	EXCEDRIN (MIGRAINE RELIEF)						
+!	GLAXOSMITHKLINE CONS	250MG;250MG;65MG	N020802	001	Jan 14, 1998	Apr	CTNA

ACETAMINOPHEN; IBUPROFEN

	TABLET;ORAL						
	ACETAMINOPHEN AND IBUPROFEN						
>A>	BIONPHARMA	250MG;125MG	A216999	001	Aug 01, 2023	Jul	NEWA
>A>	GRANULES	250MG;125MG	A216592	001	Jul 13, 2023	Jul	NEWA
	L PERRIGO CO	250MG;125MG	A214836	001	Feb 28, 2023	Feb	NEWA
	MARKSANS PHARMA	250MG;125MG	A216994	001	Jul 10, 2023	Jun	NEWA

ALCAFTADINE

	SOLUTION/DROPS;OPHTHALMIC						
	ALCAFTADINE						
	EUGIA PHARMA	0.25%	A210659	001	Jun 23, 2023	Jun	NEWA

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL						
	CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE						
	AUROBINDO PHARMA LTD	5MG;120MG	A212409	001	Mar 08, 2023	Feb	NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

	SOLUTION;TOPICAL						
	SOLUPREP S						
+!	3M HEALTH CARE	2%;70%	N208288	001	Aug 08, 2018	Mar	CTNA

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

	TABLET, EXTENDED RELEASE;ORAL						
	GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE						
>A>	DR REDDYS	30MG;600MG	A217340	001	Aug 01, 2023	Jul	NEWA
>A>		60MG;1.2GM	A217340	002	Aug 01, 2023	Jul	NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

	TABLET;ORAL						
	NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE						
	COREPHARMA	25MG;220MG	A211830	001	Aug 22, 2019	Feb	CAHN

ESOMEPRAZOLE MAGNESIUM

	CAPSULE, DELAYED RELEASE;ORAL						
	ESOMEPRAZOLE MAGNESIUM						
	GUARDIAN DRUG	EQ 20MG BASE	A216149	001	Mar 15, 2023	Mar	NEWA
	TABLET, DELAYED RELEASE;ORAL						
	ESOMEPRAZOLE MAGNESIUM						
	AUROBINDO PHARMA LTD	EQ 20MG BASE	A214473	001	Jul 12, 2023	Jun	NEWA

FAMOTIDINE

	TABLET;ORAL						
	FAMOTIDINE						
	MARKSANS PHARMA	10MG	A217543	001	Mar 08, 2023	Feb	NEWA
		20MG	A217543	002	Mar 08, 2023	Feb	NEWA

FEXOFENADINE HYDROCHLORIDE

	SUSPENSION;ORAL						
	FEXOFENADINE HYDROCHLORIDE						
	AUROBINDO PHARMA LTD	30MG/5ML	A213466	001	May 23, 2023	May	NEWA
	TABLET;ORAL						
	CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY						
	AUROBINDO PHARMA USA	30MG	A202039	001	Nov 19, 2014	Apr	CAHN
	FEXOFENADINE HYDROCHLORIDE ALLERGY						
	AUROBINDO PHARMA USA	60MG	A202039	002	Nov 19, 2014	Apr	CAHN
		180MG	A202039	003	Nov 19, 2014	Apr	CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL						
	GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE						
	@ GRANULES	600MG;60MG	A216082	001	Aug 22, 2022	Feb DISC
	@	1.2GM;120MG	A216082	002	Aug 22, 2022	Feb DISC

IBUPROFEN

	SUSPENSION;ORAL						
	IBUPROFEN						
	@ ARISE	100MG/5ML	A200457	001	Aug 18, 2011	Jun DISC
	SUSPENSION/DROPS;ORAL						
	IBUPROFEN						
>A>	TARO PHARMS	40MG/ML	A217261	001	Aug 08, 2023	Jul NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

	TABLET;ORAL						
	IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE						
	AUROBINDO PHARMA LTD	200MG;30MG	A213565	001	Mar 10, 2023	Mar NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

	TABLET;ORAL						
	LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE						
	@ GRANULES	2MG;125MG	A215981	001	Aug 29, 2022	Feb DISC

LORATADINE

	CAPSULE;ORAL						
	LORATADINE						
	AUROBINDO PHARMA	10MG	A211900	001	Mar 24, 2023	Mar NEWA
	TABLET;ORAL						
	LORATADINE						
>A>	HETERO LABS LTD V	10MG	A211718	001	Jul 28, 2023	Jul NEWA

MOMETASONE FUROATE

	SPRAY, METERED;NASAL						
	MOMETASONE FUROATE						
	AMNEAL	0.05MG/SPRAY	A217460	001	Jun 14, 2023	Jun NFTG

NALOXONE HYDROCHLORIDE

	SPRAY, METERED;NASAL						
	NALOXONE HYDROCHLORIDE						
>A>	PADAGIS ISRAEL	4MG/SPRAY	A211951	001	Jun 21, 2022	Jul CMKT
	NARCAN						
	+! EMERGENT	4MG/SPRAY	N208411	001	Nov 18, 2015	Mar CMKT
>A>	RIVIVE						
>A>	+! HARM REDUCTION THERP	3MG/SPRAY	N217722	001	Jul 28, 2023	Jul NEWA

NAPROXEN SODIUM

	CAPSULE;ORAL						
	NAPROXEN SODIUM						
	@ STRIDES PHARMA	EQ 200MG BASE	A215472	001	Aug 17, 2022	Feb DISC

NICOTINE POLACRILEX

	GUM, CHEWING;BUCCAL						
	NICOTINE POLACRILEX						
	@ FERTIN PHARMA	EQ 4MG BASE	A214354	001	Dec 21, 2022	Jun DISC

NORGESTREL

	TABLET;ORAL						
	OPILL						
>A>	+ @ LABORATOIRE HRA	0.075MG	N017031	001		Jul CMKT

OLOPATADINE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC						
	OLOPATADINE HYDROCHLORIDE						
	@ AKORN	EQ 0.1% BASE	A204532	001	Jan 10, 2017	Jan DISC
	@	EQ 0.2% BASE	A204723	001	Dec 05, 2017	Jan DISC

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

AUROBINDO PHARMA LTD	EQ 20MG BASE	A213201	001	Apr 28, 2023	Apr NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AUROBINDO PHARMA	20MG;1.1GM	A204923	001	Nov 07, 2016	Jun CAHN
ZYDUS	20MG;1.1GM	A203345	001	Mar 16, 2018	May CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 7 JULY 2023

NO JULY 2023 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JULY 2023 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ							
N 205551	001	8129385	Oct 05, 2027	DS DP		>A> M-294	Jun 15, 2026
		8129385*PED	Apr 05, 2028			>A> PED	Dec 15, 2026
		9242986	Dec 08, 2029	DS DP			
		9242986*PED	Jun 08, 2030				
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ PD							
N 215413	001	8129385	Oct 05, 2027	DS DP		>A> NPP	Jun 15, 2026
		8129385*PED	Apr 05, 2028			>A> PED	Dec 15, 2026
		9242986	Dec 08, 2029	DS DP			
		9242986*PED	Jun 08, 2030				
ABALOPARATIDE - TYMLOS							
N 208743	001	>A> 11680942	Jan 10, 2040	U-3322		I-907	Dec 19, 2025
		8748382	Oct 03, 2027	U-2009			
		8748382	Oct 03, 2027	U-3543			
		RE49444	Apr 28, 2031	U-2009			
		RE49444	Apr 28, 2031	U-3543			
ABEMACICLIB - VERZENIO							
N 208716	001	7855211	Dec 15, 2029	DS DP U-2132			
		7855211	Dec 15, 2029	DS DP U-2135			
		7855211	Dec 15, 2029	DS DP U-2251			
		7855211	Dec 15, 2029	DS DP U-3241			
		7855211	Dec 15, 2029	DS DP U-3242			
		7855211	Dec 15, 2029	DS DP U-3243			
		7855211	Dec 15, 2029	DS DP U-3265			
		7855211	Dec 15, 2029	DS DP U-3546			
ABEMACICLIB - VERZENIO							
N 208716	002	7855211	Dec 15, 2029	DS DP U-2132			
		7855211	Dec 15, 2029	DS DP U-2135			
		7855211	Dec 15, 2029	DS DP U-2251			
		7855211	Dec 15, 2029	DS DP U-3241			
		7855211	Dec 15, 2029	DS DP U-3242			
		7855211	Dec 15, 2029	DS DP U-3243			
		7855211	Dec 15, 2029	DS DP U-3265			
		7855211	Dec 15, 2029	DS DP U-3546			
ABEMACICLIB - VERZENIO							
N 208716	003	7855211	Dec 15, 2029	DS DP U-2132			
		7855211	Dec 15, 2029	DS DP U-2135			
		7855211	Dec 15, 2029	DS DP U-2251			
		7855211	Dec 15, 2029	DS DP U-3241			
		7855211	Dec 15, 2029	DS DP U-3242			
		7855211	Dec 15, 2029	DS DP U-3243			
		7855211	Dec 15, 2029	DS DP U-3265			
		7855211	Dec 15, 2029	DS DP U-3546			
ABROCITINIB - CIBINQO							
N 213871	001					NPP	Feb 09, 2026
ABROCITINIB - CIBINQO							
N 213871	002					NPP	Feb 09, 2026
ABROCITINIB - CIBINQO							
N 213871	003					NPP	Feb 09, 2026
ACETAMINOPHEN; IBUPROFEN - COMBOGESIC							
N 209471	001	10532036	Sep 22, 2025	U-3553		NP	Mar 01, 2026
		11197830	Feb 27, 2039	DP U-3553			
		11534407	Feb 27, 2039	DP U-3553			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ADAGRASIB - KRAZATI						
N 216340 001					NCE	Dec 12, 2027
					ODE-352	Dec 12, 2029
ADAPALENE; BENZOYL PEROXIDE - EPIDUO						
N 022320 001	8445543	Jul 12, 2027	U-1078	Y		
ALBUTEROL SULFATE; BUDESONIDE - AIRSUPRA						
N 214070 001	9415009	May 28, 2030	U-3509		NP	Jan 10, 2026
ALENDRONATE SODIUM - ALENDRONATE SODIUM						
A 214512 001					CGT	Nov 20, 2023
ALPELISIB - PIQRAY						
N 212526 001	8227462	Apr 29, 2033	DS DP U-2539			
ALPELISIB - PIQRAY						
N 212526 002	8227462	Apr 29, 2033	DS DP U-2539			
ALPELISIB - PIQRAY						
N 212526 003	8227462	Apr 29, 2033	DS DP U-2539			
ALPELISIB - VIJOICE						
N 215039 001	8227462	Apr 29, 2033	DS DP		ODE-396	Apr 05, 2029
ALPELISIB - VIJOICE						
N 215039 002	8227462	Apr 29, 2033	DS DP		ODE-396	Apr 05, 2029
ALPELISIB - VIJOICE						
N 215039 003	8227462	Apr 29, 2033	DS DP		ODE-396	Apr 05, 2029
AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN						
N 020965 001	11571478	Jan 12, 2038	U-3163			
>A>	11690914	Jan 12, 2038	U-3163			
AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ						
N 208081 001	11540981	Feb 07, 2028	DP			
AMLODIPINE BENZOATE - KATERZIA						
N 211340 001 >A>	11701326	Oct 06, 2037	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR						
N 208147 001	11590228	Sep 07, 2036	DP U-3538			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 5						
N 210526 001	11590081	Sep 24, 2038	DP U-3538			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 10						
N 210526 002	11590081	Sep 24, 2038	DP U-3538			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 15						
N 210526 003	11590081	Sep 24, 2038	DP U-3538			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 20						
N 210526 004	11590081	Sep 24, 2038	DP U-3538			
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 001	11559559	Dec 18, 2034	U-3514			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 002	11559559	Dec 18, 2034	U-3514			
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 003	11559559	Dec 18, 2034	U-3514			
APALUTAMIDE - ERLEADA						
N 210951 001	10052314	Sep 23, 2033	U-2381	Y		
	10052314	Sep 23, 2033	U-2382	Y		
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
	RE49353	Sep 23, 2033	U-2381			
APALUTAMIDE - ERLEADA						
N 210951 002	10702508	Apr 30, 2038	U-3012			
	10849888	Sep 23, 2033	U-3013			
	8445507	Sep 15, 2030	DS DP U-2237			
	8445507	Sep 15, 2030	DS DP U-2624			
	8802689	Mar 27, 2027	U-2237			
	8802689	Mar 27, 2027	U-2624			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
	9884054	Sep 23, 2033	U-2237			
	9987261	Mar 27, 2027	DP			
	RE49353	Sep 23, 2033	U-2381			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 001	11648347	Apr 06, 2034	DP			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 002	11648347	Apr 06, 2034	DP			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 003	11648347	Apr 06, 2034	DP			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 004	11648347	Apr 06, 2034	DP			
ARIPIPRAZOLE - ABILIFY ASIMTUFII						
N 217006 001	10517951	Apr 23, 2033	DP U-3245			
	10517951	Apr 23, 2033	DP U-814			
	11097007	Apr 23, 2033	DP U-3245			
	11097007	Apr 23, 2033	DP U-814			
	11638757	Apr 23, 2033	DP U-3245			
	11638757	Apr 23, 2033	DP U-814			
	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
ARIPIPRAZOLE - ABILIFY ASIMTUFII						
N 217006 002	10517951	Apr 23, 2033	DP U-3245			
	10517951	Apr 23, 2033	DP U-814			
	11097007	Apr 23, 2033	DP U-3245			
	11097007	Apr 23, 2033	DP U-814			
	11638757	Apr 23, 2033	DP U-3245			
	11638757	Apr 23, 2033	DP U-814			
	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ASPIRIN - VAZALORE						
N 203697 001	10646431	Sep 29, 2032	DP			
	10786444	Sep 29, 2032	U-3559			
ASPIRIN - VAZALORE						
N 203697 002	10646431	Sep 29, 2032	DP			
	10786444	Sep 29, 2032	U-3559			
ATOGEPANT - QULIPTA						
N 215206 001	8754096	Jul 19, 2032	DS DP U-3534		I-909	Apr 17, 2026
	9499545	Nov 10, 2031	DS DP U-3534			
ATOGEPANT - QULIPTA						
N 215206 002	8754096	Jul 19, 2032	DS DP U-3534		I-909	Apr 17, 2026
	9499545	Nov 10, 2031	DS DP U-3534			
ATOGEPANT - QULIPTA						
N 215206 003	8754096	Jul 19, 2032	DS DP U-3534		I-909	Apr 17, 2026
	9499545	Nov 10, 2031	DS DP U-3534			
ATORVASTATIN CALCIUM - ATORVALIQ						
N 213260 001	11369567	Jun 07, 2037	DP			
	11654106	Jun 07, 2037	DP U-3612			
	11654106	Jun 07, 2037	DP U-3613			
AVACOPAN - TAVNEOS						
N 214487 001	11603356	May 29, 2041	DS DP U-3558			
AVAPRITINIB - AYVAKIT						
N 212608 001					>A> ODE-434	May 22, 2030
AVAPRITINIB - AYVAKIT						
N 212608 002					>A> ODE-434	May 22, 2030
AVAPRITINIB - AYVAKIT						
N 212608 003					>A> ODE-434	May 22, 2030
AVAPRITINIB - AYVAKIT						
N 212608 004	9200002	Oct 15, 2034	DS DP U-3168		>A> I-912	May 22, 2026
	9200002	Oct 15, 2034	DS DP U-3506		>A> ODE-434	May 22, 2030
	9944651	Oct 15, 2034	DS DP U-3168			
	9944651	Oct 15, 2034	DS DP U-3506			
	9994575	Oct 15, 2034	DS DP U-3168			
	9994575	Oct 15, 2034	DS DP U-3506			
AVAPRITINIB - AYVAKIT						
N 212608 005					>A> ODE-434	May 22, 2030
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ						
N 206494 001					NPP	Dec 20, 2025
AZACITIDINE - VIDAZA						
N 050794 001					ODE-399	May 20, 2029
AZACITIDINE - ONUREG						
N 214120 001	11571436	May 14, 2029	DP			
AZACITIDINE - ONUREG						
N 214120 002	11571436	May 14, 2029	DP			
BACLOFEN - BACLOFEN						
A 217252 001					PC	Dec 16, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BACLOFEN - LYVISPAH						
N 215422 001	11654124	Jul 29, 2039	DP			
BACLOFEN - LYVISPAH						
N 215422 002	11654124	Jul 29, 2039	DP			
BACLOFEN - LYVISPAH						
N 215422 003	11654124	Jul 29, 2039	DP			
BARICITINIB - OLUMIANT						
N 207924 001	9737469	Nov 02, 2031	U-3500			
BARICITINIB - OLUMIANT						
N 207924 002	9737469	Nov 02, 2031	U-3500			
BARICITINIB - OLUMIANT						
N 207924 003	9737469	Nov 02, 2031	U-3500			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER						
N 207921 001	11559637	Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER						
N 207921 002	11559637	Jul 21, 2039	DP			
	11583643	Aug 19, 2041	DP			
BEMPEDOIC ACID - NEXLETOL						
N 211616 001	11613511	Jun 19, 2040	DS			
BEMPEDOIC ACID; EZETIMIBE - NEXLIZET						
N 211617 001	11613511	Jun 19, 2040	DS			
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
	9533955*PED	Sep 26, 2029				
BENZOYL PEROXIDE - EPSOLAY						
N 214510 001	11541026	Feb 19, 2040	U-3356			
	11628155	Dec 27, 2040	U-3356			
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO						
N 214094 001	11618733	Nov 01, 2039	U-3300			
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO						
N 214094 002	11618733	Nov 01, 2039	U-3300			
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - WYNZORA						
N 213422 001	11638711	Mar 18, 2039	DP			
BEXAGLIFLOZIN - BRENZAVVY						
N 214373 001	10533032	Jul 03, 2031	U-2214		NCE	Jan 20, 2028
	10981942	Jun 13, 2031	DS DP			
	7838499	Jan 30, 2029	DS DP U-2214			
	8106021	Aug 22, 2028	U-2214			
	8802637	Aug 22, 2028	DS DP U-2214			
	8987323	May 14, 2032	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BINIMETINIB - MEKTOVI						
N 210498 001	7777050	Mar 13, 2024	DS DP			
BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE - BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE						
A 217511 001					>A> CGT	Dec 29, 2023
BORTEZOMIB - BORTEZOMIB						
N 215331 001	11679119	Sep 23, 2042	U-3632			
	11679119	Sep 23, 2042	U-3633			
BORTEZOMIB - BORTEZOMIB						
N 215331 002	11679119	Sep 23, 2042	U-3632			
	11679119	Sep 23, 2042	U-3633			
BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)						
N 210557 001	11590209	Apr 29, 2041	U-3539			
BREXPIPRAZOLE - REXULTI						
N 205422 001					>A> I-913	May 10, 2026
BREXPIPRAZOLE - REXULTI						
N 205422 002					>A> I-913	May 10, 2026
BREXPIPRAZOLE - REXULTI						
N 205422 003					>A> I-913	May 10, 2026
BREXPIPRAZOLE - REXULTI						
N 205422 004					>A> I-913	May 10, 2026
BREXPIPRAZOLE - REXULTI						
N 205422 005					>A> I-913	May 10, 2026
BREXPIPRAZOLE - REXULTI						
N 205422 006					>A> I-913	May 10, 2026
BRIMONIDINE TARTRATE - LUMIFY						
N 208144 001	11596600	Jul 27, 2029	U-2222			
BUDESONIDE - BUDESONIDE						
A 215328 001					CGT	Oct 24, 2023
BUDESONIDE - TARPEYO						
N 215935 001					ODE-389	Dec 15, 2028
BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT AEROSPHERE						
N 216579 001	10716753	May 28, 2030	DP U-3203			
	9415009	May 28, 2030	U-3203			
BUPRENORPHINE - BRIXADI						
N 210136 001	10912772	Jul 26, 2032	U-3617		>A> NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 002	10912772	Jul 26, 2032	U-3617		>A> NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE - BRIXADI						
N 210136 002	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 003	10912772	Jul 26, 2032	U-3617		>A> NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 004	10912772	Jul 26, 2032	U-3617		>A> NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 005	10912772	Jul 26, 2032	U-3617		>A> NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 006	10912772	Jul 26, 2032	U-3617		>A> NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
BUPRENORPHINE - BRIXADI						
N 210136 007	10912772	Jul 26, 2032	U-3617		>A> NP	May 23, 2026
	11110084	Jul 26, 2032	DP U-3616			
	11135215	Jul 26, 2032	DP			
	8236292	Jan 10, 2027	DP U-3619			
	8236755	Jul 31, 2026	DP U-3620			
	8545832	Jun 06, 2025	DP U-3619			
	9937164	Jul 26, 2032	DP U-3618			
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 001	11534414	Nov 05, 2034	DP U-3419			
	11541021	Nov 05, 2034	U-3419			
	11541048	Nov 05, 2034	U-3419			
	11596627	Nov 05, 2034	U-3419			
	11617728	Nov 05, 2034	U-3419			
	11617747	Nov 05, 2034	U-3563			
CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV						
N 212690 001	11554102	Jan 11, 2033	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 001	11576894	Jul 06, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 002	11576894	Jul 06, 2030	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 003	11576894	Jul 06, 2030	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 004	11576894	Jul 06, 2030	DP			
CANNABIDIOL - EPIDIOLEX						
N 210365 001	11633369	Jun 17, 2035	DP U-2780			
	11633369	Jun 17, 2035	DP U-2781			
	11633369	Jun 17, 2035	DP U-3071			
CARBAMAZEPINE - CARNEXIV						
N 206030 001	11529357	Jan 31, 2040	DP			
CARBIDOPA; LEVODOPA - DHIVY						
N 214869 001	11439613	Mar 28, 2039	U-3557			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE47350	Jul 16, 2029	U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750		I-904	Dec 16, 2025
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7737142	Sep 17, 2029	DS DP U-3503			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-3503			
	RE49302	Jul 16, 2029	U-2543			
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 003	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 004	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 004	RE49302	Jul 16, 2029	U-2543		I-904	Dec 16, 2025
	RE49302	Jul 16, 2029	U-2544			
	RE49302	Jul 16, 2029	U-2545			
	RE49302	Jul 16, 2029	U-3503			
CENOBAMATE - XCOPRI						
N 212839 001	11654133	Jun 16, 2039	U-3610			
CENOBAMATE - XCOPRI						
N 212839 002	11654133	Jun 16, 2039	U-3610			
CENOBAMATE - XCOPRI						
N 212839 003	11654133	Jun 16, 2039	U-3610			
CENOBAMATE - XCOPRI						
N 212839 004	11654133	Jun 16, 2039	U-3610			
CENOBAMATE - XCOPRI						
N 212839 005	11654133	Jun 16, 2039	U-3610			
CENOBAMATE - XCOPRI						
N 212839 006	11654133	Jun 16, 2039	U-3610			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP S						
N 208288 001					M-292	Jan 20, 2026
CHLOROPROCAINE HYDROCHLORIDE - IHEEZO						
N 216227 001					NP	Sep 27, 2025
CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI						
N 208352 001	6706276	Sep 06, 2023	DP			
CLASCOTERONE - WINLEVI						
N 213433 001	8143240	Jan 12, 2024	U-2942			
	8865690	Jul 24, 2024	U-2942			
	9211295	Jul 24, 2024	DP			
CLOBAZAM - SYMPAZAN						
N 210833 001	11541002	Jan 31, 2040	DP U-724			
CLOBAZAM - SYMPAZAN						
N 210833 002	11541002	Jan 31, 2040	DP U-724			
CLOBAZAM - SYMPAZAN						
N 210833 003	11541002	Jan 31, 2040	DP U-724			
COBIMETINIB FUMARATE - COTELLIC						
N 206192 001	11597699	Oct 05, 2026	U-3554		ODE-416	Oct 28, 2029
COLCHICINE - LODOCO						
N 215727 001	10130585	Dec 31, 2034	U-3642			
	10206891	Jan 22, 2035	U-3641			
	10265281	Jan 22, 2035	U-3639			
	10842762	Jan 22, 2035	U-3640			
	11026899	Jan 22, 2035	U-3639			
	11026900	Jan 22, 2035	U-3639			
	11026901	Jan 22, 2035	U-3638			
	9744144	Jan 22, 2035	U-3643			
CRIZOTINIB - XALKORI						
N 202570 001					ODE-407	Jul 14, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CRIZOTINIB - XALKORI						
N 202570 002					ODE-407	Jul 14, 2029
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 210852 001	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 210852 002	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 210852 003	10849916	Jul 13, 2035	DP			
	11382923	Dec 01, 2035	DP			
CYCLOSPORINE - VERKAZIA						
N 214965 001	11612658	Jan 27, 2026	U-3560		NP	Jun 23, 2024
CYCLOSPORINE - VEVYE						
N 217469 001	10813976	Sep 22, 2037	DP	>A>	NP	May 30, 2026
	11154513	Nov 20, 2038	DP U-1900			
	11413323	Oct 11, 2039	U-3627			
	8614178	Dec 13, 2030	DP			
CYSTEINE HYDROCHLORIDE - ELCYS						
N 210660 001	11642370	Jan 15, 2039	DP			
	11648262	Jan 15, 2039	DP			
	11679125	Jan 15, 2039	DP			
	11684636	Jan 15, 2039	DP			
CYSTEINE HYDROCHLORIDE - NOURESS						
N 212535 001	11510941	Mar 02, 2039	DP			
	11510942	Jan 15, 2039	DP U-2752			
CYTARABINE; DAUNORUBICIN - VYXEOS						
N 209401 001	10028912	Oct 15, 2032	DP U-3149			
	10028912	Oct 15, 2032	DP U-3150			
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 001	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-428	Mar 16, 2030
	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024
	8415345	Jan 20, 2030	DS DP U-1406		PED	Oct 30, 2025
	8415345	Jan 20, 2030	DS DP U-2031		PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 001	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 002	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-428	Mar 16, 2030
	7994185*PED	Jul 20, 2030			PED	Dec 22, 2024
	8415345	Jan 20, 2030	DS DP U-1406		PED	Oct 30, 2025
	8415345	Jan 20, 2030	DS DP U-2031		PED	Nov 04, 2025
	8415345	Jan 20, 2030	DS DP U-2032		PED	Dec 22, 2025
	8415345	Jan 20, 2030	DS DP U-2296			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2027			
	8952018*PED	Apr 15, 2031				
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956*PED	Nov 04, 2029				
DABRAFENIB MESYLATE - TAFINLAR						
N 217514 001	11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	7994185	Jan 20, 2030	DS DP		ODE-428	Mar 16, 2030
	8415345	Jan 20, 2030	DS DP			
	8703781	Oct 15, 2030	DS DP U-3565			
	8835443	Jun 10, 2025	U-3565			
DALBAVANCIN HYDROCHLORIDE - DALVANCE						
N 021883 001	6900175	May 23, 2028	U-3499			
DAPAGLIFLOZIN - FARXIGA						
N 202293 001					>A> M-298	May 08, 2026
DAPAGLIFLOZIN - FARXIGA						
N 202293 002					>A> M-298	May 08, 2026
DAPRODUSTAT - JESDUVROQ						
N 216951 001	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
DAPRODUSTAT - JESDUVROQ						
N 216951 002	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPRODUSTAT - JESDUVROQ						
N 216951 002	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
DAPRODUSTAT - JESDUVROQ						
N 216951 003	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
DAPRODUSTAT - JESDUVROQ						
N 216951 004	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
DAPRODUSTAT - JESDUVROQ						
N 216951 005	11117871	Mar 13, 2038	DS DP U-3535		NCE	Feb 01, 2028
	11643397	Jun 27, 2023	DS U-3535			
	11649217	Mar 13, 2038	DP U-3535			
	8324208	Dec 11, 2028	DS DP			
	8557834	Jun 22, 2027	U-1238			
	8815884	Jun 22, 2027	DP U-1238			
DAROLUTAMIDE - NUBEQA						
N 212099 001	8975254	Mar 25, 2033	DS DP U-2605			
DARUNAVIR - DARUNAVIR						
A 202073 002					PC	Nov 28, 2023
DEFERIPRONE - FERRIPROX						
N 021825 001					ODE-417	Apr 30, 2028
					ODE-420	Apr 30, 2028
					ODE-421	Apr 30, 2028
DEFERIPRONE - FERRIPROX						
N 021825 002					ODE-417	Apr 30, 2028
					ODE-420	Apr 30, 2028
					ODE-421	Apr 30, 2028
DEFERIPRONE - FERRIPROX						
N 208030 001					ODE-417	Apr 30, 2028
					ODE-418	Apr 30, 2028
					ODE-419	Apr 30, 2028
DEFERIPRONE - FERRIPROX						
N 208030 002					ODE-417	Apr 30, 2028
					ODE-418	Apr 30, 2028
					ODE-419	Apr 30, 2028
DEFERIPRONE - FERRIPROX						
N 212269 001					ODE-417	Apr 30, 2028
					ODE-420	Apr 30, 2028
					ODE-421	Apr 30, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTETRABENAZINE - AUSTEDO						
N 208082 001	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11666566	Sep 18, 2033	DP			
DEUTETRABENAZINE - AUSTEDO						
N 208082 002	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11666566	Sep 18, 2033	DP			
DEUTETRABENAZINE - AUSTEDO						
N 208082 003	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11666566	Sep 18, 2033	DP			
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 001	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 002	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 002	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO XR						
N 216354 003	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 001					NPP	Dec 16, 2025
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 002					NPP	Dec 16, 2025
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 003					NPP	Dec 16, 2025
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 004					NPP	Dec 16, 2025
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 005					NPP	Dec 16, 2025
DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI						
N 215390 001	11497711	Jun 26, 2039	DP U-3645			
	11517524	Jun 26, 2039	DP U-3645			
DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI						
N 215390 002	11497711	Jun 26, 2039	DP U-3645			
	11517524	Jun 26, 2039	DP U-3645			
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 001	11559501	Jan 06, 2042	DP			
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 002	11559501	Jan 06, 2042	DP			
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 003	11559501	Jan 06, 2042	DP			
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 004	11559501	Jan 06, 2042	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DOCETAXEL - DOCETAXEL						
N 215813 001	10398785	Mar 14, 2036	DP			
DOCETAXEL - DOCETAXEL						
N 215813 002	10398785	Mar 14, 2036	DP			
DOCETAXEL - DOCETAXEL						
N 215813 003	10398785	Mar 14, 2036	DP			
DONEPEZIL HYDROCHLORIDE - ADLARITY						
N 212304 001	11648214	Sep 23, 2037	DP U-3334			
	11679086	May 26, 2037	U-3334			
DONEPEZIL HYDROCHLORIDE - ADLARITY						
N 212304 002	11648214	Sep 23, 2037	DP U-3334			
	11679086	May 26, 2037	U-3334			
DOXEPIN HYDROCHLORIDE - DOXEPIN HYDROCHLORIDE						
A 215408 001					CGT	Aug 16, 2023
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ						
N 022532 001	11617751	Jul 17, 2030	DP U-1			
	11617751	Jul 17, 2030	DP U-3572			
	11617751	Jul 17, 2030	DP U-3573			
	11617751	Jul 17, 2030	DP U-3574			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL						
N 022574 001	11617751	Jul 17, 2030	DP U-1			
	11617751	Jul 17, 2030	DP U-3572			
DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM - XACDURO (COPACKAGED)						
N 216974 001	10376499	Nov 17, 2035	DP U-2840		>A> NCE	May 23, 2028
	9309245	Apr 02, 2033	DS		>A> GAIN	May 23, 2033
	9623014	Apr 02, 2033	U-2840			
	9968593	Nov 17, 2035	DP U-2840			
EDETATE CALCIUM DISODIUM - EDETATE CALCIUM DISODIUM						
A 216435 001					>A> CGT	Jan 08, 2024
EFINACONAZOLE - JUBLIA						
N 203567 001	11654139	Oct 02, 2034	U-1969			
ELACESTRANT DIHYDROCHLORIDE - ORSERDU						
N 217639 001	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	10385008	Jan 05, 2038	DS DP			
	10420734	Oct 10, 2034	U-3524			
	10745343	Jan 05, 2038	U-3523			
	7612114	Aug 18, 2026	DS DP U-3523			
	8399520	Dec 25, 2023	DS DP U-3523			
ELACESTRANT DIHYDROCHLORIDE - ORSERDU						
N 217639 002	10071066	Oct 10, 2034	U-3524		NCE	Jan 27, 2028
	10385008	Jan 05, 2038	DS DP			
	10420734	Oct 10, 2034	U-3524			
	10745343	Jan 05, 2038	U-3523			
	7612114	Aug 18, 2026	DS DP U-3523			
	8399520	Dec 25, 2023	DS DP U-3523			
ELAGOLIX SODIUM - ORILISSA						
N 210450 001	11542239	Jul 23, 2039	DS DP			
	>A> 11690845	Aug 27, 2040	U-3654			
	>A> 11690854	Apr 19, 2038	U-3653			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELAGOLIX SODIUM - ORILISSA						
N 210450 002	11542239	Jul 23, 2039	DS DP			
>A>	11690845	Aug 27, 2040	U-3654			
ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)						
N 213388 001	11542239	Jul 23, 2039	DS DP			
>A>	11690845	Aug 27, 2040	U-3655			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 001	11564916	Aug 13, 2029	U-3525			
	11578062	Mar 25, 2031	DP U-3544			
	11639347	Apr 09, 2027	DS DP U-3587			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 002	11564916	Aug 13, 2029	U-3525			
	11578062	Mar 25, 2031	DP U-3544			
	11639347	Apr 09, 2027	DS DP U-3587			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 001	10022352	Apr 09, 2027	DP U-3596		NCE	Oct 21, 2024
	10081621	Mar 25, 2031	DP U-3600		NP	Apr 26, 2026
	10239867	Apr 09, 2027	DS DP U-3590		ODE-433	Apr 26, 2030
	10272046	Feb 27, 2033	DP U-3599			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3589			
	10793547	Dec 08, 2037	DS DP U-3588			
	11147770	Feb 27, 2033	DP U-3598			
	11179367	Dec 08, 2037	DP U-3597			
	11426407	Oct 06, 2035	DS DP U-3595			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3586			
	11564916	Aug 13, 2029	U-3585			
	11578062	Mar 25, 2031	DP U-3584			
	11639347	Apr 09, 2027	DS DP U-3583			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3589			
	8354427	Jul 06, 2026	U-3593			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3589			
	8598181	May 01, 2027	U-3589			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3592			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-3591			
	9974781	Apr 09, 2027	DP U-3589			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 002	10022352	Apr 09, 2027	DP U-3596		NCE	Oct 21, 2024
	10081621	Mar 25, 2031	DP U-3600		NP	Apr 26, 2026
	10239867	Apr 09, 2027	DS DP U-3590		ODE-433	Apr 26, 2030
	10272046	Feb 27, 2033	DP U-3599			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-3589			
	10793547	Dec 08, 2037	DS DP U-3588			
	11147770	Feb 27, 2033	DP U-3598			
	11179367	Dec 08, 2037	DP U-3597			
	11426407	Oct 06, 2035	DS DP U-3595			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3586			
	11564916	Aug 13, 2029	U-3585			
	11578062	Mar 25, 2031	DP U-3584			
	11639347	Apr 09, 2027	DS DP U-3583			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 002	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3589			
	8354427	Jul 06, 2026	U-3593			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3589			
	8598181	May 01, 2027	U-3589			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3592			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-3591			
	9974781	Apr 09, 2027	DP U-3589			
EMPAGLIFLOZIN - JARDIANCE						
N 204629 001	10258637	Apr 03, 2034	U-2290		I-869	Aug 18, 2024
	10258637*PED	Oct 03, 2034			M-82	Feb 24, 2025
	11090323	Apr 03, 2034	U-3191		>A> NPP	Jun 20, 2026
	11090323*PED	Oct 03, 2034			PED	Aug 24, 2025
	7579449	Aug 01, 2028	DS		>A> PED	Dec 20, 2026
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	U-1651			
	8551957*PED	Apr 14, 2030				
	9949997	May 17, 2034	U-2292			
	9949997	May 17, 2034	U-3199			
	9949997	May 17, 2034	U-3325			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN - JARDIANCE						
N 204629 002	10258637	Apr 03, 2034	U-2290		>A> NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			>A> PED	Dec 20, 2026
	11090323	Apr 03, 2034	U-3191			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	U-1651			
	8551957*PED	Apr 14, 2030				
	9949997	May 17, 2034	U-2292			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 001	10258637	Apr 03, 2034	U-2290			
	10258637*PED	Oct 03, 2034				
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	11090323	Apr 03, 2034	U-3191			
	11090323*PED	Oct 03, 2034				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP U-1651			
	8551957*PED	Apr 14, 2030				
	8673927	May 04, 2027	U-1652	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 001	10258637	Apr 03, 2034			U-2290	
	10258637*PED	Oct 03, 2034				
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	11090323	Apr 03, 2034			U-3191	
	11090323*PED	Oct 03, 2034				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP		U-1651	
	8551957*PED	Apr 14, 2030				
	8673927	May 04, 2027			U-1652	Y
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 002	10258637	Apr 03, 2034			U-2290	
	10258637*PED	Oct 03, 2034				
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	11090323	Apr 03, 2034			U-3191	
	11090323*PED	Oct 03, 2034				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	8551957	Oct 14, 2029	DP		U-1651	
	8551957*PED	Apr 14, 2030				
	8673927	May 04, 2027			U-1652	Y
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 001	>A> 10258637	Apr 03, 2034			U-2731	
	>A> 10258637*PED	Oct 03, 2034				
	>A> 11090323	Apr 03, 2034			U-3192	
	>A> 11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP		U-3531	
	>A> 7407955	May 02, 2025	DS DP			
	>A> 7407955*PED	Nov 02, 2025				
	>A> 7579449	Aug 01, 2028	DS			
	>A> 7579449*PED	Feb 01, 2029				
	>A> 7713938	Apr 15, 2027	DS DP			
	>A> 7713938*PED	Oct 15, 2027				
	>A> 8551957	Oct 14, 2029	DP		U-2730	
	>A> 8551957*PED	Apr 14, 2030				
	>A> 8883805	Nov 26, 2025	DP			
	>A> 8883805*PED	May 26, 2026				
	>A> 9949998	Jun 11, 2034			U-2731	
	>A> 9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 002	>A> 10258637	Apr 03, 2034			U-2731	
	>A> 10258637*PED	Oct 03, 2034				
	>A> 11090323	Apr 03, 2034			U-3192	
	>A> 11090323*PED	Oct 03, 2034				
	11564886	Mar 07, 2032	DP		U-3531	
	>A> 7407955	May 02, 2025	DS DP			
	>A> 7407955*PED	Nov 02, 2025				
	>A> 7579449	Aug 01, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614	002	>A> 7579449*PED	Feb 01, 2029				
		>A> 7713938	Apr 15, 2027	DS DP			
		>A> 7713938*PED	Oct 15, 2027				
		>A> 8551957	Oct 14, 2029	DP U-2730			
		>A> 8551957*PED	Apr 14, 2030				
		>A> 8883805	Nov 26, 2025	DP			
		>A> 8883805*PED	May 26, 2026				
		>A> 9949998	Jun 11, 2034	U-2731			
		>A> 9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614	003	>A> 10258637	Apr 03, 2034	U-2731			
		>A> 10258637*PED	Oct 03, 2034				
		>A> 11090323	Apr 03, 2034	U-3192			
		>A> 11090323*PED	Oct 03, 2034				
		11564886	Mar 07, 2032	DP U-3531			
		>A> 7407955	May 02, 2025	DS DP			
		>A> 7407955*PED	Nov 02, 2025				
		>A> 7579449	Aug 01, 2028	DS			
		>A> 7579449*PED	Feb 01, 2029				
		>A> 7713938	Apr 15, 2027	DS DP			
		>A> 7713938*PED	Oct 15, 2027				
		>A> 8551957	Oct 14, 2029	DP U-2730			
		>A> 8551957*PED	Apr 14, 2030				
		>A> 8883805	Nov 26, 2025	DP			
		>A> 8883805*PED	May 26, 2026				
		>A> 9949998	Jun 11, 2034	U-2731			
		>A> 9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614	004	>A> 10258637	Apr 03, 2034	U-2731			
		>A> 10258637*PED	Oct 03, 2034				
		>A> 11090323	Apr 03, 2034	U-3192			
		>A> 11090323*PED	Oct 03, 2034				
		>A> 7407955	May 02, 2025	DS DP			
		>A> 7407955*PED	Nov 02, 2025				
		>A> 7579449	Aug 01, 2028	DS			
		>A> 7579449*PED	Feb 01, 2029				
		>A> 7713938	Apr 15, 2027	DS DP			
		>A> 7713938*PED	Oct 15, 2027				
		>A> 8551957	Oct 14, 2029	DP U-2730			
		>A> 8551957*PED	Apr 14, 2030				
		>A> 8883805	Nov 26, 2025	DP			
		>A> 8883805*PED	May 26, 2026				
		>A> 9949998	Jun 11, 2034	U-2731			
		>A> 9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111	001	10258637	Apr 03, 2034	U-2290		>A> NPP	Jun 20, 2026
		10258637*PED	Oct 03, 2034			>A> PED	Dec 20, 2026
		10610489	Sep 30, 2030	DP			
		10610489*PED	Mar 30, 2031				
		11090323	Apr 03, 2034	U-3193			
		11090323*PED	Oct 03, 2034				
		7579449	Aug 01, 2028	DS			
		7579449*PED	Feb 01, 2029				
		7713938	Apr 15, 2027	DS DP			
		7713938*PED	Oct 15, 2027				
		9949997	May 17, 2034	U-3532			
		9949997	May 17, 2034	U-3533			
		9949997*PED	Nov 17, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111	002	10258637	Apr 03, 2034	U-2290		>A> NPP	Jun 20, 2026
		10258637*PED	Oct 03, 2034			>A> PED	Dec 20, 2026
		10610489	Sep 30, 2030	DP			
		10610489*PED	Mar 30, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 002	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 003	10258637	Apr 03, 2034	U-2290		>A> NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			>A> PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 004	10258637	Apr 03, 2034	U-2290		>A> NPP	Jun 20, 2026
	10258637*PED	Oct 03, 2034			>A> PED	Dec 20, 2026
	10610489	Sep 30, 2030	DP			
	10610489*PED	Mar 30, 2031				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 001	10258637	Apr 03, 2034	U-2290		>A> M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			>A> PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 002	10258637	Apr 03, 2034	U-2290		>A> M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			>A> PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 002	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 003	10258637	Apr 03, 2034	U-2290		>A> M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			>A> PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 004	10258637	Apr 03, 2034	U-2290		>A> M-296	Jun 20, 2026
	10258637*PED	Oct 03, 2034			>A> PED	Dec 20, 2026
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	10596120*PED	Sep 07, 2032				
	11090323	Apr 03, 2034	U-3193			
	11090323*PED	Oct 03, 2034				
	7579449	Aug 01, 2028	DS			
	7579449*PED	Feb 01, 2029				
	7713938	Apr 15, 2027	DS DP			
	7713938*PED	Oct 15, 2027				
	9949997	May 17, 2034	U-3532			
	9949997	May 17, 2034	U-3533			
	9949997*PED	Nov 17, 2034				
	9949998	Jun 11, 2034	U-2290			
	9949998*PED	Dec 11, 2034				
ENCORAFENIB - BRAFTOVI						
N 210496 002	8501758	Aug 27, 2030	DS DP			
	>A> RE49556	Feb 27, 2030	DS DP			
EPHEDRINE SULFATE - EMERPHED						
N 213407 001	11571398	May 16, 2040	U-3183			
EPHEDRINE SULFATE - EMERPHED						
N 213407 002	11464752	May 16, 2040	DP			
	11571398	May 16, 2040	U-3183			
EPINEPHRINE - AUVI-Q						
N 201739 001	11590286	Dec 12, 2026	DP			
EPINEPHRINE - AUVI-Q						
N 201739 002	11590286	Dec 12, 2026	DP			
EPINEPHRINE - AUVI-Q						
N 201739 003	11590286	Dec 12, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE						
N 215875 001	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE						
N 215875 002	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE						
N 215875 003	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE						
N 215875 004	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
EPINEPHRINE - EPINEPHRINE IN 0.9% SODIUM CHLORIDE						
N 215875 005	10653646	Mar 21, 2039	DP			
	11083698	Mar 21, 2039	U-3567			
	11207280	Mar 21, 2039	DP			
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA						
N 211109 001	11578044	Oct 19, 2037	DS			
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA						
N 211109 002	11578044	Oct 19, 2037	DS			
ERDAFITINIB - BALVERSA						
N 212018 001	>A> 11684620	Feb 09, 2036	U-2518			
	>A> 11684620	Feb 09, 2036	U-3065			
	>A> 11684620	Feb 09, 2036	U-3066			
	>A> 11684620	Feb 09, 2036	U-3067			
	8895601	Apr 12, 2033	DS DP			
ERDAFITINIB - BALVERSA						
N 212018 002	>A> 11684620	Feb 09, 2036	U-2518			
	>A> 11684620	Feb 09, 2036	U-3065			
	>A> 11684620	Feb 09, 2036	U-3066			
	>A> 11684620	Feb 09, 2036	U-3067			
	8895601	Apr 12, 2033	DS DP			
ERDAFITINIB - BALVERSA						
N 212018 003	>A> 11684620	Feb 09, 2036	U-2518			
	>A> 11684620	Feb 09, 2036	U-3065			
	>A> 11684620	Feb 09, 2036	U-3066			
	>A> 11684620	Feb 09, 2036	U-3067			
	8895601	Apr 12, 2033	DS DP			
ESCITALOPRAM OXALATE - LEXAPRO						
N 021323 001					NPP	May 12, 2026
ESCITALOPRAM OXALATE - LEXAPRO						
N 021323 002					NPP	May 12, 2026
ESCITALOPRAM OXALATE - LEXAPRO						
N 021323 003					NPP	May 12, 2026
ESCITALOPRAM OXALATE - LEXAPRO						
N 021365 001					NPP	May 12, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESKETAMINE HYDROCHLORIDE - SPRAVATO						
N 211243 001	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE						
N 214846 001					M-289	Jan 27, 2026
FENFLURAMINE HYDROCHLORIDE - FINTEPLA						
N 212102 001					ODE-393	Mar 25, 2029
					PED	Sep 25, 2029
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 001	11364260	Jan 08, 2027	U-3637		>A> I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 002	11364260	Jan 08, 2027	U-3637		>A> I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 003	11364260	Jan 08, 2027	U-3637		>A> I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 003	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 004	11364260	Jan 08, 2027	U-3637		>A> I-915	May 31, 2026
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11433091	Jan 08, 2027	U-3634			
	11590097	Oct 20, 2023	DS DP U-3312			
	11590097	Oct 20, 2023	DS DP U-3313			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	7754702	Feb 15, 2028	U-3636			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	8895612	Jan 08, 2027	U-3635			
FERRIC DERISOMALTOSE - MONOFERRIC						
N 208171 001	11633489	Jun 22, 2036	U-3594			
FERRIC DERISOMALTOSE - MONOFERRIC						
N 208171 002	11633489	Jun 22, 2036	U-3594			
FERRIC DERISOMALTOSE - MONOFERRIC						
N 208171 003	11633489	Jun 22, 2036	U-3594			
FEZOLINETANT - VEOZAH						
N 216578 001	10836768	Mar 28, 2034	U-3621		NCE	May 12, 2028
	8871761	Apr 04, 2031	DS			
	9422299	Mar 28, 2034	DS DP U-3622			
	9987274	Mar 28, 2034	U-3622			
FLOTUFOLASTAT F-18 GALLIUM - POSLUMA						
N 216023 001	11413360	Nov 22, 2038	DS U-3614		NCE	May 25, 2028
	11413360	Nov 22, 2038	DS U-3615			
FLUTICASONE FUROATE - ARNUITY ELLIPTA						
N 205625 001	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE - ARNUITY ELLIPTA						
N 205625 001	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
FLUTICASONE FUROATE - ARNUITY ELLIPTA						
N 205625 002	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
FLUTICASONE FUROATE - ARNUITY ELLIPTA						
N 205625 003	8113199	Oct 23, 2027	DP		M-290	Mar 01, 2026
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA						
N 204275 001	11116721	Feb 26, 2029	DP U-1401		NPP	May 13, 2026
	11116721	Feb 26, 2029	DP U-1691			
	11116721	Feb 26, 2029	DP U-3623			
	11116721*PED	Aug 26, 2029				
	7439393	May 21, 2025	DS DP U-1401			
	7439393	May 21, 2025	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
	7439393	May 21, 2025	DS DP U-3623			
	7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	8511304	Jun 14, 2027	DP U-3623			
	8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA						
N 204275 002	11116721	Feb 26, 2029	DP U-1691			
	11116721	Feb 26, 2029	DP U-3623			
	11116721*PED	Aug 26, 2029				
	7439393	May 21, 2025	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
	7439393	May 21, 2025	DS DP U-3623			
	7439393*PED	Nov 21, 2025				
	8113199	Oct 23, 2027	DP			
	8113199*PED	Apr 23, 2028				
	8161968	Feb 05, 2028	DP			
	8161968*PED	Aug 05, 2028				
	8511304	Jun 14, 2027	DP U-1691			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA						
N 204275 002	8511304	Jun 14, 2027	DP U-3623			
	8511304*PED	Dec 14, 2027				
	8534281	Mar 08, 2030	DP			
	8534281*PED	Sep 08, 2030				
	8746242	Oct 11, 2030	DP			
	8746242*PED	Apr 11, 2031				
	9333310	Oct 02, 2027	DP			
	9333310*PED	Apr 02, 2028				
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA						
N 204275 003	11116721	Feb 26, 2029	DP U-3623		NS	May 13, 2026
	7439393	May 21, 2025	DS DP U-3623			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-3623			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 004	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 005	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 006	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 008	11357935	Sep 24, 2038	DP			
	11357935*PED	Mar 24, 2039				
	11439777	May 24, 2040	DP			
	11439777*PED	Nov 24, 2040				
	11464923	Jun 19, 2040	DP			
	11464923*PED	Dec 19, 2040				
FLUTICASONE PROPIONATE - XHANCE						
N 209022 001	11554229	Feb 23, 2036	U-2133			
	11602603	Oct 27, 2028	DP U-2133			
	8327844	Oct 24, 2023	U-2133			
	8522778	Apr 20, 2024	DP			
FOSDENOPTERIN HYDROBROMIDE - NULIBRY						
N 214018 001					M-286	Oct 27, 2025
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO						
N 210493 001	11529362	Jun 02, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO						
N 210493 002	11529362	Jun 02, 2037	DP			
FUTIBATINIB - LYTGOBI						
N 214801 001					ODE-410	Sep 30, 2029
GADOPICLENOL - ELUCIREM						
N 216986 001	11590246	Jan 17, 2040	DP			
GADOPICLENOL - ELUCIREM						
N 216986 002	11590246	Jan 17, 2040	DP			
GADOPICLENOL - ELUCIREM						
N 216986 003	11590246	Jan 17, 2040	DP			
GADOPICLENOL - ELUCIREM						
N 216986 004	11590246	Jan 17, 2040	DP			
GADOPICLENOL - ELUCIREM						
N 216986 005	11590246	Jan 17, 2040	DP			
GADOPICLENOL - ELUCIREM						
N 216986 006	11590246	Jan 17, 2040	DP			
GADOPICLENOL - ELUCIREM						
N 216986 007	11590246	Jan 17, 2040	DP			
GANAXOLONE - ZTALMY						
N 215904 001					ODE-395	Jun 01, 2029
GIVOSIRAN SODIUM - GIVLAARI						
N 212194 001	9133461	Nov 30, 2033	DS DP U-2672			
GLUCAGON - GVOKE PFS						
N 212097 001	11590205	Apr 22, 2036	DP U-2742			
GLUCAGON - GVOKE PFS						
N 212097 002	11590205	Apr 22, 2036	DP U-2742			
GLUCAGON - GVOKE HYPOPEN						
N 212097 003	11590205	Apr 22, 2036	DP U-2742			
GLUCAGON - GVOKE HYPOPEN						
N 212097 004	11590205	Apr 22, 2036	DP U-2742			
GLUCAGON - GVOKE KIT						
N 212097 005	11590205	Apr 22, 2036	DP U-2742			
GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO						
N 216903 001	10456354	Oct 25, 2038	DP			
	11110054	Oct 25, 2038	DP			
HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII						
N 209354 001	11648256	Jun 06, 2036	DP U-2625			
	11679115	Jun 06, 2036	DP U-2625			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 006	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBREXAFUNGERP CITRATE - BREXAFEMME						
N 214900 001	11534433	Jun 10, 2039	U-3159		I-903	Nov 30, 2025
	11534433	Jun 10, 2039	U-3508			
IBRUTINIB - IMBRUVICA						
N 205552 001	10478439	Jun 03, 2031	U-1650		ODE-109	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE-117	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE-152	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 02, 2025
	10478439	Jun 03, 2031	U-2665		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
>A>	11672803	Jun 03, 2031	U-1684			
>A>	11672803	Jun 03, 2031	U-1946			
>A>	11672803	Jun 03, 2031	U-2241			
>A>	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9540382*PED	Feb 18, 2034				
IBRUTINIB - IMBRUVICA						
N 205552 002	10478439	Jun 03, 2031	U-1650		ODE*	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE*	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
>A>	11672803	Jun 03, 2031	U-1684			
>A>	11672803	Jun 03, 2031	U-1946			
>A>	11672803	Jun 03, 2031	U-2241			
>A>	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 002	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
IBRUTINIB - IMBRUVICA						
N 210563 001	10478439	Jun 03, 2031	U-1650		ODE*	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE*	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
>A>	11672803	Jun 03, 2031	U-1684			
>A>	11672803	Jun 03, 2031	U-1946			
>A>	11672803	Jun 03, 2031	U-2241			
>A>	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
IBRUTINIB - IMBRUVICA						
N 210563 002	10478439	Jun 03, 2031	U-1650		ODE*	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE*	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
>A>	11672803	Jun 03, 2031	U-1684			
>A>	11672803	Jun 03, 2031	U-1946			
>A>	11672803	Jun 03, 2031	U-2241			
>A>	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 002	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
IBRUTINIB - IMBRUVICA						
N 210563 003	10478439	Jun 03, 2031	U-1650		ODE*	Mar 04, 2023
	10478439	Jun 03, 2031	U-1684		ODE*	May 06, 2023
	10478439	Jun 03, 2031	U-1946		ODE*	Aug 02, 2024
	10478439	Jun 03, 2031	U-2241		ODE-405	Aug 24, 2029
	10478439	Jun 03, 2031	U-2242		PED	Feb 24, 2030
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
>A>	11672803	Jun 03, 2031	U-1684			
>A>	11672803	Jun 03, 2031	U-1946			
>A>	11672803	Jun 03, 2031	U-2241			
>A>	11672803	Jun 03, 2031	U-2242			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
IBRUTINIB - IMBRUVICA						
N 210563 004					ODE*	Mar 04, 2023
					ODE*	May 06, 2023
					ODE*	Aug 02, 2024
					ODE-405	Aug 24, 2029
					PED	Feb 24, 2030
IBRUTINIB - IMBRUVICA						
N 217003 001	10106548	Jun 03, 2033	DS DP		ODE-405	Aug 24, 2029
	10106548*PED	Dec 03, 2033			PED	Feb 24, 2030
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 217003 001	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
INCLISIRAN SODIUM - LEQVIO						
N 214012 001	>A> 10125369	Aug 18, 2034	DS DP U-3652			
	>A> 10131907	Aug 24, 2028	DS DP U-3652			
	>A> 10266825	Nov 04, 2023	U-3652			
	>A> 10851377	Aug 25, 2036	U-3652			
	>A> 11078485	Nov 04, 2023	DS U-3652			
	>A> 8106022	Dec 12, 2029	DS DP U-3652			
	>A> 8222222	Dec 29, 2027	U-3652			
	>A> 8809292	May 10, 2027	DS DP U-3652			
	>A> 8828956	Dec 04, 2028	DS DP U-3652			
	>A> 9370582	Dec 04, 2028	DS DP U-3652			
	>A> 9708610	Jan 01, 2024	DS DP U-3652			
INDOCYANINE GREEN - SPY AGENT GREEN KIT						
N 211580 001					I-911	Jun 05, 2026
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207500 002	6812238	Oct 31, 2025	DS			
IVACAFTOR - KALYDECO						
N 203188 001	11564916	Aug 13, 2029	U-3530			
IVACAFTOR - KALYDECO						
N 207925 001	11564916	Aug 13, 2029	U-3528		>A> ODE-435	May 03, 2030
IVACAFTOR - KALYDECO						
N 207925 002	11564916	Aug 13, 2029	U-3528		>A> ODE-435	May 03, 2030
IVACAFTOR - KALYDECO						
N 207925 003	11564916	Aug 13, 2029	U-3528		>A> ODE-435	May 03, 2030
IVACAFTOR - KALYDECO						
N 207925 004	10272046	Feb 27, 2033	DP U-3605		>A> NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		>A> ODE-435	May 03, 2030
	11147770	Feb 27, 2033	DP U-3604			
	11564916	Aug 13, 2029	U-3603			
	7495103	May 20, 2027	DS DP			
	8324242	Aug 05, 2027	U-3609			
	8354427	Jul 06, 2026	U-3608			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-3607			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-3606			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO								
N 207925 005		10272046	Feb 27, 2033		DP U-3605		>A> NPP	May 03, 2026
		10646481	Aug 13, 2029		DP		>A> ODE-435	May 03, 2030
		11147770	Feb 27, 2033		DP U-3604			
		11564916	Aug 13, 2029		U-3603			
		7495103	May 20, 2027	DS	DP			
		8324242	Aug 05, 2027		U-3609			
		8354427	Jul 06, 2026		U-3608			
		8410274	Dec 28, 2026		DP			
		8629162	Jun 24, 2025		U-3607			
		8754224	Dec 28, 2026	DS	DP			
		8883206	Feb 27, 2033		DP			
		9670163	Dec 28, 2026		DP U-3606			
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)								
N 210491 001		11564916	Aug 13, 2029		U-3527			
		11578062	Mar 25, 2031		DP U-3545			
		11639347	Apr 09, 2027	DS	DP U-2569			
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)								
N 210491 002		11564916	Aug 13, 2029		U-3527			
		11578062	Mar 25, 2031		DP U-3545			
		11639347	Apr 09, 2027	DS	DP U-2569			
IVACAFTOR; LUMACAFTOR - ORKAMBI								
N 206038 001		11564916	Aug 13, 2029		U-3529			
IVACAFTOR; LUMACAFTOR - ORKAMBI								
N 206038 002		11564916	Aug 13, 2029		U-3529			
IVACAFTOR; LUMACAFTOR - ORKAMBI								
N 211358 001		11564916	Aug 13, 2029		U-3526		ODE-408	Sep 02, 2029
IVACAFTOR; LUMACAFTOR - ORKAMBI								
N 211358 002		11564916	Aug 13, 2029		U-3526		ODE-408	Sep 02, 2029
IVACAFTOR; LUMACAFTOR - ORKAMBI								
N 211358 003		11564916	Aug 13, 2029		U-3526		ODE-408	Sep 02, 2029
LACOSAMIDE - MOTPOLY XR								
N 216185 001	>A>	11337943	Jun 05, 2040		DP U-3660			
LACOSAMIDE - MOTPOLY XR								
N 216185 002	>A>	11337943	Jun 05, 2040		DP U-3660			
LACOSAMIDE - MOTPOLY XR								
N 216185 003	>A>	11337943	Jun 05, 2040		DP U-3660			
LAROTRECTINIB SULFATE - VITRAKVI								
N 211710 001		11191766	Apr 04, 2037		U-2471			
		11484535	Apr 04, 2037		U-2470			
LASMIDITAN SUCCINATE - REYVOW								
N 211280 001		7423050	Feb 17, 2028	DS	DP U-1719			
LASMIDITAN SUCCINATE - REYVOW								
N 211280 002		7423050	Feb 17, 2028	DS	DP U-1719			
LASMIDITAN SUCCINATE - REYVOW								
N 211280 003		7423050	Feb 17, 2028	DS	DP U-1719			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN						
N 208259 001	11618748	Jan 27, 2030	U-1524			
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 001					ODE*	Aug 28, 2026
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 002					ODE*	Apr 07, 2024
					ODE*	Aug 28, 2026
					PED	Oct 07, 2024
LEMBOREXANT - DAYVIGO						
N 212028 001					M-293	Apr 20, 2026
LEMBOREXANT - DAYVIGO						
N 212028 002					M-293	Apr 20, 2026
LENACAPAVIR SODIUM - SUNLENCA						
N 215973 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	10654827	Aug 17, 2037	U-3507			
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP U-3507			
LENACAPAVIR SODIUM - SUNLENCA						
N 215974 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	10654827	Aug 17, 2037	U-3507			
	11267799	Aug 16, 2038	DS			
	9951043	Feb 28, 2034	DS DP U-3507			
LENIOLISIB PHOSPHATE - JOENJA						
N 217759 001	8653092	Feb 19, 2032	DS DP		NCE	Mar 24, 2028
					ODE-430	Mar 24, 2030
LENVATINIB MESYLATE - LENVIMA						
N 206947 001	11090386	Feb 23, 2036	U-3519			
LENVATINIB MESYLATE - LENVIMA						
N 206947 002	11090386	Feb 23, 2036	U-3519			
LETERMOVIR - PREVYMIS						
N 209939 001					>A> I-916	Jun 05, 2026
					>A> ODE-423	Jun 05, 2030
LETERMOVIR - PREVYMIS						
N 209939 002					>A> I-916	Jun 05, 2026
					>A> ODE-423	Jun 05, 2030
LETERMOVIR - PREVYMIS						
N 209940 001					>A> I-916	Jun 05, 2026
					>A> ODE-423	Jun 05, 2030
LETERMOVIR - PREVYMIS						
N 209940 002					>A> I-916	Jun 05, 2026
					>A> ODE-423	Jun 05, 2030
LEUPROLIDE ACETATE - LUPRON DEPOT-PED KIT						
N 020263 009	8921326	Feb 05, 2031	DP		NS	Apr 14, 2026
	9617303	Mar 22, 2028	U-3611			
LEVOKETOCONAZOLE - RECORLEV						
N 214133 001					ODE-385	Dec 30, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOLEUCOVORIN - KHAPZORY						
N 211226 001	11541012	Mar 25, 2039	DP			
LEVOLEUCOVORIN - KHAPZORY						
N 211226 002	11541012	Mar 25, 2039	DP			
LEVONORGESTREL - LILETTA						
N 206229 001	11571328	Sep 07, 2040	DP		>A> I-917	Jun 29, 2026
LINACLOTIDE - LINZESS						
N 202811 003	10702576	Aug 11, 2031	U-1516			
	10702576	Aug 11, 2031	U-3644			
	7304036	Aug 30, 2026	DS DP U-1516			
	7304036	Aug 30, 2026	DS DP U-3644			
	8110553	Jan 28, 2024	U-1516			
	8110553	Jan 28, 2024	U-3644			
	8933030	Feb 17, 2031	DP U-1516			
	8933030	Feb 17, 2031	DP U-3644			
	9708371	Aug 16, 2033	DP U-1516			
	9708371	Aug 16, 2033	DP U-3644			
LINAGLIPTIN - TRADJENTA						
N 201280 001	10034877	Aug 05, 2029	U-2347		>A> M-295	Jun 20, 2026
	10034877*PED	Feb 05, 2030			>A> PED	Dec 20, 2026
	11033552	May 04, 2027	DP			
	11033552*PED	Nov 04, 2027				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503	Y		
	8846695*PED	Dec 04, 2030				
	8853156	Mar 05, 2031	DP U-1642			
	8853156*PED	Sep 05, 2031				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9486526	Aug 05, 2029	U-1915			
	9486526*PED	Feb 05, 2030				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 001	10022379	Apr 02, 2029	U-2339		>A> M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			>A> PED	Dec 20, 2026
	10973827	Apr 02, 2029	DP			
	10973827*PED	Oct 02, 2029				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503			
	8846695*PED	Dec 04, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 002	10022379	Apr 02, 2029	U-2339		>A> M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			>A> PED	Dec 20, 2026
	10973827	Apr 02, 2029	DP			
	10973827*PED	Oct 02, 2029				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 002	8846695*PED	Dec 04, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 003	10022379	Apr 02, 2029	U-2339		>A> M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			>A> PED	Dec 20, 2026
	10973827	Apr 02, 2029	DP			
	10973827*PED	Oct 02, 2029				
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8846695	Jun 04, 2030	U-1503	Y		
	8846695*PED	Dec 04, 2030				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR						
N 208026 001	10022379	Apr 02, 2029	U-2339		>A> M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			>A> PED	Dec 20, 2026
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9173859	May 04, 2027	DP U-1503	Y		
	9173859*PED	Nov 04, 2027				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
	9555001*PED	Sep 06, 2033				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR						
N 208026 002	10022379	Apr 02, 2029	U-2339		>A> M-295	Jun 20, 2026
	10022379*PED	Oct 02, 2029			>A> PED	Dec 20, 2026
	7407955	May 02, 2025	DS DP			
	7407955*PED	Nov 02, 2025				
	8673927	May 04, 2027	U-1503	Y		
	8673927*PED	Nov 04, 2027				
	8883805	Nov 26, 2025	DP			
	8883805*PED	May 26, 2026				
	9155705	May 21, 2030	DP			
	9155705*PED	Nov 21, 2030				
	9173859	May 04, 2027	DP U-1503	Y		
	9173859*PED	Nov 04, 2027				
	9415016	Apr 02, 2029	DP			
	9415016*PED	Oct 02, 2029				
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
	9555001*PED	Sep 06, 2033				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOTEPREDNOL ETABONATE - LOTEMAX SM						
N 208219 001	11534395	Jan 26, 2036	DP U-2764			
LOTEPREDNOL ETABONATE - INVELTYS						
N 210565 001	11642317	May 03, 2033	DP			
LOTEPREDNOL ETABONATE - EYSUVIS						
N 210933 001	11596599	May 03, 2033	U-2985			
	11642317	May 03, 2033	DP			
LUMASIRAN SODIUM - OXLUMO						
N 214103 001					ODE-415	Oct 06, 2029
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 001	>A> 11690842	Aug 30, 2039	DP U-3362			
	>A> 11690842	Aug 30, 2039	DP U-3363			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 002	>A> 11690842	Aug 30, 2039	DP U-3362			
	>A> 11690842	Aug 30, 2039	DP U-3363			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 003	>A> 11690842	Aug 30, 2039	DP U-3362			
	>A> 11690842	Aug 30, 2039	DP U-3363			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 001	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 002	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 003	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 004	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 005	9907794	May 26, 2026	DP			
	9907794*PED	Nov 26, 2026				
MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE						
N 215344 001					>A> NP	Jun 15, 2026
MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB						
N 213135 001	11638697	Aug 04, 2037	DP			
MARALIXIBAT CHLORIDE - LIVMARLI						
N 214662 001					NPP	Mar 13, 2026
					ODE-429	Mar 13, 2030
MARIBAVIR - LIVTENCITY						
N 215596 001	>A> 11684632	Jan 04, 2032	U-3650		ODE-388	Nov 23, 2028
MAVACAMTEN - CAMZYOS						
N 214998 001					>A> M-297	Jun 15, 2026
					ODE-398	Apr 28, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MAVACAMTEN - CAMZYOS						
N 214998 002					>A> M-297	Jun 15, 2026
					ODE-398	Apr 28, 2029
MAVACAMTEN - CAMZYOS						
N 214998 003					>A> M-297	Jun 15, 2026
					ODE-398	Apr 28, 2029
MAVACAMTEN - CAMZYOS						
N 214998 004					>A> M-297	Jun 15, 2026
					ODE-398	Apr 28, 2029
MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO						
N 214383 001	6992207	Jun 25, 2024	DS DP U-3093			
METHOTREXATE - OTREXUP						
N 204824 001	>A> 11684723	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 002	>A> 11684723	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 003	>A> 11684723	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 004	>A> 11684723	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 005	>A> 11684723	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 006	>A> 11684723	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 007	>A> 11684723	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 008	>A> 11684723	Mar 10, 2029	DP			
METHSUXIMIDE - METHSUXIMIDE						
A 217213 001					CGT	Oct 28, 2023
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 001	11633389	Aug 14, 2033	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 002	11633389	Aug 14, 2033	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 003	11633389	Aug 14, 2033	DP			
METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI						
N 209388 001	11628150	Dec 22, 2029	DP U-2843			
MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE						
A 216159 001					>A> PC	Jan 02, 2024
MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE						
A 216159 002					>A> PC	Jan 02, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIGALASTAT HYDROCHLORIDE - GALAFOLD							
N 208623	001	11612593	May 30, 2038	DS			
		11612594	May 30, 2038	DS			
		11622962	Mar 17, 2039	DS			
		11633387	May 30, 2038	DS			
		11633388	Mar 25, 2039	U-2371			
		11642334	Feb 20, 2039	U-2371			
		11666564	May 30, 2038	U-2371			
MITAPIVAT SULFATE - PYRUKYND							
N 216196	001	>A> RE49582	Feb 24, 2031	DS DP		ODE-392	Feb 17, 2029
MITAPIVAT SULFATE - PYRUKYND							
N 216196	002	>A> RE49582	Feb 24, 2031	DS DP		ODE-392	Feb 17, 2029
MITAPIVAT SULFATE - PYRUKYND							
N 216196	003	>A> RE49582	Feb 24, 2031	DS DP		ODE-392	Feb 17, 2029
MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS							
N 211746	001	>A> 11679210	Sep 03, 2038	DP			
MONOMETHYL FUMARATE - BAFIERTAM							
N 210296	001	11590095	Mar 18, 2036	U-1384			
NALMEFENE HYDROCHLORIDE - OPVEE							
N 217470	001	11458091	Jul 10, 2038	DP U-3630	>A>	NP	May 22, 2026
NALOXONE HYDROCHLORIDE - EVZIO							
N 205787	001	11590286	Dec 12, 2026	DP			
NALOXONE HYDROCHLORIDE - REXTOVY							
N 208969	001					NP	Mar 07, 2026
NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)							
N 209862	001	11590286	Dec 12, 2026	DP			
NALOXONE HYDROCHLORIDE - KLOXXADO							
N 212045	001	11617713	Aug 26, 2034	DP U-3110			
		11628139	Aug 26, 2034	DP U-3110			
NALOXONE HYDROCHLORIDE - ZIMHI							
N 212854	001	11571518	Jun 14, 2041	DP U-3515			
		11571518	Jun 14, 2041	DP U-3516			
		11571518	Jun 14, 2041	DP U-3517			
NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)							
N 215457	001	11590286	Dec 12, 2026	DP			
NETARSUDIL MESYLATE - RHOPRESSA							
N 208254	001	11618748	Jan 27, 2030	U-1524			
NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO							
N 205718	001	11559523	Nov 18, 2030	DP U-3522			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER							
N 019734	002	11547758	Apr 18, 2027	U-1029			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER							
N 019734	003	11547758	Apr 18, 2027	U-1029			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER						
N 019734 004	11547758	Apr 18, 2027	U-1029			
NIMODIPINE - NYMALIZE						
N 203340 002	11517563	Apr 16, 2038	DP	Y		
NINTEDANIB ESYLATE - OFEV						
N 205832 001	10154990	Jan 08, 2026	U-2620			
NINTEDANIB ESYLATE - OFEV						
N 205832 002	10154990	Jan 08, 2026	U-2620			
NIRAPARIB TOSYLATE - ZEJULA						
N 208447 001	11673877	Mar 27, 2038	DP U-3646			
	11673877	Mar 27, 2038	DP U-3647			
NIRAPARIB TOSYLATE - ZEJULA						
N 214876 001	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP U-3646			
	11673877	Mar 27, 2038	DP U-3647			
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			
NIRAPARIB TOSYLATE - ZEJULA						
N 214876 002	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP U-3646			
	11673877	Mar 27, 2038	DP U-3647			
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			
NIRAPARIB TOSYLATE - ZEJULA						
N 214876 003	11091459	Mar 27, 2038	DP			
	11673877	Mar 27, 2038	DP U-3646			
	11673877	Mar 27, 2038	DP U-3647			
	8071579	Aug 12, 2027	U-2655			
	8071623	Mar 27, 2031	DS DP			
	8143241	Aug 12, 2027	U-2655			
	8436185	Apr 24, 2029	DS			
	8859562	Aug 04, 2031	U-2655			
NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)						
N 217188 001	11351149	Aug 05, 2041	DS DP U-3629		NCE	May 25, 2028
	11541034	Oct 31, 2041	U-3629			
NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)						
N 217188 002					NCE	May 25, 2028
NITRIC OXIDE - GENOSYL						
N 202860 001	11511252	Sep 21, 2029	DP			
	11554241	Aug 18, 2025	U-3037			
>A>	11672938	Jul 22, 2040	U-3037			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
N 214628 001	11602508	Jan 30, 2038	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
N 214628 002	11602508	Jan 30, 2038	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
N 214628 003	11602508	Jan 30, 2038	DP			
ODEVIXIBAT - BYLVAY						
N 215498 001	10011633	Nov 08, 2031	U-3186		>A> I-918	Jun 13, 2026
	10011633	Nov 08, 2031	U-3187		>A> ODE-436	Jun 13, 2030
	10011633	Nov 08, 2031	U-3648			
	10011633	Nov 08, 2031	U-3649			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
ODEVIXIBAT - BYLVAY						
N 215498 002	10011633	Nov 08, 2031	U-3186		>A> I-918	Jun 13, 2026
	10011633	Nov 08, 2031	U-3187		>A> ODE-436	Jun 13, 2030
	10011633	Nov 08, 2031	U-3648			
	10011633	Nov 08, 2031	U-3649			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
ODEVIXIBAT - BYLVAY						
N 215498 003	10011633	Nov 08, 2031	U-3186		>A> I-918	Jun 13, 2026
	10011633	Nov 08, 2031	U-3187		>A> ODE-436	Jun 13, 2030
	10011633	Nov 08, 2031	U-3648			
	10011633	Nov 08, 2031	U-3649			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ODEVIXIBAT - BYLVAY						
N 215498 003	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
ODEVIXIBAT - BYLVAY						
N 215498 004	10011633	Nov 08, 2031	U-3186		>A> I-918	Jun 13, 2026
	10011633	Nov 08, 2031	U-3187		>A> ODE-436	Jun 13, 2030
	10011633	Nov 08, 2031	U-3648			
	10011633	Nov 08, 2031	U-3649			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3187			
	10093697	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3649			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10487111	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3649			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	10981952	Nov 08, 2031	U-3648			
	10981952	Nov 08, 2031	U-3649			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	11365182	Jun 20, 2039	U-3648			
	11365182	Jun 20, 2039	U-3649			
	11583539	Nov 12, 2041	U-3186			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3187			
	9694018	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3649			
OLAPARIB - LYNPARZA						
N 208558 001	11633396	Oct 07, 2029	DP		>A> I-914	May 31, 2026
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8071579	Aug 12, 2027	U-3631			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLAPARIB - LYNPARZA						
N 208558 001	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-3631			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8859562	Aug 04, 2031	U-3631			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9169235	Mar 12, 2024	U-3631			
OLAPARIB - LYNPARZA						
N 208558 002	11633396	Oct 07, 2029	DP		>A> I-914	May 31, 2026
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8071579	Aug 12, 2027	U-3631			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-3631			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLAPARIB - LYNPARZA						
N 208558 002	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8859562	Aug 04, 2031	U-3631			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9169235	Mar 12, 2024	U-3631			
OLUTASIDENIB - REZLIDHIA						
N 215814 001					NCE	Dec 01, 2027
					ODE-413	Dec 01, 2029
OMADACYCLINE TOSYLATE - NUZYRA						
N 209816 001	7553828	Jun 02, 2024	DS			
OMADACYCLINE TOSYLATE - NUZYRA						
N 209817 001	7553828	Jun 02, 2024	DS			
OMAVELOXOLONE - SKYCLARYS						
N 216718 001	11091430	Apr 20, 2029	U-3552		NCE	Feb 28, 2028
	8124799	Dec 03, 2029	DS		ODE-427	Feb 28, 2030
	8440854	Apr 20, 2029	DP			
	8993640	Apr 24, 2033	DS DP			
	9670147	Apr 20, 2029	DS			
	9701709	Apr 24, 2033	DS DP			
OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEP						
N 213593 001	11633478	Jul 16, 2039	DP			
OMIDENEPAG ISOPROPYL - OMLONTI						
N 215092 001	11666563	Jul 16, 2039	U-3454			
PACRITINIB CITRATE - VONJO						
N 208712 001					ODE-397	Feb 28, 2029
PAFOLACIANINE SODIUM - CYTALUX						
N 214907 001					I-905	Dec 16, 2025
					ODE-390	Nov 29, 2028
PALIPERIDONE PALMITATE - INVEGA HAFYERA						
N 207946 005	11666697	Nov 24, 2041	U-3626			
PALIPERIDONE PALMITATE - INVEGA HAFYERA						
N 207946 006	11666697	Nov 24, 2041	U-3626			
PEGCETACOPLAN - EMPAVELI						
N 215014 001	11661441	Jan 13, 2033	DS U-3124		M-288	Feb 08, 2026
PEGCETACOPLAN - SYFOVRE						
N 217171 001	10035822	Nov 15, 2033	DS		NCE	May 14, 2026
	10125171	Aug 02, 2033	DS		NP	Feb 22, 2026
	10875893	Nov 15, 2033	DS U-3540			
	11292815	Nov 15, 2033	DS DP U-3540			
	11661441	Jan 13, 2033	DS U-3540			
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	8168584	Apr 07, 2027	U-3540			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEGCETACOPLAN - SYFOVRE						
N 217171 001	8168584	Apr 07, 2027	U-3542			
	9056076	Oct 25, 2026	U-3540			
	9169307	Nov 18, 2027	DS U-3541			
PEMETREXED DISODIUM - PEMETREXED						
N 215179 001	11147817	Mar 26, 2035	DP			
PEMETREXED DISODIUM - PEMETREXED						
N 215179 002	11147817	Mar 26, 2035	DP			
PEMETREXED DISODIUM - PEMETREXED						
N 215179 003	11147817	Mar 26, 2035	DP			
PEMIGATINIB - PEMAZYRE						
N 213736 001	11628162	Aug 30, 2040	U-3568		ODE-404	Aug 26, 2029
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
PEMIGATINIB - PEMAZYRE						
N 213736 002	11628162	Aug 30, 2040	U-3568		ODE-404	Aug 26, 2029
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
PEMIGATINIB - PEMAZYRE						
N 213736 003	11628162	Aug 30, 2040	U-3568		ODE-404	Aug 26, 2029
	11628162	Aug 30, 2040	U-3569			
	11628162	Aug 30, 2040	U-3570			
	11628162	Aug 30, 2040	U-3571			
PERAMPANEL - FYCOMPA						
N 202834 001	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 202834 002	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 202834 003	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 202834 004	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 202834 005	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PERAMPANEL - FYCOMPA						
N 202834 005	6949571	Jun 08, 2024	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 202834 006	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 208277 001	6949571	Jun 08, 2024	DS DP U-106			
	6949571	Jun 08, 2024	DS DP U-2088			
	6949571	Jun 08, 2024	DS DP U-2089			
	6949571	Jun 08, 2024	DS DP U-2428			
	6949571	Jun 08, 2024	DS DP U-2429			
PERFLUOROHEXYLOCTANE - MIEBO						
N 216675 001	10058615	Sep 12, 2033	U-1900	>A>	NCE	May 18, 2028
	10369117	Sep 12, 2033	U-1900			
	10449164	Sep 12, 2033	U-1900			
	10507132	Jun 21, 2037	U-1900			
	10576154	Sep 12, 2033	U-1900			
	11357738	Sep 29, 2036	DP			
PHENOBARBITAL SODIUM - SEZABY						
N 215910 001					ODE-414	Nov 17, 2029
PHENTOLAMINE MESYLATE - ORAVERSE						
N 022159 001	7229630	Jul 31, 2023	DP			
	7575757	Jul 31, 2023	DP			
PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE						
A 216496 001					CGT	Jul 17, 2023
PHENYLEPHRINE HYDROCHLORIDE - IMMPHENTIV						
N 203826 004	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			
PHENYLEPHRINE HYDROCHLORIDE - IMMPHENTIV						
N 203826 005	11213480	Sep 26, 2036	DP			
	11471400	Aug 05, 2036	DP			
PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI						
N 215352 001					NP	May 05, 2026
PILOCARPINE HYDROCHLORIDE - VUITY						
N 214028 001	10610518	Apr 24, 2039	U-3252		D-187	Mar 28, 2026
	10610518	Apr 24, 2039	U-3561			
	10610518	Apr 24, 2039	U-3562			
	11285134	Apr 24, 2039	U-3252			
	11285134	Apr 24, 2039	U-3561			
	11285134	Apr 24, 2039	U-3562			
PIRTOBRUTINIB - JAYPIRCA						
N 216059 001	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	10695323	Dec 16, 2036	DS DP U-3518			
	10918622	Dec 16, 2036	U-3518			
PIRTOBRUTINIB - JAYPIRCA						
N 216059 002	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	10695323	Dec 16, 2036	DS DP U-3518			
	10918622	Dec 16, 2036	U-3518			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRTOBRUTINIB - JAYPIRCA						
N 216059 002	10342780	Dec 16, 2036	DS DP		NCE	Jan 27, 2028
	10464905	Dec 16, 2036	U-3518		ODE-424	Jan 27, 2030
	10695323	Dec 16, 2036	DS DP U-3518			
	10918622	Dec 16, 2036	U-3518			
POSACONAZOLE - POSACONAZOLE						
A 208768 001					PC	Dec 26, 2023
PREDNISOLONE - PREDNISOLONE						
A 215673 001					CGT	Nov 18, 2023
QUIZARTINIB DIHYDROCHLORIDE - VANFLYTA						
N 216993 001				>A>	ODE-437	Jul 20, 2030
QUIZARTINIB DIHYDROCHLORIDE - VANFLYTA						
N 216993 002				>A>	ODE-437	Jul 20, 2030
RALTEGRAVIR POTASSIUM - ISENTRESS						
N 022145 001	8771733	Jun 02, 2030	DS DP U-257			
	8852632	Jan 28, 2028	DS DP U-257			
RALTEGRAVIR POTASSIUM - ISENTRESS HD						
N 022145 002	8771733	Jun 02, 2030	DS DP U-257			
RALTEGRAVIR POTASSIUM - ISENTRESS						
N 203045 002	8771733	Jun 02, 2030	DS DP U-257			
RELUGOLIX - ORGOVYX						
N 214621 001	11583526	Sep 29, 2037	U-3020			
REVEFENACIN - YUPELRI						
N 210598 001	11691948	Jul 14, 2030	DP			
REZAFUNGIN ACETATE - REZZAYO						
N 217417 001	10702573	Mar 14, 2033	DS DP U-3566		NCE	Mar 22, 2028
	11197909	Jul 14, 2038	DS DP U-3566		ODE-426	Mar 22, 2030
	11654196	Mar 02, 2032	DS DP U-3566		GAIN	Mar 22, 2033
	8722619	Mar 02, 2032	DS DP U-3566		GAIN	Mar 22, 2035
	9526835	Mar 14, 2033	DS DP U-3566			
RIFAXIMIN - XIFAXAN						
N 021361 002	11564912	Feb 26, 2029	U-3511			
	11564912	Feb 26, 2029	U-3512			
RIPRETINIB - QINLOCK						
N 213973 001	11529336	Aug 12, 2040	U-3382			
	11534432	Aug 12, 2040	U-3442			
	11576903	Dec 30, 2040	DP			
	11576904	Aug 12, 2040	U-3537			
	11612591	Dec 30, 2040	DP			
RISDIPLAM - EVRYSDI						
N 213535 001	11534444	Oct 04, 2038	U-1943		ODE-400	May 27, 2029
RISPERIDONE - RYKINDO						
N 212849 001	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - RYKINDO						
N 212849 002	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - RYKINDO						
N 212849 003	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - RYKINDO						
N 212849 004	10098882	Apr 10, 2032	DP U-3513			
	10406161	Apr 10, 2032	DP U-3513			
	11110094	Apr 10, 2032	DP			
	9446135	Apr 10, 2032	DP U-3513			
	9532991	Apr 10, 2032	DP U-3513			
RISPERIDONE - UZEDY						
N 213586 001	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 002	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 003	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 004	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - UZEDY						
N 213586 005	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 006	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RISPERIDONE - UZEDY						
N 213586 007	10736965	Jan 12, 2025	DP		NP	Apr 28, 2026
	8221778	Nov 12, 2027	DP U-543			
	8741327	Nov 12, 2027	DP U-543			
	8802127	Jan 12, 2025	DP			
	9023897	Apr 05, 2033	DP			
	9439905	Jan 12, 2025	DP U-543			
	9717799	Jan 12, 2025	DP			
	9895447	Jan 12, 2025	DP			
	9925268	Jan 12, 2025	DP			
RITLECITINIB TOSYLATE - LITFULO						
N 215830 001 >A>	9617258	Dec 03, 2034	DS DP	>A>	NCE	Jun 23, 2028
RIZATRIPTAN BENZOATE - RIZAFILM						
N 205394 001 >A>	9301948	Jul 30, 2034	DS DP			
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 001					M-285	Dec 19, 2025
					PED	Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 002					M-285	Dec 19, 2025
					PED	Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 003					M-285	Dec 19, 2025
					PED	Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 004					M-285	Dec 19, 2025
					PED	Jun 19, 2026
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 005					M-285	Dec 19, 2025
					PED	Jun 19, 2026
RUXOLITINIB PHOSPHATE - OPZELURA						
N 215309 001	11510923	Sep 04, 2040	U-3505			
	11571425	May 20, 2031	DP			
	11590136	May 20, 2031	U-3229			
	11590136	May 20, 2031	U-3404			
	11590137	Sep 04, 2040	U-3505			
	11590138	Jun 10, 2040	U-3551			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - OPZELURA						
N 215309 001	11602536	May 05, 2041	U-3550			
SECNIDAZOLE - SOLOSEC						
N 209363 001	11602522	Sep 04, 2035	DP U-3169			
	11602522	Sep 04, 2035	DP U-3302			
	11684607	Sep 16, 2035	DP U-2583			
	11684607	Sep 16, 2035	DP U-3169			
	11684607	Sep 16, 2035	DP U-3270			
	11684607	Sep 16, 2035	DP U-3302			
SELINEXOR - XPOVIO						
N 212306 001	8999996	Jul 03, 2033	DS DP			
SELINEXOR - XPOVIO						
N 212306 002	8999996	Jul 03, 2033	DS DP			
SELINEXOR - XPOVIO						
N 212306 003	8999996	Jul 03, 2033	DS DP			
SELINEXOR - XPOVIO						
N 212306 004	8999996	Jul 03, 2033	DS DP			
SELPERCATINIB - RETEVMO						
N 213246 001					ODE-409	Sep 21, 2029
					ODE-412	Sep 21, 2029
SELPERCATINIB - RETEVMO						
N 213246 002					ODE-409	Sep 21, 2029
					ODE-412	Sep 21, 2029
SELUMETINIB SULFATE - KOSELUGO						
N 213756 001	7425637	Mar 13, 2024	DS			
SELUMETINIB SULFATE - KOSELUGO						
N 213756 002	7425637	Mar 13, 2024	DS			
SEMAGLUTIDE - WEGOVY						
N 215256 001					NPP	Dec 23, 2025
SEMAGLUTIDE - WEGOVY						
N 215256 002					NPP	Dec 23, 2025
SEMAGLUTIDE - WEGOVY						
N 215256 003					NPP	Dec 23, 2025
SEMAGLUTIDE - WEGOVY						
N 215256 004					NPP	Dec 23, 2025
SEMAGLUTIDE - WEGOVY						
N 215256 005					NPP	Dec 23, 2025
SETMELANOTIDE ACETATE - IMCIVREE						
N 213793 001					ODE-402	Jun 16, 2029
SILDENAFIL CITRATE - REVATIO						
N 021845 001					M-287	Jan 31, 2026
SILDENAFIL CITRATE - REVATIO						
N 022473 001					M-287	Jan 31, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SILDENAFIL CITRATE - REVATIO						
N 203109 001					M-287	Jan 31, 2026
SILDENAFIL CITRATE - LIQREV						
N 214952 001	11337979	Dec 24, 2038	DP U-3582			
	11464778	Dec 24, 2038	DP U-3582			
SIROLIMUS - FYARRO						
N 213312 001					ODE-386	Nov 22, 2028
SIROLIMUS - HYFTOR						
N 213478 001					ODE-391	Mar 22, 2029
SODIUM CHLORIDE - SODIUM CHLORIDE 23.4%						
A 217796 001				>A>	CGT	Jan 23, 2024
SODIUM OXYBATE - LUMRYZ						
N 214755 001	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
SODIUM OXYBATE - LUMRYZ						
N 214755 002	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
SODIUM OXYBATE - LUMRYZ						
N 214755 003	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			
	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
SODIUM OXYBATE - LUMRYZ						
N 214755 004	10272062	Jul 21, 2037	DP		NP	May 01, 2026
	10736866	Jul 21, 2037	DP		ODE-431	May 01, 2030
	10925844	Feb 28, 2040	DP			
	10952986	Jul 21, 2037	U-3601			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SODIUM OXYBATE - LUMRYZ						
N 214755 004	10973795	Jul 21, 2037	DP			
	11000498	Jul 21, 2037	DP U-3580			
	11052061	Jul 21, 2037	DP			
	11065224	Jul 21, 2037	DP			
	11400065	Jul 21, 2037	U-3579			
	11504347	Jul 21, 2037	DP			
	11583510	Feb 07, 2042	U-3578			
	11602512	Jul 21, 2037	U-3577			
	11602513	Jul 21, 2037	U-3576			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 001	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 002	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 003	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 004	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 005	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA						
N 214860 006	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE; TAURURSODIOL - RELYVRIO						
N 216660 001	11583542	Jul 27, 2040	DP		ODE-411	Sep 29, 2029
SODIUM THIOSULFATE - PEDMARK						
N 212937 001 >A>	10596190	Jan 05, 2038	U-3443	Y	ODE-384	Sep 20, 2029
	11617793	Jul 01, 2039	DP			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 001	11160779	Mar 19, 2040	U-3521			
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP U-3520			
	11648232	Jun 01, 2038	U-3602			
	8440715	Jun 11, 2031	U-2548			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 002	11160779	Mar 19, 2040	U-3521			
	11439597	Sep 05, 2037	DP			
	11560354	Mar 06, 2039	DP U-3520			
	11648232	Jun 01, 2038	U-3602			
	8440715	Jun 11, 2031	U-2548			
SOTAGLIFLOZIN - INPEFA						
N 216203 001	7781577	May 04, 2028	DS DP U-3628		>A> NCE	May 26, 2028
	8217156	Oct 07, 2030	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOTAGLIFLOZIN - INPEFA						
N 216203 001	8476413	May 29, 2028	DS DP U-3628			
SOTAGLIFLOZIN - INPEFA						
N 216203 002	7781577	May 04, 2028	DS DP U-3628		>A> NCE	May 26, 2028
	8217156	Oct 07, 2030	DS DP			
	8476413	May 29, 2028	DS DP U-3628			
SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE						
N 022306 001	>A> 10512620	Aug 14, 2038	U-2769			
	>A> 10512620	Aug 14, 2038	U-3547			
	10799138	Apr 05, 2039	U-3125			
	10799138	Apr 05, 2039	U-3549			
	11583216	Aug 21, 2039	U-3549			
	>A> 11696902	Aug 14, 2038	U-2769			
SOTORASIB - LUMAKRAS						
N 214665 001	11426404	Sep 15, 2040	U-3306			
SOTORASIB - LUMAKRAS						
N 214665 002	10519146	May 21, 2038	DS DP		NCE	May 28, 2026
	11236091	May 20, 2040	DS DP U-3306		ODE-352	May 28, 2028
	11426404	Sep 15, 2040	U-3306			
SPARSENTAN - FILSPARI						
N 216403 001	9993461	Mar 29, 2030	U-3269		NCE	Feb 17, 2028
					ODE-389	Feb 17, 2030
SPARSENTAN - FILSPARI						
N 216403 002	9993461	Mar 29, 2030	U-3269		NCE	Feb 17, 2028
					ODE-389	Feb 17, 2030
STIRIPENTOL - DIACOMIT						
N 206709 001					ODE-403	Jul 14, 2029
STIRIPENTOL - DIACOMIT						
N 206709 002					ODE-403	Jul 14, 2029
STIRIPENTOL - DIACOMIT						
N 207223 001					ODE-403	Jul 14, 2029
STIRIPENTOL - DIACOMIT						
N 207223 002					ODE-403	Jul 14, 2029
SUFENTANIL CITRATE - DSUVIA						
N 209128 001	>A> 11672738	Feb 02, 2038	DP			
	>A> 11676691	Mar 16, 2030	DP			
SUGAMMADEX SODIUM - BRIDION						
N 022225 001					M-291	Jan 22, 2024
SUGAMMADEX SODIUM - BRIDION						
N 022225 002					M-291	Jan 22, 2024
SUMATRIPTAN SUCCINATE - ONZETRA XSAIL						
N 206099 001	11571531	Feb 23, 2026	U-1809			
TADALAFIL - TADLIQ						
N 214522 001	11666576	Dec 24, 2038	DP U-3397			
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 001	>A> 10780088	Jul 27, 2029	U-3651			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 003	>A> 10780088	Jul 27, 2029	U-3651			
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 005	>A> 10189837	Oct 20, 2031	DS DP		>A> NCE	Oct 16, 2023
	>A> 10780088	Jul 27, 2029	U-3651			
	>A> 8012976	Oct 19, 2029	DS DP			
	>A> 8420650	Jul 27, 2029	DS DP			
	>A> 8735392	Oct 20, 2031	DS DP			
	>A> 9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 006	>A> 10189837	Oct 20, 2031	DS DP		>A> NCE	Oct 16, 2023
	>A> 10780088	Jul 27, 2029	U-3651			
	>A> 8012976	Oct 19, 2029	DS DP			
	>A> 8420650	Jul 27, 2029	DS DP			
	>A> 8735392	Oct 20, 2031	DS DP			
	>A> 9820985	Jul 27, 2029	U-2437			
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 022304 001					>A> NPP	Jul 03, 2026
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 022304 002					>A> NPP	Jul 03, 2026
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 022304 003					>A> NPP	Jul 03, 2026
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 203794 001					>A> NPP	Jul 03, 2026
TAPINAROF - VTAMA						
N 215272 001	11590088	Nov 13, 2039	U-2625			
	11597692	Nov 13, 2038	DS DP			
	11612573	May 19, 2036	U-2625			
	11617724	May 19, 2036	DP			
	11622945	May 19, 2036	DP			
TASIMELTEON - HETLIOZ						
N 205677 001	11566011	Feb 12, 2035	DS DP			
	11633377	Jan 25, 2033	U-2149			
	11633377	Jan 25, 2033	U-3003			
TASIMELTEON - HETLIOZ LQ						
N 214517 001	11566011	Feb 12, 2035	DS DP			
	11633377	Jan 25, 2033	U-3003			
TAZAROTENE - ARAZLO						
N 211882 001	11679116	Jun 06, 2036	DP			
TAZEMETOSTAT HYDROBROMIDE - TAZVERIK						
N 211723 001	8410088	Jan 23, 2034	DS DP			
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209549 001					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209549 002					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209601 001					PC	Sep 08, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209601 002					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209613 001					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209613 002					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209638 001					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209638 002					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209663 001					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209663 002					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209668 001					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209668 002					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209690 001					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209690 002					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209700 001					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209700 002					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209710 001					PC	Sep 08, 2023
TERIFLUNOMIDE - TERIFLUNOMIDE						
A 209710 002					PC	Sep 08, 2023
TERLIPRESSIN ACETATE - TERLIVAZ						
N 022231 001					ODE-406	Sep 14, 2029
TESTOSTERONE CYPIONATE - TESTOSTERONE CYPIONATE						
N 216318 001	11642355	Mar 25, 2039	DP			
TESTOSTERONE UNDECANOATE - JATENZO						
N 206089 001	11564933	Apr 12, 2039	U-1103			
TESTOSTERONE UNDECANOATE - JATENZO						
N 206089 002	11564933	Apr 12, 2039	U-1103			
TESTOSTERONE UNDECANOATE - JATENZO						
N 206089 003	11564933	Apr 12, 2039	U-1103			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE UNDECANOATE - TLANDO							
N 208088	001	11559530	Nov 28, 2037	U-1500			
TESTOSTERONE UNDECANOATE - KYZATREX							
N 213953	001	11590146	Dec 31, 2030	DP			
		11617758	Mar 15, 2033	DP U-2506			
TESTOSTERONE UNDECANOATE - KYZATREX							
N 213953	002	11590146	Dec 31, 2030	DP			
		11617758	Mar 15, 2033	DP U-2506			
TESTOSTERONE UNDECANOATE - KYZATREX							
N 213953	003	11590146	Dec 31, 2030	DP			
		11617758	Mar 15, 2033	DP U-2506			
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF							
N 207981	001	>A> 10456399	Feb 03, 2037	U-2642			
		>A> 10456399	Feb 03, 2037	U-3657			
		>A> 10456399	Feb 03, 2037	U-3658			
		>A> 10960004	Feb 03, 2037	U-2642			
		>A> 10960004	Feb 03, 2037	U-3657			
		>A> 10960004	Feb 03, 2037	U-3658			
		>A> 9943537	Sep 05, 2034	U-3659			
		>A> RE46284	Sep 22, 2029	U-1751			
		>A> RE46284	Sep 22, 2029	U-2503			
		>A> RE46284	Sep 22, 2029	U-3656			
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF							
N 207981	002	>A> 10456399	Feb 03, 2037	U-2642			
		>A> 10456399	Feb 03, 2037	U-3657			
		>A> 10456399	Feb 03, 2037	U-3658			
		>A> 10960004	Feb 03, 2037	U-2642			
		>A> 10960004	Feb 03, 2037	U-3657			
		>A> 10960004	Feb 03, 2037	U-3658			
		>A> 9943537	Sep 05, 2034	U-3659			
		>A> RE46284	Sep 22, 2029	U-1751			
		>A> RE46284	Sep 22, 2029	U-2503			
		>A> RE46284	Sep 22, 2029	U-3656			
TIVOZANIB HYDROCHLORIDE - FOTIVDA							
N 212904	001	6821987	Apr 26, 2024	DS DP U-3100			
TIVOZANIB HYDROCHLORIDE - FOTIVDA							
N 212904	002	6821987	Apr 26, 2024	DS DP U-3100			
TOFERSEN - QALSODY							
N 215887	001	10385341	Apr 01, 2035	DS DP		NCE	Apr 25, 2028
		10669546	Apr 01, 2035	U-3575		ODE-432	Apr 25, 2030
		10968453	Apr 01, 2035	U-3575			
TOPIRAMATE - EPRONTIA							
N 214679	001	11633374	Aug 21, 2040	DP			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114	001	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
		10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
		7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
		7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
		8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
		8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
		8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
		8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
		8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
		8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
		8703781	Oct 15, 2030	DS DP U-2305			
		8703781*PED	Apr 15, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 001	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 002	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			
	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 003	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	10869869*PED	Mar 02, 2034			I-908	Mar 16, 2026
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	7378423*PED	Nov 29, 2027			ODE-182	Apr 30, 2025
	8580304	Jan 28, 2032	DP		ODE-183	May 04, 2025
	8580304*PED	Jul 28, 2032			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP U-1712		PED	Dec 22, 2024
	8703781	Oct 15, 2030	DS DP U-2020		PED	Oct 30, 2025
	8703781	Oct 15, 2030	DS DP U-2037		PED	Nov 04, 2025
	8703781	Oct 15, 2030	DS DP U-2302		PED	Dec 22, 2025
	8703781	Oct 15, 2030	DS DP U-2305			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8835443*PED	Dec 10, 2025				
	8952018	Oct 15, 2030	U-2020			
	8952018*PED	Apr 15, 2031				
	9155706	Jan 28, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 003	9155706*PED	Jul 28, 2032				
	9271941	Jan 28, 2032	DP			
	9271941*PED	Jul 28, 2032				
	9399021	Jan 28, 2032	DP			
	9399021*PED	Jul 28, 2032				
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 217513 001	7378423	May 29, 2027	DS DP		NP	Mar 16, 2026
	8703781	Oct 15, 2030	DS DP U-3564		ODE-428	Mar 16, 2030
	8835443	Jun 10, 2025	U-3564			
TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR						
N 215760 001					ODE-401	Apr 28, 2029
TRIFAROTENE - AKLIEF						
N 211527 001	7807708	Jul 19, 2031	DS DP			
TRILACICLIB DIHYDROCHLORIDE - COSELA						
N 214200 001	11529352	Jul 23, 2039	U-3504			
TROFINETIDE - DAYBUE						
N 217026 001	11370755	Aug 03, 2040	DS DP		NCE	Mar 10, 2028
	9212204	Jan 27, 2032	U-3556		ODE-425	Mar 10, 2030
TUCATINIB - TUKYSA						
N 213411 001	11207324	Apr 27, 2038	U-3510		I-906	Jan 19, 2026
					ODE-422	Jan 19, 2030
TUCATINIB - TUKYSA						
N 213411 002	11207324	Apr 27, 2038	U-3510		I-906	Jan 19, 2026
					ODE-422	Jan 19, 2030
UPADACITINIB - RINVOQ						
N 211675 001	11524964	Oct 17, 2036	U-3371	>A>	I-919	May 18, 2026
	11535624	Oct 17, 2036	U-3255			
	11535625	Oct 17, 2036	U-3298			
	11564922	Mar 09, 2038	U-3624			
	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
>A>	11680069	Oct 17, 2036	DS DP			
	8962629	Jan 15, 2031	DS U-3255			
	8962629	Jan 15, 2031	DS U-3275			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3371			
	8962629	Jan 15, 2031	DS U-3624			
UPADACITINIB - RINVOQ						
N 211675 002	11535626	Oct 17, 2036	U-3298	>A>	I-919	May 18, 2026
	11661425	Oct 17, 2036	DS DP			
>A>	11680069	Oct 17, 2036	DS DP			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3624			
UPADACITINIB - RINVOQ						
N 211675 003	11564922	Mar 09, 2038	U-3624	>A>	I-919	May 18, 2026
	11607411	Mar 09, 2038	U-3341			
	11661425	Oct 17, 2036	DS DP			
>A>	11680069	Oct 17, 2036	DS DP			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3624			
VANCOMYCIN - VANCOMYCIN						
N 213895 001	11517609	Nov 06, 2035	U-282			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
A 215338 001					CGT	Dec 20, 2023
VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT						
N 208910 001	11638692	Mar 13, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT						
N 208910 002	11638692	Mar 13, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
N 211962 001	11628200	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
N 211962 002	11628200	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
N 211962 003	11628200	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
N 211962 004	11628200	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
N 211962 005	11628200	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
N 211962 006	11628200	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE						
N 211962 007	11628200	Nov 06, 2035	DP			
VASOPRESSIN - VASOSTRICT						
N 204485 006	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
VENETOCLAX - VENCLEXTA						
N 208573 001	11590128	Sep 06, 2033	U-3548			
VENETOCLAX - VENCLEXTA						
N 208573 002	11590128	Sep 06, 2033	U-3548			
VENETOCLAX - VENCLEXTA						
N 208573 003	11590128	Sep 06, 2033	U-3548			
VOCLOSPORIN - LUPKYNIS						
N 213716 001	11622991	Dec 07, 2037	U-3056			
VOSORITIDE - VOXZOGO						
N 214938 001					ODE-387	Nov 19, 2028
VOSORITIDE - VOXZOGO						
N 214938 002					ODE-387	Nov 19, 2028
VOSORITIDE - VOXZOGO						
N 214938 003					ODE-387	Nov 19, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 07 - July 2023

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VOXELOTOR - OXBRYTA						
N 213137 001					ODE-394	Dec 17, 2028
VOXELOTOR - OXBRYTA						
N 213137 002					ODE-394	Dec 17, 2028
VOXELOTOR - OXBRYTA						
N 216157 001					ODE-394	Dec 17, 2028
VUTRISIRAN SODIUM - AMVUTTRA						
N 215515 001					ODE-212	Jun 13, 2029
XENON XE-129 HYPERPOLARIZED - XENOVIEW						
N 214375 001	10583205	Feb 20, 2035	DP		NCE	Dec 23, 2027
	11052161	Dec 29, 2035	DP			
ZANUBRUTINIB - BRUKINSA						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-817	Jan 19, 2026
	10570139	Apr 22, 2034	U-2145		ODE-274	Jan 19, 2030
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11591340	Aug 15, 2037	U-1745			
	11591340	Aug 15, 2037	U-2145			
	11591340	Aug 15, 2037	U-2537			
	11591340	Aug 15, 2037	U-2666			
	11591340	Aug 15, 2037	U-3063			
	11591340	Aug 15, 2037	U-3486			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
ZAVEGEPANT HYDROCHLORIDE - ZAVZPRET						
N 216386 001	7220862	Jan 21, 2024	DS DP		NCE	Mar 09, 2028
	7314883	Dec 05, 2023	U-3555			
	8481546	Oct 07, 2031	DS DP U-3555			
ZINC SULFATE - ZINC SULFATE						
A 216145 001					CGT	Aug 14, 2023

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 43rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm